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Preface 
Angina is the most common disorder affecting patients with ischemic heart disease. 
Indeed, the reported prevalence of angina approximates 10.2 million patients in the
USA and it has been estimated that 500,000 new cases of stable angina occur each year.
In this book we reviewed the novel mechanisms, such as inflammation factors and 
genetic determinants, that play a pivotal role in the pathophysiology of angina and
that might have potential therapeutic implications in the future (Chapter 1). In 
addition, because of its prevalence, it is important to distinguish angina due to
ischemic heart disease from angina-like chest syndrome, due to digestive tract
disorder. At this regard, the pathophisiology, the diagnosis and the treatment of 
angina-like chest syndrome were carefully reviewed (Chapter 2). 
The treatment of angina is based on several conventional agents, nevertheless new
drugs with novel mechanism of action, i.e. ranolazine, nicordandil, ivabradine, have 
been proposed in specific subsets (Chapter 3). However, nitrates, calcium channel
blockers and beta adrenergic blockers are the most widely used and studied anti-
anginal medications, representing the cornerstone in the treatment of angina 
secondary to coronary artery disease (Chapter 4 and Chapter 5). Finally, the role of
enhanced external counterpulsation and alternative non-medical, non-surgical
therapies were also reported, focusing on their potentials, as well as their current 
limitations.
Therefore, this book provides a thorough review of fundamental principles of
diagnosis, pathophysiology and treatment of angina pectoris, representing an 
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Inflammation and Genetics of Inflammation  
in Cardiovascular Diseases 
Maria Bucova 
Institute of Immunology, School of Medicine Comenius University, Bratislava 
Slovakia 
1. Introduction 
Inflammation is a complex of defensive mechanisms reacting to the entry of harmful agents 
to the organism or cells in order to eliminate or at least to dilute the agent, repair damaged 
cells or tissue and restore homeostasis. From this definition it is clear, that inflammation 
does not accompany only infectious diseases but also others, causing cell, tissue or organ 
injury and serves primarily defensively (Table 1). An exaggerated, chronic long lasting or 
non-adequately regulated inflammatory response could be the cause of adverse reactions 
and could lead to pathology (Bucova, 2002b). 
Inflammation plays an important role also in the etiology of ischemic heart disease (IHD), 
myocardial infarction (MI), angina pectoris (AP) and hypertension, however, its mechanism 
in various stages of pathological process is not well understood (Bucova et al., 2008a; Itoh et 
al., 2007; Kuka et al., 2010; Li, 2005; Pickering et al., 2007, Ross 1999). If the cause of IHD is 
atherosclerosis or other, it is accompanied by inflammation. Various types of inflammatory 
cells, cytokines, chemokines and other soluble factors were confirmed to be involved in this 
process. (Armstrong et al 2006; Aukrust et al., 2001; Brunetti et al., 2006; Bucova et al., 2008a; 
Ferencik et al., 2007). 
 
1. Infectious - bacteria, fungi, viruses  
2. Mechanical – scratching, cutting 
3. Physical – burning, radiation 
4. Allergic 
5. Autoimmune  
6. Atherosclerosis and cardiovascular diseases  
7. Cancer 
8. Nutritional disorders - hypoxia, lack of proteins, vitamins, etc. 
9. Other causes 
Table 1. Inflammation and its induction agents 
2. Immune mechanisms and cardiovascular diseases 
Inflammation and immune system activation are strongly involved in the pathogenesis of 
atherosclerosis and cardiovascular diseases. Atherosclerosis is now considered to be a 
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chronic inflammatory disease of the arterial wall where both innate and adaptive immune 
mechanisms contribute to disease initiation and progression (Table 2).  
 
Non-specific innate immunity Specific adaptive immunity Autoimmunity 
1. CELLULAR 1. CELLULAR 1. CELLULAR 
    monocytes, macrophages,  
    neutrophils, eosinophils,  
    NK- cells 
T helper cells (Th1, Th2, Th17) 
T cytotoxic cells (Tc) 
 regulatory T cells 
 (innate and induced) 
Tc - lymphocytes 
2. HUMORAL 2. HUMORAL 2. HUMORAL 
    cytokines TNF-, IL-1, IL-6, 
    chemokines  
    (MCP-1/CCL2, CXCL16, ...) 
    MMP-9, complement, 
    acute phase proteins, 
    histamin, chymase, tryptase,   
    endogenous vasoconstrictors, 
    elastase, ... 
cytokines IFN-, IL-12, IL-2,  
IL-4, IL-10, IL-17, IL-33, TGF- 
specific antibodies 
 3. RECEPTORS (non-specific) 3. Receptors (specific)  
    PRR 
    (CD14, TLR, Dectins, TREM-1,  
    RAGE, CR1, CR3, CR4, CRP ...)  
    FcR, scavenger receptors  
T cell receptor (TCR) 
B cell receptor (BCR) 
 
 4. MECHANISMS 4. MECHANISMS  
     inflammation, 
     innate imunity  
     (phagocytosis,  
     complement activation, ...) 
     antigen presentation, 
     potentiation of adaptive 
     immunity 
 polarization of T cells, 
 activation of specific  
 immunity  
  
antibodies against 
self, damaged  
or changed 
antigens 
 (oxLDL, HSP, ...) 
Legend: NK- natural killer, TNF – tumor necrosis factor, IL-1 – interleukin 1, MCP-1 – macrophage 
chemotactic protein, PRR – pattern recognition receptors, TLR – toll like receptors, TREM-1 (triggering 
receptor expressed on myelocytes, RAGE – receptor for advanced glycation end product, CR1, CR3, 
CR4 – complement receptors, FcR – receptor for Fc fragment of immunoglobulins, IFN- - interferon - 
gama, TGF- - transforming growth factor beta, oxLDL – oxidized low density lipoprotein, HSP – heat 
shock protein. 
Table 2. Main immune mechanims involved in cardiovascular diseases 
To main players of the innate immune system belong macrophages, mastocytes and from 
soluble factors complement components, pro-inflammatory cytokines (tumor necrosis factor 
(TNF), interleukin-1 (IL-1) and IL-6, chemokines (monocyte chemoattractant protein - MCP-
1/CCL2) and acute phase proteins, mainly C-reactive protein (CRP), serum albumin A 
(SAA) and pentraxins (PTX).  
Adaptive immune mechanisms involved in the pathogenesis of cardiovascular diseases are 
represented predominantly by T helper 1 type (Th1), Th2 and Th17 lymphocytes and 
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immune mechanisms associated with them (Chen et al., 2010; Mostafazadeh et al., 2011) 
(Table 2). Th1 immunity insures defence against intracellular pathogenic microorganisms, 
viruses, fungi and tumors, Th2 against extracellular pathogenic microorganisms and 
helmints and Th17 against extracellular bacterial infection and fungal infection. Exaggerated 
response of any of mentioned type of immunity contributes to the pathogenesis of various 
autoimmune inflammatory diseases (Fouser et al., 2008; Mucida et al., 2010; Quian et al., 
2010). Cytokines activating these cells and/or produced by these cells and regulating the 
activity of these cells play a great role in development of atherosclerosis and cardiovascular 
diseases. The array of cytokines involved in pathogenesis of atherosclerosis is similar to 
those used by immune effector cells to kill foreign pathogens and damaged or diseased host 
cells. These are mainly IL-2, interferon-gama (IFN-), IL-10, IL-4, IL-17, IL-33 and 
transforming growth factor-beta (TGF-) (Chen et al., 2010; Hansson et al., 2005). Regulatory 
T cells – both innate and induced, controlling the activity of helper T cells are other 
important components of adaptive immunity (Cheng et al., 2008; George, 2008). 
Macrophages belonging to non-specific innate immune mechanisms amplify the adaptive 
immune response as antigen presenting cells that after having ingested and processed the 
foreign particle present an immunogenic fragment from it to naive Th0 lymphocytes and 
start and shift the immune response to the right direction.  
Autoimmune response to at least two major autoantigens – oxidized lipoproteins (oxLDL) 
and heat shock proteins (HSPs) also potentiate inflammation. Namely, HSP60, an 
endogenous molecule with a chaperone activity, normally located in the mitochondria can 
be translocated into the cell membrane in response to stress stimuli. It can be released also 
by stressed or injured cells but also by activated monocytes and macrophages. HSPs in host 
can likewise be derived from microorganisms during infection, e.g. by Helicobacter pylori.  
2.1 The innate and adaptive immunity 
The innate immune response starts non-specifically as an inflammatory response that 
develops after pattern recognition receptors (PRR) at the surface of our immune cells 
(macrophages, dendritic cells, ...) recognize common molecular features originating either 
from microorganisms - pathogen associated molecular patterns (PAMPs), or from our own 
body, e.g. from damaged cells – damage associated molecular patterns (DAMPs) (Fig. 1, 
Table 3). Both PAMPs and DAMPs represent to immune system signals of threatening and 
bind these molecular patterns by PRR receptors  immune sensors of non-specific innate 
immunity. To these endogenous DAMPs called also alarmins belong both newly formed 
(HSPs, heat shock proteins), altered and modified endogenous antigens (oxLDL, oxidized 
low density lipoprotein cholesterol), or substances released from damaged or necrotic cells. 
The binding of any PAMPs and DAMPs to concrete PRR results in signal transduction, 
activation of transcription factors and production of early pro-inflammatory cytokines 
(TNF-, IL-1 and IL-6) and chemokines from immune and injured endothelial cells (Chen et 
al., 2010; Eldfeldt et al., 2002; Ferencik, 2007; Miyake,  2007). 
From this point of view the inflammatory response could be triggered directly by infectious 
but also by some sterile non-infectious stimuli. To the most intensively studied PRR with the 
involvement in the process of atherosclerosis belong toll like receptors TLR4 and TLR2, 
CD14 receptor and RAGE (receptor for advanced glycation end products) (Bierhaus et al., 
2006; Bucova, 2006; Park et al., 2004).  
The expression of adhesive molecules on both endothelial cells and leukocytes increases, 
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Fig. 1. Infectious and non-infectious inflammation induced by binding exogenous PAMPs 
and endogenous DAMPs by PRR. 
 
PAMPs 
(pathogen associated molecular 
patterns) 
- microorganisms and their 
products 
DAMPs 
(damage associated molecular patterns) 
- damaged or changed self cells and structures, 




flagelin, zymozan, ssRNA, dsRNA, 
CpG motifs of DNA, ... 
hyaluronic acid, heparan sulfat, extra-domene 
A of fibronectin, HSP 60, HSP 70, uric acid 
(crystallic form), HMGB1, IL-33, fibrinogen, 
hyperglycaemia, hyperkaliemia, .... 
Legend: ssRNA – single stranded ribonucleic acid, dsRNA – double stranded ribonucleic acid, DNA – 
deoxyribonucleic acid, HSP 60 – heat shock protein 60, HMGB1 – high mobility group box 1 protein, IL-
33 – interleukin 33 
Table 3. Some of the most important  PAMPs and DAMPs  
macrophages, ingest particles of oxLDL and transform into foam cells. Other substance with  
strong pro-inflammatory activity that serves also as alarmin or inflammatory mediator of 
tissue injury is high mobility group box 1 protein (HMGB1). HMGB1 is released both from 
injured endothelial cells and activated monocytes and macrophages, the next source of this 
protein are necrotic cells (Chang et al., 2011; Yang et al., 2010). 
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Released pro-inflammatory cytokines enhance the production of acute phase proteins in the 
liver and aggravate the inflammation. The pivotal transcription factor involved in the 
induction of specific pro-inflammatory genes is NF-B (Barnes & Karin, 1997). Its activation 
might also represent a mechanism by which CRP amplifies and perpetuates the 
inflammatory response  (Liuzzo et al., 2007) (Fig.1). 
Inflammatory process in endothelial cell wall goes along with the activation of adaptive T 
cell imunity. Macrophages as antigen presenting cells present exogenous or endogenous 
antigens to naïve helper T cells (Th0), cells of the specific adaptive immunity. After naïve 
Th0 cells recognize the antigen (oxLDL, HSPs, components of microorganisms, ...),  they 
differentiate into T helper type 1 (Th1) cells that produce interferon-gamma (IFN-), the 
main Th1 type cytokine (Bucova, 2002a; Chen et al, 2010) (Fig. 2, Table 2). IFN- further 
activates macrophages and foam cells, and amounts their production of proinflammatory 
cytokines and chemokines and the process of atherosclerosis is enhanced. This is the second 
step or wave of inflammatory response activation. The balance between  pro- and anti-
inflammatory responses regulates the magnitude of the inflammatory response within the 
plaque, the plaque instability and thrombus formation.  
Th1 cells exhibit a strong pro-atherogenic effect that is balanced by anti-atherogenic effect of 
regulatory T cells and defined cytokines released from Th2 lymphocytes – interleukin- IL-5 
and IL-33. Th2 related IL-4 seems to be pro-atherogenic (Chen et al., 2010; Taleb et al, 2010). 
 
 







Fig. 1. Infectious and non-infectious inflammation induced by binding exogenous PAMPs 
and endogenous DAMPs by PRR. 
 
PAMPs 
(pathogen associated molecular 
patterns) 
- microorganisms and their 
products 
DAMPs 
(damage associated molecular patterns) 
- damaged or changed self cells and structures, 




flagelin, zymozan, ssRNA, dsRNA, 
CpG motifs of DNA, ... 
hyaluronic acid, heparan sulfat, extra-domene 
A of fibronectin, HSP 60, HSP 70, uric acid 
(crystallic form), HMGB1, IL-33, fibrinogen, 
hyperglycaemia, hyperkaliemia, .... 
Legend: ssRNA – single stranded ribonucleic acid, dsRNA – double stranded ribonucleic acid, DNA – 
deoxyribonucleic acid, HSP 60 – heat shock protein 60, HMGB1 – high mobility group box 1 protein, IL-
33 – interleukin 33 
Table 3. Some of the most important  PAMPs and DAMPs  
macrophages, ingest particles of oxLDL and transform into foam cells. Other substance with  
strong pro-inflammatory activity that serves also as alarmin or inflammatory mediator of 
tissue injury is high mobility group box 1 protein (HMGB1). HMGB1 is released both from 
injured endothelial cells and activated monocytes and macrophages, the next source of this 
protein are necrotic cells (Chang et al., 2011; Yang et al., 2010). 
 
Inflammation and Genetics of Inflammation in Cardiovascular Diseases 
 
5 
Released pro-inflammatory cytokines enhance the production of acute phase proteins in the 
liver and aggravate the inflammation. The pivotal transcription factor involved in the 
induction of specific pro-inflammatory genes is NF-B (Barnes & Karin, 1997). Its activation 
might also represent a mechanism by which CRP amplifies and perpetuates the 
inflammatory response  (Liuzzo et al., 2007) (Fig.1). 
Inflammatory process in endothelial cell wall goes along with the activation of adaptive T 
cell imunity. Macrophages as antigen presenting cells present exogenous or endogenous 
antigens to naïve helper T cells (Th0), cells of the specific adaptive immunity. After naïve 
Th0 cells recognize the antigen (oxLDL, HSPs, components of microorganisms, ...),  they 
differentiate into T helper type 1 (Th1) cells that produce interferon-gamma (IFN-), the 
main Th1 type cytokine (Bucova, 2002a; Chen et al, 2010) (Fig. 2, Table 2). IFN- further 
activates macrophages and foam cells, and amounts their production of proinflammatory 
cytokines and chemokines and the process of atherosclerosis is enhanced. This is the second 
step or wave of inflammatory response activation. The balance between  pro- and anti-
inflammatory responses regulates the magnitude of the inflammatory response within the 
plaque, the plaque instability and thrombus formation.  
Th1 cells exhibit a strong pro-atherogenic effect that is balanced by anti-atherogenic effect of 
regulatory T cells and defined cytokines released from Th2 lymphocytes – interleukin- IL-5 
and IL-33. Th2 related IL-4 seems to be pro-atherogenic (Chen et al., 2010; Taleb et al, 2010). 
 
 






Next cells that trigger the inflammatory response in arterial cell wall are Th17 cells, 
lymphocytes that produce a wast bulk of a strong proinflammatory cytokine IL-17 that leads 
to elevated production of proinflammatory cytokines TNF-, IL-1 and IL-6 as well as 
proinflammatory chemokine MCP-1 (monocyte chemotactic protein) and other neutrophil 
mobilizing proteins. IL-17 is involved in the pathogenesis of several autoimmune diseases 
and asthma, its role in atherosclerosis development remains controversial. However, recent 
studies provide more direct evidence that IL-17 seems to be predominantly pro-atherogenic 
(Chen et al., 2010). 
3. Atherosclerosis and inflammation 
Atherosclerosis is an inflammatory disease characterized by vascular injury, lipid 
accumulation as well as massive infiltration of immune cells in the endothelial wall. Both 
microbial and self-antigens are responsible for a persistent activation of immune and non-
immune cells, thus leading to a condition of chronic smuldering arterial inflammation. At 
present, atherosclerosis is considered to be an inflammatory disease and atherosclerotic 
plaque inflammation the cause of intima erosion, rupture and subsequent ischemia 
(Kraaijeveld et al., 2007; Libby, 2002, Ross, 1999). 
Endothelial cell wall inflammation is based on genetic predisposition with mutual 
interaction between genes and genes, infections and other environmental factors. Repeted 
inflammatory processes lead to atherosclerosis development, coronary plaque rupture and 
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The question is, whether the inflammation is the cause or the result of the atherosclerotic 
plaque rupture. The answer is, both. Intact endothelium is non-sticky and resistant against 
deposition of any substances into endothelial cell wall (Fig. 4). So, endothelial dysfunction 
(ED) initiated by both infectious and non-infectious processes  (e.g. metabolic syndrome – 
MetS) is now recognized to play a critical role in the initiation and progression of 
atherosclerotic vascular disease (Al-Quasi et al., 2008; Bakker et al., 2009; Lamon & Hajjar, 
2008). CRP, which levels raise during inflammation contributes to the induction of endothelial 
cell activation and dysfunction (Deveraj et al., 2010; Grad et al., 2007; Schwartz et al., 2007; 
Teoh  et al., 2008; Venogupal et al., 2003). Patients with MetS have increased plasma levels of 
oxLDL (Holvoet et al., 2004)  and recently it was found that CRP promotes increased oxLDL 
uptake by vessel wall and cholesterol ester accumulation in Wistar rats (Singh et al., 2008). 
 
 
Fig. 4. Local inflammation in endothelial cell wall 
Lipid deposition (oxLDL) is accompanied by inflammation – macrophages and T-
lymphocytes enter vessel wall and foam cells (macrophages filled with oxLDL particles) 
develop (Eriksson, 2004). Recruitment of macrophages to the artery wall is one of the first 
steps in early atherosclerotic lesion formation. Macrophages become activated, produce a 
large amount of pro-inflammatory cytokines, chemokines and HMGB1 and potentiate 
inflammation. They release also MMP-9 (matrix metaloproteinase), smooth muscle cells 
proliferate and intima becomes thickened. Later, fibrosis develops and calcification appears 
in vessel wall. The more intensive is the inflammation, the higher is the activation of 
macrophages and atherosclerotic plaque is more unstable, and the thickening of fibrous cap 
progrediates. In the case of a plaque rupture, tissue factor expressed by activated 
macrophages facilitate activation of thrombocytes, thrombus formation and subsequent 
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ischemia/reperfusion injury is HMGB1 and thereby it functions as early mediator of tissue 
injury (Chang et al., 2011; Yang et al., 2011). 
Chemokines from activated macrophages attract also other immune cells to the site of 
inflammation – T cells, NK cells and mast cells that aggravate the inflammation. Activated 
mastocytes support instability of the atherosclerotic plaque by histamine, molecule with pro-
inflammatory activity, chymase and tryptase production and support coronary spasm 
development by the production of endogenous vasoconstrictors. Next mediators are 
complement components and C-reactive protein (CRP) (Devaraj et al., 2010; Onat et al., 2011). 
The ability of macrophages to become activated is extremely important in the atherosclerotic 
plaque rupture. In subjects with a genetically higher ability of macrophage activation, the 
rupture and subsequent thrombosis and ischemia may develop in a smaller atherosclerotic 
plaque, even in a limited coronary atheroma (Kondo et al., 2003). This means that two identical 
atheromas do not need to be identical and differ in their prognosis. The difference is 
determined by genetic polymorphisms, e.g. by different ability of macrophages to become 
activated. In particular, the key role of macrophages in this process has been proven by 
findings in an animal model - mice deficient for macrophage colony stimulating factor were 
protected from atherosclerosis. 
Inflammation of vascular cell wall is a crucial problem and early proinflammatory 
cytokines, late proinflammatory cytokine HMGB1, chemokines, and acute phase proteins 
play a great role in it. Key immune system molecules involved in the process of 
atherosclerosis and cardiovascular disease development are those involved in the process of 
inflammation and in the process of antigen presentation, monocytes, macrophages, 
mastocytes and Th1 immunity activation. Preferentially, these are early proinflammatory 
cytokines TNF-, IL-1, IL-6, chemokines MCP-1/CCL2, CXCL16, MIP-1-, proinflammatory 
cytokine IL-17, late proinflammatory cytokine HMGB1, INF- - main Th1 macrophage  
activating cytokine,  IP-10 (IFN- inducing protein) and IL-12, the key Th1 inducing 
cytokine. On the other hand, IL-10 and TGF- - mediators with anti-inflammatory, 
immunoregulatory and immunosuppresive activity control this pathology. It was found that 
besides Th1 lymphocytes, both T cytotoxic cells and NK cells take part in the process of 
atherosclerosis (Griva et al., 2010; Wang et al., 2010). 
In the last years, other molecules as neopterin and procalcitonin are also studied in relation 
to inflammation and risk of cardiovascular disease development and prognosis. A great 
interest is devoted to HMGB1.  
While acute inflammation serves to resolve pathogen infection and promotes tissue repair, 
persistent inflammation results in maladaptive tissue remodelling and damage and often 
serves as the precursor for arterial remodelling that underlies the increase of age –associated 
arterial diseases. The inflammation plays also an important role in the development of post-
ischemic organ dysfunction in acute coronary syndromes, and in the healing process after 
myocardial infarction  (Dewald et al., 2005). These facts highlight the value of non-specific 
inflammatory markers in patients with cardiovascular diseases.  
4. Nonspecific inflammatory markers and cardiovascular diseases 
4.1 C-reactive protein (CRP). Production, regulation of the production and 
plasma/serum levels of CRP 
CRP, a part of an acute phase reaction, previously considered to be a marker of underlying 
infection or tissue injury, was later found also as a marker of chronic low-grade non-
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infectious systemic inflammation. Associations between increased levels of CRP and clinical 
course of the acute MI and other acute coronary syndrome were found (Berk et al., 1990; De 
Beer et al., 1982; Kardys et al., 2006; Pepys  Hirschfield, 2003).  
It was confirmed that CRP is a better risk predictor of the cardiovascular events then LDL 
levels (Ridker, 2003). Its increased levels are considered a risk factor for atherosclerosis 
progression and complications even in healthy individuals (Dvorakova  Poledne, 2004). 
Increased levels of hsCRP were found also in patients with chronic heart failure, diastolic 
heart failure and dilated cardiomyopathy (Ishikawa et al., 2006; Michowitz et al., 2008; Xue 
et al., 2006). 
At least six major prospective studies support the hypothesis that elevated CRP levels 
contribute to increased cardiovascular risk (Devaraj et al., 2010; Ridker et al., 2000). These 
are the Physician’s Health Study (PHS) (Ridker et al., 1998), Women’s Healthy Study (WHS) 
(Ridker et al., 2003), Atherosclerosis Risk in Communities (ARIC) study (Ballantyne et al., 
2005), and Air Force/Texas Coronary Atherosclerosis Prevention Study 
(AFCAPS/TexCAPS) (Downs et al., 1998) in the United States and the Monitoring Trends 
and Determinants on Cardiovascular Diseases/Cooperative Health Research in the Region 
of Augsburg (MONICA/KORA Augsburg) (Koenig et al., 2008) and the Age 
Gene/Environment Susceptibility (AGES)-Reykjavik studies in Europe (Eiriksdottir, 2006). 
CRP is nowadays added to so called soluble pattern recognition receptors (PRR), sensors of 
threatening, that recognize some evolutionary conserved substances both from external 
intruders on the surface of microorganisms and internal structures that originate from our 
damaged cells, organs or tissues. Some molecules of danger synthesized during threatening of 
our organism could also be recognized by CRP (Raz, 2007; Sandor & Buc, 2005). After binding 
to them, the human CRP activates different humoral factors (the complement system), cells 
(phagocytes) and transducing signals. That evokes the immune response against the intruders 
and mediates a potent pro-inflammatory pathophysiological effects, too. 
Plasma CRP is produced mostly by hepatocytes and is under the regulation of cytokine IL-6. 
Normal values range round 1,3 mg . L-1 in adults (Maruna 2005). Median CRP levels are 
somehow higher in apparently healthy adults compared to blood donors and are 
characteristic for a given individual. CRP levels do not demonstrate seasonal neither diurnal 
variations and are not influenced by food intake (Pepys & Hirschfield, 2003; Szalai et al., 
2002). CRP levels have a tendency to increase with age, reflecting an increased incidence of 
subclinical pathologic processes (Cerovska et al., 2006; Koenig et al., 1999). After a stimulus, 
plasma CRP levels increase above 5 mg. L-1 in 6 hours, and reach the maximum within 48 
hours. After that, the level of CRP returns to very low „reference values“ in plasma with the 
same speed.  
Gene coding for CRP is localized on the chromosome 1 (1q2.12.5) and the main inductor of 
gene transcription is IL-6. IL-1 and complement act synergically (Buc & Bucova, 2007; 
Cerovska et al., 2006; Krejsek & Kopecky, 2004). The expression of CRP is regulated mainly 
at transcription level. Post-transcription mechanisms play also an important regulatory role, 
e.g. during inflammation CRP stay in the endoplasmatic reticulum is shortened from 18 
hours to 75 minutes, enabling a faster CRP production (Krejsek & Kopecky, 2004). The half-
life of CRP in plasma is approximately 19 hours and is constant during various conditions in 
healthy and sick people. Therefore, the only factor determining the level of CRP is its 
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4.2 High sensitive CRP (hsCRP)  
In the mid of 1990s, a new method ELISA - imunoassay was established to evaluate the level 
of high sensitive CRP (hsCRP), which has much higher sensitivity than classic methods used 
previously. It has been proved that higher levels of hsCRP, previously considered to be 
within normal range, have a strong predictive value in the development of coronary events 
in the future. First studies concerned patients with stable, unstable and severe unstable 
angina. These studies showed the predictive value of hsCRP levels regarding future 
coronary events (Liuzzo et al., 1994; Thompson et al., 1995) and brought a lot of interest into 
the predictive values of hsCRP. Studies demonstrating the relationship between higher level 
of hsCRP and future atherothrombotic events, such as coronary events, stroke, peripheral 
artery disease, were initiated (Arena et al., 2006; Kraus et al., 2007; Ridker et al., 2000). A 
cardiovascular risk scale according to hsCRP levels was developed (Pearson et al., 2003) 
(Table 4).  
 
Cardiovascular risk hsCRP level 
Low < 1   mg . l-1 
Medium 1  2   mg . l-1 
High 2  3   mg . l-1 
Infection 3  10  mg . l-1 
Table 4. HsCRP scale of cardiovascular risk according to the American Heart Association 
(Pearson et al., 2003) 
4.3 CRP – A contributing factor for increased cardiovascular risk in metabolic 
syndrome 
Metabolic syndrome (MetS) was characterised by a cluster of abnormalities, with insulin 
resistance and adiposity as central features (Reaven et al., 2005; Eckel et al., 2005; Haffner & 
Cassells, 2003). Five diagnostic criteria for MetS have been identified by the National 
Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III), and the presence 
of any of these three features — central obesity, dyslipidemia (high triglycerides, low high-
density lipoprotein [HDL] cholesterol), hypertension, and impaired fasting glucose — is 
considered sufficient to diagnose the syndrome (Expert Panel, 2001). About 24% of US 
adults have MetS, and the prevalence increases with age (44% at age 60 years) (Ford, 2005). 
44% of US population over 50 years meeting the NCEP-ATP III criteria has MetS (Alexander 
et al., 2003).  
Metabolic syndrome (MetS) characterised by chronic low-grade inflammation is associated 
with increased propensity for cardiovascular disease and diabetes development. MetS and 
cardiovascular disease individuals with MetS have an increased burden of cardiovascular 
disease (CVD) complications (Devaraj et al., 2010; Lakka et al.; 2002). Men with MetS, even 
in the absence of baseline coronary artery disease (CAD) or diabetes, had a significantly 
increased mortality from CAD. It was found that in individuals with MetS, the risk for 
coronary heart disease (CHD) and stroke was increased threefold (P<0.001) and the risk for 
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cardiovascular mortality was increased sixfold (P<0.001) (Lakka et al., 2002; Alexander et al., 
2003; Devaraj et al., 2004). Individuals with MetS without diabetes had higher CHD 
prevalence (13.9%), and those with both MetS and diabetes had the highest prevalence of 
CHD (19.2%) compared with those with neither (Alexander et al., 2003). 
Plasma levels of CRP are elevated in individuals with MetS. They were  shown to be 
strongly associated with insulin resistence calculated from the homeostatic model 
assessment, blood pressure, low HDL, and triglycerides, and also to levels of the  
proinflammatory cytokines TNF- and IL-6. Body mass index and insulin resistance were 
the strongest determinants of the inflammatory state. There is a linear relationship between 
the number of metabolic features and increasing levels of hsCRP. HsCRP was positively 
correlated with body mass index, waist circumference, blood pressure, triglycerides, 
cholesterol, low-density lipoprotein (LDL) cholesterol, plasma glucose, and fasting insulin, 
and it was inversely correlated with HDL cholesterol and the insulin sensitivity index. The 
strongest associations were observed between CRP levels, central adiposity, and insulin 
resistance. 
Ridker et al. (2000, 2003) evaluated inter-relationships between CRP, MetS, and incident 
cardiovascular events among apparently healthy women who were followed for an 8-year 
period for myocardial infarction, stroke, coronary revascularization, or cardiovascular 
death. 24% of the cohort had MetS at study entry. They found that women with hsCRP 
levels of less than 3 mg/L without MetS had the best cardiovascular survival, whereas those 
with hsCRP levels greater than 3 mg/L with MetS had the worst cardiovascular survival. 
Other studies also support the hypothesis that an increased hsCRP level in the setting of 
MetS confers an increased risk of future cardiovascular events.  
Thus, it has been proposed that hsCRP should be added as a clinical criterion for MetS and 
for creation of an hsCRP-modified CHD risk score (Ridker et al., 2000). In addition to the 
prognostic information that hsCRP evaluation might add to the current definition of MetS, 
there are several other practical benefits of hsCRP measurement (Devaraj et al., 2010). First, 
hsCRP is strongly associated with components of MetS that are difficult to measure in 
routine clinical practice, such as impaired fibrinolysis and insulin resistence (Yudkin et al., 
2004, Festa et al., 2000). Also, the widespread availability of commercial assays for hsCRP 
has made its measurement simple and inexpensive. In addition, as hsCRP does not display 
diurnal variation and demonstrates long-term stability comparable with cholesterol, it can 
be reliably evaluated with a single nonfasting measurement. The addition of hsCRP 
measurement to diagnosis of the MetS may significantly improve the early detection of risk 
for future diabetes and cardiovascular events in individuals (Ridker et al., 2004). 
4.4 CRP, cytokines, chemokines and other nonspecific inflammatory markers  
The level of CRP closely correlates with other non-specific inflammatory markers, which 
show similar although less significant predictive association with future coronary event 
(Danesh et al., 1998, 1999). Many studies have shown that increased levels of fibrinogen, 
CRP and IL-6 are associated with the risk of coronary heart disease, clinical course, 
prognosis and severity of atherosclerosis (Jenny et at., 2007; Sukhija et al., 2007). Similar 
association was found with the level of IL-8, where the risk of coronary heart diseases was 
higher in men compared to women and was independent from both traditional risk factors 
and CRP (Boekholdt et al., 2004). Authors could not exclude the possibility that IL-8 
reflected a pre-clinical atherosclerosis. Concentrations of complement components, mainly 
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mortality and severity of cardiovascular disease (Blanghy et al., 2007; Iltumur et al., 2005; 
Palikhe et al., 2007).  
Zouridakis et al. (2004) showed 4 markers predicting rapid progression of coronary heart 
disease – CRP, sICAM (soluble intercellular adhesive molecules), neopterin and MMP-9 
Their levels are higher in „progressors“ than in „non-progressors”. According to their 
results the patients with CRP concentration in the medium quartile had 3-fold risk of 
coronary heart disease progression compared to the patients in the lowest quartile, and 
patients with sICAM levels higher than 271,4 ng.ml-1 (average) had 4-fold increased risk 
compared to the patients in the lowest quartile. Individuals with neopterin level higher than 
7,5 nmol . L-1 (medium quartile) have 5-fold increased risk of coronary heart disease 
development and progression compared to individuals with neopterin levels in the lowest 
quartile. Patients with MMP-9 concentration higher than 47,9 g.l-1 (median) have 3-fold 
increased risk of coronary heart disease progression compared to the patients in the lowest 
quartile. As the last two markers are indicators of the activity of macrophages that are key 
cells playing a causative role in the process of atherosclerosis, the evaluation of their activity  
seems to be useful in patients at risk. A systemic therapy might prevent development or 
progression of coronary heart disease. 
4.5 CRP and proinflammatory cytokines – The cause and the result of the 
inflammatory process 
It is questionable to what extend are pro-inflammatory cytokines and CRP purely acute 
phase markers and to what extend are they active inflammatory participants. Increased 
levels of IL-6 were found in patients with unstable angina, where inflammatory reaction 
may promote conversion of a stable atherosclerotic plaque to an unstable one (Biasucci et al., 
1996).   It was also found that plasma CRP level can predict future cardiovascular events or 
mortality due to coronary heart disease even in healthy individuals (Dvorakova & Poledne, 
2004; Kardys et al., 2006; Koenig et al., 2006). CRP predicts cardiovascular risk even in 
Japanese, who generally have lover levels (Saito et al., 2007). These findings show the 
possibility that both the progression of atheroma and the plaque rupture might be predicted 
by a follow-up of CRP levels. The role of TNF-alfa and IL-6 in the atherogenesis and 
thrombosis was also shown. Pro-inflammatory cytokines TNF-alfa, IL-6, IL-1 and also CRP 
are in large amounts produced except of liver also by adipocytes (Mohamed et al.,1997; 
Yudkin et al.,1999). Production of IL-6 in obese patients and approximately 30% of IL-6 in 
healthy individuals comes from adipocytes. These cytokines inhibit insulin signalization 
and cause insulin resistance, and also enhance the development of endothelial dysfunction – 
they increase the expression of adhesive molecules, pro-thrombotic factors, acute phase 
proteins, which can increase a cardiovascular risk via a feed back mechanism (Conen et al., 
2006; Kremen et al., 2006). It was found that, both CRP and pro-inflammatory cytokine 
levels correlate with blood pressure, dyslipidemia, HDL (high density lipoprotein 
cholesterol) and level of triglycerides, smoking, diabetes, insulin resistance, markers of 
endothelial dysfunction and obesity (Bermudez et al., 2002; Cerovska et al., 2006; Chambers 
et al., 2001; Dvorakova & Poledne, 2004; Ford, 1999; Frohlich et al., 2000). The correlation 
with BMI (body mass index) was also found, which could partially reflect the fact that the 
majority of basal CRP and IL-6 is produced in adipocytes (Danesh et al., 1999). Weight 
decrease was associated with plasma CRP decrease even in healthy individuals (Mohamed-
Ali et al., 1997). 
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In the pathogenesis of coronary heart disease and atherosclerosis, chemokines play an 
important role, too. The most important are: MCP-1 (monocyte chemotactic protein), MIP-
1 (macrophage inflammatory protein), IP-10 (IFN-gama inducible protein, with Mr =10 
000), RANTES (regulated on activation normal T-cell expressed and secreted) and eotaxin 
(Rothenbacher et al., 2006). MCP-1, called also CCL2 (MCP-1/CCL2) is chemotactic to 
monocytes, T-lymphocytes and NK cells and participates in the development and 
restoration of diseases characterized with infiltration of monocytes (Gu et al., 1998; 1999). It 
modulates fibroblasts and endothelial cells function and has an important role in the 
pathogenesis of myocardial infarction, thrombotic occlusion, myocardial ischemia, and also 
in the reperfusion and healing process after myocardial infarction (Dewald et al., 2005). 
Tarzami et al. showed that MCP-1/CCL2 had a dual role in myocardial ischemia – beside 
chemotactic activity protected myocardial cells against hypoxia induced cell death (Tarzami 
et al., 2002; 2005).  
4.6 Non-specific inflammatory markers in cardiovascular diseases – what do they 
reflect? 
Another question is, what exactly these non-specific markers reflect. Four possibilities can 
be found and three of them directly or indirectly highlight the role of atherosclerosis: 1. 
Atherosclerosis, plaque development, its instability, rupture and resulting atherothrombosis 
are inflammatory events. The first assumption could be that increased levels of 
inflammatory markers reflects inflammation of the vessel wall. This is possible, but some 
contradictory results concerning the level of CRP and atherosclerotic plaque size exist. This 
discrepancy could be explained by genetic polymorphism causing a different ability of 
macrophages to be activated as it was mentioned above, which explains a possible rupture 
even in a small atherosclerotic plaque (Kondo et al., 2003). Chronic systemic non-vascular 
infection is also pro-atherogenic and acute systemic inflammatory episodes are markedly 
associated with atherosclerotic processes (Rotenbacher et al., 2006). CRP could reflect 
inflammation in some other part of organism, although the correlation of Chlamydia 
pneumonie and Helicobacter pylori antibodies with the development of coronary heart 
disease is not very clear (Danesh et al., 2000). Generally, the above mentioned associations of 
CRP and IL-6 levels with BMI and IHD risk factors increase the possibility that 
inflammatory markers associated with the risk of atherothrombosis could reflect a certain 
metabolic state, which is also pro-atherogenic and is a predisposition to atherothrombotic 
events, that means it is also pro-inflammatory. In fact, CRP level predicts development of 
type 2 diabetes independently from traditional risk factors (Freeman et al., 2002). In insulin-
resistant obese individuals, increased CRP levels decrease in parallel with the improvement 
of insulin resistance related to weight loss (Mc Laughlin et al., 2002). The fourth possibility is 
the fact that individuals differ in their sensitivity to various stimuli leading to acute phase 
proteins production. Therefore, those who are „higher CRP responders“, either due to 
genetic mechanism or other acquired mechanism (for example, BMI) are simple more 
sensible to atherosclerosis progression and complications. 
4.7 CRP - a cause of cardiovascular disease 
CRP has been traditionally thought to be a bystander marker of vascular inflammation, 
without playing a direct role in CVD. Now, increasing evidence suggests that CRP may 
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Aggregated CRP binds to and opsonizes LDL and VLDL (very low density lipoprotein), 
subsequently activates complement and mediates uptake of these particles by macrophages 
that transforme in foam cells (Pickering et al., 2007; Thomson et al., 1995).        
Several reports demonstrated the presence of CRP within atheromatous plaque where it 
preceeds and mediates monocyte recruitment (Jian-Jun  Chun-Hong, 2004). CRP was 
found to be widely distributed in early human atherosclerotic lesions of human coronary 
arteries with two predominant manifestations. First, the majority of foam cells below the 
endothelium showed positive staining for CRP. This staining was clearly cell associated, 
mainly along the cell surface. Second, CRP was deposited diffusely rather than focally in the 
deep fibroelastic layer and the fibromuscular layer of the intima adjacent to the media 
(Cerovska et al., 2006). CRP activates the classical pathway of complement and has been 
shown to colocalize with the membrane attack complex (C5b-C9)   in early atherosclerotic 
lesions in the fibromuscular layer of the intima, which contains predominantly smooth 
muscle cells (Cerovska et al., 2006; Szalai et al., 2002).  
CRP can stimulate tissue factor production by macrophages, the main stimulus for initiating 
coagulation, upregulates the expression of adhesion molecules ICAM-1 and VCAM-1 
(vascular adhesion molecule-1) by endothelial cells and mediates proinflammatory factor 
induction in artery wall as well as circulating monocytes (Aukrust et al., 2007; Liuzzo et al., 
1994; Kraus et al., 2007; Pickering et al., 2007). In addition, CRP mediates MCP-1 induction 
in endothelial cells (Aukrust et al., 2007; Liuzzo et al., 1994). 
CRP also stimulates the release of inflammatory cytokines TNF-a, IL-1b, IL-6 and may also 
directly act as a proinflammatory stimulus to phagocytic cells by binding to the FcRII 
receptor (Buc & Bucova., 2007). Furthemore, monocytes from healthy subjects were also 
found to exhibit an enhanced production of IL-6 in response to CRP and this response was 
significantly inhibited by simvastatin in a dose-dependent manner (Krejsek & Kopecky., 
2004). IL-6 production increases very rapidly, 4 h after CRP stimulation and therefore 
continues to rise at a slower rate, reaching a peak at 24 h.  
Devaraj et al. (2009) outlined that CRP contributes to increased cardiovascular risk by 
inducing endothelial cell dysfunction and activating monocytes. 
These data suggest that CRP may indeed be a direct proinflammatory factor involved in the 
initiation and progression of atherosclerosis. 
4.8 HMGB1 
HMGB1, formerly known as a nuclear nonhistone protein, that stabilizes nucleosomes, has 
DNA-binding properties, facilitates gene transcription, and have an essential position in 
DNA repair (Lange & Vasquez, 2009; Lotze & Tracey, 2005; Wang et al., 2007,). Later studies 
identified the extracellular form of HMGB1 as a critical mediator of inflammation, mainly 
sepsis and also as a factor that promotes tissue repair and regeneration (Fink, 2007; De MR 
et al., 2007; Klune et al., 2008).      
HMGB1 is likely to be released into extracellular milieu in two ways - passively from 
necrotic or injured cells (e.g. after ischemic/reperfusion injury – IRI) and actively by 
activated monocytes and macrophages (Ulloa & Messmer, 2006). This extracellular HMGB1 
acts as alarmin and signaling through RAGE,  TLR2 and TLR4 leads to the activation of NF-
B, which induces the production of proinflammatory cytokines and angiogenic factors in 
both hematopoietic and  endothelial cells.  
Its key role has been revealed in lethal endotoxemia and sepsis and as it is released later 
than other pro-inflammatory cytokines (after 16-32 h) it became known as a “late mediator 
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of sepsis” or “late proinflammatory cytokine” (Wang et al., 1999, 2007). Recently identified 
biological activities of HMGB1 include chemotactic activity, activation of monocytes/ 
macrophages to release proinflammatory cytokines, upregulation of endothelial cell 
adhesion molecules, stimulation of epithelial cell barrier failure, and mediation of fewer and 
anorexia (Wang et al., 2004). More recently, HMGB1 was recognized as a proangiogenic 
factor, and seems to be able to attract also stem cells to the area of injury and inflammation, 
activate them and promote thus healing and regeneration (De MR et al., 2007;  Klune et al., 
2008). Interestingly, HMGB1 can act also on local stem cells, activate them, promote their 
differentiation and facilitate the healing process directly from local sources (Lolmede et al., 
2009; Yiang et al., 2010). The discovery of HMGB1 as a critical mediator of inflammation in 
different inflammatory diseases has stimulated tremendous interest in the field of 
inflammation research. HMGB1 protein contributes to development of autoimmune 
diseases, and its role in growth and spread of many types of tumours has also been revealed 
(Abdulahad et al., 2010; Tang et al., 2010). Thus, HMGB1 represents a potential target in 
therapy of various disorders related to inflammation (Yang and Tracey, 2010). 
HMGB1 is structurally composed of three different domains: two homologous DNA-
binding sequences entitled box A and box B and a highly, negatively charged C terminus. 
The B box domain is responsible for proinflammatory activity of the molecule, whereas the 
A box region has an antagonistic, anti-inflammatory effect with therapeutic potential. 
Administration of highly purified, recombinant A box protein or neutralizing antibodies 
against HMGB1 rescued mice from lethal sepsis (Huang et al., 2010). 
Many recent studies demonstrated that HMGB1 played a pivotal role in cardiovascular 
diseases, such as atherosclerosis, myocardial ischemia/reperfusion injury (IRI), heart failure, 
and myocardial infarction. Elevated levels of HMGB1 has been detected in patients with 
coronary artery diseases (CAD), in patients with cerebral and myocardial ischemia, in IRI of 
the heart and is a novel predictor of adverse clinical outcomes after acute myocardial 
infarction (Goldstein et al., 2006; Kohno et al., 2009; Yan et al., 2009).  
Injury of endothelium is essential for the initiation of atherosclerosis as it leads to the 
attraction of macrophages. Progression of atherosclerosis goes along with prolonged pro-
inflammatory response (Mullaly and Kubes 2004). It was revealed that HMGB1 and RAGE 
are expressed in endothelial cells, smooth muscle cells, and macrophages of atherosclerotic 
lesions (Kalinina et al., 2004). Moreover, activated vascular smooth muscle cells are the 
source of HMGB1 in human advanced atherosclerotic lesions (Innoue et al., 2007). Therefore, 
up-regulation and secretion of HMGB1 may lead to intensification of inflammatory response 
in endothelial lesions, promote further atherosclerotic changes and thus may be related to 
the severity of coronary artery stenosis (Innoue et al., 2007). 
4.8.1 HMGB1 in ischemic and reperfusion injury 
Many factors have been revealed to be involved in IRI including nitric oxide or plenty of 
cytokines released under proinflammatory conditions in the afflicted area in many organs 
i.e. heart, brain, kidney or liver (Matsuki et al., 2006; Hsieh et al., 2007). Recent studies 
suggest potential implication of HMGB1 in the pathogenesis of IRI (Goldstein et al., 2006). 
IRI leads to tissue damage and high amounts of HMGB1 protein are released around the 
central ischemic area (Kim et al., 2006). 
4.8.2 HMGB1 in positive feedback mechanism 
HMGB1 seems to be involved in positive feedback mechanism, that may help to sustain 
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dependently induces the production of HMGB1 through the p38 MAPK pathway 
(Kawahara et al., 2008). In return, HMGB1 triggers the expression of other proinflammatory 
cytokines and reinforces this way the proinflammatory process (Andersson et al., 2000; 
Wang et al., 1999). Endothelial cells express HMGB1, as well as its receptors RAGE, TLR2 
and TLR4 and signalling through theses receptors leads to activation of NFkappaB, which 
can subsequently induce the expression of HMGB1 receptors (van Beijnum et al., 2008) 
These studies suggest that HMGB1 may be a critical proinflammatory cytokine and may 
play an important role in the pathogenesis of CAD.  
Hu et al. (2009) has found markedly increased level of serum HMGB1 that correlated with 
severity of coronary artery stenosis in patients with stable (SAP) and unstable angina 
pectoris (USAP), especially in SAP patients. In addition, a strong correlation between 
angiographic Gensini score and serum level of HMGB1 has been found. However, in 
subgroup analysis the serum level of HMGB1 was significantly correlated only with 
angiographic Gensini score in SAP patients, not USAP patients. These results indicated, that 
the level of serum HMGB1 may predict the degree of coronary artery stenosis in patients 
with SAP and HMGB1 may be involved in the pathogenesis of USAP (Hu et al., 2009). The 
serum level of HMGB1 positively correlated with the serum level of hs-CRP, TNF- and IL-
6 in patients with CAD (Hu et al., 2009; Yan et al., 2009).  These results are in agreement 
with previous observations that there is a cross-talk between HMGB1 and other 
proinflammatory cytokines and CRP. 
Passively released from necrotic cells or actively secreted by activated 
monocytes/macrophages, or other cells, HMGB1 functions as an inflammatory stimulus 
that upregulates the production of early proinflammatory cytokines TNF-, IL-1, IL-6, and 
different inflammatory proteins (MIP- 1, MIP-1), and subsequently CRP (Andersson et al., 
2000; Sama et al., 2004). Interestingly, HMGB1 alone can directly stimulate the production of 
CRP which is an independent predictor of coronary artery disease extent in patient with 
stable and unstable angina pectoris (Arroyo-Espliguero et al., 2009; Niccoli et al., 2008). 
4.8.3 HMGB1 and therapy in cardiovascular diseases  
HMGB1 is considered as a potential clinical therapy, in association with myocardial 
infarction. The possibility of evaluating HMGB1 as a regenerative and proliferative agent in 
the myocardium was first suggested by Palumbo et al. (2004). They demonstrated that 
HMGB1 induced migration and proliferation of blood vessel mesangioblasts, which are 
blood vessel stem cells. Later, Limana et al. (2005) discusses the role of HMGB1 in initiating 
activation and differentiation of endogenous cardiac stem cells in a mouse model of 
myocardial infarction. The capacity of HMGB1 to promote the development of mouse 
cardiomyocytes and initiate repair of myocardial infarction is quite remarkable. An 
exogenous HMGB1 directly injected to peri-infarcted area contributes to increased amount 
of myocytes inside the area of infarcted cardiomyocytes that goes along with improved 
outcome confirmed by structural and functional measures (Klune et al., 2008;  Limana et al., 
2005). These examples support effect of HMGB1 in regenerative processes.  
Human cardiac stem cells (CSCs) can be obtained fairly readily from cardiac surgery 
specimens, and they have been characterized to a very limited extent. As such, it is too early 
to comment on similarities and differences between mouse and human CSCs, as too little is 
known about adult human CSCs. Moreover, the use of HMGB1 like any other drugs or 
molecules that activate resident stem cells in vivo might circumvent the need for „classical“ 
stem cell therapy. Interestingly, the mechanism by which HMGB1 works is not yet clear. 
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They current working hypothesis is that it functions by interfering with pro-apoptotic 
pathways (Rosenberg  Oppenheim, 2007). 
4.9 Neopterin 
Among the immune inflammatory cells, activated macrophages contribute significantly to 
atherosclerosis plaque progression, fibrous cap disruption and intracoronary trombus 
formation (Avanzas & Kaski, 2009). Macrophages are a marker of unstable atherosclerotic 
plaque, may release lytic enzymes that degrade the fibrous cap, produce rupture of the 
atherosclerotic plaque and therefore play a significant role in the pathophysiology of acute 
coronary syndrome (Moreno et al, 1994).  
IFN-gama – a cytokine produced by activated Th1 cells is centrally involved in 
atherosclerosis – related inflammation and monocyte/macrophage activation and 
contributes to this process. In activated macrophages IFN-gama stimulates conversion of 
tryptophan to kynurenine and production of neopterine (Pedersen et al., 2011). Enhanced 
tryptophan degradation in patients with coronary heart disease was found to correlate with 
enhanced neopterin formation. 
Neopterin, a pteridine, by-product of the guanosine triphosphate pathway is an activation 
marker for monocytes/macrophages (Sugioka et al., 2010a, 2010b), marker of inflammation 
and Th1 immune system activation (Pacileo et al., 2007; Murr et al., 2002). In the past several 
years, the measurements of neopterin concentrations in body fluids including plasma, 
serum, urine and cerebrospinal fluid has revealed its potential role in the prediction of long-
term prognosis in both patients with viral infections, HIV-1 infection, severe systemic 
inflammatory diseases, several autoimmune diseases, renal transplant rejection, cancer 
(Kozłowska-Murawska  Obuchowicz, 2008; Plata-Nazar et al., 2004; Sucher et al., 2010). By 
neopterin measurements, not only the extent of monocyte/macrophage and Th1 immune 
system activation but also the extent of oxidative stress could be estimated (Murr et al., 
2002). 
Elevated plasma/serum levels of neopterin have also been reported in patients with coronary 
disease compared to controls and in recent years it has become apparent that increased 
neopterin concentrations are an independent marker for cardiovascular disease (Fuchs et al., 
2009). Neopterin serves also as a good biomarker of plaque inflammation, its instability in both 
coronary and carotid atherosclerotic lesions (Sugioka et al., 2010a), and as a marker for 
cardiovascular risk (Avanzas  Kaski, 2009). In particular, neopterin predicts future major 
cardiac and vascular adverse events in patients suffering from coronary artery disease 
(Avanzas et al., 2005; De Rosa et al., 2011; Pacileo et al., 2007). Serum neopterin is an 
independent predictor of major adverse coronary events and may also serve as a useful 
marker for risk stratification in patients with chronic stable angina pectoris. 
Coronary angiographic studies have shown a relationship between increased circulating 
levels of neopterin and the presence of complex coronary lesions in patients with unstable 
angina pectoris. Moreower, higher prevalence of neopterin-positive macrophages was found 
in culprit lesions in patients with UAP than in those with stable angina pectoris (SAP), so 
neopterin could serve as  an important biomarker of plaque instability in both coronary and 
carotid atherosclerotic lesions (Sugioka et al., 2010a, 2010b). However, plasma neopterin 
levels were significantly higher also in SAP patients  with complex carotid plaques than 
those in noncomplex plaques (Sugioka et al., 2010b). This marker of macrophage activation 
may be useful for risk stratification even in patients with chronic stable angina (Avanzas et 
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Left ventricular ejection fraction (LVEF) is the strongest predictor of survival in patients 
with chronic stable angina (CSA). Baseline neopterin levels - but not CRP - showed a 
significant inverse correlation with LVEF. Increased serum neopterin concentrations 
inversely correlate with LVEF values and high neopterin levels are a predictor of LV 
dysfunction in patients with CSA, irrespective of the extent and severity of coronary artery 
disease. Neopterin may thus be clinically useful for patient risk stratification (Estévez-
Loureiro et al., 2009). 
4.10 Procalcitonin 
Procalcitonin (PCT) was originally described in 1984 as a 116 amino-acid protein and now is 
known as a highly selective and specific marker for early diagnosis of sepsis. Procalcitonin 
(PCT) - prohormon of calcitonin, is under basal condition produced only by C-type cells of 
thyroid and neuroendocrine cells of the lung. Thus, the basal plasma level of PCT in healthy 
individuals is very low, under detection limit - below 0.05 ng/ml. Under systemic bacterial 
infection preferentially of bacterial origin, the levels of PCT raise very quickly because 
almost all cells of human body start to be the source of PCT and the level of this molecule 
rapidly increases, it can reach several hundred of ng/ml. That is why is PCT considered as a 
hormokine, an acute phase marker and an early marker of systemic bacterial infection. The 
levels of PCT are elevated also under the conditions of non-infectious systemic 
inflammatory processes, this elevation is not so high. Elevation of PCT is mediated directly 
by microorganisms or indirectly by pro-inflammatory cytokines (Bucova, 2005).  
So far, data on plasma/serum PCT levels in patients with cardiogenic shock and in those 
with acute coronary syndromes (ACS) are scarce and controversial. While some studies 
report that PCT levels are increased in ACS patients on admission, other investigations 
document that plasma PCT concentrations are in the normal range. Ataoğlu et al. (2010) 
found that higher PCT levels within 48 h post-admission may reflect an inflammatory state 
that is associated with increased early and 6-month mortality. Picariello et al. (2009) 
reported that the degree of myocardial ischemia (clinically indicated by the whole spectrum 
of ACS, from unstable angina to cardiogenic shock following ST-elevation myocardial 
infarction) and the related inflammatory response are better reflected by C-reactive protein 
than by PCT, which seems to be more sensitive to a higher degree of inflammatory activation, 
being positive only in patients with cardiogenic shock. Few studies investigated the dynamics 
of PCT in cardiac acute patients, and, despite the paucity of data and differences in patients' 
selection criteria, an increase in PCT values seems to be associated with the development of 
complications. In acute cardiac patients, the clinical values of procalcitonin rely not on its 
absolute value, but only on its kinetics over time (Picariello et al., 2009). 
5. Genetic background of inflammation in cardiovascular diseases  
5.1 Main terms 
People differ in the risk of development and death due to various diseases including 
cardiovascular disease, and differ also in inflammatory reactions (Bucova et al., 2008a; Javor 
et al., 2007). Inter-individual genetic differences play an important role.  
Human diseases are roughly divided into three categories according to genetic factors: 1. 
„monogenic diseases“ (caused by one gene defect), 2. complex diseases (with multigenic or 
polygenic predisposition) and 3. diseases without genetic predisposition. The best results 
were achieved in „monogenic diseases“. Recently, the attention is shifted to complex 
diseases caused by several genes, including majority of socially burden diseases (Fig. 5). 
 




Fig. 5. The most frequent DNA polymorphisms 
Genetic polymorphism means that more than one allele (variant) of gene is present in 
population. It is referred to when the frequency of the most frequent gene allele in 
population is lower than 99%, e.g. when the frequency of the rare gene allele is higher than 
1%. Single nucleotide polymorphism (SNP) belongs to the most common types of genetic 
polymorphism, including exchange, insertion or deletion, and repetitive polymorphisms 
(Fig. 5). The number of SNP polymorphisms in genome is estimated to 10 millions (Hafler et 
al., 2005). Gene variants, influencing gene expression, are called functional gene 
polymorphisms. SNP polymorphism may be present in coding, regulatory and in non-
coding gene regions (Tsuchiya et al., 2002).    
While the polymorphisms in coding regions tend to change the structure of primary protein 
or result in protein defect, the polymorphisms in regulatory gene areas, influencing gene 
transcription, may affect gene expression. It is suggested that majority of polymorphisms 
playing a role in genetic predisposition of complex diseases, are found in regulatory gene 
areas (Tsuchiya et al., 2002).  
Individual genetic susceptibility to complex diseases is present, when an inter-individual 
difference in disease risk exists, not determined by environmental factors. Regarding 
diseases, we distinguish susceptibility gene variants (allele), which predispose for disease 
development (they are more frequently found in patients compared to general population) 
and protective alleles, which on the contrary, are less common in patients than in healthy 
subjects.  
5.2 Genetics, inflammation and cardiovascular diseases 
The inheritance of cardiovascular diseases is polygenic, i.e. several genes can influence their 
development and clinical course. Except of polymorphisms of genes coding for 
homocystein, lipid metabolism, factors of coagulation, 2 – adrenergic receptors, genes 
regulating blood pressure and others, inflammatory factors genes play an important role, 
too (Arnett et al., 2007; Horne et al., 2007; Markovic et al., 2007; Ozanne et al., 2007). These 
genes are numerous and gene polymorphisms related to different stages of inflammatory 
response have been found (Andreotti et al., 2002; Bernardo et al., 2006; Espliguero et al., 
2005). 
5.2.1 Genetics of CRP      
The basal level of CRP both in patients and healthy controls are genetically determined. In 
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were relatively stable. It means, that knowledge in CRP genetic component may contribute 
to the stratification of so far healthy individuals into groups with higher or lower risk for 
cardiovascular disease development (Crawford et al., 2006; Szalai et al., 2005). 
The human CRP gene lies on chromosome 1, within a conserved region that encodes for 
proteins critical to the immune system and to intercellular communication (Bucova et al., 
2008b; D’Aiuto et al., 2005, Suk et al., 2005). Dupuis et al. (2005) found that multiple genes 
on chromosome 1 may influence inflammatory biomarker levels and may have a potential 
role in development of cardiovascular disease. They hypothesised that production of 
biomarkers of vascular inflammation is modulated both genetically and by environmental 
factors.  
Family studies estimates of CRP ranging from 27–40%, and it is hypothesized that genetic 
variation in the CRP gene may influence plasma CRP levels and subsequent risk of CHD. 
Several studies have reported individual single nucleotide polymorphisms (SNPs) to be 
associated with CRP levels and Risk of Incident Coronary Heart Disease in Two Nested 
Case-Control Studies. 
Szalai et al. (2005) sequenced 1156 nucleotides long promoter area of the CRP gene and 
identified two SNPs - one bi-allelic (-409A/G) and one three-allelic (-390C/T/A), which 
modulated basal CRP concentration in healthy individuals by influencing transcription 
factor binding. The results of „Framingham heart study“ in 1640 unrelated participants 
revealed in 9 from 13 studied SNPs a relationship with CRP level (Kathiresan et al., 2006). 
Knowing factors, which regulate plasma CRP levels, either basal or induced by infection or 
other inflammation, is very important also for the cardiovascular risk prediction. It was 
found that patients with homozygous +1444TT allele of CRP gene had significantly higher 
plasma CRP levels induced by inflammatory stimulus (D´Aiuto et al., 2005). This effect was 
independent from IL-6 concentration, IL-6 -174G/C SNP and conventional cardiovascular 
risk factors.  
The production of CRP is except of CRP gene regulated also by other genes coding for IL-6, 
IL-1 beta and IL-1Ra (Fishman et al., 1998; Kathiresan et al., 2006; Latkovskis et al., 2004; 
Szalai et al., 2005; Vickers et al., 2002). In 160 patients with angiographically confirmed 
coronary heart disease, the association of higher plasma CRP level with the presence of IL-
1B (+3954)T allele was found as well as a possible relationship between IL-1RN(VNTR)*2 
allele and lower CRP concentrations (Latkovskis et al., 2004). 
Acute coronary syndrome is associated with the activation of endothelial cells and systemic 
inflammation. It was found that genetic variations in the IL-1 locus influenced inflammatory 
processes – the IL-1RN*2 and the –511 alleles, respectively, contributed to changes in the 
plasma level of soluble markers of endothelial inflammation such as von Willebrand factor 
(vWF) and E-selectin (Ray et al., 2002). A correlation between higher plasma CRP level and 
presence of CD14 260TT homozygous allele was also found, which could be associated with 
the higher ability of macrophages to become activated and produce pro-inflammatory 
cytokines (Bernardo et al., 2006; Espliguero et al., 2005). 
Bucova et al. (2009a) found an association of MCP-1 -2518 A/G single nucleotide 
polymorphism with the serum level of CRP in Slovak patients with ischemic heart disease, 
angina pectoris, and hypertension.  
Additionally, a genome-wide association study has been performed among 6 345 apparently 
healthy women in whom 336 108 single nucleotide proteins were evaluated as potential 
determinants of plasma CRP concentration (Devaraj, 2010). Overall, seven loci that associate 
with plasma CRP levels were found. It was concluded that common variations in several 
genes involved in metabolic and inflammatory regulation have significant effects on CRP 
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levels, consistent with the identification of CRP as a useful biomarker of risk for incident 
vascular disease and diabetes. Two of these loci (GCKR and HNF1A) are suspected or 
known to be associated with maturity-onset diabetes of the young, one is a gene-desert 
region on 12q23.2, and the remaining four loci are in or near the leptin receptor protein 
gene, the apolipoprotein E gene, the IL-6 receptor protein gene, or the CRP gene itself. The 
protein products of six of these seven loci are directly involved in MetS, insulin resistance, 
β-cell function, weight homeostasis, and/or premature atherothrombosis.  
Thus, there is a possibility that individuals vary in their sensitivity to intercurrent low-grade 
acute-phase stimuli to which everybody is exposed, and that those who are higher “CRP 
responders” through genetic and/or acquired mechanisms, are also more susceptible to 
progression and complications of atherosclerosis (Dewald et al., 2005).  
Understanding the factors that directly or indirectly regulate the CRP release at baseline and 
during inflammation is very important in context of coronary risk prediction. More scientific 
groups studied CRP gene polymorphisms and found that basal levels of CRP both in 
patients and healthy controls are genetically determined and under repeated examination in 
healthy subjects relatively stable. Thus understanding the genetic background of CRP that 
regulate basal but also by infection or any type of inflammation induced concentration of 
CRP might contribute to stratification of healthy subjects to different groups with higher or 
lower degree of cardiovascular disease development (Cermakova et al., 2005; Pearson at al. 
2003; Szalai et al., 2002)   
5.2.2 Gene polymorphisms of MCP-1/CCL2 and CCR2 and the risk of cardiovascular 
disease development 
Pro-inflammatory cytokines and chemokines play an important role in the pathogenesis of 
heart diseases (Rothenbacher et al., 2006). Gene polymorphisms of chemokine MCP-
1/CCL2, a molecule that plays an important role in atherosclerosis, and its receptor CCR2 
belong to most studied one (Arakelyan et al., 2005; Bucova et al., 2008a; Petrkova et al. 2003). 
MCP-1/CCL2 is a potent chemoattractant for monocytes, T cells and NK cells. MCP-1 
induces the transmigration of CCR2+ monocytes from the circulation, promotes their 
differentiation to lipid-laden macrophages (Gerszten et al., 1999; Tabata  et al., 2003)  and  
contributes to the proliferation of arterial smooth muscle cells (Viedt et al., 2002)  which, 
along the macrophages, constitute the key cellular components of atherosclerotic plaques. 
This chemokine plays a dual role in myocardial ischaemia. In addition to several negative 
roles in the process of atherosclerosis, thrombotic occlusion of a coronary artery and in the 
process of reperfusion, this chemokine protects myocytes from hypoxia-induced cell death 
and has also positive effect in myocardial infarct healing (Dewald et al., 2005; Tarzami et al., 
2002, 2005). 
Polymorphism of MCP-1 and its receptor CCR2 have been implicated as susceptibility factor 
for chronic stable angina pectoris, ischemic heart disease and myocardial infarction by 
several independent investigators (Petrkova et al., 2003; Ortlepp et al., 2003), even in  
hypertensive ischemic heart disease assymptomatic patients (Penz et al., 2010). An 
association of CCR2 polymorphisms with the number of closed coronary artery vessels in 
coronary artery disease was also found (Cha SH et al., 2007). Deletion of MCP-1/CCL2 or 
CCR2 resulted in a large (50%-80%) reduction in atherosclerotic plaque size (Boring et 
al.,1998; Gu et al., 1999). However, the data on contribution of the MCP-1 polymorphisms to 
the pathogenesis of coronary atherosclerosis are not uniform. McDermott et al. found that 
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Several studies have reported individual single nucleotide polymorphisms (SNPs) to be 
associated with CRP levels and Risk of Incident Coronary Heart Disease in Two Nested 
Case-Control Studies. 
Szalai et al. (2005) sequenced 1156 nucleotides long promoter area of the CRP gene and 
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Acute coronary syndrome is associated with the activation of endothelial cells and systemic 
inflammation. It was found that genetic variations in the IL-1 locus influenced inflammatory 
processes – the IL-1RN*2 and the –511 alleles, respectively, contributed to changes in the 
plasma level of soluble markers of endothelial inflammation such as von Willebrand factor 
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levels, consistent with the identification of CRP as a useful biomarker of risk for incident 
vascular disease and diabetes. Two of these loci (GCKR and HNF1A) are suspected or 
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2003; Szalai et al., 2002)   
5.2.2 Gene polymorphisms of MCP-1/CCL2 and CCR2 and the risk of cardiovascular 
disease development 
Pro-inflammatory cytokines and chemokines play an important role in the pathogenesis of 
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2002, 2005). 
Polymorphism of MCP-1 and its receptor CCR2 have been implicated as susceptibility factor 
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several independent investigators (Petrkova et al., 2003; Ortlepp et al., 2003), even in  
hypertensive ischemic heart disease assymptomatic patients (Penz et al., 2010). An 
association of CCR2 polymorphisms with the number of closed coronary artery vessels in 
coronary artery disease was also found (Cha SH et al., 2007). Deletion of MCP-1/CCL2 or 
CCR2 resulted in a large (50%-80%) reduction in atherosclerotic plaque size (Boring et 
al.,1998; Gu et al., 1999). However, the data on contribution of the MCP-1 polymorphisms to 
the pathogenesis of coronary atherosclerosis are not uniform. McDermott et al. found that 





both myocardial infarction occurrence and higher MCP-1 plasma level. Increased MCP-1 
levels were associated with age, smoking, BMI and waist to hip ratio (Mc Dermott et al., 
2005). In other study, the plasma MCP-1 level was independently associated with the 
prognosis of patients with acute coronary syndrome (Deo et al., 2004). Higher levels of 
MCP-1 were associated with higher age, Caucasian race, early onset of coronary heart 
disease, smoking, hypertension, hypercholesterolemia and higher hsCRP levels (Deo et al., 
2004). Similar association was found in the group of patients with detected calcium in 
coronary arteries.  
It was found that CCR2 -/- mice show smaller area of infarction after ischemic-reperfusion 
injury, what correlated with decreased oxidative stress of their leucocytes (Hayasaki et al., 
2006). So it seems that CCL2/CCR2 axis plays an important role in post-ischemic and post-
reperfusion inflammation and could become a new therapeutic goal in selected 
cardiovascular diseases as well as in stroke in future. It is assumed that CCL2/CCR2 axis 
inhibition disrupts ischemic-reperfusion injury by decreasing edema, leucocyte infiltration 
and expression of inflammatory mediators (Dimitrijevic et al., 2007). However, the studies of 
Tarzami et al. showed that MCP-1/CCL2 played a dual role in myocardial ischemia – beside 
chemotaxis it also protected myocardial myocytes from hypoxia induced death (Tarzami et 
al., 2002, 2005). Nevertheless, there is a difference in the role of inflammation in acute and 
later stages of pathological process (Rosas 2007). 
Vascular inflammation plays a central role in atherosclerosis and inflammatory biomarkers, 
such as CRP, IL-6, MCP and sICAM predict risk of cardiovascular disease (Dupuis et al., 
2005). Thus finding genes that influence systemic levels of inflammatory biomarkers may 
provide insight into genetic determinants of vascular inflammation and cardiovascular 
disease.  
6. Conclusion 
Biomarkers of vascular inflammation have genetic, inflammatory and environmental 
determinants. Identifying genes influencing inflammation, environmental determinants, 
their interrelationships and early inflammatory biomarkers could help us to improve our 
understanding of pathophysiology and subsequently carefully consider eventual use of anti-
inflammatory agents. 
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1. Introduction 
Chest pain is a common problem in health care, especially due to its prevalence, the 
utilization of resources according to the cost of medical procedures, and diagnostic process 
difficulties. Precordial discomfort occurs in 13-30% of the adult population per year (Cayley, 
2005; Dickman & Fass, 2006; Eslick & Talley, 2004; Eslick et al., 2005; Eslick, 2008; Fass, 2008; 
Fass & Navarro-Rodriguez, 2008; Laird et al., 2004; Ruigómez et al., 2006, 2009), and in 20-
40% population during their lifetime (Ruigómez et al., 2006, 2009). About 1.5-5% of the 
general population seeks a primary care doctor consultation because of chest pain episodes 
(Cayley, 2005; Erhardt et al, 2002; Eslick, 2008; Fox, 2005; Sheps et al., 2004). Moreover, it is 
the cause of 634,000 per year cardiologist consultations in the US (Mant et al., 2004), 5% of 
visits to emergency departments in the UK, and 40% of non-surgical emergency admissions 
mainly due to acute coronary syndrome suspicion (Ruigómez et al., 2006). Among these 
patients, only in 15-40% was ischaemic heart disease (IHD) diagnosed on discharge and 
features of myocardial infarction presented in only 8-10% (Dickman & Fass, 2006; Liuzzo et 
al., 2005). The analysis by Hollander et al. (2007) has also shown that among patients 
admitted due to acute coronary syndrome suspicion, myocardial infarction was confirmed 
in only 4%. Moreover, it has been known for a number of years that about 10-36% of all 
patients who qualify for coronarography have a normal coronary angiogram (Dickman & 
Fass, 2006; Dobrzycki et al., 2005; Eslick et al., 2005; Eslick, 2008]. These data corroborate the 
most recent study by Patel et al. (2010), who conclude that the diagnostic yield of elective 
coronary angiography (about 20% of all procedures) amounted only to 38% (60% did not 
influence patients’ treatment), in spite of almost 70% of the patients undergoing elective 
coronary angiography having had positive findings on non-invasive examination (resting 
electrocardiography, echocardiography, computed tomography, or stress testing). They 
were also consistent with my recent work, which, among other things, has shown that 
exercise-provoked chest pain was accompanied by significant ST interval depression in 
about 60% of subjects with normal coronary angiogram, and 40% of subjects with significant 
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The above-mentioned data can be summarized as follows:  
 non-invasive diagnoses of chest pain and qualification for coronary angiography and 
percutaneous procedures are still not perfect;  
 the most frequent causes of this symptom do not originate in the cardiovascular system; 
and 
 symptom sources other than cardiac should be taken into account more frequently.  
On the other hand, these conclusions should not change the prevailing principle that each 
chest pain episode must be recognized as a potential alarm symptom; the exclusion of life-
threatening conditions, including ischaemic heart disease, should remain the basis of chest 
pain diagnostic procedures. For this reason, it seems a better solution even to overuse coronary 
angiograms or coronary artery calcification scores (CAC) using multi-slice computer 
tomography, than miss the detection of severely ill patients. However, it should also always be 
taken into consideration that invasive cardiological diagnostic procedures give the most 
benefits to patients with acute chest pain episodes, and in patients with recurrent symptoms, 
extracardiac sources ought to be more frequently considered (Patel et al., 2010).  
It is possible that changes in diagnostic algorithms of chest pain diagnosis and therapy not 
only decrease the prevalence of this symptom, but might also decrease the costs of health 
care. Such reductions would be considerable, as the medical procedures connected with 
chest pain symptoms utilize a noticeable part of health care resources. The annual cost of the 
medical care of patients with recurrent chest pain in the US ranges from $350 million to $1.8 
billion (Leise et al., 2010), and has even reached $3-8 billion (Eslick & Talley, 2004; Eslick et 
al., 2005; Eslick, 2008; Liuzzo et al., 2005; Mant et al., 2004). In the UK, it consumes 
approximately 1% of the health care budget (Fox, 2005). However, the real costs of recurrent 
chest pain are greater because of the social expenditure connected with this symptom (Eslick 
& Talley, 2004; Eslick et al., 2005; Eslick, 2008; Katerndahl, 2004). Within the one to five-year 
follow-up period, about 40% of patients with recurrent chest pain are hospitalized at least 
once due to chest pain, 30% receive a subsequent coronary angiogram (Bugiardini et al., 
2005), nearly 30% of patients are unemployed and receive a disability pension, and in 60% of 
individuals recurrent chest pain limits their physical activity, causing displeasure regarding 
physicians’ competence in 66-81% (Dickman & Fass, 2006).  
There may be a number of reasons for unsatisfactory data concerning the prevalence and 
treatment outcome in patients with recurrent chest pain. To counter this, the many well-
known causes of chest pain episodes ought to be analysed, as they have various degrees of 
clinical importance and may originate from cardiovascular system dysfunction (due to 
myocardial ischaemia or non-ischaemic reasons), the respiratory system, digestive tract, or 
begin in the skeleton (Cayley, 2005; Eslick & Talley, 2004; Eslick et al., 2005; Eslick, 2008; 
Laird et al., 2004). Symptoms deriving from each of these sources may be further aggravated 
by reactions of depression or panic disorders (Dickman & Fass, 2006; Fass, 2008; Fass & 
Navarro-Rodriguez, 2008). Moreover, the respective causes of chest pain may coexist and 
overlap (e.g. the cardiovascular with the gastroenterological or musculoskeletal), and 
disorders of one system may disturb the function of the others, masking the true cause of 
symptom evoking. These complicated relationships connected with chest pain make it 
difficult to diagnose and treat the chest pain source, favour symptom recurrence, and 
increase resource utilization. Precision in the analysis of symptom characteristics remains 
the pivotal diagnostic method of chest pain origin because of the aforementioned low 
diagnostic yield of non-invasive cardiovascular examinations and elective coronarography 
(Patel et al., 2010). In particular, the localization, radiation and character of chest pain 
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episodes should be evaluated, as well as any aggravating and alleviating factors (Potts & 
Bass, 1995; Swap & Nagurney, 2005). Angina pectoris is a particular type of chest pain. It is 
defined as precordial discomfort, sometimes radiating to the jaw or arm, which is provoked 
by effort, emotional stress, cold or wind, and withdraws after rest or nitroglycerine use. 
However, too many times it is forgotten that these criteria are applicable to chest pain 
episodes originating not only from the cardiovascular system, but also from the digestive 
tract, especially from the oesophagus, stomach and gall bladder. Moreover, angina pectoris 
may be caused by myocardial ischaemia, resulting not only from coronary artery narrowing, 
but also from extracardiac disorders, which leads to an imbalance between myocardial 
oxygen supply and requirement (e.g. anaemia, thyrotoxicosis). Anaemia is frequently 
secondary to many digestive tract diseases, such as acute and/or chronic bleeding from the 
alimentary tract (erosions, ulcers, neoplasm), malabsorption, maldigestion, blood 
sequestration or autoimmunological reactions. In this way, disorders of the digestive tract 
can also favour angina pectoris exacerbation. Therefore, although certain elements of the 
chest pain history are associated with increased (radiating to shoulder(s), or arms, or 
precipitation by exertion) or decreased (pain like stabbing, pleuritic, positional, or 
reproducible by palpation) likelihoods of a diagnosis of angina pectoris, none of them alone 
or in combination identify a group of patients, who do not need a further diagnostic testing 
(Swap & Nagurney, 2005). 
To summarize, angina pectoris is an important, prevalent symptom, utilizing enormous 
quantities of resources, which is considered all too frequently as a typical symptom of 
coronary artery disease (CAD), but rarely as a symptom of at least two types of digestive 
tract disease. The first group concerns diseases which evoke angina-like chest pain from the 
oesophagus, stomach and gall bladder by the stimulation of their chemo-, mechano-, and/or 
thermoreceptors; the second group manifests clinically as anaemia, which leads to 
insufficient oxygen supply to the heart. It is important to realize that both these kinds of 
digestive tract diseases may overlap with CAD, aggravating precordial symptoms or 
mimicking atherosclerosis progression. These gastroenterological aspects of angina pectoris 
will be analysed in this chapter in detail.  
2. Epidemiology 
Coronary artery disease (CAD) is the most frequent cause of morbidity and mortality in 
developed countries. As a result of such epidemiological data, almost each chest pain 
episode is considered as originating from the heart. However, recurrent, angina-like chest 
pain originating from e.g. the oesophagus is also a frequent problem in everyday practice, 
mainly due to the high prevalence of alimentary tract diseases in the general population. 
Recurrent chest pain which is non-cardiac in origin is defined as substernal chest pain in the 
absence of significant epicardial coronary artery stenoses (Eslick & Talley, 2004; Eslick et al., 
2005; Eslick, 2008; Dickman & Fass, 2006; Fass, 2008; Hebbard, 2010; Leise et al., 2010). It is 
reported every year by about 13-30% of adults, without sex preference. It is experienced 
during a typical lifespan by approximately 20-40% of the population, with a decrease in 
prevalence with increasing age (Eslick & Talley, 2004; Eslick et al., 2005; Eslick, 2008; 
Dickman & Fass, 2006; Fass, 2008; Ruigómez et al., 2006, 2009). The majority of patients with 
recurrent chest pain which is non-cardiac in origin continue to report episodes of long-term 
symptoms. In the study by Potts and Bass (1995), 75% of the surviving patients with 
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reported every year by about 13-30% of adults, without sex preference. It is experienced 
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recurrent chest pain which is non-cardiac in origin continue to report episodes of long-term 
symptoms. In the study by Potts and Bass (1995), 75% of the surviving patients with 





occurrence of precordial discomfort 11 years later, and 34% reported weekly chest pain 
symptoms.   
The most prevalent cause of non-cardiac chest pain (NCCP) is gastro-oesophageal reflux 
disease (GERD), which accounts for up to 60% of cases (Leise et al., 2010). The occurrence of 
its main symptom, heartburn, at least once per month is reported by about 36-44% of the 
adult population, 14% once per week, and 7% every day (Lemire, 1997). On the other hand, 
a chest pain sensation is experienced by about 37% of patients with heartburn occurring 
once per week, 30% of individuals with more seldom symptom occurrence, and about 8% 
without the feeling of pyrosis (Fass and Navarro-Rodriguez, 2008).  
It is generally estimated that gastroenterological abnormalities have a similar prevalence in 
patients both with and without significant coronary artery narrowing, which shows a 
possibility to overlap e.g. GERD and CAD symptoms (Budzyński et al., 2008; Budzyński 
2010a, 2010c; Cooke et al., 1998; Dobrzycki et al., 2005; Mehta et al., 1996; Ruigómez et al., 
2006, 2009; Schofield et al., 1987, 1989). Only a few authors have suggested a lower 
coexistence of oesophageal disorders in subjects with CAD (Adamek et al., 1999; Battaglia et 
al., 2005). On the other hand, the probability of diagnosing the respective functional 
oesophageal disorders (GERD, motility disorders, visceral hypersensitivity) as a cause of 
non-cardiac chest pain (NCCP) depends on the location of the patient’s consultation. They 
were the cause of non-cardiac chest pain (NCCP) in 0.6-25% of patients of general 
practitioners, in 46% of patients admitted to Cardiological Intensive Care Units because of 
acute chest pain, in 60-70% of patients with angina-like chest pain and a normal coronary 
angiogram, and in 30-80% of patients with obstructive coronary lesions and chronic precordial 
discomfort non-responsive to optimal anti-angina therapy (Budzyński et al., 2008; Dobrzycki 
et al., 2005; Rosztóczy et al., 2007; Świątkowski et al., 2004). Therefore, NCCP caused by 
gastrointestinal, mainly oesophageal, disorders may coexist with CAD in as many as 30-80% of 
patients. This is very high but clinically very important, as disease overlapping, which causes a 
great deal of confusion and clinical doubt, is related to at least three factors: the 
epidemiological, the pharmacological, and the pathophysiological (Budzyński et al., 2008).  
Epidemiological causes of the frequent coexistence of digestive and cardiovascular disorders 
result from a high prevalence of diseases sourced from both systems and have similar risk 
factors. Both gastroenterological and cardiovascular diseases are found more frequently in 
older and obese patients, those suffering from hypertension, diabetes, and obstructive sleep 
apnoea, as well as in smokers, alcohol drinkers and caffeine over-users (Budzyński et al., 
2008; Fass & Dickman, 2006;). The frequent coexistence of gastroenterological and 
cardiovascular diseases also depends on pharmacological causes due to the adverse effects 
of drugs recommended in the therapy for both system disorders. It is generally known that 
calcium channel antagonists (e.g. amlodipine, verapamil and diltiazem), nitrates, blockers of 
alpha-1 adrenergic receptors, and betamimetics may decrease with lower oesophageal 
sphincter (LOS) pressure and favour gastro-oesophageal reflux, the most frequent cause of 
NCCP. It should also be taken into consideration that aspirin-induced gastropathy is a 
potential cause of NCCP (Hsiao et al., 2009). Its symptoms frequently disappear after 
empirical therapy with proton pump inhibitors (PPIs), but this has not been confirmed by all 
authors. Moreover, some medicines used in the treatment of gastroenterological disorders 
may show pharmacological or pharmacodynamic interactions with drugs recommended for 
cardiovascular diseases, e.g. omeprazole decreases the bioavailability of digoxin, warfarin 
and clopidogrel. The last interaction in particular caught the investigator’s attention 
following publication by Juurlink et al. (2009), who reported a greater prevalence of acute 
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coronary syndromes and myocardial infarction in patients taking omeprazole, rabeprazole 
or lansoprazole for the purpose of preventing gastrointestinal bleeding during dual anti-
platelet therapy. Although recent publications have not confirmed the clinical importance of 
this interaction, their authors and panels of experts have recommended caution in co-
prescribing PPIs with clopidogrel (American College of Cardiology Foundation [ACCF], 
2010; American Society for Gastrointestinal Endoscopy [ASGE], 2009; Bhatt et al., 2008; de 
Aquino Lima & Brophy, 2010; Laine & Hennekens, 2010). There is also divergent 
information concerning the interaction between PPIs and acetylsalicylic acid, showing no 
effect (Adamopoulos et al., 2009), an increase (Kasprzak et al., 2009), and a decrease (Würtz 
et al., 2010) in anti-platelet aspirin activity.   
Finally, the high prevalence of the coexistence of cardiovascular and gastroenterological 
chest pain causes may also result from pathophysiological factors, mainly the inflammatory 
and neural pathways for linked angina (Chauhan et al., 1996; Hoff et al., 2010; Makk et al., 
2000; Rosztóczy et al., 2007). They are connected in the mechanism of a vicious circle, in 
which gastro-oesophageal reflux induces myocardial ischaemia, and products of the 
anaerobic myocardial metabolism due to ischaemia in turn provoke gastro-oesophageal 
reflux, dysphagia, or hiccups (Hoff et al., 2010; Krysiak et al., 2008; Stec et al., 2010). These 
problems are explained in detail in a separate subsection (4b).   
3. Prognosis  
Patients with recurrent chest pain and normal coronary angiogram (i.e. NCCP) have a 
relatively good life expectancy prognosis. The 30-day mortality connected with this 
symptom is estimated at 0.3-1.1% (Eslick & Talley, 2004; Eslick et al., 2005; Eslick, 2008), the 
risk of major cardiovascular event (death, myocardial infarction) with an odds ratio (OR) 
amounting to 2.3 (95% CI, 1.3-4.1) (Ruigómez et al., 2006, 2009), and the need for emergency 
coronary intervention amounting to approximately 4% (Hollander et al., 2007). However, in 
the recent study by Leise et al. (2010), patients with NCCP which is gastrointestinal in origin 
displayed less overall survival at all time points compared with their counterparts with 
NCCP of unknown origin, specifically 70.1% at 10 years and 51.8% at 20 years. This was 
mainly explained by the overlapping of cardiovascular risk factors in patients with GERD. 
Whereas, in the paper by Munk et al. (2008), the 10-year relative risk of hospitalization for 
ischaemic heart disease (a discharge diagnosis of myocardial infarction, angina and/or heart 
failure) following a normal upper endoscopy among 386 Danish patients with unexplained 
chest/epigastric pain was 1.6 (95% CI, 1.1–2.2), compared with 3,973 population controls. 
The adjusted mortality rate ratio was the greatest within the first year after an upper 
endoscopy and amounted to 2.4 (95% CI, 1.3–4.5). The difference faded with time, and the 
10-year adjusted mortality rate ratio amounted to 1.1 (95% CI, 0.9–1.5). The increased 
mortality among these patients stemmed from alcohol dependence, pneumonia (not as a 
complication of the endoscopy), and lung cancer, but not IHD.  
On the other hand, patients with recurrent chest pain have a poor prognosis in relation to 
symptoms receding. They also present a high annual rate (50-81%) of chest pain recurrence 
(Ruigómez et al., 2006, 2009). Unemployment connected with this symptom occurrence 
concerns 41-50% of patients (Eslick & Talley, 2004; Eslick et al., 2005; Eslick, 2008; Fass, 2008; 
Fass & Dickman, 2006; Fass & Navarro-Rodriguez, 2008).  
The aforementioned data justify undertaking the effort to establish the most precise 





occurrence of precordial discomfort 11 years later, and 34% reported weekly chest pain 
symptoms.   
The most prevalent cause of non-cardiac chest pain (NCCP) is gastro-oesophageal reflux 
disease (GERD), which accounts for up to 60% of cases (Leise et al., 2010). The occurrence of 
its main symptom, heartburn, at least once per month is reported by about 36-44% of the 
adult population, 14% once per week, and 7% every day (Lemire, 1997). On the other hand, 
a chest pain sensation is experienced by about 37% of patients with heartburn occurring 
once per week, 30% of individuals with more seldom symptom occurrence, and about 8% 
without the feeling of pyrosis (Fass and Navarro-Rodriguez, 2008).  
It is generally estimated that gastroenterological abnormalities have a similar prevalence in 
patients both with and without significant coronary artery narrowing, which shows a 
possibility to overlap e.g. GERD and CAD symptoms (Budzyński et al., 2008; Budzyński 
2010a, 2010c; Cooke et al., 1998; Dobrzycki et al., 2005; Mehta et al., 1996; Ruigómez et al., 
2006, 2009; Schofield et al., 1987, 1989). Only a few authors have suggested a lower 
coexistence of oesophageal disorders in subjects with CAD (Adamek et al., 1999; Battaglia et 
al., 2005). On the other hand, the probability of diagnosing the respective functional 
oesophageal disorders (GERD, motility disorders, visceral hypersensitivity) as a cause of 
non-cardiac chest pain (NCCP) depends on the location of the patient’s consultation. They 
were the cause of non-cardiac chest pain (NCCP) in 0.6-25% of patients of general 
practitioners, in 46% of patients admitted to Cardiological Intensive Care Units because of 
acute chest pain, in 60-70% of patients with angina-like chest pain and a normal coronary 
angiogram, and in 30-80% of patients with obstructive coronary lesions and chronic precordial 
discomfort non-responsive to optimal anti-angina therapy (Budzyński et al., 2008; Dobrzycki 
et al., 2005; Rosztóczy et al., 2007; Świątkowski et al., 2004). Therefore, NCCP caused by 
gastrointestinal, mainly oesophageal, disorders may coexist with CAD in as many as 30-80% of 
patients. This is very high but clinically very important, as disease overlapping, which causes a 
great deal of confusion and clinical doubt, is related to at least three factors: the 
epidemiological, the pharmacological, and the pathophysiological (Budzyński et al., 2008).  
Epidemiological causes of the frequent coexistence of digestive and cardiovascular disorders 
result from a high prevalence of diseases sourced from both systems and have similar risk 
factors. Both gastroenterological and cardiovascular diseases are found more frequently in 
older and obese patients, those suffering from hypertension, diabetes, and obstructive sleep 
apnoea, as well as in smokers, alcohol drinkers and caffeine over-users (Budzyński et al., 
2008; Fass & Dickman, 2006;). The frequent coexistence of gastroenterological and 
cardiovascular diseases also depends on pharmacological causes due to the adverse effects 
of drugs recommended in the therapy for both system disorders. It is generally known that 
calcium channel antagonists (e.g. amlodipine, verapamil and diltiazem), nitrates, blockers of 
alpha-1 adrenergic receptors, and betamimetics may decrease with lower oesophageal 
sphincter (LOS) pressure and favour gastro-oesophageal reflux, the most frequent cause of 
NCCP. It should also be taken into consideration that aspirin-induced gastropathy is a 
potential cause of NCCP (Hsiao et al., 2009). Its symptoms frequently disappear after 
empirical therapy with proton pump inhibitors (PPIs), but this has not been confirmed by all 
authors. Moreover, some medicines used in the treatment of gastroenterological disorders 
may show pharmacological or pharmacodynamic interactions with drugs recommended for 
cardiovascular diseases, e.g. omeprazole decreases the bioavailability of digoxin, warfarin 
and clopidogrel. The last interaction in particular caught the investigator’s attention 
following publication by Juurlink et al. (2009), who reported a greater prevalence of acute 
 
Angina-Like Chest Pain as a Symptom of Digestive Tract Disorders 
 
39 
coronary syndromes and myocardial infarction in patients taking omeprazole, rabeprazole 
or lansoprazole for the purpose of preventing gastrointestinal bleeding during dual anti-
platelet therapy. Although recent publications have not confirmed the clinical importance of 
this interaction, their authors and panels of experts have recommended caution in co-
prescribing PPIs with clopidogrel (American College of Cardiology Foundation [ACCF], 
2010; American Society for Gastrointestinal Endoscopy [ASGE], 2009; Bhatt et al., 2008; de 
Aquino Lima & Brophy, 2010; Laine & Hennekens, 2010). There is also divergent 
information concerning the interaction between PPIs and acetylsalicylic acid, showing no 
effect (Adamopoulos et al., 2009), an increase (Kasprzak et al., 2009), and a decrease (Würtz 
et al., 2010) in anti-platelet aspirin activity.   
Finally, the high prevalence of the coexistence of cardiovascular and gastroenterological 
chest pain causes may also result from pathophysiological factors, mainly the inflammatory 
and neural pathways for linked angina (Chauhan et al., 1996; Hoff et al., 2010; Makk et al., 
2000; Rosztóczy et al., 2007). They are connected in the mechanism of a vicious circle, in 
which gastro-oesophageal reflux induces myocardial ischaemia, and products of the 
anaerobic myocardial metabolism due to ischaemia in turn provoke gastro-oesophageal 
reflux, dysphagia, or hiccups (Hoff et al., 2010; Krysiak et al., 2008; Stec et al., 2010). These 
problems are explained in detail in a separate subsection (4b).   
3. Prognosis  
Patients with recurrent chest pain and normal coronary angiogram (i.e. NCCP) have a 
relatively good life expectancy prognosis. The 30-day mortality connected with this 
symptom is estimated at 0.3-1.1% (Eslick & Talley, 2004; Eslick et al., 2005; Eslick, 2008), the 
risk of major cardiovascular event (death, myocardial infarction) with an odds ratio (OR) 
amounting to 2.3 (95% CI, 1.3-4.1) (Ruigómez et al., 2006, 2009), and the need for emergency 
coronary intervention amounting to approximately 4% (Hollander et al., 2007). However, in 
the recent study by Leise et al. (2010), patients with NCCP which is gastrointestinal in origin 
displayed less overall survival at all time points compared with their counterparts with 
NCCP of unknown origin, specifically 70.1% at 10 years and 51.8% at 20 years. This was 
mainly explained by the overlapping of cardiovascular risk factors in patients with GERD. 
Whereas, in the paper by Munk et al. (2008), the 10-year relative risk of hospitalization for 
ischaemic heart disease (a discharge diagnosis of myocardial infarction, angina and/or heart 
failure) following a normal upper endoscopy among 386 Danish patients with unexplained 
chest/epigastric pain was 1.6 (95% CI, 1.1–2.2), compared with 3,973 population controls. 
The adjusted mortality rate ratio was the greatest within the first year after an upper 
endoscopy and amounted to 2.4 (95% CI, 1.3–4.5). The difference faded with time, and the 
10-year adjusted mortality rate ratio amounted to 1.1 (95% CI, 0.9–1.5). The increased 
mortality among these patients stemmed from alcohol dependence, pneumonia (not as a 
complication of the endoscopy), and lung cancer, but not IHD.  
On the other hand, patients with recurrent chest pain have a poor prognosis in relation to 
symptoms receding. They also present a high annual rate (50-81%) of chest pain recurrence 
(Ruigómez et al., 2006, 2009). Unemployment connected with this symptom occurrence 
concerns 41-50% of patients (Eslick & Talley, 2004; Eslick et al., 2005; Eslick, 2008; Fass, 2008; 
Fass & Dickman, 2006; Fass & Navarro-Rodriguez, 2008).  
The aforementioned data justify undertaking the effort to establish the most precise 





the patient by explaining some of the non-dangerous reasons for chest pain occurrence. 
Moreover, the diagnosis of the real source of distressing complaints makes possible a 
specific treatment recommendation. It is effective in different degrees in about 80% of 
patients, decreasing NCCP episode recurrence and hospitalization necessity, improving 
patients’ health-related quality of life, and reducing the health care costs (Cheung et al., 
2009; Dickman & Fass, 2006; Fass, 2008; Fass & Dickman, 2006; Fass & Navarro-Rodriguez, 
2008; Laheij et al., 2003; Sheps et al., 2004). The diagnosis of GERD as a source of NCCP and 
the recommendation of the prolonged use of PPIs has decreased the risk of chest pain 
recurrence by 46% and the number of patients needing to be treated (NNT) has amounted to 
3 (95%CI, 2-4) (Cremonini et al., 2005). Whereas, undiagnosed chest pain has been shown to 
increase the risk of hospitalization due to CAD and all-cause mortality during 10 years of 
follow-up (Munk et al., 2008).  
4. Pathophysiology    
As has been mentioned, angina-like chest pain presents typical features of visceral pain 
which may be symptomatic of both ischaemic heart diseases and digestive tract disorders. 
To the first group of diseases belong both patients with coronary artery narrowing, known 
as patients with CAD, and subjects with a normal or almost normal coronary artery 
angiogram (“non-visible”, “non-obstructive atherosclerotic coronary disease” (Bataglia et 
al., 2005). Chest pain occurring in patients with a normal coronary angiogram is frequently 
called NCCP. It may be caused by extracardiac diseases, mainly digestive tract disorders 
(Labenz, 2010). However, it should also be taken into account that it may also be sourced by 
missed coronary angiogram lesions, microvascular coronary dysfunction (cardiac syndrome 
X), coronary spasm, or secondary angina (e.g. aortic valve dysfunction, tachycardia, 
thyrotoxicosis, anaemia) (Bugiardini et al., 2005).  
The relationships between the digestive tract and cardiovascular system are complicated 
and stem from epidemiological, pharmacological (described above) and pathophysiological 
factors. Each of them concerns both patients with a normal coronary angiogram and with 
CAD, and may lead to symptom mimicry and overlapping. There are at least three 
pathomechanisms evoking angina-like chest pain in the course of digestive tract diseases:  
a. chest pain is evoked by stimulation of digestive tract pain receptors and mimics angina;  
b. digestive tract diseases via neural and inflammatory pathways disturb myocardial 
perfusion and evoke chest pain which is cardiac in origin due to myocardial ischaemia, 
although the true cause of the symptoms is located e.g. in the oesophagus;  
c. chest pain, cardiac in origin, is secondary to an imbalance between oxygen supply and 
myocardial demand due to anaemia, which is frequently secondary to various diseases 
of the alimentary tract.   
4.1 Angina-like chest pain which is digestive tract in origin 
The most common example of the first pathophysiological group of chest pain is GERD, 
responsible for 50-60% of the causes of NCCP (Dickman &  Fass, 2006; Eslick & Talley, 2004; 
Eslick et al., 2005; Eslick, 2008; Fass & Dickman, 2006; Fass & Navarro-Rodriguez, 2008; 
Hebbard, 2010; Tipnis et al., 2007; Tougas et al., 2001). The main symptoms of GERD are 
heartburn (pyrosis), regurgitation, or the “reflux chest pain syndrome” distinguished by the 
 
Angina-Like Chest Pain as a Symptom of Digestive Tract Disorders 
 
41 
definition and classification of GERD developed by the Montreal Consensus Group in 2006 
(Vakil et al., 2006). The other diseases which may mimic angina pectoris, frequently known 
as non-GERD-related NCCP, are as follows: oesophagitis caused by non-reflux-related 
factors (such as infections or being drug induced); oesophageal motility disorders; hiatal 
hernia; gastric and duodenal ulcer disease; drug- (aspirin, non-steroidal anti-inflammatory 
drugs) induced gastropathy; acquired hepato-diaphragmatic migration of the hepatic 
flexure of the colon (Chilaiditi's syndrome); cholecystitis; and acute pancreatitis (Dickman & 
Fass, 2006; Drewes et al., 2006; Eslick & Talley, 2004; Eslick et al., 2005; Eslick, 2008; Fass & 
Dickman, 2006; Fass & Navarro-Rodriguez, 2008; Ruigómez et al., 2006, 2009, , Sorrentino et 
al., 2005). The Rome Criteria III also distinguish a particular kind of non-cardiac chest pain, 
called “functional chest pain of presumed esophageal origin”, which is defined as midline 
discomfort which is not of burning quality, lasting at least three months, with an onset at least 
six months prior to diagnosis, and an absence of GERD and histopathology-based oesophageal 
motility disorders (Drossman, 2006). My own observations have also shown that exercise-
induced oesophageal motility disorders, such as exercise-provoked oesophageal spasm 
(EPOS) or exercise-provoked gastro-oesophageal acid reflux, may play some role in the 
pathogenesis of angina-like chest pain in at least 22% of patients with recurrent symptoms 
(Budzyński, 2010a, 2010b). It is worth underlining that nearly 80% of the patients with 
functional chest pain simultaneously present symptoms of other functional disorders, 
primarily irritable bowel syndrome (27%) and abdominal bloating (22%) (Dickman & Fass, 
2006; Fass & Navarro-Rodriguez, 2008). Their coexistence with chest pain may help in 
appropriate diagnoses. The aforementioned mainly oesophageal and gastric abnormalities 
may be accompanied by endoscopically visible morphological changes in mucosa or not. Some 
of these differences in the clinical course of GERD have been classified by the Global 
Consensus Group in Montreal, which, among oesophageal syndromes, enumerates: (a) 
symptomatic syndromes (without oesophageal erosions) concerning approximately 60% of 
patients, and (b) syndromes with oesophageal injury (erosive oesophagitis, oesophageal 
strictures, Barrett’s oesophagus, oesophageal adenocarcinoma) (Sarkar et al., 2004; Vakil et al., 
2006). In this way, oesophageal erosions are present in 10-70% of patients with NCCP (Fass 
and Navarro-Rodriguez, 2008); therefore, a lack of endoscopic abnormalities does not exclude 
both a GERD and an oesophageal origin of NCCP.  
The above-mentioned diseases of the oesophagus, stomach, colon, pancreas or gall bladder 
evoke angina-like chest pain by the activation of local pain receptors, both chemical and 
mechanical (e.g. ASIC, TRPV, P2X and TREK), by inflammatory mediators, kinins, pepsin, 
bile acids, changes in oesophageal pH, pressure (oesophageal distension, volume, shear 
stress), or temperature, and by the induction of a secondary local motility response, 
expressed by hypermotility, oesophageal long muscle shortening, high amplitude 
oesophageal peristalsis, oesophageal distension or prolonged oesophageal contractions 
(Drewes et al., 2006; Sifrim et al., 2007; Tipnis et al., 2007). However, the intensity of the 
clinical manifestation of these disorders is related to the threshold of receptor stimulation. 
Its decrease is frequently known as visceral hypersensitivity (Dickman & Fass, 2006; Drewes 
et al., 2006; Eslick & Talley, 2004; Eslick et al., 2005; Eslick, 2008; Fass & Dickman, 2006; Fass 
& Navarro-Rodriguez, 2008). It is enumerated as one of the main pathomechanisms of 
symptoms in the course of cardiac syndrome X, mitral prolapse syndrome, irritable 
oesophagus, functional dyspepsia, irritable bowel syndrome (IBS), and fibromyalgia 
(Katerndahl, 2004; Hammet et al., 2003; North et al., 2007). The recently published 
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oesophageal hypersensitivity plays an important role in 75% of patients with functional 
(non-cardiac and non-reflux) chest pain. The basis of this disorder is a decrease in the pain 
threshold, both at the central and peripheral perception levels (Dickman & Fass, 2006; Fass 
& Dickman, 2006; Sheps et al., 2004; Sifrim et al., 2007). The range of the change in this 
threshold may be modulated by a number of factors influencing the function of the brain-
gut axis (Mayer & Tillisch, 2011; Sheps et al., 2004). These factors are as follows:  
 personal (female gender, age between 15-34, incorrect response of the autonomic 
nervous system, psychiatric disorders, stress, sleep disturbances, oesophagitis or 
gastritis, mucosal mastocyte infiltration, allodynia); 
 environmental (stress, Helicobacter pylori (Hp) infection, dietary factors, especially a fatty 
diet) (Remes-Troche, 2010; Sheps et al., 2004; Sifrim et al., 2007; Tougas et al., 2001).  
The modulation of the central pain threshold in patients with unexplained chest pain, CAD 
and occult GERD may also be related to chronic receptor stimulation and/or the coexistence of 
psychiatric disorder (Drewes et al., 2006; Lenfant, 2010; Remes-Troche, 2010). Sarkar et al. 
(2004) have reported a decrease in allodynia after therapy with PPIs. Whereas, Makk et al. 
(2000) have shown a greater oesophageal acid sensitivity (a lower pain threshold) in 
individuals with a normal coronary angiogram and patients undergoing coronary angioplasty 
than in those with coronary artery narrowing and undergoing coronary angiography alone. 
Moreover, in approximately 70% of patients with NCCP, anxiety, depression or somatization 
have been observed (Dickman & Fass, 2006; Eslick & Talley, 2004; Eslick et al., 2005; Eslick, 
2008; Fass & Dickman, 2006; Fass & Navarro- Rodriguez, 2008; Katerndahl, 2004). In these 
subjects, NCCP amelioration and a decrease in pain hypersensitivity were found after therapy 
with antidepressants such as imipramine, sertraline or trazodone in controlled and 
uncontrolled investigations (Dickman & Fass, 2006; Eslick & Talley, 2004; Eslick et al., 2005; 
Eslick, 2008; Fass & Dickman, 2006; Fass & Navarro-Rodriguez, 2008). Psychiatric disorders, 
besides decreasing the pain threshold, may also evoke chest pain by hyperventilation and 
secondary coronary arteries and/or oesophageal spasm (Chauhan et al., 1996). As a result, the 
following markers of a psychiatric basis for recurrent chest pain were proposed: atypical 
character of symptoms, female gender, younger age, a high level of anxiety, and a neurotic 
personality (Ringstrom and Freedman, 2006).  
The character of the pain occurring in the course of digestive tract diseases may be similar to 
that of acute coronary syndrome or recurrent stable angina pectoris. The simple explanation 
of this fact involves the visceral features of the pain and the anatomical localization of the 
heart and oesophagus in the chest. The latter factor causes the overlap of the head areas in 
brain sensory representations of the oesophagus and heart. However, the anatomical 
relationships between the oesophagus and the heart may produce symptoms in some more 
immediate way. Namely, the extended left atrium, due to e.g. mitral valve disease or left 
ventricle cardiac failure, may press the oesophagus, evoking changes in intra-oesophageal 
pressure, mechanical receptor stimulation or disturbance in the oesophageal passage, 
known as cardiac dysphagia or odynophagia (angina-like chest pain which is oesophageal 
in origin). These disorders may also, through pressure receptor stimulation, activate vagal 
neural reflexes leading to a decrease in myocardial perfusion (angina-like chest pain which 
is cardiac in origin), described in detail in part b of this section. On the other hand, an 
enlarged oesophagus, due to e.g. achalasia or oesophageal carcinoma, producing left atrium 
compression, may also evoke local ischaemia of the atrial muscle and/or activation of 
mechano-electrical coupling, raising the local dispersion in the functional potential of atrial 
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muscle cells and producing re-entry loops. These disorders may manifest clinically as chest 
pain or arrhythmia (Budzyński & Pulkowski, 2009; Duygu et al., 2008; Upile et al., 2006).  
To summarize, chest pain originating from the oesophagus may be similar to cardiac-
derived angina pectoris. It may be caused by activation receptors in the digestive tract and 
motor dysfunction of the oesophageal wall. The intensity of the clinical manifestation of 
these disturbances is modulated by the frequent presence of visceral hypersensitivity. These 
complicated relationships have explained the confusion and misdiagnosis often 
accompanying chest pain diagnosis.  
4.2 Angina-like chest pain which is cardiac in origin but induced by digestive tract 
disorders  
Apart from the above-mentioned resemblance of chest pain originating from the heart and 
the oesophagus, as well as the overlapping of symptoms evoked both by cardiovascular and 
alimentary tract diseases, the clinical doubts concerning the true source of chest pain, 
whether cardiac or oesophageal, are augmented by the second of the distinguishing 
pathomechanisms of chest pain caused by diseases of the digestive tract: the activation of 
neural and inflammatory pathways which in turn may decrease myocardial perfusion.  
Neural reflex loops between the heart and oesophagus have been found both in human and 
animals. Stimulation of oesophageal chemo-, mechano- and thermoreceptors, apart from 
provoking chest pain of oesophageal origin in about half (49-56%) of patients with a normal 
coronary angiogram (cardiac syndrome X), coronary artery spasm or obturative lesions in 
coronarography (patients with CAD), may also activate vagally-mediated, viscero-visceral 
neural reflexes (e.g.  cardio-oesophageal reflex) (Budzyński et al., 2008; Budzyński, 2010c; 
Charng et al., 1988; Chauhan et al., 1996; Dobrzycki et al., 2005; Drewes et al., 2006; Fass & 
Dickman, 2006; Makk et al., 2000; Manfrini et al., 2006; Rasmussen et al., 1986; Rosztóczy et 
al., 2007) or a viscero-somatic neural reflex (Drewes et al., 2006; Jou et al., 2002). The first 
reflex may evoke ischaemic chest pain, cardiac in origin, resulting from diminished 
myocardial perfusion and secondary to pre-arteriole contraction (Chauhan et al., 1996; Makk 
et al., 2000; Rosztóczy et al., 2007); the second, viscero-somatic reflex, causes an increase in 
the spinotrapezius muscle contractions both after cardiac and oesophageal receptor 
stimulation via convergent pathways in the sympathetic nerves (Jou et al., 2002). The last 
reflex is responsible for the somatic component of pain evoked by the stimulation of 
visceral, cardiac or oesophageal receptors. Moreover, afferent stimulus originating from the 
oesophagus, stomach or gall bladder may also interfere with stimulus derived from the 
heart in the spinal cord, which is a further cause of the resemblance of symptoms deriving 
both from the digestive tract and the cardiovascular system (Sheps et al., 2004).  
However, the aforementioned reflexes (neural loops) do not function in all subjects but only 
in about half  (Chauhan et al., 1996; Makk et al., 2000; Mehta et al., 1996; Rosztóczy et al., 
2007); this results from the modulation of the impulse transmission along nervous pathways 
by coexistent mental or psychiatric disorders, the balance between the sympathetic and 
parasympathetic parts of the autonomic nervous system and the threshold of receptor 
stimulation, which is decreased in patients with visceral hypersensitivity. These suggestions 
are supported by papers showing a relatively high prevalence of panic or depressive 
disorders in approximately half of patients, with both cardiovascular and digestive tract 
diseases (Lenfant, 2010). Autonomic nervous system imbalance has also been found in up to 
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pylori infection (Budzyński et al., 2004), functional dyspepsia, irritable bowel syndrome 
(Mayer & Tillisch, 2011), or chronic heart failure. Modulation of visceral reflex activity by 
these cofactors may cause the activity of cardio-oesophageal reflexes not to manifest 
clinically in all subjects. Dobrzycki et al. (2005) have suggested that those most susceptible to 
the clinically important effect of cardio-oesophageal reflex activity seem to be patients with 
CAD, because in this patient group even slight coronary reserve impairment may be 
clinically important. On the other hand, Rosztóczy et al. (2007), using a combination of an 
oesophageal acid perfusion test and transoesophageal Doppler echocardiographic coronary 
flow measurement, have shown that 49% of subjects presented coronary spasm in response 
to oesophageal acidification more frequently than either epicardial coronary artery disease 
or microvascular coronary disease, probably due to signs of cardio-oesophageal reflex 
activation. In the gastroenterological work-up, they had higher DeMeester scores, an 
increased number of reflux episodes, a fraction time below pH 4, and prolonged acid reflux 
episodes. These data corroborate the paper by Sarkar et al. (2004), who observed the 
reversible influence of chronic oesophageal mucosa exposure to acid on the visceral pain 
threshold, one of the mechanisms modulating visceral, vagally-mediated reflex activity. The 
importance of the role of the parasympathetic nervous system for subjects with NCCP has 
also been shown by Tougas et al. (2001). In their study, 67% of patients with a normal 
coronary angiogram presented angina-like chest pain after oesophageal acid infusion. Chest 
pain in “acid-sensitive patients” was accompanied by a higher baseline heart rate and lower 
baseline vagal activity (estimated using heart rate variability [HRV] analysis) than “acid-
insensitive patients”. During acid infusion, vagal cardiac outflow (expressed as a high 
frequency component of HRV) increased in “acid-sensitive” but not in “acid-insensitive” 
patients (Tougas et al., 2001). 
The endpoint of the aforementioned complicated influence of the nervous system on the 
interrelationships between the cardiovascular and alimentary systems is myocardial 
ischaemia, which may manifest clinically in 49-56% of patients as angina pectoris, 
arrhythmia and syncope (Chauhan et al., 1996; Cubattoli et al., 2009; Cuomo et al., 2006; 
Makk et al., 2000; Mehta et al., 1996; Rosztóczy et al., 2007). This symptomatic decrease in 
myocardial perfusion after oesophageal stimulation by acid was produced by epicardial 
coronary artery spasm (Rosztóczy et al., 2007) or by contraction of the prearterioles 
(Chauhan et al., 1996). The neural pathway for these effects (so- called linked angina) was 
proven by the lack of similar perfusion changes in heart transplant recipients (Chauhan et 
al., 1996). However, the aforementioned reflexive decrease in myocardial perfusion was 
accompanied by ischaemic electrocardiographic (ECG) changes in only a few works 
(Budzyński et al., 2008; Dobrzycki et al., 2005; Rosztóczy et al., 2007; Singh et al., 1992; 
Świątkowski et al., 2004).  
However, the above-described mechanism is only the first on the arc of the cardio-
oesophageal loop of feedback. The second, opposite arm of this loop may be stimulated by 
the products of anaerobic myocardial metabolism, mainly bradykinin (Caldwell et al., 1994; 
Krysiak et al., 2008), invasive cardiac manoeuvres, manipulation, coronary angioplasty 
(Makk et al., 2000) or cardiac arrhythmia (Stec et al., 2010). Such activation may lead to 
reflexive oesophageal motility disorders or a decrease in lower oesophageal sphincter (LOS) 
pressure, which facilitates gastro-oesophageal reflux occurrence, changes in oesophageal 
pH, potential reflexive activation of a cardio-oesophageal reflex and a reduction in 
myocardial perfusion (Caldwell et al., 1994). Described as reflexive, bidirectional, neuro-
hormonal mechanisms connect the pathogenesis of the digestive tract and cardiovascular 
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diseases in a vicious circle. Moreover, some studies have shown that the described 
associations between oesophageal and vascular spasm may also result from myogenic 
mechanisms and may be an overall effect of smooth muscle hypercontractility, depending 
on the individual concerned (Adamek et al., 1998a, 1998b, 1999; Makk et al., 2000; Manfrini 
et al., 2006; Rasmussen et al., 1986). The myogenic component of coronary-oesophageal 
interrelationships has been suggested by the coexistence of oesophageal spasm alongside 
coronary artery spasm, hypertension, migraine and Raynaud’s symptoms.   
The occurrence of angina-like chest pain, as well as other cardiac symptoms such as 
arrhythmia, or syncope may also be secondary to inflammatory factors often deriving from 
the digestive tract. The role of inflammatory processes in cardiovascular disease 
pathogenesis has been investigated for many years. At least two mechanisms have been 
distinguished for the influence of inflammation on cardiac function: local and systemic. The 
first has been mentioned by Weigl et al. (2003), who have suggested the possibility of local 
inflammatory process propagation through the oesophageal wall producing local 
pericarditis or atrial myocarditis. These histological abnormalities can be a substrate of chest 
pain or arrhythmia (Navarese et al., 2010; Stőlberger & Finsterer, 2003). However, there is 
more to be said for the role of a systemic inflammatory response in the pathogenesis of chest 
pain which is cardiac in origin but evoked or intensified by digestive tract diseases. Systemic 
inflammatory factors known as cytokines (e.g. TNF-alpha, IL-1, IL-6) or adhesion molecules 
(e.g. VCAM-1, ICAM-1) are involved in the pathogenesis of atherosclerosis, endothelial 
dysfunction, and cardiac arrhythmia, mainly atrial fibrillation. Their synthesis may be 
stimulated in the course of many of the diseases of the alimentary tract, such as periodontal 
diseases, oesophagitis, gastritis, ileitis, inflammatory bowel diseases, liver cirrhosis, 
pancreatitis, and neoplasm (Shanker & Kakkar, 2009; Stőlberger & Finsterer, 2003). Some 
reports, including my own data, have also shown the unfavourable effect of Helicobacter 
pylori infection, not only on the course of digestive tract diseases, but also on the course of 
recurrent angina-like chest pain (Budzyński, 2011), changes in autonomic nervous system 
balance (Budzyński et al., 2004) and atherosclerosis progression (Franceschi et al., 2009). 
CagA seropositivity has been significantly and positively associated with the occurrence of 
acute coronary events, atherosclerosis progression and arrhythmia prevalence (Bunch et al., 
2008a, 2008b; Francesci et al., 2009; Miyazaki et al., 2006). The positive relationship between 
Hp infection and cardiac syndrome X (Celik et al., 2010; Eskandarian et al., 2006; Rasmi & 
Raeisi, 2009) has also been reported but not confirmed by others (Saleh et al., 2005). 
Whereas, Sandifer et al. (1996), based on the results of the EUROGAST Study Group, had 
shown a negative association between the seroprevalence of antibodies to Hp and the death 
rate from ischaemic heart disease.  
Numerous mechanisms for the influence of Hp on atherosclerosis complications have been 
suggested. They may act directly on atherosclerotic plaques, as suggested by the results of 
Kowalski et al. (2001), who revealed the presence of Hp DNA in atherosclerotic lesions and 
an increase in coronary artery diameter after microorganism eradication. It has also been 
implied that mimicry occurs between the cytotoxin-associated gene-A (CagA) antigen 
expressed by some Hp strains and the protein presented in atherosclerotic plaques 
(Franceschi et al., 2009). Hp infection, similarly to periodontal infection (Shanker & Kakkar, 
2009) or the hepatitis C virus (Ramdeen et al., 2008), may also act as one amongst a number 
of factors taking part in the mechanisms of pathogen burden through the following: non-
specific inflammatory pathway stimulation (e.g. hs-CRP increase); the induction of 
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shown a negative association between the seroprevalence of antibodies to Hp and the death 
rate from ischaemic heart disease.  
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suggested. They may act directly on atherosclerotic plaques, as suggested by the results of 
Kowalski et al. (2001), who revealed the presence of Hp DNA in atherosclerotic lesions and 
an increase in coronary artery diameter after microorganism eradication. It has also been 
implied that mimicry occurs between the cytotoxin-associated gene-A (CagA) antigen 
expressed by some Hp strains and the protein presented in atherosclerotic plaques 
(Franceschi et al., 2009). Hp infection, similarly to periodontal infection (Shanker & Kakkar, 
2009) or the hepatitis C virus (Ramdeen et al., 2008), may also act as one amongst a number 
of factors taking part in the mechanisms of pathogen burden through the following: non-
specific inflammatory pathway stimulation (e.g. hs-CRP increase); the induction of 





(e.g. VCAM-1, ICAM-1); the over-synthesis of pro-atherogenic cytokines (e.g. IL-1 beta, IL-6, 
TNF-alpha); changes in autonomic nervous system balance (Budzyński et al., 2004; 
Budzyński, 2011; Celik et al., 2010; Rasmi & Raeisi, 2009); and the production of metabolic 
abnormalities, such as hypertriglyceridaemia, increased LDL cholesterol levels, plasma lipid 
oxidation, hyperfibrinogenaemia, altered blood coagulation and leukocytosis. The role of 
Hp infection as a cause of myocarditis and ECG changes in patients with persistent chest 
pain has also been reported (Navarese et al., 2010). Apart from the aforementioned 
mechanisms, Hp infection may also affect the occurrence of angina-like chest pain which is 
gastroenterological in origin, being one of the pathogenic factors of gastritis, gastric and 
duodenal ulcer disease. Hp infection may also play a role in GERD pathogenesis via 
impaired vagal control of LOS pressure and a decrease in the release of ghrelin, a prokinetic 
hormone (Thor & Blaut, 2006).  
The described systemic inflammatory process mediators, e.g. deriving from the digestive 
tract, could influence cardiac symptom occurrence, not only by direct action on the vascular 
wall, but also via neuroimmune- endocrine crosstalk (Collins et al., 2009; Grundy et al., 2006; 
Marques et al., 2010; Wood, 2007). Inflammation mediators, especially cytokines such as 
TNF-alpha, interleukin-1 and interleukin-6, may stimulate both the hypothalamus and brain 
stem. The outcome of the first is the activation of the pituitary-suprarenal axis, which leads 
to increased cortisol and adrenalin secretion, and of the second is sympathetic activation. 
The consequence of such neuroendocrine stimulation may be chest pain, myocardial 
infarction, arrhythmia, sudden death or an increase in intestinal permeability due to 
digestive tract ischaemia. Its effect may in turn be an increase in cytokine secretion and the 
activation of immunological cells: lymphocytes, monocytes, macrophages and granulocytes 
possessing surface receptors for a number of neuroendocrine products. These can then 
stimulate vessel walls, induce endothelial dysfunction, atherosclerotic plaque instability and 
in turn produce neuroendocrine imbalance (Marques et al., 2010; Saleh et al., 2005). In this 
way, the aforementioned relationships involve the cardiological and gastroenterological 
symptoms in the second neuroimmune-endocrine vicious circle mechanism.  
In summary, neural loops, inflammatory processes and neuroimmune-endocrine crosstalk 
activated by digestive tract disorders may be the second group, in addition to digestive tract 
abnormalities, of important factors evoking chest pain which is cardiac in origin. It may 
result from myocarditis and/or a progression or reversible reduction in myocardial 
perfusion. These processes may play a role in patients both with and without significant 
coronary artery narrowing.  
4.3 Angina-like chest pain which is cardiac in origin but secondary to anaemia caused 
by diseases of the alimentary tract  
The main cause of ischaemic heart disease and its typical symptom of angina pectoris is an 
imbalance between coronary blood supply and myocardial requirement. This shows that 
besides a decrease in blood delivery to the myocardium, angina-like chest pain may also be 
evoked or exacerbated by inadequate oxygen supply due to anaemia. Rapidly or slowly 
progressing anaemia may be a symptom of many digestive tract diseases, both of the upper 
and lower parts. It may be an effect of bleeding, malabsorption, maldigestion, blood 
sequestration or autoimmunological reactions (Zhu et al., 2010). For this reason, diagnostic 
procedures for the digestive tract, including biochemical and serological examinations, 
ultrasonography, panendoscopy, colonoscopy, and in special cases capsule endoscopy and 
single or double balloon enteroscopy, should be recommended for each male, 
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postmenopausal women, and younger females when the quantity of blood loss during 
menstruation is insufficient to explain the presence of anaemia (Zhu et al., 2010).  
However, both cardiologists and gastroenterologists should also take into account that acute 
bleeding into the digestive tract or slowly progressing iron deficiency anaemia may also be a 
symptom of the haemorrhagic complications of the anti-thrombotic therapy (e.g. aspirin, 
clopidogrel, heparin, bivalirudin, etc.) which is fundamental in the treatment of acute 
coronary syndromes and stable angina pectoris (Dai et al., 2009; Nema et al., 2008). Of these 
complications, 50% occur in the digestive tract (To et al., 2009). Prior to endoscopic 
procedures, especially with a high risk of haemorrhagic complications (e.g. polypectomy or 
mucosal resection), the risk of the discontinuation of dual anti-platelet therapy in particular 
should be estimated (ASGE, 2009; ACCF, 2010; Bhatt et al., 2008). This is very important, as 
clopidogrel withdrawal may lead to cardiac stent thrombosis in 15-40% of cases; it is 
associated with a myocardial infarct rate of 50% and a related death rate of approximately 
20% (ASGE, 2009). Therefore, in such clinical situations, consultation between cardiologist 
and gastroenterologist is needed to avoid patients being treated from a single organ 
perspective of the relative risks (cardiology vs. gastrointestinal) but with a more global 
balanced risk assessment instead to optimize patient outcomes.  
The above deliberation shows the need for accuracy in evaluating angina pectoris symptom 
pathomechanisms (primary or secondary) to avoid the iatrogenic, clinically overt or silent 
haemorrhagic complications of anti-thrombotic drugs. Misdiagnosis or the inadequate 
taking of a medical history may lead to anaemia occurrence or aggravation, an increase in 
chest pain severity, unnecessary coronary angiogram performance, or death during 
haemorrhagic shock. One potential clinical scenario may take the following course: angina 
pectoris (stable or acute coronary syndrome) + latent digestive tract disease  treatment 
with aspirin and clopidogrel and/or warfarin or heparin  haemorrhagic complications 
(clinically overt or silent)  secondary anaemia and/or haemodynamic complications  
exacerbation of chest pain severity  coronary angiogram performance, percutaneous 
coronary intervention and the need for prolonged dual anti-platelet therapy  an increase 
in the intensity of bleeding from the digestive tract, anaemia aggravation and a further 
increase in angina pectoris severity. In this way, clinically overt or latent bleeding from the 
digestive tract and secondary anaemia, besides the aforementioned neural cardio-
oesophageal loop and neuroimmune crosstalk, may be the third vicious circle mechanism, in 
which gastroenterological disorders, exacerbated or complicated by anti-platelet or anti-
thrombotic treatment, may increase angina pectoris severity.  
5. Diagnosis  
According to current opinion, all patients with chest pain should first be evaluated for a 
cardiac cause of their symptoms (Fass & Dickman, 2006; Potts & Bass, 1995). To make this 
easier, some authors recommend estimating the probability of cardiac chest pain origin on 
the basis of tests with nitroglycerine and the number of atherosclerosis risk factors. In spite 
of some doubts concerning the low specificity of a nitroglycerine test (Fass & Dickman, 
2006), chest pain disappearance within five minutes after one dose of 400 mcg of short-
acting nitrates, a cardiac or gastroenterological symptom source should be considered, 
rather than a psychiatric one. Afterwards, if the tests present more than two atherosclerosis 
risk factors, a cardiological diagnostic pathway should be taken first (an ECG, stress test, 
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patients have fewer than three risk factors, the following sequence of procedures in the 
diagnosis of angina-like chest pain presumed to be of oesophageal origin is proposed: 
complete the Carlsson-Dent questionnaire; empirical therapy with proton pump inhibitors 
(PPIs), known as the “omeprazole test”; endoscopy; 24-hour ambulatory oesophageal pH-
metry; 24-hour multichannel intraluminal oesophageal impedance with pH-metry 
examination, in particular with an analysis of the symptom index (SI) or symptom association 
probability (SAP); stationary oesophageal manometry; 24-hour oesophageal manometry with 
SI or SAP evaluation; brain imaging; as well as psychiatric examination (Dickman & Fass, 
2006; Eslick & Talley, 2004; Eslick et al., 2005; Eslick, 2008; Fass & Dickman, 2006; Fass & 
Navarro-Rodriguez, 2008; Hewson et al., 1990; Oranu and Vaezi, 2010; Sheps et al., 2004). The 
recently proposed diagnostic methods for NCCP presumed to be of oesophageal origin are as 
follows: a magnifying endoscopy with high resolution imaging (to show oesophageal mucosa 
microerosions), prolonged oesophageal pH-metry using the wireless Bravo method, high 
resolution manometry, high frequency intraoesophageal ultrasonography (HFIUS), impedance 
planimetry, and multi-slice computer tomography. However, their usefulness in the diagnosis 
of chest pain requires confirmation (Dickman & Fass, 2006; Fass & Dickman; George & 
Movahed, 2010; Hebbard, 2010).  
The Carlsson-Dent questionnaire (CDQ) is a simple but old diagnostic tool for the detection 
of GERD, the main cause of NCCP without alarm symptoms or the suspicion of the other 
possible GERD complications (Numans & de Wit, 2003). It has been validated in European 
patients. In comparison with oesophageal pH-metry and endoscopy, it is estimated as 
having good sensitivity (89-94%) and a positive predictive value (55-90%) for the detection 
of GERD.    
Empirical therapy with a triple standard dose of PPI (e.g. 40-0-20 mg of omeprazole) gives 
valuable information about GERD being the reason of NCCP. It is a simple, available, 
sensitive and cost-effective tool, but the specificity is insufficient to put this test into practice 
as the single objective diagnostic criterion, mainly due to risks connected with false 
undiagnosed CAD. Its sensitivity and specificity in the diagnosis of GER-related chest pain 
in comparison with oesophageal pH-metry reaches 69-95% and 57-86% respectively (Fass & 
Dickman, 2006; Dickman et al., 2005; Wang et al., 2005). However, this test may be less 
valuable for patients in whom symptoms appear less frequently than twice a week 
(Cremonini et al., 2005). On the other hand, taking this limitation into account, testing with 
PPIs can be used as a diagnostic (lasting 1-2 weeks) and as a diagnostic-therapeutic test (1-4 
months of “therapy as investigation”). Chest pain disappearance after the respective period 
should be interpreted as confirmation of clinical associations between acid regurgitation and 
symptom occurrence. The economic aspects of NCCP diagnosis also see much of the use of 
this test in clinical practice. A one-week test with PPI decreased the overall costs of NCCP 
diagnosis by $573-1,338, mainly due to the reduction in the number of panendoscopies 
performed (by 81%), 24-hour oesophageal pH-metry (by 79%), and remains the functional 
diagnostic examination for NCCP (Fass & Navarro-Rodriguez, 2008). Unfortunately, this 
test was not validated in patients with CAD, in whom GERD symptom prevalence and 
overlapping seems to be clinically important. Of this group, GERD-related chest pain 
episodes were found in 30-46% of patients (Budzyński et al., 2008; Dobrzycki et al., 2005). 
These overlapped with chest pain of cardiac origin, being indistinguishable from angina 
pectoris resulting from myocardial ischaemia and leading to symptom persistence. In the 
RITA-3 study, 24% of participants still reported angina in the II-IV class according to the 
CCS classification over one year after percutaneous coronary intervention (Kim et al., 2005; 
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Poole-Wilson et al., 2006). In light of this, such empirical testing with PPIs seems to be worth 
recommending for each patient with refractory angina. Unfortunately, the recent 
recommendation concerning refractory angina by Kones (2010) does not refer to such a 
possibility. However, due to possible potential dangerous interactions between clopidogrel 
and PPIs, this test should be avoided in patients on dual anti-platelet therapy (ACCF, 2010; 
Bhatt et al., 2008). Our own investigations have also shown the necessity for careful 
interpretation of testing with PPIs due to an increase found in nitric oxide bioavailability 
after rabeprazole therapy (Kłopocka et al., 2006) and beta-endorphin plasma levels 
(Budzyński et al., 2010). These substances produced during therapy with PPIs may mask the 
true chest pain source, including that of cardiac in origin.  
Endoscopy is the most recommendable exploratory procedure in patients with GERD 
symptoms, fundamentally heartburn and regurgitation, especially when alarm symptoms 
appear. On the other hand, 50-75% of GERD and 10-70% of NCCP patients have a normal 
endoscopy examination (non-erosive GERD) (Dickman & Fass, 2006; Fass & Dickman, 2006). 
The recent report by Dickman et al. (2007a), on the basis of the results of upper endoscopy 
undergone for NCCP and GERD in a group of respectively 3,688 and 32,981 consecutive 
patients, has shown a normal upper endoscopy in 44.1% of NCCP patients and 38.8% of 
those with GERD. Of the NCCP group, 28.6% had a hiatal hernia, 19.4% erosive 
oesophagitis, 4.4% Barrett's oesophagus, and 3.6% stricture/stenosis. Peptic ulcers were 
found in 2% of the NCCP patients. Thus, endoscopy does not appear to be dispensable in a 
large group of patients with NCCP. It is likely that the new generation of endoscopy 
equipment - magnifying endoscopy - would be helpful in the detection of oesophageal 
mucosa microerosions, but it is unable to provide certainty of the clinically important 
association between NCCP and oesophageal lesions found. Therefore, the greatest clinical 
importance of endoscopy is the possibility of diagnosis, including mucosal biopsy and 
treatment of the morphologic cause of alarm symptoms and the source of haemorrhaging 
from the digestive tract. Thus, awareness should be accompanied by the knowledge that 
normal endoscopy does not exclude a gastroenterological cause of NCCP in patients who 
also have confirmed CAD.   
Twenty-four-hour oesophageal pH-metry has been considered the most sensitive and 
specific test in the diagnosis of GERD and GER-related chest pain. Although 41-43% of 
patients with NCCP fulfilled the criteria for pathological GERD (Leise et al., 2010), a significant 
percentage of patients (about 25%) in whom symptoms corresponded with heartburn had 
rather normal results for 24-hour pH monitoring examinations (Talaie et al., 2009). This 
discrepancy resulted from the method limitation, as 24-hour oesophageal pH-metry detects 
acid reflux, and NCCP may also be provoked by the regurgitation of alkaline or neutral gastric 
content. Therefore, for NCCP diagnosis, especially in patients who are non-responsive to 
empirical therapy with PPIs, 24-hour simultaneous oesophageal impedance and pH 
monitoring seems to be more useful, mainly due to the possibility of non-acid gastro-
oesophageal reflux (GER) diagnosis (Sifrim & Blondeau, 2006; Sifrim et al., 2009). An 
additional but practically the most valuable feature of this tool is the possibility of SI and SAP 
analysis. These enable the evaluation of the relationships between symptom occurrence and 
oesophageal function disorders which are not only related to the regurgitation of hydrochlorid 
acid. Only such a proven relationship gives an acceptable probability that oesophageal 
disorders are truly the reason for recurrent symptom episodes, and has been the basis of the 
identification of “GER-related” and “non-GER-related” chest pain (Dickman & Fass, 2006; Fass 
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associations between chest pain occurrence and oesophageal acidification is the Bernstein test. 
Recently, it has not been practically applied, but formerly it was widely used, not only as a 
diagnostic tool, but primarily in scientific investigation (Chauhan et al., 1996; Makk et al., 2000; 
Rosztóczy et al., 2007; Schofield et al., 1987, 1989).  
Stationary oesophageal manometry, as well as recently introduced high resolution 
oesophageal manometry, has minor importance in NCCP diagnosis, mainly due to 
difficulties with confirming the association between chest pain episodes and motility 
disorders, and the still unsatisfactory treatment effects (Fass & Dickman, 2006; Hershcovici 
& Fass, 2010; Nam et al., 2006). However, 24-hour oesophageal function monitoring is 
potentially more useful, mainly due to the possibility of examining performance during 
patients’ everyday activity, the greater probability of symptom occurrence during 
examination and the possibility of correlating their presence with oesophageal disorders 
(using an SI index or SAP). Moreover, there is now the opportunity to evaluate oesophageal 
pH and motility correlation on the basis of a greater number of analysed parameters in 
computer software. On the other hand, the usefulness of both oesophageal pH-metry, 
impedance examination and 24-hour oesophageal manometry is restricted to patients with 
daily, or at least every two days, symptom prevalence (Singh et al., 1992). Diagnosis of an 
NCCP source using 24-hour pH-metry or manometry has been obtained in 46% of patients 
in whom symptoms occurred at least once per day and only in 11% of subjects with chest 
pain of less frequency (Janssens et al., 1986). In the study by Eslick  (2008), following 
examination of the most numerous population of patients with non-GER-related chest pain 
to have been assessed in this way, the distribution of oesophageal motility abnormalities 
was as follows: normal manometry in 70%, nutcracker oesophagus (14.4%), non-specific 
oesophageal motor disorder (10.8%), diffuse oesophageal spasm (3%), and other (1,8%). In 
other papers, nutcracker oesophagus was the most prevalent oesophageal dysmotility in 
patients with chest pain (Fass & Dickman, 2006; Fornari et al., 2008). Some authors have 
reported a greater prevalence of oesophageal motility disorders in patients admitted due to 
chest pain having a normal coronary angiogram than in patients with CAD (Adamek et al., 
1999; Battaglia et al., 2005). Whereas, it has not only been my own experience, based on 
patients non-responsive to empirical therapy with PPIs, which has shown a similar 
frequency of oesophageal dysmotility in patients both with and without significant coronary 
artery narrowing (Budzyński, 2010b; Cooke et al., 1998).  
As has been mentioned, the clinical usefulness of oesophageal motility examination does not 
seem to be of great value (Dickman & Fass, 2006; Fass & Dickman, 2006; Nam et al., 2006). 
Trials involving the provocative use of ergonovine, tensilon, bethanechol and pentagastrin, 
or oesophageal extension with a balloon have not improved diagnostic efficacy either. My 
own experience has shown the clinical usefulness of exercise-provoked oesophageal 
dysmotility diagnosis using simultaneous oesophageal manometry and ECG monitoring 
during a treadmill stress test. Some exercise-provoked oesophageal motility disorder 
appeared in 22% of patients with recurrent angina-like chest pain non-responsive to 
empirical therapy with PPIs (Budzyński et al., 2010; Budzyński, 2010a). The occurrence of 
angina-like chest pain, oesophageal acidification for more than 10 s, and increased 
simultaneous contractions above 55% during a treadmill stress test had greater than 80% 
specificity for diagnosing GER–related and non–GER–related chest pain. The practical 
message coming from these observations was that patients with recurrent chest pain, who 
did not report e.g. chest pain during a treadmill stress test, have a low (20%) probability of 
recognizing an oesophageal reason for their symptoms (Budzyński, 2010a).  
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High frequency intraluminal ultrasound (HFIUS) is an available but rarely used 
examination, which makes it possible to assess the oesophageal muscle wall thickness in 
order to evaluate the longitudinal muscle contraction and oesophageal shortening in 
patients with oesophageal symptoms, including NCCP. Studies conducted using this 
technique suggest that prolonged oesophageal wall thickening can be connected with chest 
pain and heartburn episodes (Boesmans et al., 2010; Sifrim & Blondeau, 2006; Sifrim et al., 
2009). This examination has also helped to exclude oesophageal ischaemia from the 
mechanism of chest pain which is gastroenterological in origin (Hoff et al., 2010).  
The possibility of having so many gastroenterological examinations for chest pain source 
diagnoses may lead to problems with making the correct choice. The practical diagnostic 
algorithm for NCCP presumed to be oesophageal in origin has been proposed by Fass and 
Navarro-Rodriguez (2008). In all patients with a suspected gastroenterological source of 
chest pain, after the exclusion of a cardiac origin, they suggest analysing the presence of 
alarm symptoms (e.g. fever, stomach pain at night, weight loss, anaemia, and signs of 
bleeding from the digestive tract). If any of these is present, a panendoscopy should first be 
conducted and treatment should be chosen depending on the diagnosis. In patients without 
alarm signs, symptom evaluation and testing with PPIs was proposed as the first diagnostic 
step. In responders to empirical therapy, PPIs should be continued. In patients who fail this 
test, oesophageal pH-metry “on-therapy”, manometry and other gastroenterological 
investigations, including psychiatric assessment, should be considered.  
Careful application of this algorithm in patients with CAD is justified by the proven 
overlapping of oesophageal chest pain sources in about 30-46% of patients with CAD and 
cardiac syndrome X (Budzyński et al., 2008; Dobrzycki et al., 2005; Hewson et al., 1990; 
Oranu & Vaezi, 2010; Singh et al., 1992). Moreover, about 20% of all myocardial ischaemia 
episodes in patients with CAD correlated with pathological acid gastro-oesophageal reflux 
episodes, and were recognized as reflexive myocardial silent ischaemia or ischaemic cardiac 
chest pain due to cardio-oesophageal reflex activation (Dobrzycki et al., 2005). In light of 
these neurally-mediated cardio- oesophageal interrelationships, a comparison of the 
coronary reserve in a non-invasive evaluation before and after empirical therapy with PPIs 
seems to be worth recommending in stable CAD patients, before the next coronarography 
performance. A decrease in the signs of myocardial ischaemia after one- or two-week-long 
therapies with PPIs may help to recognize exacerbation of myocardial ischaemia due to 
oesophageal chemo- receptor activation, which is possible in about half of patients with 
CAD or cardiac syndrome X (Budzyński et al., 2008; Chauhan et al, 1996; Rosztóczy et al., 
2007; Świątkowski et al., 2004). In non-responders to PPI therapy, similarly to patients with 
NCCP, endoscopy, oesophageal impedance with pH-metry, oesophageal manometry with 
or without exercise provocation, as well as psychiatric examination, might be helpful (Fass 
& Navarro- Rodrigues, 2008; Katerndahl, 2004).   
6. Treatment  
Once the accurate diagnosis of the source of angina-like chest pain has been established, a 
specific therapy should be recommended. If recurrent chest pain originates only from the 
heart, due to either ischaemic cardiac or non-ischaemic cardiac disease, typical anti-angina 
pharmacotherapy and/or myocardial revascularization should be recommended, taking 
into account the results of the Clinical Outcomes Utilizing Revascularization and Aggressive 
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in origin, a number of methods have been proposed (Kones, 2010). They are as follows: 
percutaneous myocardial laser revascularization (PMLR) (McGillion et al., 2010); spinal cord 
stimulation (SCS) (Lanza et al., 2011); enhanced external counterpulsation (EECP); 
percutaneous application of low frequency ultrasound, i.e. mechanical shock waves with 
ECG gating; angiogenesis stimulation by the VEGF gene and CD34+ stem cell therapy; etc.  
Individuals with angina-like chest pain with normal coronary angiogram and patients with 
CAD and overlapping gastroenterological symptoms may achieve symptomatic 
improvement after therapy oriented to oesophageal disorders (Phan et al., 2009). Such 
therapy may consist of long-term treatment with PPIs, therapy with calcium antagonists 
(Budzyński, 2010a; Budzyński et al., 2010), Helicobacter pylori eradication (Budzyński, 2011), 
as well as tricyclic antidepressants (Eslick, 2008; Fass, 2008; Fass & Navarro-Rodriguez, 
2008), selective serotonin reuptake inhibitors (citalopram, sertaline) or trazodone (Broekaert 
et al., 2006). Recent studies have also indicated the favourable effect of theophylline (Rao et 
al., 2007), botulinum toxin (Achem, 2008; Fass & Navarro-Rodriguez, 2008), acupuncture 
(Dickman et al., 2007b; Macpherson and Dumville, 2007; Pfab et al., 2011), melatonin due to 
its positive cardiological and gastroenterological action (Dominiguez-Rodriguez et al., 2009; 
Konturek et al., 2008; Pereira, 2006), hypnotherapy (Jones et al., 2006; Palsson and 
Whitehead, 2006), transcutaneous electrical nerve stimulation (TENS) (Borjesson et al., 1998), 
oesophageal dilatation, oesophagomyotomy and Nissen fundoplication (Achem, 2008; 
Dickman & Fass, 2006; Phan et al., 2009).  
The outcome of long-term therapy with PPIs in patients with NCCP has been widely 
studied (Bautista et al, 2004; Cremonini et al., 2005, 2010; Dickman et al., 2005; Dickman & 
Fass, 2006; Liuzzo et al., 2005; Wang et al, 2005). These drugs have shown a favourable effect 
in 80% of patients with “GER-related” chest pain (Dickman & Fass, 2006). The relative risk 
reduction for continued chest pain after PPI therapy was 0.54 (95% CI, 0.41-0.71), with an 
NNT amounting to 3 (Cremonini et al., 2005). The recent meta-analysis by Cremonini et al. 
(2010) has also shown an advantage with therapy using a PPI over a placebo with an odds 
ratio of 3.75 (95% CI, 2.78-4.96), as well as a high placebo response amounting to 18.85% 
(range 2.94%-47.06%). Successful therapy with PPIs is most likely in patients with a GERD 
diagnosis (Gąsiorowska et al., 2009; Oranu & Vaezi, 2010; Seo et al., 2010). Among these 
subjects, acid exposure time (AET), symptom association probability (SAP), and the 
symptom index (SI) obtained from 24-hour oesophageal pH-metry or 24-hour oesophageal 
impedance with pH analysis are considered the predictors of a favourable therapeutic 
outcome (Kushnir et al., 2010).  
Until now, there have only been a few works evaluating the role of therapy with PPIs in 
patients with CAD and recurrent chest pain suspected to be non-cardiac in origin and 
overlapping ischaemic, cardiac-derived chest pain (Budzyński et al., 2008; Dobrzycki et al., 
2005; Liuzzo et al., 2005; Mehta et al., 1996; Świątkowski et al., 2004). All of them, including 
our own work, have evidenced a decrease in chest pain severity and amelioration in health-
related quality of life estimated using the SF-36 survey, as well as an improvement in ECG 
signs of myocardial ischaemia, both during a treadmill stress test (a reduction in subject 
percentage with a significant decrease in ST interval during the stress test) and during 24-
hour ECG Holter monitoring (a decrease in the number of ST-segment depression episodes 
and total duration of ischaemic episodes-total ischaemic burden) after therapy with PPIs. 
Liuzzo et al. (2005), studying a veteran patient population with documented CAD, showed 
through multivariate analysis and proton pump inhibitor therapy that they could 
independently predict a significant reduction in the prevalence of patients experiencing 
 
Angina-Like Chest Pain as a Symptom of Digestive Tract Disorders 
 
53 
chest pain (OR = 0.09), emergency department visits (OR = 0.15), and hospitalization (OR = 
0.14) for chest pain. On the other hand, our own results have shown that the mentioned 
favourable PPI effect on the angina pectoris course in patients with CAD should be carefully 
interpreted because it might not only result from the decrease in cardio-oesophageal reflex 
activation and therapy with aspirin-induced gastropathy, but also from the increase in nitric 
oxide bioavailability observed after therapy with rabeprazole in an open-label trial 
(Kłopocka et al., 2006), as well as the increase in the beta-endorphin plasma level revealed 
for omeprazole in a randomized, double-blind, placebo-controlled, crossover study 
(Budzyński et al., 2010).  
As has been mentioned, besides a decrease in oesophageal acid exposure time and a 
reduction in GER-related myocardial ischaemic episodes, PPIs may also improve the course 
of angina-like chest pain by the alleviation of symptoms related to gastric disease (gastric 
and duodenal ulcer disease), by preventing and treating aspirin-induced gastropathy, as 
well as by reducing the risk of haemorrhagic complications from the upper part of the 
digestive tract and the prevention of secondary anaemia (ACCF, 2010; Bhatt et al., 2008; 
Hsiao et al., 2009). Tailored PPI prescription should prevail over the generalized in their 
recommendation for use with patients on dual anti-platelet therapy because of reported and 
still not definitely excluded potentially life-threatening interactions between PPIs and anti-
platelet drugs (clopidogrel, aspirin). Pantoprazole or esomeprazole should be chosen for 
gastroprotection or time intervals between respective medicines should be recommended 
(ACCF, 2010; Bhatt et al., 2008). The easiest method for the last option is the 
recommendation of PPIs in the morning and clopidogrel in the evening.  
In patients with recurrent chest pain and GERD diagnosed using oesophageal 
pH/impedance monitoring and non-responsive to PPIs, many other kinds of therapy have 
been proposed, including the following: doubling the PPI dose, switching to another PPI, 
adding histamine type 2-receptor antagonists at night, baclofen recommendation, as well as 
laparoscopic or open surgery (Dickman & Fass, 2006; Hershcovici & Fass, 2010; Kushnir et 
al, 2010; Oranu & Vaezi, 2010; Labenz, 2010). The exclusion of eosinophilic oesophagitis in 
patients with NCCP and aged under 45, atopy or dysphagia might also be helpful (Garcia-
Compeăn et al., 2011). Dickman et al. (2007b) found acupuncture added to a single dose of 
PPI to be more effective than doubling the proton pump inhibitor dose in controlling GERD-
related symptoms in patients who had failed with standard dose proton pump inhibitors.  
Calcium antagonists, such as verapamil, diltiazem, nifedipine and amlodipine, have mainly 
been used in therapy for NCCP due to hypertensive oesophageal motility disorders 
diagnosed using stationary manometry (Dickman & Fass, 2006; Fass & Navarro-Rodriguez, 
2006). The reported effects of these drugs in patients with recurrent angina-like chest pain 
were ambiguous. Some studies have shown a favourable outcome for this group of drugs, 
some have not confirmed it (Dickman & Fass, 2006; Eslick et al., 2005; Eslick, 2008; Fass & 
Dickman, 2006). Our own, recently published investigation has shown that patients with 
recurrent angina-like chest pain non-responsive to treatment with PPIs and an established 
diagnosis of exercise-provoked oesophageal spasm (EPOS), for whom a calcium antagonist 
was recommended due to exercise-provoked oesophageal spasm, had a significantly lower 
risk of hospitalization due to suspected acute coronary syndrome in the 2.7-year follow-up 
period than the remaining patients (NNT = 3.5) (Budzyński et al., 2010). In my own work it 
has been documented that Hp eradication had a similar favourable outcome (NNT = 2.7) 
(Budzyński, 2011). The rationales behind this therapy were the above-cited role of this 
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Psychiatric disorders and anxiety focusing on the heart are common in patients with NCCP 
(Achem, 2008; Dickmann & Fass, 2006; Fass & Navarro-Rodriguez, 2008; Katerndahl, 2004). 
They may act as individual factors or via the increase in visceral hypersensitivity. Some 
studies have shown oesophageal motility abnormalities as markers of depressive or panic 
disorders. The last were found in 80% of patients with NCCP and oesophageal motor 
dysfunction and in 30% of subjects with a normal coronary angiogram and oesophageal 
examinations (Dickman & Fass, 2006). Eslick et al. (2005) have even recommended empirical 
therapy with tricyclic antidepressants in patients with recurrent chest pain non-responsive 
to PPIs. The rationale behind such a recommendation is that antidepressants act as pain 
modulators. In patients with NCCP, behaviour therapy involving trazodone, imipramine, 
amitriptyline, nortriptyline, citalopram, desipramine and sertraline was used for this 
purpose (Broekaert et al., 2006; Eslick, 2008; Fass, 2008; Fass & Navarro-Rodriguez, 2008). 
Their clinical efficacy was confirmed both in uncontrolled and in randomized, placebo-
controlled trials. However, the prescribing of these drugs should always be carried out 
carefully, because of the potential cardiovascular risk of tricyclic antidepressants connected 
with their adverse effects, such as prolonged QT intervals, hypertension, postural 
hypotension, and effects on heart rate variability (Hamer et al., 2011). Probably because of 
this, non-pharmacological methods which could potentially be efficient in subjects with 
NCCP have been investigated, such as hypnotherapy, behaviour therapy, and acupuncture 
(Dickman et al., 2007b; Pfab et al., 2011; Yin and Chen, 2010; Zhang et al., 2010). 
Acupuncture has had a favourable effect on gastric emptying, oesophageal motility, and in 
patients with GERD, a potential substrate of non-cardiac chest pain. In the study by 
Macpherson and Dumville (2007), 42% of the patients investigated with a diagnosis of 
NCCP made in a Rapid Access Chest Pain Unit reported that they would consider 
acupuncture, 36% reported that they would not, and 22% did not know. Moreover, in the 
pilot study by Gąsiorowska et al. (2009), a favourable effect of 18 Johrei sessions (a kind of 
meditation) during six weeks in comparison to waiting-list control patients with functional 
chest pain was found. The clinical outcome of the mentioned methods is, among other 
things, explained by a decrease in visceral hypersensitivity, for which one of the mediators 
may be endogenous opioids, one of the potential pathways of the effect of PPIs (Budzyński 
et al., 2010). However, it should be checked for each patient as to whether his or her panic or 
depressive symptoms are the true cause of chest pain recurrence or its cofactor, and not an 
effect of symptom duration chronicity and the lack of an appropriate diagnosis.  
However, particularly in populations with high cardiovascular risk, the appropriate control 
of cardiovascular risk factors is very important in therapy for patients with angina-like chest 
pain. The recent study by Leise et al. (2010) has shown that patients with recurrent angina-
like chest pain which is gastroenterological but unknown in origin (NCCP-U), in spite of 
generally being considered as having low cardiac morbidity and mortality, may ultimately 
show a higher cardiovascular and non-cardiovascular death risk. In this analysis, whose 
results should still be interpreted with limitations, the NCCP group with a diagnosis of 
gastrointestinal disorder displayed less overall survival at all time points, specifically 70.1% 
at 10 years and 51.8% at 20 years, compared with their NCCP-U counterparts. The 
independent death risk factors in adjusted univariate analysis using Cox’s proportional 
hazards model were as follows: age, the Charlson comorbidity index, previous CABG, and 
previous valvular disease. No specific cardiac or gastroenterological tests or their absence 
was associated with mortality. The authors explain their observations by the effect of the 
coexistence of gastroenterological disorders with latent non-ischaemic cardiovascular 
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disease, coronary artery spasm (Charng et al., 1988; Makk et al., 2000; Manfrini et al., 2006; 
Rasmussen et al., 1986), microvascular disease (cardiac syndrome X) or at least endothelial 
dysfunction. An important aspect might also be an overlapping of risk factors for both 
systems’ diseases, such as obesity, obstructive sleep apnoea, hypertension, smoking, and 
diabetes mellitus.  
On the other hand, the study by Leise et al. (2010) has also shown that proper management 
of patients with recurrent chest pain which is extracardiac in origin is still a great challenge 
for physicians. During a 20-year follow-up period since an initial visit to an emergency 
department due to a recurrent chest pain experience, 49% of patients sought subsequent 
care from the emergency department, 42% had repeated cardiology evaluations, and only 
15% were seen by a gastroenterologist. Thirty-eight percent underwent oesophago- 
gastroduodenoscopy, but very few underwent manometry or a pH probe.  
7. Study limitations 
The main limitations concerning investigations on the pathogenesis, diagnosis and 
treatment for patients with recurrent angina-like chest pain, both in patients with and 
without significant coronary artery narrowing, have been the small number of subject 
groups, which on average included a little over 100 participants. Only in three studies were 
the subject groups larger. The other limitations have involved the lack of or a short follow-
up period, recommendations of different medication and their doses, non-homogeneous 
definitions of oesophageal disorders, the establishment of different study endpoints, and 
only single-centre experience presentations.    
8. Future research  
Further studies should validate the test of empirical therapy with PPIs in patients with 
CAD. It would also be significant if the mechanisms for the visceral hypersensitivity leading 
to a decrease in the chest pain threshold could be identified. The evaluation of some new 
diagnostic methods, including analysis for cerebral evoked potentials, would also be useful. 
Moreover, it seems to be important to check once more and re-evaluate the appropriate 
indications for coronary angiography, both because of its costs and its inseparable exposure 
to procedure-connected health risks and substantial radiation. All the recommended 
examinations, both cardiological and gastroenterological, should be connected with precise 
investigations into cardio-oesophageal and other vagally-mediated reflexes and on the 
determination of factors predicting their clinical importance. New therapeutic methods for 
recurrent angina-like non-cardiac chest pain should also be investigated, although critical 
analysis of relationships between benefits and costs should be performed.    
9. Conclusions 
 Angina-like chest pain is a common problem in health care because of its prevalence, 
diagnostic difficulties, resource utilization and potential connection with a reduced 
health-related quality of life and shorter survival times. This symptom is conditioned by 
biological, psychological and social factors.  
 Angina pectoris may be caused by diseases of the cardiovascular system, digestive tract, 
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supply and oxygen requirement (e.g. anaemia or thyrotoxicosis). In respective patients, 
potential chest pain causes may overlap and influence each other. Therefore, NCCP 
may be present in patients both with and without heart diseases. However, the main 
and first purpose of its diagnostic procedures should be to exclude potentially life-
threatening origins.   
 Digestive tract diseases may cause angina-like chest pain along at least three pathways. 
Chest pain may originate from: (1) the oesophagus, stomach or gall bladder, due to 
stimulation of their chemo-, mechano-, and/or thermoreceptors; (2) the heart due to 
activation of cardio-oesophageal neural reflexes and secondary diminished myocardial 
perfusion; as well as (3) the heart due to a decrease in myocardial oxygen supply in the 
course of anaemia, secondary to acute or chronic alimentary tract bleeding, 
malabsorption, maldigestion, blood sequestration or autoimmunological reactions. 
Helicobacter pylori infection may play a role in all of these mechanisms.  
 The misdiagnosis of cardio-oesophageal interrelationships may lead to the progressive 
acceleration of the course of the disorders of both systems and the intensity of their 
symptoms. This occurs in at least three vicious circle mechanisms: neural, inflammatory 
(neuro-immune crosstalk), and the haemorrhagic complications of anti-thrombotic 
drugs expressed as anaemia.  
 The most frequent causes of NCCP are as follows: GERD, oesophageal motility 
disorders and panic abnormalities. Their diagnosis needs many times to use more 
advanced and more specialized diagnostic methods than panendoscopy, such as 
oesophageal impedance, pH-metry, manometry, or endosonography.  
 In the diagnosis of recurrent chest pain of possible oesophageal origin, the most 
important factor is to confirm the relationship between chest pain episode occurrence 
and oesophageal disorders. Such a possibility is provided by the test of empirical 
therapy using PPIs (the “omeprazole test”) and, in non-responsive cases, 24-hour 
oesophageal pH-metry, impedance or manometry with SI or SAP analysis. These help 
to recognize the source of chest pain in 40-80% of patients.  
 The usefulness of exercise-provoked oesophageal disorders, such as exercise-provoked 
gastro-oesophageal reflux or oesophageal spasm, needs to be evaluated. Any further 
investigations need also to estimate the interrelationships between the course of 
cardiovascular and gastroenterological tests as predictors of false positives in their 
outcomes.  
 Therapy for recurrent, angina-like chest pain should be based on the detailed diagnosis 
of its origin (whether cardiac or extracardiac), an assessment of its possible influence on 
myocardial perfusion, and the control of cardiovascular risk factors.  
 Modern cardiac and gastrointestinal diagnostic methods would probably help to better 
recognize NCCP pathophysiology, facilitating its diagnosis and treatment. However, 
they will need to be critically evaluated, not only in relation to potential clinical 
usefulness, but also in accordance with risk-benefit and benefit-cost ratios. 
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1. Introduction 
As it has been mentioned in the previous chapters, Angina pectoris, commonly known as 
angina, is severe chest pain and discomfort due to myocardial ischemia. A lack of blood, 
hence a lack of oxygen supply for heart muscle, will cause this pain which can be because of 
narrowed and blocked coronary arteries. In other words, angina can be assumed to play the 
role of a protective mechanism to signal myocardial ischemia.  
There are different kinds of angina. Stable, unstable, Prinzmetal’s or variant angina and 
latterly discovered type called microvascular angina which is caused by small blood vessels, 
not artery damage. 
Although the amount of mortalities and morbidities of heart diseases and additionally the 
diagnostic techniques in this field underwent drastic improvements, still there are many 
patients complaining about angina pectoris mostly as a restricting pain. Due to the report of 
American Heart Association statistics committee and stroke statistics subcommittee in 2010, 
the prevalence of angina pectoris has become 9.8 million, translating to almost 30 thousand 
per million. This amount in Europe has been estimated to be around 20 - 40 thousand per 
million (Fox, Garcia et al. 2006; Fernandez, Tandar et al. 2010; Lioyd-Jones, Adams et al. 
2010). In another study performed in US, it has been mentioned that 1 in 4 patients is 
experiencing angina pectoris following myocardial infarction. With regard to the annual 
occurrence of MI in US which is 1.5 million cases, there are significant amount of people in 
each year suffering from angina. Therefore, curing angina pectoris is of high importance 
(Plomondon, Magid et al. 2007).  
Although one of the main goals in angina treatment is relief of symptoms, amelioration of 
the position, especially pain, will unexpectedly cause the ischemia to proceed and so, the 
consequence will be cardiac injury. Considering this problem, due to American and 
European drug regulators the anti-anginal medicines also needs to possess anti-ischemia 
effects, as well. Other purposes of angina pectoris treatment are slowing progression of the 
disease and reduction of future events, especially heart attacks and, of course, death by 
treating the underlying heart condition. Treatments for angina include lifestyle changes, 
medicines, medical procedures, cardiac rehabilitation, and other therapies and will depend 
on the severity of the symptoms, severity of the underlying disease, and extent of damage to 
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not artery damage. 
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In recent decades, pharmaceutical scientists focus has been on design of systems which can 
manage to release the medication with a steady or a controlled speed. These delivery 
systems are called "novel".  
The application of novel drug delivery systems in angina therapy show their importance 
through controlling release of a medication with short therapeutic index or decreasing the 
drug dosage intervals which can increase patients' compliance in following up the therapy 
or even it can control the release of drug according to the chronobiology  (Dehghan, 
Aboofazeli et al. 2010; Mandal, Biswas et al. 2010).  
In this chapter, medications and pharmacotherapy of angina pectoris will be mainly 
discussed. At the end of chapter one will be informed of conventional and novel 
medications for treatment of angina. 
2. Anti-angina currently used medicines 
In angina therapy drugs are playing an important role. A variety of medicines with different 
dosage forms and amounts are prescribed in each type of angina. Since the main cause of 
angina is lack of oxygen supply in the coronary arteries, the anti-anginal agents usually play 
their roles through increasing oxygen delivery or decreasing oxygen requirement of the 
tissue or both. Obviously, ascending the amount of oxygen delivery is possible with 
vasodilation and reduced oxygen demand can be caused by cardioinhibitors which reduce 
heart rate and contractility. There are still other mechanisms that may occur in treating 
angina pectoris. For instance, anti-thrombotic drugs which avoid formation of thrombus, 
like anticoagulants, are involved in angina therapy. Figure 1 shows a schematic 
classification of conventional anti-anginal medications. 
Regularly, in angina pharmacotherapy, medications are prescribed for three different 
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long period. 2) To prevent attacks before some exercises or robust activities. 3) To relief the 
pain and pressure of an attack when it begins. 
Generally, there are five main types of medicines, which help to relief, control symptoms 
and increase blood flow and oxygen supply to the heart muscle:  
 Nitrates  
 Beta-blockers  
 Calcium channel blockers  
 Anti-platelets 
 Statin drugs  
Moreover, due to the patient's condition, other medications can be prescribed by the 
specialist, as well. And also these drugs can be prescribed in combination which in most 
cases it works more efficiently than monotherapy. 
2.1 Nitrates and nitrites  
Here the term "nitrates" is taken to include both nitrates and nitrites avoiding repetition. But 
it is presumed that the nitrates can only reduce to nitrites for exerting their action. 
Nitrates are one of the oldest medications for angina. They are potent vasodilators that open 
up the arteries, improving blood flow to the body (including heart) which raises the oxygen 
supply of myocardium.  There are two kinds of nitrates: short acting nitrate preparation and 
long acting nitrate preparation. Short acting ones usually are used to ease angina pains 
and/or to prevent developing an anginal attack before an exercise that is likely to cause one. 
Whilst the long acting productions are prescribed in a regular daily basis for the patients 
with frequent anginal pains and it is not useful for rapid pain relief. 
The most important drug of this group is Nitroglycerin (glyceryl trinitrate) which was the 
first medication used in 1879 by William Murrell for the treatment of angina pectoris and, its 
immediate release forms, still remains the therapeutic mainstay for patients suffering from 
classic and variant angina. Nitroglycerin is often administered sublingually for rapid relief 
of angina sudden attack (Murrell 1879). The main drugs of this group include: nitroglycerin 
or glyceyl trinitrate (GTN), isosorbide dinitrate, isosorbide mononitrate, pentaerythritol 
tetranitrate (PETN) and amyl nitrite. 
2.1.1 Mechanism of action 
Nitrates in the smooth muscle of both venous and arterial beds, are denitrated into nitric 
oxide (NO) which is a potent vasodilator. This vasodilatation relieves anginal pain through 
different mechanisms. Veins dilation will reduce cardiac workload and consequently, 
oxygen demand. Coronary dilation will increase blood flow to ischemic areas. And finally 
dilation of arterioles will lower the afterload and so cardiac workload. 
The released NO from nitrates activates guanylate cyclase and increases the amount of 
cyclic guanine monophosphate (cGMP). cGMP which is a second messenger, activates 
protein kinase. Myosin light chains dephosphorylate by protein kinase. As a result, the 
smooth muscle becomes relaxed. Additionally, decreased intracellular calcium levels by 
cGMP are another mechanism of smooth muscle relaxation (Katzung, Masters et al. 2009). 
2.1.2 Pharmacokinetics 
The nitrates undergo first-pass effect in liver excluding isosorbide mononitrate. Thus, 
despite their high absorption from the GI, nitrates absorption into the systemic circulation is 
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incomplete; i.e., oral preparations have slow onset of action (except sublingual tablets) 
which is not pleasant when quick relief is required. So, there are available dosage forms 
with short onset time. 
Nitrates distribute extensively throughout the body and their bonding to plasma protein has 
been estimated to be around 60%.  
Nitrates undergo metabolism in liver by the enzyme glutathione organic nitrate reductase. 
For example the yielded active metabolites for nitroglycerin are glyceryl dinitrates and 
mononitrates. 
The metabolites of nitrates are excreted in urine, except isosorbide moninitrate, that less 
than 1% of it is eliminated in urine. Elimination half-lives of nitrates differ depending on the 
kind of nitrate and administration route. Table 1 indicates elimination half-lives of some 
preparation of nitrates. 
2.1.3 Adverse reactions 
Acute side effects: Throbbing headache and dizziness are the most common side effect of 
nitrates (these are probably consequences of blood vessles vasodilation). Orthostatic 
hypotension is another common side effect of using nitrates. There is a rare situation named 
"nitrite syncope". In which the nitrate-induced hypotension is severe and thus, the lowered 
blood pressure will cause slowing of heart rate, nausea, shivering and syncope. The adverse 
effects of gastrointestinal tract include nausea and vomiting. 
Nitrate tolerance: Continuous uptake of nitrates (any kind) in high dose may cause tolerance. 
In tolerance, the nitrate's effect will become weak or disappear completely. Although, the 
mechanism of tolerance has been poorly understood but diminished amount of nitric oxide 
and systemic compensation can be partly responsible for this phenomenon. The well-known 
so called "Monday disease" is a touchable example of nitrate tolerance that has happened in 
industries, especially where explosives are manufactured(Rutherford 1995; Munzel, Daiber 
et al. 2005).  
2.1.4 Dosage forms 
According to different indications of nitrates, considering two main groups of long- and 
short- acting nitrates, there are a wide range of preparation forms to fulfill the patients' 
demands (table 1). 
Short acting and long acting anti-anginal agents are being prescribed due to their onset 
and duration of action. For rapid cardiac response, nitroglycerin formulations with short 
onset (sublingual tablets or pump sprays) are administered. At the commencement of an 
attach, exactly when the patient starts to feel the chest pain or before starting an activity, 
one 0.3 or 0.4 mg pill or one metered dose of spray can be taken and patient can repeat it 
every 5 minutes, if necessary, up to maximum three doses. These dosage ranges for 
isosorbide dinitrate is fairly different. In this case, sublingual 2.5 to 10 mg tablets should 
be taken. The repetition dose is every 2-3 hours during acute phase and 4-6 hours for 
prophylaxis. 
Long acting nitroglycerin sustained-release tablets are prescribed 2.5-13 mg every 6-12 
hours. Alternatively, the topical form or the patches can be used instead. Isosorbide dinitrate 
extended-release formulations are administered 40-80 mg twice daily. 
In any case, it is necessary to have 10-12 hours nitrate-free interval per day due to 
prevention of nitrate tolerance (Cutler, Eff et al. 1995; Katzung, Masters et al. 2009). 
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Tablets (sublingual) 0.15, 0.3, 0.4 and 0.6 mg 1/2–1 hr 
Tablets (buccal and 
controlled-release) 1, 2 and 3 mg 3-5 hr buccal 
Capsules 
(sustained-release) 2.5, 6.5, 9 and 13 mg 5 hr 
Aerosol (lingual) 0.4 mg/metered spray 1/2–1 hr 




100, 200 and 400 
mcg/ml  
Topical 2% ointment 2-12 hr 
Transdermal 
(patches) 
0.1, 0.2, 0.4, 0.6 and 0.8 
mg/hour systems 24 hr 
Isosorbide dinitrate 
Tablets 5, 10, 20, 30 and 40 mg 5-6 hr 
Tablets (sublingual) 2.5, 5 and 10 mg 1/2–2 hr 
Tablets  
(extended-release) 40 mg 5-6 hr 
Tablets (chewable) 5 and 10 mg 1/2–2 hr 
Capsules 
(extended-release) 40 mg 5-6 hr 
Isosorbide 
mononitrate 
Tablets 10 and 20 mg Unknown 
Tablets  
(extended-release) 30, 60 and 120 mg  
Amyl nitrite Solution (inhalation) 50 mg 5 min 
Table 1. Commercialized dosage forms of nitrates (Christensen, Comerford et al. 2003). 
2.2 Beta blockers 
Beta blockers have been used for over 35 years to treat both angina and high blood pressure 
(hypertension). These medications through beta blockade slow the heart rate, decrease 
blood pressure, and lessen the force of contraction of the heart muscle, however, the third 
generation of beta blockers show to have vasodilatory effects through different pathways 
which will be discussed more in section 2.2.1. When taken regularly, beta-blockers are 
proven to prevent heart attacks and mortality and reduce the frequency of angina attacks 
(reinfarction). Because of their effects on the respiratory system, beta-blockers are unsuitable 
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incomplete; i.e., oral preparations have slow onset of action (except sublingual tablets) 
which is not pleasant when quick relief is required. So, there are available dosage forms 
with short onset time. 
Nitrates distribute extensively throughout the body and their bonding to plasma protein has 
been estimated to be around 60%.  
Nitrates undergo metabolism in liver by the enzyme glutathione organic nitrate reductase. 
For example the yielded active metabolites for nitroglycerin are glyceryl dinitrates and 
mononitrates. 
The metabolites of nitrates are excreted in urine, except isosorbide moninitrate, that less 
than 1% of it is eliminated in urine. Elimination half-lives of nitrates differ depending on the 
kind of nitrate and administration route. Table 1 indicates elimination half-lives of some 
preparation of nitrates. 
2.1.3 Adverse reactions 
Acute side effects: Throbbing headache and dizziness are the most common side effect of 
nitrates (these are probably consequences of blood vessles vasodilation). Orthostatic 
hypotension is another common side effect of using nitrates. There is a rare situation named 
"nitrite syncope". In which the nitrate-induced hypotension is severe and thus, the lowered 
blood pressure will cause slowing of heart rate, nausea, shivering and syncope. The adverse 
effects of gastrointestinal tract include nausea and vomiting. 
Nitrate tolerance: Continuous uptake of nitrates (any kind) in high dose may cause tolerance. 
In tolerance, the nitrate's effect will become weak or disappear completely. Although, the 
mechanism of tolerance has been poorly understood but diminished amount of nitric oxide 
and systemic compensation can be partly responsible for this phenomenon. The well-known 
so called "Monday disease" is a touchable example of nitrate tolerance that has happened in 
industries, especially where explosives are manufactured(Rutherford 1995; Munzel, Daiber 
et al. 2005).  
2.1.4 Dosage forms 
According to different indications of nitrates, considering two main groups of long- and 
short- acting nitrates, there are a wide range of preparation forms to fulfill the patients' 
demands (table 1). 
Short acting and long acting anti-anginal agents are being prescribed due to their onset 
and duration of action. For rapid cardiac response, nitroglycerin formulations with short 
onset (sublingual tablets or pump sprays) are administered. At the commencement of an 
attach, exactly when the patient starts to feel the chest pain or before starting an activity, 
one 0.3 or 0.4 mg pill or one metered dose of spray can be taken and patient can repeat it 
every 5 minutes, if necessary, up to maximum three doses. These dosage ranges for 
isosorbide dinitrate is fairly different. In this case, sublingual 2.5 to 10 mg tablets should 
be taken. The repetition dose is every 2-3 hours during acute phase and 4-6 hours for 
prophylaxis. 
Long acting nitroglycerin sustained-release tablets are prescribed 2.5-13 mg every 6-12 
hours. Alternatively, the topical form or the patches can be used instead. Isosorbide dinitrate 
extended-release formulations are administered 40-80 mg twice daily. 
In any case, it is necessary to have 10-12 hours nitrate-free interval per day due to 
prevention of nitrate tolerance (Cutler, Eff et al. 1995; Katzung, Masters et al. 2009). 
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Isosorbide 
mononitrate 
Tablets 10 and 20 mg Unknown 
Tablets  
(extended-release) 30, 60 and 120 mg  
Amyl nitrite Solution (inhalation) 50 mg 5 min 
Table 1. Commercialized dosage forms of nitrates (Christensen, Comerford et al. 2003). 
2.2 Beta blockers 
Beta blockers have been used for over 35 years to treat both angina and high blood pressure 
(hypertension). These medications through beta blockade slow the heart rate, decrease 
blood pressure, and lessen the force of contraction of the heart muscle, however, the third 
generation of beta blockers show to have vasodilatory effects through different pathways 
which will be discussed more in section 2.2.1. When taken regularly, beta-blockers are 
proven to prevent heart attacks and mortality and reduce the frequency of angina attacks 
(reinfarction). Because of their effects on the respiratory system, beta-blockers are unsuitable 
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for angina sufferers who have asthma or bronchitis.  Carvedilol, propranolol and atenolol 
are some of most important beta blockers. 
2.2.1 Mechanism of action 
There are three types of beta receptors in the body that control several different functions. 
Beta-1 receptors are located mostly in heart muscle and also in eye and kidneys, whilst the 
prominent part of beta-2 receptors are in upper respiratory system (bronchial vascular 
smooth muscle); however, there are a few beta-2 receptors in heart muscle. And finally beta-
3 receptors are distributed in adipose tissue. The beta receptors are targets of 
cathecolamines, especially noradernaline (norepinephrine) and adernaline (epinephrine). In 
fact, beta blockers induce their effect by preventing the normal ligand (cathecolamines) from 
binding to beta receptors. Due to their distribution sites in body, beta-1 and beta-2 blockers 
are of interest in angina therapy. Preventing adrenaline's performance on heart by beta 
blockers causes lower heart rate, contractility and blood pressure and in one words reduced 
heart's workload. Thus, the myocardial oxygen demand will decrease and this final effect is 
assumed to be the most important effect of beta blockers in angina treatment. The final 
function of beta blockers owing to their ability to be selective or nonselective, cause them to 
have different indications. The nonselective beta antagonists, blockade both beta-1 and beta-
2 receptors, whereas, the selective ones only block beta-1 receptors (cardioselective beta 
blockers). These two groups of agents that are used in angina pharmacotherapy are listed in 
table 2, seperately. 
 
Nonselective Beta blockers 
useful in angina treatment 
Selective Beta blockers 








Table 2. Selective and nonselective anti-anginal beta blockers 
As it was mentioned before, the third generation of beta-adrenoceptor antagonists 
comprises drugs with extra ability of vasodilatation. Most of them play their role by 
blocking alpha-1 receptor (labetalol, carvedilol and bucindolol). Nebivolol is the exception 
of third generation; because, the vasodilatation mechanism of this beta-1 highly selective 
blocker is by stimulating nitric oxide release (Weiss 2006; Karter 2007). 
2.2.2 Pharmacokinetics 
Most of beta blockers are quickly absorbed after oral administration (generally from small 
intestine). Moreover, their systemic absorption after topical application has been confirmed 
to be without significant delay. However, there are pharmacokinetical differences in the 
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drugs of this category which is mostly because of their hydrophilic or lipophilic affinities. 
For example the absorption of hydrophilic beta blockers such as nadolol and atenolol from 
GI is incomplete. Furthermore, this characteristics influence beta blockers indications, as 
well. Since, the lipophilic beta antagonists can pass blood brain barrier and enter CNS 
(propranolol), they are used in prophylactic treatment of migraine or vascular headache.  
Beta adrenoceptor antagonists' distribution in body is also influenced by this quality. The 
lipophilic beta blockers are more detected in biologic fluids. 
Due to solubility of beta blockers in water or lipid, their metabolism and elimination can be 
through liver or kidneys; i.e. drugs with low lipophilicity are excreted from kidneys, whilst 
more lipophilic substances are metabolized in liver.  
2.2.3 Adverse reaction 
Beta blockers are widely prescribed throughout the world in several remedies and they do 
not seem to have many severe side effects. Nevertheless, their most important unpleasant 
effects are due to inhibitory effect of nonselectives on beta-2 receptors. Since beta-2 receptors 
are mainly in bronchi, beta-2 antagonists hinder opposing the alpha 1 receptor-mediated 
vasoconstructor tone. Thus the patients with any dysfunction in their airways will 
experience serious problems. To overcome this disadvantage, new class of beta blockers 
with beta-1 selectivity and partial beta-2 agonist ability, has emerged. Beta-1 antagonists are 
preferable to the prior beta blockers, however, since bronchospasm was reported in certain 
individuals followed by selective beta blockers uptake, they are not considered completely 
"safe". 
Other adverse effects experienced by the patients are dizziness and lightheadedness 
accompanied by blurred vision. Some people may feel cold in their hands and feet as a 
result of decreased blood pressure, especially to the extremities. Moreover, beta blocker 
consumption may cause some allergic reactions like rashes and itching. 
2.2.4 Dosage forms 
Available formulations of beta blockers have been summarized in table 3. 
Among these drugs, betaxolol, bisoprolol, nadolol and penbutolol are prescribed for angina 
prophylaxis, while others are used in treatment of angina attacks.  
 
 
Generic name of 
beta receptor 
antagonist 
Dosage form Amount of active agent Dosage range 
Acebutolol Capsules 200 & 400 mg 
200 mg twice daily 
up to 800 mg and 
even higher, if 
necessary 
Atenolol Tablets 25, 50 & 100 mg 
50 mg once daily 
and can be adjusted 
after one week. 
Maximum daily 
dose is 200 mg 
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blocking alpha-1 receptor (labetalol, carvedilol and bucindolol). Nebivolol is the exception 
of third generation; because, the vasodilatation mechanism of this beta-1 highly selective 
blocker is by stimulating nitric oxide release (Weiss 2006; Karter 2007). 
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Most of beta blockers are quickly absorbed after oral administration (generally from small 
intestine). Moreover, their systemic absorption after topical application has been confirmed 
to be without significant delay. However, there are pharmacokinetical differences in the 
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drugs of this category which is mostly because of their hydrophilic or lipophilic affinities. 
For example the absorption of hydrophilic beta blockers such as nadolol and atenolol from 
GI is incomplete. Furthermore, this characteristics influence beta blockers indications, as 
well. Since, the lipophilic beta antagonists can pass blood brain barrier and enter CNS 
(propranolol), they are used in prophylactic treatment of migraine or vascular headache.  
Beta adrenoceptor antagonists' distribution in body is also influenced by this quality. The 
lipophilic beta blockers are more detected in biologic fluids. 
Due to solubility of beta blockers in water or lipid, their metabolism and elimination can be 
through liver or kidneys; i.e. drugs with low lipophilicity are excreted from kidneys, whilst 
more lipophilic substances are metabolized in liver.  
2.2.3 Adverse reaction 
Beta blockers are widely prescribed throughout the world in several remedies and they do 
not seem to have many severe side effects. Nevertheless, their most important unpleasant 
effects are due to inhibitory effect of nonselectives on beta-2 receptors. Since beta-2 receptors 
are mainly in bronchi, beta-2 antagonists hinder opposing the alpha 1 receptor-mediated 
vasoconstructor tone. Thus the patients with any dysfunction in their airways will 
experience serious problems. To overcome this disadvantage, new class of beta blockers 
with beta-1 selectivity and partial beta-2 agonist ability, has emerged. Beta-1 antagonists are 
preferable to the prior beta blockers, however, since bronchospasm was reported in certain 
individuals followed by selective beta blockers uptake, they are not considered completely 
"safe". 
Other adverse effects experienced by the patients are dizziness and lightheadedness 
accompanied by blurred vision. Some people may feel cold in their hands and feet as a 
result of decreased blood pressure, especially to the extremities. Moreover, beta blocker 
consumption may cause some allergic reactions like rashes and itching. 
2.2.4 Dosage forms 
Available formulations of beta blockers have been summarized in table 3. 
Among these drugs, betaxolol, bisoprolol, nadolol and penbutolol are prescribed for angina 
prophylaxis, while others are used in treatment of angina attacks.  
 
 
Generic name of 
beta receptor 
antagonist 
Dosage form Amount of active agent Dosage range 
Acebutolol Capsules 200 & 400 mg 
200 mg twice daily 
up to 800 mg and 
even higher, if 
necessary 
Atenolol Tablets 25, 50 & 100 mg 
50 mg once daily 
and can be adjusted 
after one week. 
Maximum daily 
dose is 200 mg 
 
Angina Pectoris 78
Generic name of 
beta receptor 
antagonist 
Dosage form Amount of active agent Dosage range 
Betaxolol Tablets (film-coated) 10 & 20 mg 
10-20 mg once a 
day. Can be 
increased to 50 
mg/day after one or 
two weeks of 
inadequate response 
Bisoprolol Tablets  5 & 10 mg 
5 mg per day, can be 
increased every 
three days, up to 20 
mg 
Carvedilol Tablets  
Started with 6.25mg 
twice a day and can 
be continued up to 
50mg per day 
Labetalol 
(Quyyumi, Wright 
et al. 1985) 
Tablets  
(film-coated) 100, 200 & 300 mg  
Metoprolol 
Tablets 50 & 100 mg 100 to 400 mg in divided doses 
Tablets  
(extended-release) 
25, 50, 100 & 200 
mg 100 to 400 mg daily 
Nadolol Tablets 20, 40, 80, 120 & 160 mg 
40 mg per day. Can 
be increased up to 
even 240 in certain 
time intervals 
Penbutolol Tablets 20 mg 20-40 mg once a day 




60, 80, 120 & 160 
mg 
Tablets or solution 
can be administered 
40-320 mg in three 
or four doses daily 
and the long-acting 
forms are given 
once a day, 
however, it can 
increase 
Tablets 10, 20, 40, 60 & 80 mg 
Solution 4, 8 & 80 mg/ml 
Timolol Tablets 5, 10 & 20 mg 
10-30 mg twice 
daily(Arronow, 
1980) 
Table 3. Beta blockers dosage forms which are used as anti-anginal agents (Christensen, 
Comerford et al. 2003) 
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2.3 Calcium channel blockers (CCBs) 
Calcium channel blockers, also called slow calcium channel antagonists or slow channel 
blockers, inhibit calcium ion movement through slow channels in cardiac and smooth 
muscles. CCBs are mostly used for treatment of classic and variant angina. Also, they are 
particularly beneficial if angina is caused by arterial spasms (Prinzmetal's variant angina) 
rather than blockage.  
Drugs of this category are classified into two classes, dihydropyridines (DHPs) and non-
dihydropyridines (non-DHPs). The non-DHPs are again comprises of three further 
compounds: phenylalkylamines, benzothiazepines and tertralols (Ryman and Gurk-Turner 
1999). The most selective calcium channel blockers belong to dihydropyridines.  
2.3.1 Mechanisms of action 
CCBs blockade the calcium ion influx into vascular smooth muscle cells and cardiac 
myocytes across the voltage gated slow channels. Thus the intracellular calcium levels will 
diminish. Since, the most important ion for muscle contractility is assumed to be calcium, as 
a result of decreased calcium levels, vasodilatation of both coronary and peripheral arteries 
and lower cardiac conduction will be observed. Vasodilatations will cause low blood 
pressure and consequently, less heart afterload and oxygen demand. 
2.3.2 Pharmacokinetics 
CCBs are usually well absorbed following oral administration, although they can have 
different bioavailability due to their metabolism.  
They are widely distributed in body fluids with a high protein-binding affinity. It is proved 
that protein binding percentage of dihydropyridines is higher than non-dihydropyridines. 
Most of Calcium channel blockers are metabolized and cleared hepatically and less than 5% 
is secreted unchanged in urine. And some of them undergo extensive first-pass metabolism 
which will influence drug's plasma level and half life. Thus, it should be taken into account 
in dose adjustment. 
Elimination half-lives of old CCBs are rather short (3-8 hours), whereas the newer ones (esp. 
new DHPs) have been designed to last longer in body (Opie 1989; Piepho 1991). 
2.3.3 Adverse reactions 
Generally, the side effects of CCBs are not really common but still the incidence of some 
adverse reactions has been reported in a number of patients. Peripheral vasodilatation 
accounts for the major side effects of DHPs like flushing, headache, rashes, excessive 
hypotension, peripheral edema (esp. Pedal edema) and palpitation (reflecting reflex 
tachycardia) (Sirker, Missouris et al. 2001). The later effect is the reason that most of DHPs 
are not preferred in treatment of angina pectoris.  
Non-DHPs side effects are mostly because of the muscle relaxation effect; for instance, they 
can cause severe bradycardia, or can influence electrical conduction system of heart. This 
relaxation in smooth muscles of intestine and colon may cause constipation. Constipation is 
followed by verapamil administration.  
2.3.4 Dosage forms 
Two main classes of slow channel blockers, have different mode of actions and thus, diverse 
indications. Although all calcium channel blockers seem to be effective in treatment of stable 
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2.3 Calcium channel blockers (CCBs) 
Calcium channel blockers, also called slow calcium channel antagonists or slow channel 
blockers, inhibit calcium ion movement through slow channels in cardiac and smooth 
muscles. CCBs are mostly used for treatment of classic and variant angina. Also, they are 
particularly beneficial if angina is caused by arterial spasms (Prinzmetal's variant angina) 
rather than blockage.  
Drugs of this category are classified into two classes, dihydropyridines (DHPs) and non-
dihydropyridines (non-DHPs). The non-DHPs are again comprises of three further 
compounds: phenylalkylamines, benzothiazepines and tertralols (Ryman and Gurk-Turner 
1999). The most selective calcium channel blockers belong to dihydropyridines.  
2.3.1 Mechanisms of action 
CCBs blockade the calcium ion influx into vascular smooth muscle cells and cardiac 
myocytes across the voltage gated slow channels. Thus the intracellular calcium levels will 
diminish. Since, the most important ion for muscle contractility is assumed to be calcium, as 
a result of decreased calcium levels, vasodilatation of both coronary and peripheral arteries 
and lower cardiac conduction will be observed. Vasodilatations will cause low blood 
pressure and consequently, less heart afterload and oxygen demand. 
2.3.2 Pharmacokinetics 
CCBs are usually well absorbed following oral administration, although they can have 
different bioavailability due to their metabolism.  
They are widely distributed in body fluids with a high protein-binding affinity. It is proved 
that protein binding percentage of dihydropyridines is higher than non-dihydropyridines. 
Most of Calcium channel blockers are metabolized and cleared hepatically and less than 5% 
is secreted unchanged in urine. And some of them undergo extensive first-pass metabolism 
which will influence drug's plasma level and half life. Thus, it should be taken into account 
in dose adjustment. 
Elimination half-lives of old CCBs are rather short (3-8 hours), whereas the newer ones (esp. 
new DHPs) have been designed to last longer in body (Opie 1989; Piepho 1991). 
2.3.3 Adverse reactions 
Generally, the side effects of CCBs are not really common but still the incidence of some 
adverse reactions has been reported in a number of patients. Peripheral vasodilatation 
accounts for the major side effects of DHPs like flushing, headache, rashes, excessive 
hypotension, peripheral edema (esp. Pedal edema) and palpitation (reflecting reflex 
tachycardia) (Sirker, Missouris et al. 2001). The later effect is the reason that most of DHPs 
are not preferred in treatment of angina pectoris.  
Non-DHPs side effects are mostly because of the muscle relaxation effect; for instance, they 
can cause severe bradycardia, or can influence electrical conduction system of heart. This 
relaxation in smooth muscles of intestine and colon may cause constipation. Constipation is 
followed by verapamil administration.  
2.3.4 Dosage forms 
Two main classes of slow channel blockers, have different mode of actions and thus, diverse 
indications. Although all calcium channel blockers seem to be effective in treatment of stable 
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angina, causing reflex tachycardia, the dihydropyridines usually are not administered for 
this purpose. The only FDA approved DHPs as the treatments for angina are nifedipine, 
amlodipine, nicardipine and biperidil of which nifedipine and amlodipine are used in both 
vasospastic and chronic stable angina, while biperidil and nicardipine's application is 
limited to just chronic stable angina (Ryman and Gurk-Turner 1999; Helms, Quan et al. 
2006). Table 4 displays dosage forms of some CCBs which are used in angina therapy. 
Mibefradil, of tertralol subgroup, was used as an anti-anginal agent but was withdrawn 








Dosage form Amount of active 
agent 
Dosage range 
Amlodipine Tablets 2.5, 5 & 10 mg 5-10 mg daily 
Nicardipine Capsules 20 & 30 mg 20-40 mg three times 
a day 
Nifedipine Capsules 10 & 20 mg 10-20 mg three times 
a day, can increase 




30, 60 & 90 mg 30 to 60 mg once 
daily 
Bepridil Tablets (film-coated) 200 & 300 mg 200 up to maximum 
400 mg daily 





Dosage form Amount of active 
agent 
Dosage range 
Diltiazem Tablets 30, 60, 90 & 120 mg Start with 30 mg three 
times a day and can 
be increase up to 360 




multiple 60-mg units of 
diltiazem) 




60, 90, 120, 180, 240, 
300, 360 & 420 mg 
 




120, 180 &240 mg  
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 Capsules 
(sustained-release) 
100, 120, 180, 
200,240, 300 




120, 180 & 240 mg  
Table 4. Calcium channel blockers administered in angina therapy (dosage forms and 
dosing ranges) (Christensen, Comerford et al. 2003)  
2.4 Anti-platelets   
These anti-thrombotic drugs prevent platelet clumping and so thrombus formation in blood 
circulation. There are several subgroups of antiplatelets such as: cyclooxygenase inhibitors, 
adenosine diphosphate (ADP) receptor inhibitors (contains thienopyridines), glycoprotein 
IIB/IIIA inhibitors and adenosine reuptake inhibitors. Anti-plateletes, dislike anti-
coagulants, have the most anti-clot effect in arterial circulation. Since aspirin and clopidogrel 
are this group's mainly prescribed drugs in angina, in this section they will be discussed in 
details. Ticlopidine is another thienopyridine that has been shown to have effects on 
treatment of unstable angina. But according to the results of some studies, ticlopidine have 
more adverse effects than clopidogrel (Hankey, Sudlow et al. 2000). 
Aspirin has clot-preventing properties within the coronary arteries or other blood vessels. 
Daily aspirin therapy is advised to patients, unless they have problems tolerating it. In this 
case, clopidogrel can be used instead. However, one recent study showed that in patients 
suffering stable angina, treatment with aspirin and clopidogrel indicates greater platelet 
formation blockade rather than monotherapy with aspirin alone (Saha, Berglund et al. 2008). 
2.4.1 Mechanism of action 
Since aspirin has many indications, it can act through different biologic pathways. Aspirin 
anti-platelet and with less importance anti-inflammatory effects are believed to be the main 
mechanisms in treating angina pectoris. 
Anti-platelet and anti-inflammatory: While administered in low doses, aspirin inhibits 
prostaglandin synthetase action and therefore avoid clotting followed by preventing 
thromboxane A2, the platelet-aggregating substance, formation. Aspirin owes this ability of 
prostaglandins and thromboxanes suppression to irreversible inactivation of the 
cyclooxygenase (COX) enzyme. As the chemical structure of aspirin can be observed in fig.2, 
its free acetyl group is attached to a serine residue in the active site of COX enzyme through 
a covalent bond. This is the reason of difference between aspirin and the similar anti-
inflammatory NSAIDs group which are reversible inhibitors.  
Although if the dose of aspirin rises, it will interferes with prostacyclin production and so 
this will negate the anticlotting properties.   
The exact mechanism of aspirin's anti-inflammatory action is not completely understood but 
it is mostly believed that the ability to inhibit prostaglandin synthesis can influence 
synthesis or action of other mediators of inflammation by restraining them. 
Clopidogrel is a selective adenosine diphosphate (ADP) antagonist. It irreversibly blocks the 
ADP receptor on the platelet cell membrane and consequently the glycoprotein IIb/IIIa 
cannot be activated and so platelet aggregation will be avoided (Savi, Nurden et al. 1998).  
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Dosage form Amount of active 
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Dosage range 
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 Capsules 
(sustained-release) 
100, 120, 180, 
200,240, 300 




120, 180 & 240 mg  
Table 4. Calcium channel blockers administered in angina therapy (dosage forms and 
dosing ranges) (Christensen, Comerford et al. 2003)  
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suffering stable angina, treatment with aspirin and clopidogrel indicates greater platelet 
formation blockade rather than monotherapy with aspirin alone (Saha, Berglund et al. 2008). 
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Since aspirin has many indications, it can act through different biologic pathways. Aspirin 
anti-platelet and with less importance anti-inflammatory effects are believed to be the main 
mechanisms in treating angina pectoris. 
Anti-platelet and anti-inflammatory: While administered in low doses, aspirin inhibits 
prostaglandin synthetase action and therefore avoid clotting followed by preventing 
thromboxane A2, the platelet-aggregating substance, formation. Aspirin owes this ability of 
prostaglandins and thromboxanes suppression to irreversible inactivation of the 
cyclooxygenase (COX) enzyme. As the chemical structure of aspirin can be observed in fig.2, 
its free acetyl group is attached to a serine residue in the active site of COX enzyme through 
a covalent bond. This is the reason of difference between aspirin and the similar anti-
inflammatory NSAIDs group which are reversible inhibitors.  
Although if the dose of aspirin rises, it will interferes with prostacyclin production and so 
this will negate the anticlotting properties.   
The exact mechanism of aspirin's anti-inflammatory action is not completely understood but 
it is mostly believed that the ability to inhibit prostaglandin synthesis can influence 
synthesis or action of other mediators of inflammation by restraining them. 
Clopidogrel is a selective adenosine diphosphate (ADP) antagonist. It irreversibly blocks the 
ADP receptor on the platelet cell membrane and consequently the glycoprotein IIb/IIIa 




Fig. 2. Chemical structure of aspirin 
2.4.2 Pharmacokinetics 
Since aspirin is a weak organic acid with a pKa equal to 3.5, in oral dosage form it is 
expected to absorb in stomach and proximal small intestine in nonionized form; because in 
these areas the acidic environment dominates.  
Suddenly after absorption it is metabolized into acetic acid and salicylate. This rapid 
metabolism is resulting in high concentrations of salicylates in most body liquids and fluids. 
Therapeutic salicylate blood level for anti-inflammatory effect is 150 to 300 mcg/ml. Salicylates 
have rather high protein binding ranged from 75 to 90% depending on blood level. 
Salicylate is excreted by the kidneys with first-order kinetics and its elimination half-life has 
estimated to be between 2 and 4.5 hours depending on the aspirin administered dose (in 
toxic doses this range reaches 15 to 30 hours) (Hartwig-Otto 1983). 
Clopidogrel is a prodrug and after rapid oral absorption, it is converted to the active agent 
in liver. The half life of this active agent is 8 hours.  
Clopidogrel is eliminated almost equally from urine and feces.  
2.4.3 Adverse reactions 
One of the main adverse effects of aspirin is gastric upset. Especially when taken in high 
doses the risk of gastrointestinal bleeding increases. Aspirin uptake can be also 
accompanied by nausea and heartburn. 
The patient taking aspirin is advised to be monitored frequently; the main reason is because 
it may cause leucopenia, thrombocytopenia and prolonged bleeding time. 
Other rare but severe side effects include Rey's syndrome, anaphylaxis and angioedema. 
Some of clopidogrel's side effects are neutropenia, hemorrhage and skin rash. 
2.4.4 Dosage forms 
There are several dosage forms of these medications available in the market. As aspirin is 
considered to be multifunctional, the only forms that can be used in treatment of angina are 
in table 5. 
2.5 Statins  
Statins or HMG CoA reductase inhibitors, lower cholesterol and have been shown to 
stabilize the fatty plaque on the inner lining of the coronary artery, even when the blood 
cholesterol is normal or minimally increased.  Due to recent research statins can 
atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin (Dehghan, Aboofazeli et al. 
2010; Dvir and Battler 2010). 
2.5.1 Mechanisms of action 
Since hyperlipidemia has been proved to be one of the main reasons for coronary heart 
diseases, lowering lipid levels in bloods can decrease the incidence of cardiovascular 
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disease. The most effective impact of statins on the patients suffering from anginal attacks is 
believed to be through lowering the LDL cholesterol level in plasma (Khan 2006). 
HMG CoA reductase is an enzyme responsible for mevalonate production. In lipid forming 
pathway, mevalonate is finally transformed to cholesterol. Statins which have some 
structural similarities with this HMG CoA, can competitively attach to the enzyme and 
block it. Therefore, the speed of cholesterol biosynthesis will decline. Statins play their role 
in angina therapy through other mechanisms, as well.  
Researchers have defined some other modes of actions for statins, rather than lipid 
lowering, in managing heart related diseases like anti-inflammatory, plaque stability and 
prevention of clotting. These beneficial effects are independent from lipid lowering 
characteristics (Furberg 1999). 
 
Name Drug Form Amount of Active Agent Dosage Ranges 
Aspirin Tablets 81 and 325 mg  
Prevention doses: 81 
to 325mg daily or 
every other day; 
Treatment doses: 160 





 Tablets (enteric-coated) 81, 100, 162, 165 and 325 mg 
 Tablets (chewable) 81 and 100 mg 
 Tablets (effervescent) 100 mg 
 Suppositories 120, 125, 200 and 300 mg 
Clopidogrel Tablets 75 mg 75 mg once a day 
Table 5. Available dosage forms of aspirin and clopidogrel for angina treatment 
2.5.2 Pharmacokinetics 
The pharmacokinetic characteristics of statins vary widely due to their different structures 
which determine their water or lipid solubility. Quite lipophilic statins are atorvastatin, 
simvastatin, lovastatin, fluvastatin, cerivastatin and pitavastatin; whereas pravastatin and 
rosuvastatin are relatively hydrophilic. Obviously, the lipophilic compounds have rapid 
absorption and distribute easily in biologic fluids. 
Almost all of lipophilic statins are metabolized hepatically by cytochrome P450 enzymes 
and due to their efficient first-pass effect their bioavailability varies from 5% to 60%. Whilst, 
the hydrophilic statins have longer half lives and excreted both through liver and kidneys. 
HMG CoA reductase inhibitors have half lives ranged from less than 5 hours in simvastatin 
up to 22 hours in pravastatin and 20 – 30 hour in some metabolites of atorvastatin (Garcia, 
Reinoso et al. 2003; Schachter 2004). 
2.5.3 Adverse reactions 
Although statins considered being among the safest drugs, the most important but 
infrequent side effect of statins is because of their metabolism pathway (cytochrome P450) 
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2.5.1 Mechanisms of action 
Since hyperlipidemia has been proved to be one of the main reasons for coronary heart 
diseases, lowering lipid levels in bloods can decrease the incidence of cardiovascular 
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disease. The most effective impact of statins on the patients suffering from anginal attacks is 
believed to be through lowering the LDL cholesterol level in plasma (Khan 2006). 
HMG CoA reductase is an enzyme responsible for mevalonate production. In lipid forming 
pathway, mevalonate is finally transformed to cholesterol. Statins which have some 
structural similarities with this HMG CoA, can competitively attach to the enzyme and 
block it. Therefore, the speed of cholesterol biosynthesis will decline. Statins play their role 
in angina therapy through other mechanisms, as well.  
Researchers have defined some other modes of actions for statins, rather than lipid 
lowering, in managing heart related diseases like anti-inflammatory, plaque stability and 
prevention of clotting. These beneficial effects are independent from lipid lowering 
characteristics (Furberg 1999). 
 
Name Drug Form Amount of Active Agent Dosage Ranges 
Aspirin Tablets 81 and 325 mg  
Prevention doses: 81 
to 325mg daily or 
every other day; 
Treatment doses: 160 





 Tablets (enteric-coated) 81, 100, 162, 165 and 325 mg 
 Tablets (chewable) 81 and 100 mg 
 Tablets (effervescent) 100 mg 
 Suppositories 120, 125, 200 and 300 mg 
Clopidogrel Tablets 75 mg 75 mg once a day 
Table 5. Available dosage forms of aspirin and clopidogrel for angina treatment 
2.5.2 Pharmacokinetics 
The pharmacokinetic characteristics of statins vary widely due to their different structures 
which determine their water or lipid solubility. Quite lipophilic statins are atorvastatin, 
simvastatin, lovastatin, fluvastatin, cerivastatin and pitavastatin; whereas pravastatin and 
rosuvastatin are relatively hydrophilic. Obviously, the lipophilic compounds have rapid 
absorption and distribute easily in biologic fluids. 
Almost all of lipophilic statins are metabolized hepatically by cytochrome P450 enzymes 
and due to their efficient first-pass effect their bioavailability varies from 5% to 60%. Whilst, 
the hydrophilic statins have longer half lives and excreted both through liver and kidneys. 
HMG CoA reductase inhibitors have half lives ranged from less than 5 hours in simvastatin 
up to 22 hours in pravastatin and 20 – 30 hour in some metabolites of atorvastatin (Garcia, 
Reinoso et al. 2003; Schachter 2004). 
2.5.3 Adverse reactions 
Although statins considered being among the safest drugs, the most important but 
infrequent side effect of statins is because of their metabolism pathway (cytochrome P450) 
which can cause myopathy and hepatotoxicity and of course serious interactions with other 
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substances. Myopathy appears as pain and weakness in muscles and rarely rhabdomyolysis. 
One of statins called cerivasatin was withdrawn from the market due to fatal 
rhabdomyolysis reports, in 2001. 
Other side effects address the liver. Statins can increase amount of hepatic enzymes. This 
increase, if severe, will cause liver damage. Therefore, the medication can be changed to 
another statin.  
2.5.4 Dosage forms 
Atorvastatin, fluvastatin, pravastatin, rosuvastatin and simvastatin are frequently 
prescribed as treatments of angina pectoris. More information about the different 
formulations and dosage of these drugs can be found in table 6.  
 
Generic 
name of beta 
receptor 
antagonist 
Dosage form Amount of active agent Dosage range 
Atorvastatin Tablets (film-coated) 10, 20, 40 & 80 mg 
Starting with 10-40 mg once a 
day, can be increased up to 80 
mg daily for maintenance dose 





80 mg 80 mg once a day 
Pravastatin Tablets 10, 20, 40 & 80 mg 
Usually 40 or 80 mg/day, 
however, it can be 10 or 20 mg in 
renal or hepatic dysfunction 
Rosuvastatin Tablets 5, 10, 20 & 40 mg 5 to 40 mg once daily (max starting dose is 20 mg) 
Simvastatin Tablets 5, 10, 20, 40 & 80 mg 
Starting from 5 or 10 mg and 
continue with up to 80 mg 
Table 6. Statins used in angina therapy. 
3. New drugs with novel mechanisms of action 
3.1 Ranolazine 
Ranolazine is a piperazine derivative which has been proved as an anti-anginal and anti-
ischemic agent. Although its mode of action is totally different from other anti-anginal 
medications and is not clearly understood, some studies show that ranolazine main 
mechanism in angina is through blockade of late Na current in sarcolemma (late INa). 
In patients with heart failure and chronic angina, in addition to normal Na flow into cells 
there is a late Na ion current which increases intracellular Na levels. Elevated levels of Na in 
the cell influence Ca flow and finally contractility of myocardium, leading to incomplete 
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relaxation and heart muscle dysfunction. Ranolazine by inhibition of late Na current helps 
the ischemic condition to recover (Maier 2009).  
Ralolazine has a variable absorption after oral administration. It is highly metabolized in 
liver and intestine. Ranolazine excreted into both feces and urine.  
This drug is available as extended-release tablets and usually is prescribed 500 to 1000 mg 
once daily (FDA 2006; Dvir and Battler 2010). 
3.2 Nicorandil 
Nicorandil is a nicotinamide ester that is classified as an ATP- sensitive potassium channel 
opener and it has also some nitrate-like activating effects. This medication is a vasodilator 
able to dilate both arterial and venous systems resulting in reduced pre- and afterload. 
Nicorandil's nitrate component is responsible for venous vasodilatation and the arteries and 
arterioles vasodilatation is developed by opening K+ channels. 
This potassium channel agonist is highly absorbed from GI. It is not seriously undergo first-
pass effect thus it is expected to have high bioavailability (75-100%). Its major route of 
elimination is kidneys. 
Gastrointestinal ulceration and discomfort, headache, flushing and weakness have been 
reported to be main adverse reactions to nicorandil (Frydman 1992; Hiremath, Valluru et al. 
2010).  
3.3 Ivabradine 
Ivabradine is the first specific and selective inhibitor of the If channel in the sinus node 
become commercialized (If  is a name for mixed Na+-K+ inward flow). This drug has 
bradycardic effects and lowers the heart rate that may prevent myocardial ischemia and 
angina pectoris; however its pharmacologic benefits have not been proved to be useful in 
the whole patients suffering from stable angina. It may be used in patients who have beta-
blockers intolerance. 
Ivabradine is being absorbed completely and has a bioavailability around 40% due to first-
pass effect. Its elimination is mainly through hepatic metabolism. 
Since the f channels are located in the retina as well, the major side effects accompanying 
ivabradine consumption are visual symptoms like headache, dizziness and luminous/visual 
phenomenon. Thus, ivabradine may influence driving task (Macher and Levy 2009; Dvir 
and Battler 2010; Farrer 2010; Fernandez, Tandar et al. 2010). 
3.4 Trimetazidine 
Trimetazidine is a metabolic agent which is considered as the first cytoprotective anti-
ischemic compound. This drug inhibits fatty acid metabolism by partially blocking 3-
ketoacyl CoA thiolase. And by this means, enhances the glucose consumption of 
myocardium, exactly opposed to what happened in ischemia. Therefore, increased glucose 
oxidation will result in decreased oxygen demand.  
Trimetazidine is widely used outside North America as an effective agent for treatment of 
stable angina; however it is not proved to be used in US (Di Napoli and Taccardi 2009; 
Fernandez, Tandar et al. 2010). 
3.5 Fasudil 
Fasudil is a potent rho-kinase inhibitor, Ca+ antagonist and vasodilator. Inhibiting rho-
kinase will influence the contractility of vascular smooth muscle. 
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mechanism in angina is through blockade of late Na current in sarcolemma (late INa). 
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there is a late Na ion current which increases intracellular Na levels. Elevated levels of Na in 
the cell influence Ca flow and finally contractility of myocardium, leading to incomplete 
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relaxation and heart muscle dysfunction. Ranolazine by inhibition of late Na current helps 
the ischemic condition to recover (Maier 2009).  
Ralolazine has a variable absorption after oral administration. It is highly metabolized in 
liver and intestine. Ranolazine excreted into both feces and urine.  
This drug is available as extended-release tablets and usually is prescribed 500 to 1000 mg 
once daily (FDA 2006; Dvir and Battler 2010). 
3.2 Nicorandil 
Nicorandil is a nicotinamide ester that is classified as an ATP- sensitive potassium channel 
opener and it has also some nitrate-like activating effects. This medication is a vasodilator 
able to dilate both arterial and venous systems resulting in reduced pre- and afterload. 
Nicorandil's nitrate component is responsible for venous vasodilatation and the arteries and 
arterioles vasodilatation is developed by opening K+ channels. 
This potassium channel agonist is highly absorbed from GI. It is not seriously undergo first-
pass effect thus it is expected to have high bioavailability (75-100%). Its major route of 
elimination is kidneys. 
Gastrointestinal ulceration and discomfort, headache, flushing and weakness have been 
reported to be main adverse reactions to nicorandil (Frydman 1992; Hiremath, Valluru et al. 
2010).  
3.3 Ivabradine 
Ivabradine is the first specific and selective inhibitor of the If channel in the sinus node 
become commercialized (If  is a name for mixed Na+-K+ inward flow). This drug has 
bradycardic effects and lowers the heart rate that may prevent myocardial ischemia and 
angina pectoris; however its pharmacologic benefits have not been proved to be useful in 
the whole patients suffering from stable angina. It may be used in patients who have beta-
blockers intolerance. 
Ivabradine is being absorbed completely and has a bioavailability around 40% due to first-
pass effect. Its elimination is mainly through hepatic metabolism. 
Since the f channels are located in the retina as well, the major side effects accompanying 
ivabradine consumption are visual symptoms like headache, dizziness and luminous/visual 
phenomenon. Thus, ivabradine may influence driving task (Macher and Levy 2009; Dvir 
and Battler 2010; Farrer 2010; Fernandez, Tandar et al. 2010). 
3.4 Trimetazidine 
Trimetazidine is a metabolic agent which is considered as the first cytoprotective anti-
ischemic compound. This drug inhibits fatty acid metabolism by partially blocking 3-
ketoacyl CoA thiolase. And by this means, enhances the glucose consumption of 
myocardium, exactly opposed to what happened in ischemia. Therefore, increased glucose 
oxidation will result in decreased oxygen demand.  
Trimetazidine is widely used outside North America as an effective agent for treatment of 
stable angina; however it is not proved to be used in US (Di Napoli and Taccardi 2009; 
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3.5 Fasudil 
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kinase will influence the contractility of vascular smooth muscle. 
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One of indications of fusadil is in adjunct therapy of vasospasdic and stable angina (Vicari, 
Chaitman et al. 2005).  
More anti-anginal drugs are under development and further studies and longer follow ups 
are required to establish their place in treatment of patients with coronary artery disease.       
4. Current researches 
Traditional therapies for angina pectoris have focused largely on heart rate reduction and 
coronary vasodilation. On the other hand, considering the pharmaceutical aspect, the 
conventional dosage forms are not sufficient for all medications and in some cases there are 
progressive demands on novel drug formulations to reduce the dose intervals, to obtain 
drug levels constant in patients' blood and release the medication following biological 
rhythm. Additionally, route of administration plays an important role in efficacy and even 
toxicity of the drug. 
4.1 Timed-release drug delivery system 
Drug delivery systems (DDS) that can precisely control the release rates have had an 
enormous impact on the health care system. Of this category controlled-release or sustained-
release drug delivery systems are one of the most beneficial and advantageous drug 
delivery technologies that are used in particular medications to control their release. In the 
last two decades there has been a remarkable improvement in the field of novel drug 
delivery systems. Carrier technology offers an intelligent approach for drug delivery by 
coupling the drug to a carrier particle such as microspheres, nanoparticles, liposomes, etc, 
which modulates the release and absorption characteristics of the drug (Vasir, Tambwekar 
et al. 2003; Dehghan, Aboofazeli et al. 2010).  
The candidates for being embedded in these systems should meet some qualifications, of 
which, short half life, narrow therapeutic index and high first-pass effect can be mentioned. 
As it was shown previously in this chapter, there are several timed-controlled formulations 
available for use in angina therapy. 
4.2 Pulsatile drug delivery system 
It has been proved that in cardiovascular disease there are some morning increases in 
capillary resistance, vascular reactivity and platelet agreeability which decrease latter in the 
day. Therefore, there is a higher possibility (or risk) of myocardial infarction and sudden 
cardiac death before noon rather than evening. Furthermore, the obtained data from several 
studies show that the time of medication administration can influence its pharmacodynamic 
and pharmacokinetic.  
Considering these facts, scientists have developed a novel drug delivery system named 
pulsatile drug delivery based on chronobiology in which drug is released from supporting 
carriers in response to different stimuli. The carriers can react to pH, temperature, magnetic or 
electric field, ultrasound, light and mechanic forces. Carriers are usually polymers which own 
certain characteristics such as safety, biocompatibility ability to respond to external stimuli. 
There are some FDA approved chronotherapeutic products. Verapamil and propranolol are 
two samples of this category which is specifically designed to lower morning increased 
blood pressure. In the near future, there will be medications possessing this technology for 
treatment of angina (portaluppi, 2007 & Mandal, 2010).   
 
Conventional and Novel Pharmacotherapy of Angina Pectoris 87 
5. Conclusion 
Decades of research in these fields results in promising achievements. Still there are several 
studies aiming to develop new agents with novel mechanisms of action, to develop agents 
overcoming the problems and limitations of traditional and conventional medications and 
or their dosage forms more, to carry clinical trials focusing on combination therapy for 
reduction of adverse effects and finally to select the new agents which have mortality benefit 
when added to standard therapy. 
6. References 
Christensen, L., K. Comerford, et al., Eds. (2003). AHFS Drug Handbook, Lippincot Williams 
& Wilkins. 
Cutler, N. R., J. Eff, et al. (1995). "Dose-ranging study of a new, once-daily diltiazem 
fofrmulation for patients with stable angina." J Clin Pharmacol 35(2): 189-195. 
Dehghan, S., R. Aboofazeli, et al. (2010). "Formulation optimization of nifedipine containing 
microspheres using factorial design." African J Pharm and Pharamcol 4(6): 346-354. 
Di Napoli, P. and A. A. Taccardi (2009). "Trimetazidine: the future of cardiac function?" 
Future Cardiol 5(5): 421-424. 
Dvir, D. and A. Battler (2010). "Conventional and novel drug therapeutics to relief 
myocardial ischemia." Cardiovasc Drugs Ther 24: 319-323. 
Farrer, F. (2010). "New or novel drugs 2009." SA Pharm J: 29-33. 
FDA. (2006). "Ranexa (ranolazine) extended-release tablets." from 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021526s004lbl.pdf. 
Fernandez, S. F., A. Tandar, et al. (2010). "Emerging medical treatment for angina pectoris." 
Expert Opin. 15(1): 283-298. 
Fox, K., M. A. Garcia, et al. (2006). "Task force on the management of stable angina pectoris 
of the European Society of Cardiology. ESC committee for practice guidelines 
(CPG). Guidelines on the management of stable angina pectoris: executive 
summarry: the Task Force on the Management of Stable Angina Pectoris of the 
European Society of Cardiology." Eur Heart J 27: 1341-1381. 
Frydman, A. (1992). "Pharmacokinetic profile of nicorandil in humans: an overview." J 
Cardiovasc Pharmacol 20 Suppl 3: S34-44. 
Furberg, C. D. (1999). "Natural statins and stroke risk." Circulation 99: 185-188. 
Garcia, M. J., R. F. Reinoso, et al. (2003). "Clinical pharmacokinetics of statins." Methods Find 
Exp Clin Pharmacol 25(6): 457-481. 
Hankey, G. J., C. L. M. Sudlow, et al. (2000). "Thienopyridines or aspirin to prevent stroke 
and other serious vascular events in patients at high risk of vascular disease?: A 
systematic review of the evidence from randomized trials." Stroke 31: 1779-1784. 
Hartwig-Otto, H. (1983). "Pharmacokinetic considerations of common analgesics and 
antipyretics." Am J Med 75(5A): 30-37. 
Helms, R. A., D. J. Quan, et al. (2006). Textbook of therapeutics. Philadelphia, Lippincott 
Williams & Wilkins. 
Hiremath, J. G., R. Valluru, et al. (2010). "Pharmaceutical aspects of nicorandil." Int J Pharm 
and Pharm Sci 2(4): 24-29. 
Karter, Y. (2007). "Nebivolol: more than a highly selective Beta blocker." Recent Pat 
Cardiovasc Drug Discov 2(2): 152-155. 
 
Angina Pectoris 86
One of indications of fusadil is in adjunct therapy of vasospasdic and stable angina (Vicari, 
Chaitman et al. 2005).  
More anti-anginal drugs are under development and further studies and longer follow ups 
are required to establish their place in treatment of patients with coronary artery disease.       
4. Current researches 
Traditional therapies for angina pectoris have focused largely on heart rate reduction and 
coronary vasodilation. On the other hand, considering the pharmaceutical aspect, the 
conventional dosage forms are not sufficient for all medications and in some cases there are 
progressive demands on novel drug formulations to reduce the dose intervals, to obtain 
drug levels constant in patients' blood and release the medication following biological 
rhythm. Additionally, route of administration plays an important role in efficacy and even 
toxicity of the drug. 
4.1 Timed-release drug delivery system 
Drug delivery systems (DDS) that can precisely control the release rates have had an 
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which modulates the release and absorption characteristics of the drug (Vasir, Tambwekar 
et al. 2003; Dehghan, Aboofazeli et al. 2010).  
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5. Conclusion 
Decades of research in these fields results in promising achievements. Still there are several 
studies aiming to develop new agents with novel mechanisms of action, to develop agents 
overcoming the problems and limitations of traditional and conventional medications and 
or their dosage forms more, to carry clinical trials focusing on combination therapy for 
reduction of adverse effects and finally to select the new agents which have mortality benefit 
when added to standard therapy. 
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1. Introduction 
Ischemic heart disease is the world’s leading cause of mortality and also causes widespread 
morbidity and limitation of life-style. Coronary artery disease (CAD) is the predominant 
cause of ischemic heart disease and generally results from fixed coronary artery obstruction 
that limits myocardial oxygen delivery  relative to demand. Mortality associated with CAD 
is relatively high and was estimated at more than 1¼ million deaths in industrialized 
countries in 2001 (Lopez et al., 2006). Of note, CAD is projected to remain the primary basis 
of mortality at least through year 2030 (Mathers & Loncar, 2006). The impact of CAD on 
quality of life is even more impressive. The symptom that most commonly limits life-style in 
patients with CAD is angina pectoris. Angina pectoris is a symptom characterized by (1) 
substernal chest discomfort that is (2) predictably provoked by exertion or emotional stress, 
(3) lasts up to 20 minutes after the triggering activity is stopped, and (4) is relieved within 
minutes by nitroglycerin or rest. If all of these criteria are met, the symptom is called 
“typical angina pectoris”; if only 2 are met, the symptom is called “atypical angina”. If one 
or none are met, the symptom probably is non-cardiac in origin (Diamond et al., 1983). 
Typical angina has several different causes but predominantly results from CAD. Indeed, 
the presence of typical angina predicts CAD with a likelihood of 90%, while the association 
of atypical angina with CAD is reported to be 50%. CAD with ischemia also can cause other 
symptoms, such as abnormal chest sensations that do not meet the criteria for angina, 
dizziness, palpitation, dyspnea, etc. 
Angina pectoris is the presenting symptom in 50% of those with CAD (O'Rourke, 2010). 
Most often, this symptom is “stable”, i.e., after its onset, it occurs at a relatively predictable 
workload, frequency and severity. By convention, stable angina manifests little change in 
these characteristics over 2 weeks, though some variation can be expected if change occurs 
in myocardial oxygen demand, physical stress or ambient temperature (Braunwald et al., 
1994). In general, stable angina correlates with the stability or quiescence of an 
atherosclerotic plaque. Almost 20% of acute myocardial infarctions (MI) are preceded by 
chronic stable angina (Thom et al., 2006). This symptom must be distinguished from the less 
frequent “unstable angina”, considered to occur when angina first is manifest (“new onset 
angina”), or when angina-like discomfort is present at rest (i.e., without the activity/ 
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these characteristics over 2 weeks, though some variation can be expected if change occurs 
in myocardial oxygen demand, physical stress or ambient temperature (Braunwald et al., 
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atherosclerotic plaque. Almost 20% of acute myocardial infarctions (MI) are preceded by 
chronic stable angina (Thom et al., 2006). This symptom must be distinguished from the less 
frequent “unstable angina”, considered to occur when angina first is manifest (“new onset 





emotional stress trigger of typical angina), or when angina severity and frequency progress 
relatively rapidly. Most importantly, patients with unstable angina can be divided into low, 
intermediate or high short term risk of death or nonfatal MI (Gibbons et al., 1999). Patients 
at high and intermediate risk often have coronary artery plaques that have recently 
ruptured. Their risk of death is intermediate between that of patients with acute MI and 
patients with stable angina. Stable angina pectoris (hereafter denoted as “angina”) is 
common and disabling, affecting 30,000 to 40,000 per 1 million people in Europe and United 
States (Julian, 1997). As of 2006, approximately 10.2 million patients had angina in the 
United States. Angina often seriously limits routine daily activities and frequently leads to 
premature retirement from work (Julian, 1997). Despite availability and application of 
multiple anti-anginal drugs and mechanical therapy, angina remains very common in 
patients with known CAD, affecting 30 to 50% of such individuals (Gehi et al., 2008). One in 
3 patients with stable angina will have more than one episode per week. Epidemiologically, 
self reported angina substantially increases the risk of coronary events compared to its 
absence; this risk increases even more when angina is associated with exercise induced 
ischemia (Gehi et al., 2008). Regardless of the negative impact of angina on quality of life, in 
one study almost half of general practitioners considered angina in their patients to be 
optimally controlled in the face of persistent weekly symptoms (Beltrame et al., 2009).  
This chapter will review therapies currently available and in development for relief of acute 
episodes of angina and, more importantly, for prevention of this symptom in its chronic 
stable form (Table 1). Because, angina from CAD develops from myocardial oxygen supply-
demand imbalance, therapy for patients with CAD and angina is targeted to restore this 
balance. Indeed, the United States Food and Drug Administration will not approve a 
therapy for angina unless both the symptoms and the underlying ischemia are relieved in 
pre-approval testing because of concerns for patient safety if this symptomatic warning of 
ischemia is masked and the inciting activity continues. The major determinants of 
myocardial oxygen demand are heart rate (Fox et al., 2007; Heusch, 2008), systolic blood 
pressure and contractility. Indeed, experimentally, a twofold increase in any of these 
determinants of oxygen consumption requires approximately 50% increase in coronary 
blood flow if ischemia is to be avoided (Libby et al., 2008). The primary determinants of 
myocardial oxygen supply are coronary artery patency, perfusion pressure, arterial oxygen 
content and duration of diastole, when coronary flow occurs. Because of the high resting 
oxygen extraction by myocardial tissue, increase in myocardial oxygen consumption is 
primarily compensated by proportional increases in coronary flow and oxygen delivery.  
In patients with CAD, comprehensive management focuses not only on prevention and 
relief of the symptom but also on prevention of other sequelae common in patients with 
angina, including myocardial infarction, heart failure and death. Importantly, however, 
most antianginal therapies, pharmacological and mechanical, have not been assessed for 
their impact on adverse outcomes in patients with chronic stable angina. Management of 
patients with angina include life style modifications to prevent symptoms as well as to 
minimize known risk factors for adverse events, medications to prevent angina or to relieve 
acute episodes, medications to relieve risk factors (cholesterol-lowering agents, 
antihypertensive drugs, etc.), medications known to prevent other sequelae of CAD (e.g., 
anti-platelet drugs, certain angiotensin converting enzyme inhibitors) and revascularization 
or other mechanical therapy to relieve angina if it is inadequately managed with drugs 
alone. 
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Biological Therapy Putative Actions  
1. Transmyocardial laser 
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2. Angiogenic gene therapy angiogenesis ↑oxygen supply 
HR=heart rate, K=potassium, LV=left ventricle, NO=nitric oxide 
Table 1. Antianginal anti-ischemic therapies, proven and putative 
Therapies shown to be effective in relieving acute episodes are limited to rapid onset, short 
acting nitrates and, though seldom used today, carotid sinus or spinal cord stimulation, all 
reviewed in this chapter. Prevention of angina can be achieved with a variety of drugs, 
though those most frequently employed today are beta blockers, calcium channel blockers 
and long acting nitrates. These and the other newer drugs now available will also be 
reviewed below. The various mechanical options, including coronary artery bypass grafting 
surgery, percutaneous coronary angioplasty, enhanced external counterpulsation, and laser-
mediated angiogenesis, will be summarized. Finally, the current status of approaches that 
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are not yet established but which hold promise for benefit and are under intensive study, 
including angiogenesis stimulated by growth factors directly or by gene insertions, and stem 
cell therapy, will be reviewed. Table 1 summarizes various approaches, pharmacological, 
mechanical and biological, now available or in relatively late stages of development. 
2. Pharmacological therapy 
2.1 Nitrates 
Nitrates have been the staple of treatment for acute episodes of angina pectoris for almost 
150 years, since the description of the effect of amyl nitrate for this condition in 1867 
(Brunton, 1867). Indeed, such use of amyl nitrate was included in the Lillian Hellman play, 
“The Little Foxes”, set just after the Civil War. Though the use of amyl nitrate has declined 
to application largely for diagnostic hemodynamic profiling for other conditions (e.g., 
idiopathic hypertrophic subaortic stenosis) other nitrates and, most particularly 
nitroglycerin, introduced by Murrell for this purpose in 1878 (Murrell, 1879), have gained 
enduring use, both for treatment of acute episodes and for prophylaxis.  
2.1.1 Pharmacological effects  
Like all anti-anginal anti-ischemic drugs, nitrates act to improve the imbalance of 
myocardial oxygen supply and demand that underlies angina (Grayson et al., 1967). Nitrates 
are believed to induce vasodilatation by interacting with sulfhydryl groups on nitrate 
receptors on cell membranes (Goldstein, 1979). The prototype nitrate, nitroglycerin, 
combines with sulfhydryls within smooth muscle cells, where the resulting molecule is 
biotransformed to an active form, S-nitrosothiol, by mitochondrial aldehyde dehydrogenase 
(Abrams, 1980). This short-lived compound activates intracellular guanylate cyclase to 
produce cyclic guanosine monophosphate. This molecule directly initiates smooth muscle 
relaxation to cause vasodilatation by decreasing myocytic intracellular calcium, either by 
inhibition of calcium ion entry or by promotion of calcium exit (Ignarro et al., 1981). This 
pharmacological effect renders nitroglycerin a potent vasodilator. Experimental studies 
suggest that nitroglycerin’s action as a venodilator may exceed that as an arterial and 
arteriolar dilator, though the drug acts on both sides of the circulation. It has been suggested 
that reduction in left ventricular (LV) preload, resulting from venous dilatation, is the 
primary basis for the drug-induced reduction in myocardial oxygen demand and, perhaps, 
the increase in myocardial oxygen supply observed with nitroglycerin and, thus, may be the 
primary basis for its anti-anginal anti-ischemic effect (Goldstein, 1979). However, reduction 
in LV outflow impedance due its arterial and arteriolar effects likely also is involved.  
Experimental evidence suggests that nitrates also may act directly to increase myocardial 
oxygen supply by dilatation of coronary arteries and arterioles. Conversion to nitric oxide, a 
deficiency of which is the putative basis of “endothelial dysfunction” observed in many 
patients with CAD (Parker & Parker, 1998), provides potential for vasodilatation and 
enhancement of coronary blood flow. However, the practical importance of this effect is 
unclear, since the calcified state of many atherosclerotic coronary arteries is likely to limit 
potential for arterial dilatation. Experimental evidence also suggests nitroglycerin may 
preferentially affect collateral vessels within the myocardium to increase flow to ischemic 
regions. Finally, as a result of preload reduction, nitroglycerin reduces LV diastolic pressure 
potentially enhancing perfusion pressure during diastole when most coronary flow occurs. 
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are not yet established but which hold promise for benefit and are under intensive study, 
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oxygen supply by dilatation of coronary arteries and arterioles. Conversion to nitric oxide, a 
deficiency of which is the putative basis of “endothelial dysfunction” observed in many 
patients with CAD (Parker & Parker, 1998), provides potential for vasodilatation and 
enhancement of coronary blood flow. However, the practical importance of this effect is 
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potentially enhancing perfusion pressure during diastole when most coronary flow occurs. 





vulnerable, though little change in total myocardial perfusion appears to be associated with 
this effect (Bottcher et al., 2002). Finally, in experimental studies, nitroglycerin has 
antithrombogenic action, apparently mediated via stimulation of guanylate cyclase in 
platelets (Munzel et al., 2002). This effect would tend to minimize platelet aggregation. The 
clinical importance of this change, particularly for angina, is not known.  
Irrespective of the underlying mechanisms, nitrates have been well demonstrated to 
increase exercise tolerance in patients with ischemic heart disease from CAD, while 
reducing ischemia as measured by increased time to ST segment depression during exercise 
in patients with chronic stable angina (Ben-Dor & Battler, 2007). Nitrates have additive effect 
when they are combined with beta-blockers or calcium channel blockers (Gibbons et al., 
2003).  
2.1.2 Clinical application 
Nitroglycerin preparations are available as sublingual tablets, buccal spray and ointment 
(both in immediately available and prolonged release [“patch”] forms), the latter for 
prophylaxis rather than for treatment of acute episodes. Nitroglycerin tablets lose potency 
when exposed to light and, hence, are stored in dark containers. The sublingual preparation 
is the treatment of choice for acute episodes of angina because this mode of administration 
enables absorption without first pass metabolism in the liver, resulting rapidly in 
therapeutic concentrations in the circulation. (Buccal spray has a similar advantage.) From 
drug levels in the plasma, the half-lives of the compounds differ markedly, nitroglycerin 
having a half-life of 2-3 min, isosorbide dinitrate (ISDN) 20-30 min and isosorbide 
mononitrate (ISMN) 4-5 h (Olsson & Allgen, 1992). The beneficial clinical effect of 
nitroglycerin has a half-life of 30 minutes; its hemodynamic effects are seen even after 2 
hours (Goldstein & Epstein, 1973). 
Metabolism to inactive forms occurs in the liver. The usual dose of nitroglycerin for relief of 
an acute angina episode is 0.4 mg by the sublingual route, though smaller (and larger) doses 
are effective in some patients. Nitroglycerin spray dispenses 0.4 mg metered, aerosolized 
doses, which are better absorbed in patients with dry mucous membranes. There is evidence 
to show that when used in sublingual form, nitroglycerin is an effective antianginal and 
anti-ischemic agent that can abort an attack of established angina and, when taken 
prophylactically, prolong exercise tolerance (Aronow, 1973; Detry & Bruce, 1971; Goldstein 
et al., 1971). If symptoms persist after a single dose, additional doses can be given, usually at 
5 minute intervals, though lack of relief with as much as 1.2 mg in a 15 minute interval 
suggests an acute coronary syndrome and should lead to emergency evaluation. Several 
long acting forms of nitrates have been developed. Their pharmacokinetics are such that 
they are not used for relief of acute angina episodes, but their persistence in the circulation 
and at active cellular sites can provide effective prophylaxis against angina. The most 
commonly employed are topical nitroglycerin ointment or nitroglycerin adherent to patches, 
oral ISDN and oral ISMN.  
Topical cutaneous administration of nitroglycerin is possible either with an ointment or a 
polymer patch impregnated with the drug. Nitroglycerin ointment usually is applied in 0.5 
– 2 inch doses, containing 15 mg of nitroglycerin per inch. The drug is effective for about 6 
hours by this route. Absorption can be impeded if skin perfusion is minimized by 
hypotension or impaired cardiac output. Nitroglycerin patches release the drug at a rate of 
0.1 to 0.8 mg/hour (depending on patch size) and are effective for approximately 12 to 18 
hours. Tolerance generally is absent if the patch is used for no more than 12 to 14 hours 
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daily. Oral ISDN has relatively low bioavailability, undergoing rapid hepatic metabolism. It 
is usually administered in a dose of 30 mg 3 to 4 times daily. The antianginal effect lasts for 6 
hours after the first dose, with decreased effect with each successive dose. Nitrate tolerance 
develops when it is administered four times daily. A dosing schedule permitting 
intermittent 10-12 hour nitrate free intervals helps to prevent tolerance.  
ISMN is the active metabolite of ISDN. When administered orally, it doesn’t undergo first 
pass metabolism and provides effective management of chronic stable angina. Steady state 
plasma concentration is achieved within 2 hours and its effect lasts for at least 8 hours. 
Tolerance is not reported when ISMN is administered once daily, but tolerance is common 
with twice daily dosing. A sustained release preparation is available in a dosage range from 
30 to 240 mg daily. Nitroglycerin can also be used as an intravenous preparation with 
titration to symptoms and blood pressure. Though not strictly relevant for relief of chronic 
stable angina, this form has been used for patients with frequent (“unstable”) angina at rest 
and requiring hospitalization (Frishman, 1985). It has also been used during acute coronary 
syndromes and has been effective in reducing ischemia during acute myocardial infarction 
(Borer et al., 1975) as well as in improving hemodynamics and reducing symptoms in heart 
failure, with or without infarction (Frishman, 1985).  
2.1.3 Adverse effects  
Most common adverse effects of nitrates and, specifically, of nitroglycerin, include 
headache, hypotension and flushing. These effects are due to vasodilatation. 
Methemoglobinemia is rare but reported after nitrate administration, most commonly after 
high doses of the intravenous form. Tolerance is reported with all forms of nitroglycerin. 
Tolerance to antianginal effects develops rapidly in humans during long-term, 4 times daily 
therapy with ISDN and continuous therapy with nitroglycerin patches (Crean et al., 1984; 
James et al., 1985; Parker & Fung, 1984; Reichek et al., 1984). The putative mechanism of 
tolerance is drug-induced generation of superoxide anions in the affected vessels, leading to 
impaired biotransformation and decreased responsiveness to nitric oxide (Gori & Parker, 
2004). Tolerance can be best avoided by providing a nitrate free period, optimally of 10 to12 
hours. Development of tolerance is rarely a problem when nitroglycerin sublingual tablets 
are taken intermittently, either for relief of an acute symptom or for short-term prophylaxis 
before activities predictably associated with angina. Some studies have shown that 
angiotensin receptor blockers may prevent nitrate tolerance (Hirai et al., 2003). Patients can 
develop rebound symptoms after abruptly stopping nitrates. With the recent increase in the 
use of sildenafil, a phosphodiesterase inhibitor, the dangers of interaction with nitrates have 
been highlighted, leading to proscription of this combination to prevent severe and 
potentially lethal hypotension.  
2.2 Calcium channel blockers 
Calcium Channel Blockers (CCB) bind to and inhibit L-type calcium channels, reducing 
calcium influx into cells. Intracellular calcium deprivation relaxes smooth muscle cells, 
causing vasodilatation in the peripheral and coronary beds and, in normal coronary arteries 
and perhaps diseased arteries, increased coronary blood flow. The 2 major subdivisions of 
CCBs are dihydropyridines (DHP) like nifedipine, amlodipine, felodipine, and nicardipine, 
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2.2.1 Pharmacological effects  
CCBs’ main effect on angina is lowering myocardial oxygen demand by peripheral vascular 
smooth muscle relaxation. The result is to reduce blood pressure and impedance to LV 
outflow, in turn reducing myocardial wall tension, myocardial work load and oxygen 
consumption. However, they may cause dilatation of coronary arteries, as well, and thus 
may increase coronary blood flow/ myocardial perfusion. CCBs have been shown to be 
specifically and particularly effective in vasospastic angina pectoris (including “Prinzmetal’s 
angina”) and may be useful in effort-induced angina in part by relieving vasospasm 
associated with fixed obstructive lesions in some patients. In addition to vascular smooth 
muscle relaxation, the non-dihydropyridines also cause blockade of calcium entry into 
myocytes, leading to negative chronotropic effects due to action on the sinoatrial and 
atrioventricular nodal cells, and negative inotropic effects leading to depressed contractility 
due to action on ventricular myocytes. 
Experimentally, calcium plays an integral role in the process of atherogenesis. Hence, it has 
been theorized that CCBs are anti-atherogenic. Some studies have shown that CCBs reduce 
the progression of atherosclerosis as measured by carotid intima-media thickness but there 
has been no difference in coronary atherosclerosis. The ENCORE I trial demonstrated that 
nifedipine improved coronary endothelial function in the most constricted segment 
(Azancot, 2003) and the ENCORE II study showed that nifedipine improved coronary 
endothelial function but had no effect on plaque volume (Luscher et al., 2009). The NICOLE 
study showed no effect of CCBs on reduction of angiographic progression of CAD (Dens et 
al., 2003). Thus, clinical studies to date provide equivocal evidence of anti-atherogenesis but 
stronger support for improvement of endothelial function. 
2.2.2 Clinical application  
From multiple trials, CCBs decrease the frequency of angina, reduce the need for nitrates, 
extend treadmill walking time, and improve ischemic ST-segment changes on exercise 
testing and electrocardiographic monitoring (Gibbons et al., 2003; Heidenreich et al., 1999; 
Nissen et al., 2004; Rice et al., 1990). Amlodipine, in particular, may have some independent 
action in relieving diastolic dysfunction other than by a reduction in blood pressure (Tapp et 
al., 2010), potentially improving myocardial oxygen supply by enhancing perfusion 
pressure. CCBs are used in patients who cannot tolerate β-blockers or in combination with 
other anti-ischemic agents for additive benefit. Though clearly effective antianginal agents, 
CCBs have not been found to modify the natural progression of CAD and have no effect on 
cardiovascular or all cause mortality in patients with CAD. DHP tend to cause reflex 
tachycardia because of lowering of blood pressure; this effect can be blunted by concomitant 
use of β-blockers. If clinically needed, verapamil or diltiazem may be used with caution to 
lower heart rate or slow atrioventricular (AV) conduction further when ventricular function 
is preserved. In a case control study among enrollees of the Group Health Cooperative of 
Puget Sound, a link was reported between short-acting nifedipine and coronary events 
when the drug was used as primary therapy for hypertension (Psaty et al., 1995). However, 
short-acting nifedipine never has been approved by the FDA for use for this indication (i.e., 
its use was “off label”), and its application for this purpose by the Puget Sound group was 
an act of highly questionable judgment. Meta-analysis by Furberg et al showed that 
nifedipine is associated with dose related increase in mortality in patients with CAD, a 
study which included patients with acute coronary syndromes (ACS) (Furberg et al., 1995). 
However, the only trial included in the meta-analysis that involved patients with stable 
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angina was the International Nifedipine trial on Antiatherosclerotic Therapy (INTACT), 
which showed that patients on nifedipine had retardation of atherosclerotic disease by 
angiogram, though clinical symptoms were not reported (Lichtlen et al., 1990). A Coronary 
Disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system 
(ACTION) study reported that, in patients with stable angina and hypertension, long-acting 
nifedipine was acceptably safe (no increased incidence of myocardial infarction, heart 
failure or death), but there was no evidence of improvement in mortality or other major 
cardiac endpoints and no reduction in refractory angina in already maximally medically 
treated patients (Poole-Wilson et al., 2004; Sierra & Coca, 2008). In addition to 
vasodilatation, verapamil acts in part through its negative inotropic effect. Diltiazem has 
greater vasodilatory actions than verapamil. Both verapamil and diltiazem are 
contraindicated in patients with uncompensated heart failure because of their negative 
inotropic effects, whereas amlodipine and felodipine are relatively safe when LV 
dysfunction is present, particularly if compensated clinically (Sierra & Coca, 2008). Use of 
non-dihydropyridines after complex myocardial infarctions should be avoided, as well, 
because of the possibility of HF. 
Although CCBs are effective anti-ischemic agents, they do not improve mortality in patients 
with ACS. DHP can also cause reflex tachycardia which can be deleterious in acute ischemia 
by increasing myocardial oxygen demand. In addition, DHP-induced hypotension may 
detrimentally lower coronary perfusion pressure. A meta-analysis of trials of CCBs and long 
acting nitrates did not show any difference in clinical outcomes between these types of 
agents (Heidenreich et al., 1999). Nifedipine is a potent, long-acting vasodilator that has 
proved highly efficacious in relieving angina caused by coronary vasospasm. In vivo, it 
exerts no myocardial depressant effects and has no antiarrhythmic properties. Nifedipine is 
available in doses of 10-30 mg given 3 times daily and in sustained release preparations in 
doses of 60 to 120 mg that can be administered once daily. Onset of action is 20 minutes after 
administration and half life is 2-5 hours. Steady state concentrations are reached in 48 hours. 
Immediate release formulation is not recommended for hypertension because of concerns of 
sudden hemodynamic compromise but it is still approved for coronary spasm and 
management of angina. Treatment with nifedipine can safely be combined with 
administration of a β receptor blocking agent.  
Verapamil is usually started with 40 mg three times daily and titrated to a maximum dose of 
480 mg daily. Sustained release preparations are available and can be given in doses of 120 
mg daily to 480 mg daily. Onset of action of verapamil is in 30 minutes; elimination half life 
is 3-7 hours. Diltiazem is available in doses of 30-90 mg given up to four times daily. A 
sustained release or long-acting form usually is administered at a starting dose of 120 mg 
daily and can be increased to 360 mg daily. Its onset of action is within 30-60 minutes and it 
has a half life of 3-7 hours. It can take up to 2 weeks to achieve maximal effect of diltiazem. 
2.2.3 Adverse effects  
Common side effects of headache, dizziness, flushing and edema (particularly with DHP) 
are due to vasodilatation. Verapamil and diltiazem can interact with other negative 
chronotropic or negative inotropic agents to produce substantial bradycardia, conduction 
disturbances or clinically overt heart failure. CCBs may also suppress lower esophageal 
sphincter contraction and worsen gastroesophageal reflux. Particularly with verapamil and, 
to a lesser extent with diltiazem, bowel motility can be importantly reduced, causing 
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doses of 60 to 120 mg that can be administered once daily. Onset of action is 20 minutes after 
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drugs. CCBs inhibit the CYPA4 enzyme in the liver and, therefore, may raise levels of statins 
and  other drugs, resulting in adverse effects of the drugs so affected (Furberg et al., 1978). 
By blocking the microsomal enzymes, the liver enzymes that metabolize CCBs, cimetidine 
and grapefruit juice may raise blood CCB concentrations. Since magnesium is a calcium 
antagonist, magnesium supplements may enhance the actions of CCBs, particularly 
nifedipine. 
2.3 Beta-blockers 
Adrenergic receptors are G-protein-coupled molecules stimulated by circulating 
catecholamines. These receptors are broadly classified into α and β groups. Effects of β-
receptors are mediated by adenyl cyclase. β-receptors are further classified into β1 and β2 
subtypes. β1 stimulation results in increased chronotropy, inotropy, automaticity, release of 
renin from juxtaglomerular cells and lipolysis. β2 effects include relaxation of bronchial, 
vascular and other smooth muscle, with dilatation of peripheral, coronary, and carotid 
arteries, and promotion of glycogenolysis and gluconeogenesis. β-blockers are effective in 
preventing angina because they lower heart rate, reduce blood pressure, and reduce 
contractility, thereby reducing myocardial oxygen demand (Gibbons et al., 2003). However, 
of these effects, current data indicate that the most important is reduction in heart rate, the 
primary determinant of myocardial oxygen demand (Andrews et al., 1993; Borer et al., 2003; 
Daly et al., 2010). Most antianginal effects of β-blockers result from β1 inhibition. Also, 
because of the heart rate reduction, β-blockers can enhance myocardial oxygen supply by 
prolonging diastole, when coronary perfusion occurs. However, by blocking β2 receptors 
that can mediate coronary vasodilatation, some β-blockers can allow unopposed α-
adrenergic stimulation, leading to coronary vasoconstriction and mitigating the potentially 
beneficial effects of prolongation of diastole. β-blockers also have negative lusitropic 
(relaxation) effects on the myocardium, minimizing the rate at which LV pressure falls 
during diastole and, thus, minimizing the increase in perfusion pressure that otherwise 
might be expected during prolonged diastole that drives coronary flow. 
2.3.1 Pharmacological effects  
Some β-blockers are partial agonists, manifesting intrinsic sympathomimetic activity, 
blunting secondary preventive benefits (Freemantle et al., 1999). These generally are not 
used for angina prevention. Some newer β-blockers, such as labetalol, carvedilol, and 
bucindolol, also have partial α1-adrenergic blocking effects, causing vasodilatation. Others 
have antiarrhythmic effects – propranolol, metoprolol, and carvedilol have effects similar to 
“class I” (sodium-channel blockade) antiarrhythmics, while sotalol has a “class III” 
(potassium channel blockade) effect. Further, experimentally, carvedilol and its metabolites 
have antioxidant and antiproliferative properties that inhibit apoptosis. Most β-blockers are 
well absorbed. β-blockers that are lipid-soluble, such as propranolol and metoprolol, have 
short half-lives because they are metabolized by the liver. Hydrophilic β-blockers such as 
atenolol and nadolol are eliminated through kidney and have longer half-lives.  
Atenolol is usually started with a dose of 50 mg daily and can be titrated to a suggested 
maximal dose of 200 mg daily. Metoprolol can be started with 50-100 mg daily and titrated 
for heart rate and blood pressure. When used to prevent angina, β-blockers generally are 
titrated to a resting heart rate of 50–60 bpm and an exercise heart rate 75% of the rate that 
precipitates ischemia. In patients with severe angina, target heart rates of 50 bpm are 
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sometimes used if neither symptoms (fatigue, lightheadedness) nor atrioventricular block 
supervenes. 
2.3.2 Clinical application  
β-blockers have been primary therapeutics for angina management  since early after their 
development (Hoekenga & Abrams, 1984); indeed, slowing heart rate to prevent angina was 
the primary reason for their development, for which a Nobel Prize was awarded. Many β-
blockers have been studied in chronic stable angina (Furberg et al., 1978; Jackson et al., 
1978). β-blockers have been shown to reduce mortality in patients with relatively recent MI, 
primary angioplasty for ST elevation MI and CHF with LV dysfunction. However, no 
randomized trials ever have been performed to assess the effects of β-blockers on natural 
history outcomes in patients only with stable angina. Hence β-blockers are titrated for 
maximal symptom benefit with least adverse effects. No differences have been shown in 
antianginal effects of different beta blockers when they are titrated to similar heart rate 
reductions. β-blockers can be combined with nitrates, CCBs and other antianginals to 
enhance symptom relief. 
2.3.3 Adverse effects  
Absolute contraindications to β-blockers are severe bradycardia with or without conduction 
system disease, severe asthma or peripheral vascular disease with rest ischemia, depression, 
and acute decompensated heart failure (HF). β-blockers may cause dyslipidemia (increase in 
triglycerides and decrease in high-density lipoprotein cholesterol). The most common 
adverse effect is fatigue, a common complaint of patients receiving these agents. Mild 
depression, lack of motivation and erectile dysfunction have been well reported. β-blockers 
may blunt the tachycardic response to hypoglycemia in diabetics; worsening of 
hypoglycemia in diabetics on oral agents or insulin has been reported. β-blockers enhance 
insulin resistance, possibly accounting for the hyperglycemia. Patients with cocaine-induced 
coronary vasoconstriction may also react adversely when given β-blockers, with 
hypertension and seizures. Similarly, since β-adrenergic receptors may be up-regulated 
when patients are treated with β-blockers, these agents should not be abruptly discontinued, 
lest rebound vasoconstriction precipitate unstable angina or even MI or death (Miller et al., 
1975; Psaty et al., 1990). Patients with asthma, claudication, or HF whose symptoms increase 
with β-blockers should be appropriately monitored and reevaluated for possible 
substitution with CCBs. 
2.4 Ranolazine 
Ranolazine is a piperazine derivative that has been shown to prevent stable angina pectoris. 
This agent was approved by FDA in 2006 for use in combination with other antianginals 
when angina is not adequately controlled with established therapies. 
2.4.1 Pharmacological effects 
The pharmacological effects most likely to underlie ranolazine’s antianginal action are not 
fully elucidated. Several such effects have been suggested. Ranolazine has been shown to 
alter myocyte metabolism to favor oxidation of glucose over fatty acid by partial fatty acid 
oxidation (p-FOX) (Clarke et al., 1996). Less oxygen is required to metabolize glucose than 
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allowing more mechanical activity for a given oxygen supply. However, in formal clinical 
testing, though time to angina was increased with ranolazine versus placebo, no evidence 
was found that cardiac workload at angina was increased when angina occurred, thus 
casting doubt on improved metabolic efficiency as the underlying cause of the drug’s 
benefit. Experimentally, ranolazine reduces calcium overload in the ischemic myocyte 
through inhibition of the late sodium current (INa) (Antzelevitch et al., 2004; Belardinelli L, 
2004). Excess intracellular sodium activates the sodium-calcium exchanger and can result in 
intracellular calcium overload via reverse transport of the sodium calcium exchanger. 
Ranolazine appears to minimize the intracellular consequences of myocardial ischemia by 
reducing excess late sodium ion influx, thereby reducing calcium overload (Chaitman & 
Sano, 2007). Indeed, the drug is now labeled to indicate that sodium channel inhibition is the 
most likely basis of its activity. However, the drug also has modest alpha- and β-blocking 
properties. Ranolazine is extensively metabolized by cytochrome P450 (mainly the 3A4 
enzyme) and excreted mainly in urine, predominantly as metabolites (Abdallah & Jerling, 
2005; Chu N, 2003). The elimination half life in healthy individuals is 5.3 to 8.9 hours which 
is significantly increased in severe renal impairment (Jerling & Abdallah, 2005).  
2.4.2 Clinical application  
Ranolazine has been investigated in Monotherapy Assessment of Ranolazine in Stable 
Angina (MARISA) trial, in which the drug was found to be well tolerated and effective in 
increasing exercise duration and time to ST segment depression in a dose dependent 
manner (Chaitman, 2002). In the Combination Assessment of Ranolazine in Stable Angina 
(CARISA) study, ranolazine was compared to placebo on a background of treatment with 
either atenolol 50 mg daily, amlodipine 5 mg daily, or diltiazem 180 mg daily. Ranolazine 
was effective in increasing exercise duration and mean time to onset of angina compared to 
placebo. There was also reduction in the frequency of angina as well as nitroglycerin use 
compared to placebo. In this trial, a higher dose of ranolazine (1000 mg twice daily) 
provided no extra benefit compared to the lower dose (750 mg twice daily) (Chaitman et al., 
2004). In the Efficacy of Ranolazine in Chronic Angina (ERICA) trial, ranolazine was 
compared to a placebo on a background of amlodipine 10 mg daily. Again, ranolazine 
resulted in lower frequency of angina and nitroglycerin consumption and similar frequency 
of adverse effects (Stone et al., 2006). In the Metabolic Efficiency with Ranolazine for Less 
Ischemia in Non-ST Elevation (MERLIN-TIMI-36) trial, 6560 patients with acute coronary 
syndromes were randomized within 48 hours of symptom onset, to intravenous ranolazine 
or a placebo, in addition to standard therapy. Ranolazine was administered as a bolus of 200 
mg over 1 hour and then continued as an infusion for 12 to 96 hours, followed by 1000 mg 
twice daily orally. After a median follow-up of 348 days, there was no difference in all-cause 
mortality, sudden cardiac death, or frequency of symptomatic arrhythmias between 
ranolazine and placebo. Though the trial failed to support ranolazine as a means of 
improving natural history in patients with CAD, it demonstrated the overall favorable 
safety profile of ranolazine, crucial for its FDA approval given prior concerns about drug-
induced syncope and ECG QT prolongation with possible “pro-arrhythmia”, while 
supporting its effectiveness in reducing angina (Morrow et al., 2007).  
2.4.3 Adverse effects  
Ranolazine is fairly well tolerated. Adverse effects (primarily dizziness, nausea, asthenia 
and constipation) appear to be dose related. Thus, in clinical trials, fewer than 8% of patients 
 
Therapy for Angina Pectoris Secondary to Coronary Disease 
 
101 
discontinued ranolazine due to adverse effects; three quarters of these withdrawals occurred 
at the 1500 mg twice daily dose. Consequently, the approved starting dose is 500 mg twice 
daily, with possible up titration to 750 mg twice daily and 1000 mg twice daily if lower 
doses do not adequately prevent angina (Chaitman et al., 2004). An extended release (ER) 
oral preparation is also available. Ketoconazole and diltiazem can increase ranolazine 
plasma concentrations; ranolazine increases digoxin plasma concentration (Jerling & 
Abdallah, 2005; Chaitman et al., 2004). Ranolazine prolongs QTc interval in a dose related 
manner but, as noted above,  MERLIN-TIMI 36 failed to demonstrate excessive sudden 
death with the drug (Scirica et al., 2007),  nor were these suggested in earlier, shorter trials. 
2.5 Ivabradine 
The principle of heart rate slowing for prevention of angina is well established based on 
pathophysiological studies and clinical assessments of heart rate lowering drugs (Daly et al., 
2010). Indeed, heart rate is the major determinant of myocardial oxygen demand and its 
increase is a precipating factor for ischemia or angina (Andrews et al., 1993; Borer et al., 
2003; Daly et al., 2010; Fox et al., 2007; Heusch, 2008; Tardif et al., 2005). Heart rate also 
predicts outcome in epidemiologic studies of patients with CAD, as well as those with heart 
failure, hypertension, and, indeed, in unselected free living populations without apparent 
heart disease (Daly et al., 2010; Diaz et al., 2005; Fox et al., 2007; Fox et al., 2008; Fox et al., 
2008; Tardif et al., 2009). For example, the Coronary Artery Surgery Study (CASS) registry 
showed after a 14 year follow-up that cardiovascular and overall mortality was directly 
related to heart rate at entry into the study (Diaz et al., 2005). Similar results were seen in the 
placebo group of the prospective BEAUTIFUL [morBidity-mortality EvAlUaTion of the If 
inhibitor ivabradine in patients with coronary disease and left-ventricULar dysfunction] 
trial and in a retrospective assessment of the Treating to New Targets [TNT] study (Fox et 
al., 2008; Ho et al., 2010). 
2.5.1 Pharmacological effects  
As heart rate increases progressively myocardial oxygen demand increases (increase in 
myocardial work) and myocardial blood flow (and with it, potential myocardial oxygen 
supply) decreases because of reduction in the duration of diastole, when coronary flow 
occurs. When a threshold value is reached at which demand is greater than supply, ischemia 
results, often causing angina. Thus, Andrews et al showed that heart rate is a predictor of 
coronary ischemia in patients with stable CAD (Andrews et al., 1993). Ivabradine selectively 
inhibits the inward sodium–potassium If current, a relatively low amplitude primary 
modifier of the rate of spontaneous depolarization of the sino-atrial (SA) node myocytes 
(discovered in 1979 by DiFrancesco, et al (Brown et al., 1979; DiFrancesco & Camm, 2004)). 
Spontaneous depolarization, itself, is a function of other calcium and potassium currents. 
Ivabradine has no other known pharmacological actions on normal cardiovascular 
physiology. Therefore, it is considered a pure heart rate slowing drug (Thollon et al., 1994). 
Resting heart rate lowering by ivabradine is comparable to that achieved with β-blockers 
and is greater than that associated with CCBs (Pine et al., 1982; Tardif et al., 2005) for equal 
antianginal effect. The heart rate reduction is dose dependent (Borer et al., 2003; Thollon et 
al., 1994). Ivabradine is a selective and specific If inhibitor; it has no inotropic effect, no effect 
on relaxation (luisotropy), no impact on AV nodal conduction and no coronary 





allowing more mechanical activity for a given oxygen supply. However, in formal clinical 
testing, though time to angina was increased with ranolazine versus placebo, no evidence 
was found that cardiac workload at angina was increased when angina occurred, thus 
casting doubt on improved metabolic efficiency as the underlying cause of the drug’s 
benefit. Experimentally, ranolazine reduces calcium overload in the ischemic myocyte 
through inhibition of the late sodium current (INa) (Antzelevitch et al., 2004; Belardinelli L, 
2004). Excess intracellular sodium activates the sodium-calcium exchanger and can result in 
intracellular calcium overload via reverse transport of the sodium calcium exchanger. 
Ranolazine appears to minimize the intracellular consequences of myocardial ischemia by 
reducing excess late sodium ion influx, thereby reducing calcium overload (Chaitman & 
Sano, 2007). Indeed, the drug is now labeled to indicate that sodium channel inhibition is the 
most likely basis of its activity. However, the drug also has modest alpha- and β-blocking 
properties. Ranolazine is extensively metabolized by cytochrome P450 (mainly the 3A4 
enzyme) and excreted mainly in urine, predominantly as metabolites (Abdallah & Jerling, 
2005; Chu N, 2003). The elimination half life in healthy individuals is 5.3 to 8.9 hours which 
is significantly increased in severe renal impairment (Jerling & Abdallah, 2005).  
2.4.2 Clinical application  
Ranolazine has been investigated in Monotherapy Assessment of Ranolazine in Stable 
Angina (MARISA) trial, in which the drug was found to be well tolerated and effective in 
increasing exercise duration and time to ST segment depression in a dose dependent 
manner (Chaitman, 2002). In the Combination Assessment of Ranolazine in Stable Angina 
(CARISA) study, ranolazine was compared to placebo on a background of treatment with 
either atenolol 50 mg daily, amlodipine 5 mg daily, or diltiazem 180 mg daily. Ranolazine 
was effective in increasing exercise duration and mean time to onset of angina compared to 
placebo. There was also reduction in the frequency of angina as well as nitroglycerin use 
compared to placebo. In this trial, a higher dose of ranolazine (1000 mg twice daily) 
provided no extra benefit compared to the lower dose (750 mg twice daily) (Chaitman et al., 
2004). In the Efficacy of Ranolazine in Chronic Angina (ERICA) trial, ranolazine was 
compared to a placebo on a background of amlodipine 10 mg daily. Again, ranolazine 
resulted in lower frequency of angina and nitroglycerin consumption and similar frequency 
of adverse effects (Stone et al., 2006). In the Metabolic Efficiency with Ranolazine for Less 
Ischemia in Non-ST Elevation (MERLIN-TIMI-36) trial, 6560 patients with acute coronary 
syndromes were randomized within 48 hours of symptom onset, to intravenous ranolazine 
or a placebo, in addition to standard therapy. Ranolazine was administered as a bolus of 200 
mg over 1 hour and then continued as an infusion for 12 to 96 hours, followed by 1000 mg 
twice daily orally. After a median follow-up of 348 days, there was no difference in all-cause 
mortality, sudden cardiac death, or frequency of symptomatic arrhythmias between 
ranolazine and placebo. Though the trial failed to support ranolazine as a means of 
improving natural history in patients with CAD, it demonstrated the overall favorable 
safety profile of ranolazine, crucial for its FDA approval given prior concerns about drug-
induced syncope and ECG QT prolongation with possible “pro-arrhythmia”, while 
supporting its effectiveness in reducing angina (Morrow et al., 2007).  
2.4.3 Adverse effects  
Ranolazine is fairly well tolerated. Adverse effects (primarily dizziness, nausea, asthenia 
and constipation) appear to be dose related. Thus, in clinical trials, fewer than 8% of patients 
 
Therapy for Angina Pectoris Secondary to Coronary Disease 
 
101 
discontinued ranolazine due to adverse effects; three quarters of these withdrawals occurred 
at the 1500 mg twice daily dose. Consequently, the approved starting dose is 500 mg twice 
daily, with possible up titration to 750 mg twice daily and 1000 mg twice daily if lower 
doses do not adequately prevent angina (Chaitman et al., 2004). An extended release (ER) 
oral preparation is also available. Ketoconazole and diltiazem can increase ranolazine 
plasma concentrations; ranolazine increases digoxin plasma concentration (Jerling & 
Abdallah, 2005; Chaitman et al., 2004). Ranolazine prolongs QTc interval in a dose related 
manner but, as noted above,  MERLIN-TIMI 36 failed to demonstrate excessive sudden 
death with the drug (Scirica et al., 2007),  nor were these suggested in earlier, shorter trials. 
2.5 Ivabradine 
The principle of heart rate slowing for prevention of angina is well established based on 
pathophysiological studies and clinical assessments of heart rate lowering drugs (Daly et al., 
2010). Indeed, heart rate is the major determinant of myocardial oxygen demand and its 
increase is a precipating factor for ischemia or angina (Andrews et al., 1993; Borer et al., 
2003; Daly et al., 2010; Fox et al., 2007; Heusch, 2008; Tardif et al., 2005). Heart rate also 
predicts outcome in epidemiologic studies of patients with CAD, as well as those with heart 
failure, hypertension, and, indeed, in unselected free living populations without apparent 
heart disease (Daly et al., 2010; Diaz et al., 2005; Fox et al., 2007; Fox et al., 2008; Fox et al., 
2008; Tardif et al., 2009). For example, the Coronary Artery Surgery Study (CASS) registry 
showed after a 14 year follow-up that cardiovascular and overall mortality was directly 
related to heart rate at entry into the study (Diaz et al., 2005). Similar results were seen in the 
placebo group of the prospective BEAUTIFUL [morBidity-mortality EvAlUaTion of the If 
inhibitor ivabradine in patients with coronary disease and left-ventricULar dysfunction] 
trial and in a retrospective assessment of the Treating to New Targets [TNT] study (Fox et 
al., 2008; Ho et al., 2010). 
2.5.1 Pharmacological effects  
As heart rate increases progressively myocardial oxygen demand increases (increase in 
myocardial work) and myocardial blood flow (and with it, potential myocardial oxygen 
supply) decreases because of reduction in the duration of diastole, when coronary flow 
occurs. When a threshold value is reached at which demand is greater than supply, ischemia 
results, often causing angina. Thus, Andrews et al showed that heart rate is a predictor of 
coronary ischemia in patients with stable CAD (Andrews et al., 1993). Ivabradine selectively 
inhibits the inward sodium–potassium If current, a relatively low amplitude primary 
modifier of the rate of spontaneous depolarization of the sino-atrial (SA) node myocytes 
(discovered in 1979 by DiFrancesco, et al (Brown et al., 1979; DiFrancesco & Camm, 2004)). 
Spontaneous depolarization, itself, is a function of other calcium and potassium currents. 
Ivabradine has no other known pharmacological actions on normal cardiovascular 
physiology. Therefore, it is considered a pure heart rate slowing drug (Thollon et al., 1994). 
Resting heart rate lowering by ivabradine is comparable to that achieved with β-blockers 
and is greater than that associated with CCBs (Pine et al., 1982; Tardif et al., 2005) for equal 
antianginal effect. The heart rate reduction is dose dependent (Borer et al., 2003; Thollon et 
al., 1994). Ivabradine is a selective and specific If inhibitor; it has no inotropic effect, no effect 
on relaxation (luisotropy), no impact on AV nodal conduction and no coronary 





myocardial oxygen supply, maintains contractile force, preserves ventricular relaxation and 
allows coronary vasodilatation. The drug improves coronary perfusion and maintains 
cardiac performance better than alternative equieffective anti-anginal drug therapy.  
2.5.2 Clinical application  
The first placebo controlled trial of ivabradine for angina prevention (Borer et al., 2003) 
showed that increasing doses progressively reduced heart rate at rest and during exercise. 
With these changes, there was progressive increase in time to limiting angina and time to 
1mm ST depression on bicycle exercise; the drug also reduced the number of diary-reported 
weekly angina episodes (Borer et al., 2003). The  INITIATIVE (the INternatIonal TrIAl on the 
Treatment of angina with IVabradinE vs. atenolol) study compared ivabradine with 
atenolol ; ivabradine was  non-inferior to the beta blocker in increasing treadmill exercise 
tolerance and preventing angina at doses selected to cause heart rate reduction 
approximately equivalent to that achieved with atenolol (Tardif et al., 2005). Indeed, 
ivabradine nominally improved exercise parameters to a greater extent than atenolol, 
though these differences did not reach statistical significance. Ivabradine also reduced  
spontaneous  angina episodes  compared with baseline and was again equivalent to atenolol 
in this effect (Tardif et al., 2005). Importantly, when the specific increment in exercise 
duration was assessed as a function of heart rate reduction (“anti-anginal efficiency“) 
ivabradine was markedly and significantly more efficient than atenolol. When compared 
with amlodipine, ivabradine was non-inferior in improving exercise tolerance and 
preventing angina, and increasing time to 1 mm ST depression on exercise (Ruzyllo et al., 
2007). Though some concern initially was raised about the combination of ivabradine and 
beta blockers because of the potential for profound heart rate lowering, the  ASSOCIATE 
(Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients 
with chronic stable angina) trial of ivabradine versus placebo on a background of atenolol 
(Tardif et al., 2009) confirmed the experimental findings that ivabradine effect is « use 
dependent », i.e., the drug has its greatest rate-reducing effect at relatively high heart rates 
and has progessively less impact on heart rate as the pretherapy value decreases; more 
importantly, symptomatic bradycardia was rare with the combination, though significant 
antianginal efficacy was demonstrated with the combination compared with atenolol alone. 
When all clinical studies are considered, ivabradine has demonstrated consistent antianginal 
efficacy across all subpopulations, with reductions of 51% to 70% in the frequency of angina 
attacks (Tendera et al., 2009).  
Almost uniquely among antianginal drugs, ivabradine has been demonstrated to exert a 
benefit on natural history end-points/cardiac events. Thus, in BEAUTIFUL, Fox et al 
showed that, among patients with chronic stable CAD, LV ejection fraction <40%  and heart 
rate ≥70 bpm before therapy, heart rate reduction with ivabradine markedly and 
significantly reduced the incidence of fatal or non-fatal myocardial infarction, as well as the 
incidence of revascularization and non-MI acute coronary syndrome (Fox et al., 2008). In the 
BEAUTIFUL angina substudy (Fox et al, 2009) ivabradine not only reduced the frequency of 
angina, but it reduced the primary end-points of death, non-fatal myocardial infarction 
(both end-points similarly affected) or hospitalization for heart failure and improved quality 
of life. Among all patients in the subgroup (as well as those with pre-therapy heart rate ≥70 
bpm), all cause mortality fell 10% (and 13%), fatal or non-fatal myocardial infarction 
incidence fell 42% (and 73%); hospitalization for heart failure and coronary 
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revascularization fell 30% and 59% respectively (Fox et al., 2009). Though the BEAUTIFUL 
angina substudy was a “post-hoc” assessment that cannot be considered definitive, 
nonetheless, it strongly suggests that, for patients with angina, for whom ivabradine is 
already approved for marketing throughout Europe and other parts of the world, heart rate 
slowing with this drug has additional benefits, beyond angina prevention, in reducing major 
coronary events. In this regard, ivabradine is almost unique among all currently available 
anti-anginal anti-ischemic pharmacological agents. Though not specifically related to 
angina, the SHIFT (the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine 
Trial) study in patients with moderately severe to severe systolic heart failure  demonstrated 
the usefulness of ivabradine in reducing mortality or hospitalization for HF (Bohm et al., 
2010; Swedberg et al., 2010), irrespective of the etiology of HF. Since the study population of 
more than 6500 patients predominantly involved patients with ischemic etiology, SHIFT, 
together with BEAUTIFUL and the various antianginal trials, demonstrated the benefit of 
pure heart rate reduction by ivabradine in patients with CAD in all its manifestations. 
2.5.3 Adverse effects   
Ivabradine is safe in combination with β-blockers and causes only a relatively small excess 
risk of symptomatic or dose-limiting bradycardia. The drug is well tolerated; the primary 
side effect is relatively infrequent transient and reversible “phosphenes” (flashing 
scotomata), that are sufficient to cause cessation of therapy in less than 1% of patients (Fox et 
al., 2008). This symptom is attributed to blockade of the retinal h channels, similar to the SA 
nodal f channels, by ivabradine.  
2.6 Nicorandil  
Nicorandil is a coronary and peripheral vasodilator which reduces LV preload and 
afterload. It also affects potassium channels involved in ischemic preconditioning and, thus, 
is suggested to have cardioprotective effects. The drug has been used in Europe for angina 
relief in patients with angina already receiving “conventional’ antianginal drugs. 
2.6.1 Pharmacological effects   
Nicorandil is structurally a nicotinamide ester derivative. It enhances potassium ion 
conductance by opening adenosine triphosphate (ATP)-sensitive potassium channels, in 
turn activating the enzyme guanylate cyclase. Nicorandil also has a nitrate moiety and 
promotes expression of endothelial NO synthase, thus sharing nitrate smooth muscle 
relaxing properties. Consequently, the drug enhances dilatation of arterial, venous and 
epicardial coronary arteries, resulting in reduced preload, afterload and myocardial oxygen 
demand while possibly increasing myocardial oxygen supply (Jahangir et al., 2001). 
Nicorandil may be associated with improved myocardial function during ischemia-
reperfusion, cardioprotective action during ischemia, shortened action potential duration, 
and prevention of intracellular calcium toxicity (Jahangir & Terzic, 2005; Jahangir et al., 
2001; John et al., 2003; Zingman et al., 2007). 
2.6.2 Clinical application  
Nicorandil has antianginal efficacy similar to that of β-blockers, nitrates and calcium 
channels blockers. In the Impact Of Nicorandil in Angina (IONA) randomized trial, 





myocardial oxygen supply, maintains contractile force, preserves ventricular relaxation and 
allows coronary vasodilatation. The drug improves coronary perfusion and maintains 
cardiac performance better than alternative equieffective anti-anginal drug therapy.  
2.5.2 Clinical application  
The first placebo controlled trial of ivabradine for angina prevention (Borer et al., 2003) 
showed that increasing doses progressively reduced heart rate at rest and during exercise. 
With these changes, there was progressive increase in time to limiting angina and time to 
1mm ST depression on bicycle exercise; the drug also reduced the number of diary-reported 
weekly angina episodes (Borer et al., 2003). The  INITIATIVE (the INternatIonal TrIAl on the 
Treatment of angina with IVabradinE vs. atenolol) study compared ivabradine with 
atenolol ; ivabradine was  non-inferior to the beta blocker in increasing treadmill exercise 
tolerance and preventing angina at doses selected to cause heart rate reduction 
approximately equivalent to that achieved with atenolol (Tardif et al., 2005). Indeed, 
ivabradine nominally improved exercise parameters to a greater extent than atenolol, 
though these differences did not reach statistical significance. Ivabradine also reduced  
spontaneous  angina episodes  compared with baseline and was again equivalent to atenolol 
in this effect (Tardif et al., 2005). Importantly, when the specific increment in exercise 
duration was assessed as a function of heart rate reduction (“anti-anginal efficiency“) 
ivabradine was markedly and significantly more efficient than atenolol. When compared 
with amlodipine, ivabradine was non-inferior in improving exercise tolerance and 
preventing angina, and increasing time to 1 mm ST depression on exercise (Ruzyllo et al., 
2007). Though some concern initially was raised about the combination of ivabradine and 
beta blockers because of the potential for profound heart rate lowering, the  ASSOCIATE 
(Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients 
with chronic stable angina) trial of ivabradine versus placebo on a background of atenolol 
(Tardif et al., 2009) confirmed the experimental findings that ivabradine effect is « use 
dependent », i.e., the drug has its greatest rate-reducing effect at relatively high heart rates 
and has progessively less impact on heart rate as the pretherapy value decreases; more 
importantly, symptomatic bradycardia was rare with the combination, though significant 
antianginal efficacy was demonstrated with the combination compared with atenolol alone. 
When all clinical studies are considered, ivabradine has demonstrated consistent antianginal 
efficacy across all subpopulations, with reductions of 51% to 70% in the frequency of angina 
attacks (Tendera et al., 2009).  
Almost uniquely among antianginal drugs, ivabradine has been demonstrated to exert a 
benefit on natural history end-points/cardiac events. Thus, in BEAUTIFUL, Fox et al 
showed that, among patients with chronic stable CAD, LV ejection fraction <40%  and heart 
rate ≥70 bpm before therapy, heart rate reduction with ivabradine markedly and 
significantly reduced the incidence of fatal or non-fatal myocardial infarction, as well as the 
incidence of revascularization and non-MI acute coronary syndrome (Fox et al., 2008). In the 
BEAUTIFUL angina substudy (Fox et al, 2009) ivabradine not only reduced the frequency of 
angina, but it reduced the primary end-points of death, non-fatal myocardial infarction 
(both end-points similarly affected) or hospitalization for heart failure and improved quality 
of life. Among all patients in the subgroup (as well as those with pre-therapy heart rate ≥70 
bpm), all cause mortality fell 10% (and 13%), fatal or non-fatal myocardial infarction 
incidence fell 42% (and 73%); hospitalization for heart failure and coronary 
 
Therapy for Angina Pectoris Secondary to Coronary Disease 
 
103 
revascularization fell 30% and 59% respectively (Fox et al., 2009). Though the BEAUTIFUL 
angina substudy was a “post-hoc” assessment that cannot be considered definitive, 
nonetheless, it strongly suggests that, for patients with angina, for whom ivabradine is 
already approved for marketing throughout Europe and other parts of the world, heart rate 
slowing with this drug has additional benefits, beyond angina prevention, in reducing major 
coronary events. In this regard, ivabradine is almost unique among all currently available 
anti-anginal anti-ischemic pharmacological agents. Though not specifically related to 
angina, the SHIFT (the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine 
Trial) study in patients with moderately severe to severe systolic heart failure  demonstrated 
the usefulness of ivabradine in reducing mortality or hospitalization for HF (Bohm et al., 
2010; Swedberg et al., 2010), irrespective of the etiology of HF. Since the study population of 
more than 6500 patients predominantly involved patients with ischemic etiology, SHIFT, 
together with BEAUTIFUL and the various antianginal trials, demonstrated the benefit of 
pure heart rate reduction by ivabradine in patients with CAD in all its manifestations. 
2.5.3 Adverse effects   
Ivabradine is safe in combination with β-blockers and causes only a relatively small excess 
risk of symptomatic or dose-limiting bradycardia. The drug is well tolerated; the primary 
side effect is relatively infrequent transient and reversible “phosphenes” (flashing 
scotomata), that are sufficient to cause cessation of therapy in less than 1% of patients (Fox et 
al., 2008). This symptom is attributed to blockade of the retinal h channels, similar to the SA 
nodal f channels, by ivabradine.  
2.6 Nicorandil  
Nicorandil is a coronary and peripheral vasodilator which reduces LV preload and 
afterload. It also affects potassium channels involved in ischemic preconditioning and, thus, 
is suggested to have cardioprotective effects. The drug has been used in Europe for angina 
relief in patients with angina already receiving “conventional’ antianginal drugs. 
2.6.1 Pharmacological effects   
Nicorandil is structurally a nicotinamide ester derivative. It enhances potassium ion 
conductance by opening adenosine triphosphate (ATP)-sensitive potassium channels, in 
turn activating the enzyme guanylate cyclase. Nicorandil also has a nitrate moiety and 
promotes expression of endothelial NO synthase, thus sharing nitrate smooth muscle 
relaxing properties. Consequently, the drug enhances dilatation of arterial, venous and 
epicardial coronary arteries, resulting in reduced preload, afterload and myocardial oxygen 
demand while possibly increasing myocardial oxygen supply (Jahangir et al., 2001). 
Nicorandil may be associated with improved myocardial function during ischemia-
reperfusion, cardioprotective action during ischemia, shortened action potential duration, 
and prevention of intracellular calcium toxicity (Jahangir & Terzic, 2005; Jahangir et al., 
2001; John et al., 2003; Zingman et al., 2007). 
2.6.2 Clinical application  
Nicorandil has antianginal efficacy similar to that of β-blockers, nitrates and calcium 
channels blockers. In the Impact Of Nicorandil in Angina (IONA) randomized trial, 





P=0.014) in hospitalization for chest pain, MI, and cardiac death when added to standard 
antianginal therapy (Ford, 2002). However, the result was driven by effects of nicorandil on 
“hospital admission for cardiac chest pain”, and the risk reduction for cardiac death or non-
fatal MI during 1.6 years of treatment was non significant. Thus the value of the treatment 
has been disputed (Fox et al., 2006). Several small randomized trials have shown that 
Nicorandil prolongs the time to onset of ST-segment depression and exercise tolerance 
during treadmill exercise testing in patients with stable angina (Di Somma et al., 1993; 
Meeter et al., 1992; Raftery et al., 1993). Markham et al also have shown that nicorandil 
prolongs time to the onset of angina, time to 1 mm ST depression, improves exercise 
duration and reverses ischemia-related impairment in regional wall motion during exercise 
(Markham et al., 2000). In a multicenter, randomized trial (197 patients) comparing it to 
isosorbide mononitrate, nicorandil was found to be both safe and effective in preventing 
angina (Doring, 1992). A dose of 10–40 mg twice daily controls symptoms in 70%–80% of 
patients with chronic stable angina; the effect of a single administration is maintained for 
about 12 hours (Meeter et al., 1992).  
2.6.3 Adverse effects  
In the IONA trial, the drop out-rates were about 10%, mainly due to headache in the 
nicorandil group. Nicorandil is not yet approved for use in the United States, but is widely 
available for angina therapy in Europe and other countries. 
2.7 Fasudil 
Fasudil is a Rho-kinase inhibitor and a vasodilator. Rho–kinase has been identified as one of 
the effectors of the small GTP-binding protein, Rho. The Rho/Rho-kinase pathway plays an 
important role in various cellular functions including vascular smooth muscle cell 
contraction, actin cytoskeleton integrity and gene expression. As a Rho-kinase inhibitor, 
fasudil has been utilized in cerebral vasospasm, pulmonary hypertension and, recently, in 
angina. 
2.7.1 Pharmacological effects  
The Rho molecules are small GTP-binding proteins that mediate intracellular signaling by 
activation of G-protein-coupled receptors and growth factor receptors. The Rho/Rho-kinase 
signaling pathway is known to be involved in the pathogenesis of coronary artery spasm 
(Shimokawa & Takeshita, 2005). Rho molecules are  known to modulate Ca2+-sensitization 
of vascular smooth muscle cells and may act by inhibiting myosin phosphatase activity 
(Fukata et al., 2001). As a Rho-kinase inhibitor, fasudil is a vasodilator. 
2.7.2 Clinical application  
Fasudil can increase coronary artery diameter to an extent greater than that achievable with 
nitroglycerin in patients with documented vasospasm (Otsuka et al., 2008). Vasospastic 
angina precipitated by acetylcholine can be prevented by intracoronary infusion of fasudil 
(Mohri et al., 2003). When used as monotherapy, fasudil doses ranging from 5 mg three 
times daily to 40 mg three times daily have increased maximum exercise time and time to 
the onset of ST segment depression compared with baseline. Fasudil is well tolerated, with 
minimal effects on blood pressure and heart rate at rest or during exercise (Shimokawa et 
al., 2002). In a double blind, placebo controlled randomized clinical trial of 84 patients with 
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chronic stable angina, both placebo and fasudil increased exercise time on treadmill testing 
compared to baseline, but the difference between active drug and placebo was not 
statistically significant, though time to onset of ischemic ST segment depression during 
exercise was significantly prolonged compared to placebo (Vicari et al., 2005). Fasudil is not 
yet approved for use in United States. An intravenous formulation is approved in Japan to 
prevent cerebral vasospasm after subarachnoid hemorrhage. 
2.7.3 Adverse effects  
Vicari et al reported adverse effects in 41 patients and compared them to those reported 
with placebo. Overall incidence of adverse effects were similar in the 2 groups. The common 
organ systems reported to be involved were skin, subcutaneous tissue and the vascular 
system. Common disorders reported (incidence <20%) were allergic dermatitis, bruising, 
diaphoresis, facial erythema, facial flushing, hypotension or hypertension and a Raynaud-
like phenomenon. The majority of adverse events were classified as mild to moderate. No 
deaths were reported (Vicari et al., 2005). 
2.8 Trimetazidine 
Trimetazidine (1-[2,3,4-trimethoxybenzyl] piperazine dihydrochloride) is a prototype of a 
group of antianginal agents thought to act by affecting myocardial metabolism directly. 
2.8.1 Pharmacological effects  
As for most if not all antianginal drugs, the mechanism of action of trimetazidine is not fully 
clear. The proposed mechanism is direct enhancement of myocardial energy metabolism, 
resulting in cytoprotective effects (Harpey, 1989; Kay et al., 1995). Fantini et al showed that 
in isolated rat heart mitochondria, trimetazidine has an inhibitory effect on palmitoyl-
carnitine oxidation, with no significant effect on pyruvate oxidation (Fantini et al., 1994). 
This suggests that trimetazidine inhibits fatty acid oxidation in the heart. It has been shown 
that high fatty acid oxidation rates are detrimental in the setting of ischemia because of 
inhibition of the more energy efficient glucose oxidation, resulting in exacerbation of 
ischemic injury and a decrease in cardiac efficiency during reperfusion. Kantor et al 
demonstrated that trimetazidine suppresses fatty acid oxidation secondary to inhibition of 
long-chain 3-ketoacyl CoA thiolase, resulting in an increase in glucose oxidation. As a result, 
switching energy substrate preference from fatty acid oxidation to glucose oxidation may 
explain the antianginal properties of trimetazidine (Kantor et al., 2000). Unlike several other 
antianginals, trimetazidine has no effect on vascular smooth muscle and thus has been 
termed a “cellular anti-ischemic agent”. 
2.8.2 Clinical application  
The European Collaborative Working Group has demonstrated that trimetazidine is 
equivalent to propranolol in its antianginal efficiency, but is devoid of measurable 
hemodynamic effects (Detry et al., 1994). Similar results were reported in comparison with 
nifedipine (Dalla-Volta et al., 1990). Additive antianginal effects were observed when 
trimetazidine was combined with diltiazem (Levy, 1995; Manchanda & Krishnaswami, 
1997), while the benefits of combination with metoprolol were demonstrated in the 
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2.8.3 Adverse effects  
Trimetazidine is relatively safe and is very well tolerated; there are few known drug 
interactions. Because of its safety profile, compliance has been quite good. In one 
uncontrolled trial, 2.4% of patients had adverse events during an 8-week treatment period. 
Nausea was the most frequent adverse event (0.4%) (Makolkin, 2003).  
3. Non-pharmacological therapy 
Despite maximized pharmacological therapy and life style modification, many patients with 
CAD continue to suffer from angina, including so-called “refractory angina”, which is 
defined as Canadian Cardiovascular Society (CCS) class III or IV angina with marked 
limitation during ordinary physical activity or inability to perform ordinary physical 
activity without discomfort (Gowda et al., 2005). Patients with refractory angina typically 
experience poor general health status, psychological distress, impaired role functioning, 
activity restriction, and inability to manage their living situation (Brorsson et al., 2002; 
Erixson, 1997; McGillion et al., 2007). Refractory angina is debilitating and its treatment is 
challenging. In the past several decades, a number of nonpharmacological treatments have 
been developed to help resolve this problem. These therapies will be outlined in this section. 
3.1 Mechanical therapy 
3.1.2 Revascularization 
Coronary angiography and possible revascularization should be considered in patients with 
refractory angina. Revascularization includes percutaneous coronary interventions (PCI) 
and coronary artery bypass graft surgery.  
3.1.2.1 Percutaneous coronary intervention 
PCI, initially involving balloon angioplasty and later generally comprising balloon 
angioplasty plus stent placement to support and maintain the new channel, was developed  
for the relief of angina in patients refractory to medication. This remains one of the few data-
supported applications of the technique. 
3.1.2.1.1 Evidence 
A comparison of balloon angioplasty with  pharmacological therapy in  treating patients 
with single vessel CAD (ACME) showed that angioplasty resulted in a greater proportion 
of patients free of angina at 6 months and greater improvement in treadmill exercise 
duration than did pharmacological therapy (Parisi et al., 1992). This study predated the 
routine use of stents and manifested a high rate (20%) of PCI failure but nonetheless 
supported the superiority of mechanical angioplasty to drug therapy alone for angina 
prevention. The multicenter Randomized Intervention Treatment of Angina (RITA) 2 trial 
was one of the largest trials prospectively assessing the impact of balloon angioplasty vs 
medical therapy on angina. Angina was of relatively mild severity (CCS 0-2) in 80 % of 
patients (Chamberlain, 1997). Angina frequency, exercise time and quality of life all 
improved in both groups. However, the subgroup of patients with CCS≥2 derived 
significantly greater symptom-relieving benefit from PCI than from pharmacological 
therapy during a 1 year follow-up interval. By 3 years, this advantage was lost, though 
interpretation of this finding is confounded by a relatively high (23%) crossover rate of 
medically treated patients to PCI. The Atorvastatin versus Revascularization Treatment 
(AVERT) trial assessed patients with angina CCS class 0-2. In this study, half the PCI 
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group received stents as well as balloon angioplasty (Pitt et al., 1999). Patients in the PCI 
group evidenced greater improvement than those receiving pharmacological therapy.  
Bucher et al conducted a systematic review of 6 trials from 1979 through1998, including a 
total of 1904 patients with stable single vessel CAD and normal LV function (4). Balloon 
angioplasty was associated with a significant improvement in angina compared with 
pharmacological therapy alone. There was no difference of mortality or myocardial 
infarction between PCI and drug therapy (Bucher et al., 2000). Recently, 2 trials, MASS 
(Medicine, Angioplasty or Surgery Study) II (Hueb et al., 2004) and COURAGE (Clinical 
Outcomes utilizing Revascularization and Aggressive Drug Therapy) (Boden et al., 2007) 
compared PCI versus pharmacological therapy in stable CAD. MASS-II  included 611 
patients; after 1 year of follow up, 79% of patients in PCI group, 88% of patients in 
surgery group and 46% in medical therapy group were free of angina, though no 
difference was found in mortality rates among the groups. COURAGE compared initial 
PCI with “optimal medical management”. At baseline, 43% of patients either did not have 
symptoms or had Class 1 angina. After 5 years follow up, 74% of patients in the PCI group 
and 72% patients in the medical therapy group were free of angina. By this time, one-third 
of patients had crossed over from medical therapy to PCI group. No evidence of benefit 
was found in terms of mortality or major morbidity when the groups were analyzed 
according to intention to treat. 
3.1.2.1.2 Conclusion  
The decision to perform PCI for symptom relief in patients with angina remains complex 
and needs to be individualized based on analysis of  goals and risks. The relevant trials 
performed to date have important limitations for extrapolation to current decisions  
including the possible impact of recent improvements in PCI techniques, changes in 
pharmacology and alterations in the populations at risk, in part because of drug therapy 
that can modify atherosclerosis. Most trials show that PCI results in greater symptom relief 
and better exercise tolerance than drug therapy but suggest that this advantage is of 
relatively limited duration, requiring adjunctive or additional therapy to maintain anti-
anginal benefits. However, for patients with angina refractory to pharmacological therapy, 
current evidence clearly supports PCI as an appropriate therapy for symptom improvement. 
Nonetheless, because of the rapidly changing landscape of therapy noted above, the 
appropriate approach to achieve optimal symptom prevention is a moving target, and more 
studies would be useful.  
3.1.2.2 Coronary artery bypass grafting (CABG) surgery 
CABG is an important therapeutic modality for millions of patients with CAD. Surgery has 
evolved over the more than 4 decades since its introduction, both in terms of duration of 
benefit (open arteries) and in reduction of peri-operative complications. 
3.1.2.2.1 Evidence 
Early trials included the European Coronary Surgery Study (ECSS) (Varnauskas, 1988), 
Veterans Cooperative Study (Detre, 1984) and Coronary Artery Surgery Study (CASS) 
(Killip, 1983). These studies were designed to assess the benefits of CABG for survival and 
prevention of major morbidity, but provided information about angina prevention, as well. 
In each of these studies, CABG was compared with medical therapy in patients with stable 
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group received stents as well as balloon angioplasty (Pitt et al., 1999). Patients in the PCI 
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included a total of 2649 patients in which outcomes were evaluated at 5 and 10 years (Yusuf 
et al., 1994). CABG improved survival compared with pharmacological therapy. 
Importantly, though, CABG also produced greater freedom from symptoms and less use 
of antianginal medications than pharmacological therapy during a 5 year follow-up. Not 
surprisingly, benefits were greatest among those with the most severe disease at 
randomization, those with left main or multivessel disease and those with one or two 
vessel disease involving the proximal left anterior descending artery. Survival benefits 
were greater among patients with at least moderately subnormal LV ejection fraction than 
among those with normal LV performance. Bypass Angioplasty Revascularization 
Investment (BARI) trial was the largest (1829 patients) randomized study comparing 
balloon angioplasty versus CABG in symptomatic multivessel CAD (Alderman, 1996). 
After 10 years of follow up, angina rates in the two groups were similar. There were 
higher subsequent revascularization rates in balloon angioplasty group than in those who 
were randomized to CABG. Also, as noted above, MASS-II showed that 88% of patients in 
surgery group, 79% of patients in PCI group and 46% in medical therapy group were free 
of angina at pre-specified follow-up (Hueb et al., 2004). Bravata et al did a meta-analysis 
of 23 trials which included a total of 9963 patients, indicating that angina was relieved at 5 
years in 79% of PCI patients and 84% of CABG patients (Bravata et al., 2007). Data also 
indicate that approximately 80-90% patients who are symptomatic on medical therapy 
become symptom free following CABG. This benefit has been shown to extend even to 
low-risk patients in whom mortality benefit with surgery has not been shown (Yusuf et 
al., 1994).  
3.1.2.2.2 Conclusion  
Both CABG and PCI are effective in relieving angina but CABG achieves this benefit with 
less need for  repeat procedures than does PCI. In addition, though not specifically relevant 
to angina relief, several subsets of patients with chronic stable CAD can anticipate survival 
benefit from CABG; no parallel data are available for PCI. However, many of the relevant 
data were obtained with techniques and devices that have been superseded in this rapidly 
developing area. Thus, more data with the most up-to date techniques would be useful, on a 
background of the most modern pharmacological therapy to beneficially alter CAD 
progression. Nonetheless, as suggested by data from matched cohorts from the New York 
State coronary surgery database (Hannan et al., 2005), even as PCI techniques develop, 
CABG remains superior in terms of survival but the effects of newer approaches on angina 
remain to be defined. 
3.1.3 Enhanced External Counterpulsation  
Enhanced External Counterpulsation (EECP) is a non-invasive treatment that has been 
studied and employed with variable success for more than 30 years (Amin et al., 2010). 
EECP is carried out by placing compressible cuffs around the calves and lower and upper 
thighs, inflating them sequentially during diastole and deflating them simultaneously at the 
onset of systole. Throughout this process, the patient is connected to an electrocardiogram 
(ECG) and a finger plethysmograph. The R wave of the ECG is used to gate inflation and 
deflation. Treatment typically involves 35 sessions, each lasting 1 hour, undertaken over a 7-
week interval (Sinvhal et al., 2003). EECP is believed to improve coronary perfusion 
pressure through diastolic augmentation while decreasing cardiac workload by reducing 
aortic impedance during systole.  
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3.1.3.1 Evidence  
EECP is generally considered acceptably safe and is without specific contraindications. The 
few adverse effects associated with EECP generally are related to the physical characteristics 
of the equipment and its application, e.g., leg and back pain, abrasion of skin, bruising, 
blistering, edema and paresthesia (Arora et al., 1999). The effectiveness of EECP for 
refractory angina has been investigated in several studies over the last two decades. In the 
only published randomized clinical trial (Arora et al., 1999), the Multicenter Study of 
Enhanced External Counterpulsation (MUST-EECP), which involved 139 patients with 
angina and documented CAD, patients were randomised to either 35 h of active 
counterpulsation (300 mm Hg maximal cuff pressure) or inactive counterpulsation (75 mm 
Hg maximal cuff pressure) over a 4–7 week-period. Exercise duration increased in both 
groups to a similar degree (p > 0.3) and nitroglycerin use did not differ between groups 
(P>0.7). However, time to ≥1-mm ST segment depression (exercise-induced ischemia) 
increased significantly from baseline in active counterpulsation compared with inactive 
counterpulsation (p = 0.01). More active counterpulsation patients saw a decrease and fewer 
experienced an increase in angina episodes as compared with inactive counterpulsation 
patients (p < 0.05). The investigators concluded that EECP reduced angina and extended 
time to exercise-induced ischemia in patients with symptomatic CAD. Treatment was 
relatively well tolerated and was free of limiting side effects in most patients. The limitations 
of this trial include fairly stringent patient selection criteria precluding simple extrapolation 
of the data, the preponderance of patients with only Class I or II symptoms, and the lack of 
data about natural history outcomes. Also, there were more withdrawals due to adverse 
effects in active EECP group than in the control group. 
To further assess EECP effects on both exercise tolerance and cardiac function, Urano et al 
(Urano et al., 2001) examined 12 stable patients with CAD and evidence of exercise-induced 
myocardial ischemia despite conventional medical or surgical therapies. These investigators 
found that, compared with baseline values, EECP improved all exercise test parameters, 
reduced exercise-induced reversible perfusion defects by thallium scintigraphy, and 
improved diastolic filling and LV end-diastolic pressure. These hemodynamic 
improvements were associated with decreased plasma brain natriuretic peptide levels. The 
investigators concluded that EECP definitely was effective in patients with CAD. 
To clarify the mechanism underlying EECP benefits,  Shechter et al (Shechter et al., 2003)  
investigated the influence of short-term EECP on vascular endothelial function in patients 
with CAD. They used high-resolution ultrasound to assesse endothelium-dependent 
brachial artery flow-mediated dilation (FMD) and endothelium-independent nitroglycerin-
mediated vasodilation before and after EECP therapy. EECP resulted in significant 
improvement in post-intervention FMD but no significant effect on nitroglycerin-induced 
vasodilation. EECP significantly reduced angina as assessed by mean daily sublingual 
nitrate consumption and mean CCS angina class. The investigators concluded that EECP 
improved vascular endothelial function and angina in patients with CAD and refractory 
angina pectoris, suggesting a causal relation.  
Few studies have evaluated the long-term effects of EECP. Loh et al (Loh et al., 2008) used 
the International EECP Patient Registry (IEPR-1) that enrolled consecutive patients treated 
with EECP in more than 100 centers; follow-up duration was 3 years. These investigators 
found that immediately post-EECP, the proportion of patients with severe angina (CCS 
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follow-up. This is the longest follow-up from IEPR-1 to date and tends to confirm the safety 
and immediate benefits of EECP as well as suggesting that sustained symptomatic and 
quality of life benefit can be achieved in most patients for up to 3 years. However, this 
observational study lacked a control group, weakening the conclusions. Further, the results 
are impaired by patient selection and survival bias. Other non- randomized studies 
(Barsheshet et al., 2008; Holubkov et al., 2002; Shechter et al., 2003; Urano et al., 2001) have 
been difficult to interpret. All assessments need to be treated with considerable caution due 
to selection bias and absence of blinding (McKenna et al., 2009).  
3.1.3.2 Conclusion  
With its development, it was hoped that EECP would be a viable adjunct for patients with 
CAD patients and angina inadequately responsive to medication and revascularization. To 
date, results from well-designed clinical trials are relatively few. However, these data 
provide a suggestion of no more than limited clinical effectiveness. Issues of adverse effects 
and cost-effectiveness have limited application of EECP therapy. Finally, evaluation in a 
truly refractory population with predominantly Class III/IV patients has not been 
undertaken. The ACC/AHA 2002 guideline update for the management of patients with 
chronic stable angina assigns EECP therapy a level of evidence of Class IIB (the usefulness/ 
efficacy is less well established by evidence/opinion). This suggests there may be some 
benefit, but additional clinical trial data are needed before EECP can be recommended 
definitively (Gibbons et al., 2003). EECP was not mentioned in the 2007 Chronic Angina 
Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients with 
Chronic Stable Angina (Fraker et al., 2007). Thus, additional data from randomized 
controlled trials are needed with regards to exercise tolerance, angina frequency and 
nitroglycerin use, ischemia reduction and, if possible, long term benefit on quality of life, as 
well as mortality or major morbid cardiovascular events.  
3.1.4 Carotid Sinus Nerve Stimulation 
Fifty years ago, carotid sinus nerve stimulation (CSNS) to slow heart rate and, to a lesser 
extent, to lower blood pressure was conceived (Lown & Levine, 1961) as an alternative 
treatment for refractory angina. Stimulation of the carotid sinus nerves reflexly reduces the 
frequency of sympathetic efferent impulses which, in turn, results in reduction in arterial 
pressure, myocardial contractility, and heart rate; as a consequence, myocardial oxygen 
demand is diminished and angina is relieved. Small, non-randomized studies demonstrated 
that CSNS relieved angina and allowed patients to perform more exercise without 
developing angina (Braunwald et al., 1967; Epstein et al., 1969; Rotem, 1974). However, due 
to the need for invasive implantation of the stimulator using the somewhat crude methods 
of the time, CSNS never was broadly applied. Nonetheless, it proved the principle that 
angina relief could be achieved directly by altering certain hemodynamic variables.  
3.1.5 Spinal Cord Stimulation 
Spinal cord stimulation (SCS), also called dorsal column stimulation or neurostimulation, is 
a neuromodulation therapy to alleviate pain by electrically activating pain-inhibiting 
neuronal circuits in the dorsal horn and inducing paresthesia that masks the original pain 
sensations. Local anesthesia is used during SCS implantation, via an incision at the level of 
thoracic vertebrae 6-8, an electrode is inserted into the epidural space and guided via X-ray 
monitoring up to the level of the thoracic 1-2 vertebrae. Its location is adjusted until the 
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patient experiences paresthesiae within the area of the anginal pain. An extension wire is 
then tunneled subcutaneously via an incision to the left flank, where it is connected to a 
subcutaneous pulse-generator below the left costal arch. The stimulation intensity is then 
fine-tuned post-operatively. The patient can regulate the strength of the actual stimulation 
using a remote control (Borjesson et al., 2008). SCS has been successfully reported to relieve 
pain in a number of chronic conditions including neuropathic pain and peripheral vascular 
disease (Kemler et al., 2000; Kumar et al., 2007; Lee & Pilitsis, 2006). Since the late 1980s, SCS 
has been used to treat patients with chronic refractory angina who are not responsive to  
conventional medical therapy and revascularization (Murphy & Giles, 1987). Although the 
underlying mechanism is not fully elucidated, it has been proposed that SCS exerts 
beneficial effects by decreasing pain and sympathetic tone, yielding reductions in 
myocardial oxygen consumption and improved myocardial microcirculatory blood flow 
(Latif et al., 2001).  
3.1.5.1 Evidence  
Published evidence supports SCS as effective and acceptably safe for patients with 
refractory angina who are unresponsive to medical and surgical intervention (Bondesson et 
al., 2008; de Vries et al., 2007; Diedrichs et al., 2005; Dyer et al., 2008; Eddicks et al., 2007; 
Lapenna et al., 2006; McNab et al., 2006). Recently, a meta-analysis of 7 randomized 
controlled trials involving 270 patients (Taylor et al., 2009) found benefits similar to those of 
CABG and percutaneous myocardial laser revascularization (PMR). Compared to the 
control, there was some evidence of improvement in all outcomes following SCS 
implantation with significant gains observed in pooled exercise capacity and health related 
quality of life. However, the trials were small and varied considerably in quality. The 
healthcare costs of SCS appeared to be lower than CABG at 2-years follow up. One 
particular challenge of SCS evaluation is the difficulty in patient blinding, as the therapy 
produces paresthesia in the area of the pain if SCS is effective. In addition, the implantation 
procedure might produce a placebo effect, but sham operations are ethically difficult to 
justify (Van Zundert, 2007). Further high quality trials and cost effectiveness evidence is 
needed before SCS can be accepted as a routine treatment for refractory angina. 
3.1.5.2 Conclusion  
SCS has been used for treatment of refractory angina in Europe for 20 years. In the European 
Society of Cardiology guidelines on management of angina (Fox et al., 2006), SCS is accepted 
as a “well established method” for the management of refractory angina. Patients experience 
a favorable analgesic effect and positive effects on symptoms from SCS, though long-term 
effects are unknown. The ACC/AHA guidelines for the management of patients with 
chronic stable angina (Fraker et al., 2007; Gibbons et al., 2003) provided a class II b 
recommendation, suggesting that SCS should only be used in patients who cannot be 
managed adequately by medical therapy and who are not candidates for revascularization. 
3.1.6 Transmyocardial revascularization 
Transmyocardial revascularization (TMR) applies high-energy laser beams to create non-
transmural endomyocardial channels. These channels can be generated surgically, using an 
epicardial approach, or percutaneously (PMR), via catheter, an endocardial approach. The 
basis for angina prevention with TMR is unclear. The initial hypothesis was that the 
channels provided oxygenated blood from the LV to directly perfuse the myocardium; 
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patient experiences paresthesiae within the area of the anginal pain. An extension wire is 
then tunneled subcutaneously via an incision to the left flank, where it is connected to a 
subcutaneous pulse-generator below the left costal arch. The stimulation intensity is then 
fine-tuned post-operatively. The patient can regulate the strength of the actual stimulation 
using a remote control (Borjesson et al., 2008). SCS has been successfully reported to relieve 
pain in a number of chronic conditions including neuropathic pain and peripheral vascular 
disease (Kemler et al., 2000; Kumar et al., 2007; Lee & Pilitsis, 2006). Since the late 1980s, SCS 
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3.1.5.1 Evidence  
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al., 2008; de Vries et al., 2007; Diedrichs et al., 2005; Dyer et al., 2008; Eddicks et al., 2007; 
Lapenna et al., 2006; McNab et al., 2006). Recently, a meta-analysis of 7 randomized 
controlled trials involving 270 patients (Taylor et al., 2009) found benefits similar to those of 
CABG and percutaneous myocardial laser revascularization (PMR). Compared to the 
control, there was some evidence of improvement in all outcomes following SCS 
implantation with significant gains observed in pooled exercise capacity and health related 
quality of life. However, the trials were small and varied considerably in quality. The 
healthcare costs of SCS appeared to be lower than CABG at 2-years follow up. One 
particular challenge of SCS evaluation is the difficulty in patient blinding, as the therapy 
produces paresthesia in the area of the pain if SCS is effective. In addition, the implantation 
procedure might produce a placebo effect, but sham operations are ethically difficult to 
justify (Van Zundert, 2007). Further high quality trials and cost effectiveness evidence is 
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3.1.5.2 Conclusion  
SCS has been used for treatment of refractory angina in Europe for 20 years. In the European 
Society of Cardiology guidelines on management of angina (Fox et al., 2006), SCS is accepted 
as a “well established method” for the management of refractory angina. Patients experience 
a favorable analgesic effect and positive effects on symptoms from SCS, though long-term 
effects are unknown. The ACC/AHA guidelines for the management of patients with 
chronic stable angina (Fraker et al., 2007; Gibbons et al., 2003) provided a class II b 
recommendation, suggesting that SCS should only be used in patients who cannot be 
managed adequately by medical therapy and who are not candidates for revascularization. 
3.1.6 Transmyocardial revascularization 
Transmyocardial revascularization (TMR) applies high-energy laser beams to create non-
transmural endomyocardial channels. These channels can be generated surgically, using an 
epicardial approach, or percutaneously (PMR), via catheter, an endocardial approach. The 
basis for angina prevention with TMR is unclear. The initial hypothesis was that the 
channels provided oxygenated blood from the LV to directly perfuse the myocardium; 





clinical improvement may be secondary to angiogenesis, placebo effect, or myocardial 
denervation (Huikeshoven et al., 2002). TMR also has been combined with administration of 
angiogenic growth factors and/or angiogenic gene vectors introduced via the channels to 
stimulate angiogenesis (see Biological Therapy, below). 
3.1.6.1 Evidence  
Since its initial application in association with CABG in 1983, surgical TMR has been 
considered an alternative for patients with refractory angina who were not amenable to 
conventional revascularization (Smith et al., 1995). However, though several preliminary 
studies demonstrated a decrease in angina severity in most patients (Cooley et al., 1996; 
Horvath et al., 1996), subsequent randomized controlled trials (RCT) have reported 
contradictory results (Aaberge et al., 2000; Burkhoff et al., 1999; Campbell et al., 2001; Jones 
et al., 1999; March, 1999; van der Sloot et al., 2004). Briones et al (Briones et al., 2009) 
conducted a Cochrane systematic review to assess the efficacy and safety of TMR versus 
optimized drug therapy in alleviating angina and improving survival and heart function. 
The 7 RCTs included in the review involved 1137 patients of whom 559 were randomized to 
TMR. Overall, 43.8% of patients in the treatment group decreased two angina classes, 
compared to 14.8% in the control group (95% confidence interval 3.43 to 6.25). Mortality 
analyzed on an intention-to-treat basis was similar in both groups at 30 days (4.0% in the 
TMR group vs. 3.5% in the control group) and at one year (12.2% in the TMR group vs. 
11.9% in the control group). However, the per protocol 30-day mortality was 6.8% in the 
TMR group compared to 0.8% in the control group (OR 3.76 [95% CI, 1.63 to 8.66]). The 
authors concluded that evidence is insufficient to support the presumption that clinical 
benefits of TMR outweigh the potential risks. Importantly, the observed improvement in 
angina was not measured using blinded methods and is therefore subject to significant 
potential bias, and there was no difference in survival.  
PMR is less invasive than TMR, utilizing a fiberoptic catheter inserted through a femoral 
artery under conscious sedation to carry the laser energy to the endocardial surface. Laser 
firing is synchronized during systole to create a series of nontransmural channels in targeted 
regions (Oesterle et al., 1998). Recently McGillion et al (McGillion et al., 2010) conducted a 
meta-analysis to assess the effectiveness of PMR versus optimized drug therapy for 
reducing angina and improving health-related quality of life (HRQL), and exercise 
performance. Seven RCT trials, involving 1,213 participants, were included. At 12-month 
follow-up, the PMR group had more than 2 CCS class symptom reductions as well as 
improvements in HRQL, disease perception and physical limitations. However, PMR had 
no significant impact on all-cause mortality. In the secondary analyses, in which the data 
were from a single trial that employed a higher-dose laser group, the result showed no 
significant overall impact of PMR across outcomes.  
3.1.6.2 Conclusion  
When applied in carefully selected patients with refractory angina, TMR can provide 
durable reduction in self-reported angina and improvement in quality of life compared to 
drug treatment alone. However, evidence of improvement in exercise tolerance, the 
“objectification” of angina, is less strong, and impact on survival has not been 
demonstrated. For PMR, evidence is insufficient to demonstrate efficacy for angina 
prevention (and, therefore, of benefit to risk relation). Long-term outcomes of PMR are not 
clear. PMR devices have not been approved by the FDA due to lack of adequate evidence of 
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efficacy in their use. ACC/AHA guidelines (Eagle et al., 2004; Gibbons et al., 2003) 
recommend TMR as a Class IIa procedure, stating that TMR alone or in combination with 
CABG is reasonable in patients with angina refractory to medical therapy who are not 
candidates for PCI or CABG but does not recommend PMR, noting that it should still be 
considered experimental. 
3.2 Biological therapy 
3.2.1 Angiogenic gene therapy 
Angiogenesis is the biological process involving formation of new blood vessels from pre-
existing vessels under physiological or pathological conditions. In patients with chronic 
CAD, angiogenesis in response to repeated myocardial ischemia can provide collateral 
blood flow to muscle distal to sites of coronary stenoses. Theoretically, stimulation of 
angiogenesis presents an attractive approach for the treatment of CAD. Attempts at 
therapeutic angiogenesis have employed molecules (growth factors) shown experimentally 
to improve jeopardized blood supply, thereby relieving myocardial ischemia, improving 
regional and global LV performance, lessening angina, and improving clinical outcomes 
(Simons & Ware, 2003). A number of growth factors have been demonstrated to stimulate 
blood vessel growth in humans and are the focus of recent angiogenic gene therapy studies. 
These include several fibroblast growth factors (FGFs), vascular endothelial growth factors 
(VEGFs) and granulocyte/macrophage colony stimulating factor (GM-CSF) (Zachary & 
Morgan, 2011). 
3.2.1.1 Evidence  
How to effectively and safely deliver growth factors to the target tissue remains a major 
problem in therapeutic angiogenesis trials. The accepted consensus is that effective 
angiogenic intervention will require the presence of the therapeutic agent at the desired site 
of action for as long as four to six weeks. In early experience, delivery of growth factors was 
achieved either by systemic infusion or intracoronary infusion, but results were 
disappointing, perhaps because of short residence time of the infused proteins in target 
tissues. Repeated administration or the use of sustained release polymers may prove more 
effective, but remains to be tested. Introduction of angiogenic genes into the myocardium 
offers a theoretical alternative approach to delivery that might obviate the need for repeated 
administrations of short-lived proteins, and avoid the potential risks of short-term systemic 
exposure to relatively high concentrations of proteins (Simons et al., 2000). Introduction of 
angiogenic genes with both plasmid and adenoviral vectors has been associated with 
improvements in heart function and perfusion in different animal models of myocardial 
ischaemia (Hammond & McKirnan, 2001). Several clinical gene therapy trials of angiogenic 
growth factors have been conducted using either plasmid or adenoviral vectors. Effects of 
intramyocardially delivered plasmid VEGF were assessed in two randomised, double-
blinded, placebo-controlled trials, EUROINJECT-ONE (Kastrup et al., 2005) and 
NORTHERN (Stewart et al., 2009)  involving, respectively, 80 and 93 patients with severe 
stable ischemic heart disease (CCS III/IV). Neither trial demonstrated alteration in the 
primary end point, change in myocardial perfusion, by therapy, despite the use of a high 
plasmid dose (2 mg) in the NORTHERN study. There was a trend toward improvement in 
exercise treadmill time and angina reduction, but again no significant differences were 
observed. Another RCT, REVASC (Stewart et al., 2006) employed an adenoviral vector 
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observed. Another RCT, REVASC (Stewart et al., 2006) employed an adenoviral vector 





angina. In this study, a statistically significant increase in the primary end point, time to 1 
mm ST-segment depression on treadmill exercise, was observed at 26 weeks in the active 
treatment group. Another RCT, KAT (Hedman et al., 2003), compared AdVEGF165 with 
either plasmid VEGF or placebo for effect on myocardial perfusion in 103 patients. In this 
trial, the vectors were administered by intracoronary injection at angioplasty. There was no 
significant difference in the rates of restenosis between treatment groups at 6 months, but 
myocardial perfusion improved in the AdVEGF165 group compared with plasmid VEGF. In 
an 8-year follow-up study of the KAT trial, the incidence of major adverse cardiovascular 
events, cancer or diabetes did not differ between the treatment groups (Hedman et al., 2009). 
A series of AGENT trials investigated the safety and efficacy of intracoronary injections of 
an adenoviral-encoded FGF-4 gene. The AGENT-1 trial (Grines et al., 2002) enrolled 79 
patients and found a trend toward improved exercise time at four weeks in treatment group 
compared to the placebo group; when only patients with baseline exercise time ≤10 minutes 
were considered, exercise time increased significantly. The subsequent AGENT-2 trial of 52 
patients with AdFGF-4 found a nonsignificant reduction in the size of the ischemic defect on 
perfusion imaging between treatment and placebo (Kapur & Rade, 2008). However, two 
large double-blind phase III trials of Ad-FGF4 (AGENT-3 and AGENT-4) were negative for 
their primary end point although a post-hoc analysis suggested a benefit in a certain 
population of middle aged women (Henry et al., 2007).  
3.2.1.2 Conclusion  
Though therapeutic angiogenesis theoretically is an attractive option for improving the 
quality of life in chronic ischemic heart disease, no large clinical trial yet has shown 
substantial clinical benefit. However, efforts are ongoing to improve delivery and 
expression and biological efficacy of the angiogenic genes (Zachary & Morgan, 2011).  
3.2.2 Stem cell therapy 
Hematopoietic stem cells are bone marrow-derived cells capable of differentiating into a 
variety of cell types. Such cells may be obtained directly from the bone marrow or, using 
apheresis techniques, from peripheral blood, usually after stimulation with granulocyte-
colony stimulating factor (G-CSF). Cardiac stem cell therapy has been evaluated clinically 
during the past 10 years. Many clinical trials have been conducted on treatment for heart 
failure (Menasche et al., 2008; Stamm et al., 2007) and acute MI (Martin-Rendon et al., 2008) 
but the study of stem cell therapy for refractory angina is in early stages of development. 
The mechanisms of potential benefit remain uncertain. The initial hypothesis of 
transdifferentiation into cardiomyocytes no longer is generally accepted (Murry et al., 2004). 
The currently favored hypothesis is that increased angiogenesis is stimulated by angiogenic 
growth factors released by bone marrow cells, particularly by the CD34+ fraction 
(Menasche, 2011).  
3.2.2.1 Evidence  
Losordo et al (Losordo et al., 2007) showed the efficacy of intramyocardial transplantation of 
autologous G-CSF-mobilized peripheral blood CD34+ stem cells for prevention of angina. 
Twenty-four patients with CCS class III or IV angina who were undergoing optimized 
medical treatment and who were not candidates for mechanical revascularization were 
enrolled in a double-blind, randomized (3:1), placebo-controlled dose-escalating study. 
CD34+ progenitors were collected following GCSF-induced cell mobilization and apheresis. 
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Electromechanical mapping was performed to identify ischemic but viable regions of 
myocardium for injection of cells (versus saline). The intramyocardial injection of cells or 
saline did not result in cardiac enzyme elevation, perforation, or pericardial effusion. 
Neither ventricular tachycardia nor ventricular fibrillation occurred during the 
administration of G-CSF or intramyocardial injections. Efficacy parameters including angina 
frequency, nitroglycerin usage, exercise time, and CCS class showed trends that favored 
CD34+ cell–treated patients versus placebo-treated controls. A phase II b study in a larger 
population is currently under way. 
A recent RCT of intracoronary infusion with autologous bone marrow CD34+ stem cells 
involved 112 patients with intractable angina (Wang et al., 2010). No myocardial infarction 
or other major adverse event was observed during the procedure. Investigators found 
significantly greater reduction in angina frequency by diary at 3 and 6 months after active 
treatment than after control. Other efficacy parameters, such as nitroglycerin use, exercise 
time and the CCS class, also were improved by active treatment versus control, as was 
myocardial perfusion imaging assessment of ischemia. 
3.2.2.2 Conclusion  
Stem cell therapy is an investigational technique that has reduced angina frequency and 
severity by several measures in small populations with refractory angina. However, 
additional studies are required to determine the magnitude, consistency and durability of 
anti-anginal benefit, as well as the long-term safety of this approach for treatment of patients 
with angina due to CAD. 
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1. Introduction 
The knowledge of the impact of beta-blockers on Coronary Flow Reserve (CFR) is based on 
experimental and clinical studies which used invasive methods (mainly Doppler Flow Wire, 
DFW) and non-invasive tools including scintigraphic (mainly Positron Emission 
Tomography, PET), magnetic resonance and Doppler ultrasound imaging. 
Beta-blockers have a large therapeutic indication in the treatment of coronary artery disease, 
due to their anti-ischemic and anti-arrhythmic effect. The anti-ischemic effect is based on the 
oxygen sparing mechanism with a reduction in rate-pressure product. Changes in coronary 
hemodynamics associated with the administration of beta-blockers have been extensively 
studied. These drugs may affect CFR by modifying either resting or maximal coronary 
blood flow (CBF) or even both. When assessing the impact of beta-blockers on CFR it is 
important to distinguish the effects exerted by first-and second generation beta-blockers 
from those due the mechanisms of third generation beta-blockers, which are provided of 
vasodilating action.  
2. First and second generation beta-blockers and coronary flow reserve 
Animal and human experiments have shown that first- and second generation beta-blockers 
(propranolol, practolol metoprolol, atenolol) induce a reduction of CBF at rest (1-7), which 
has been mainly attributed to coronary vasoconstriction (8,9). Both non selective 
(propranolol) and selective (atenolol) beta-blocking agents have shown a gradual 
vasoconstriction, i.e., a decrease in coronary artery diameter by approximately 20-25%, over 
20 min after their acute administration, an effect which is overcome by nitrates (3). An 
alternative mechanisms for explaining the reduction of CBF at rest is provided by the 
reduction of myocardial oxygen demand since these drugs lower blood pressure and heart 
rate with variable degree (4,5). After acute injection, beta-blockers decrease myocardial 
contractility and work, leading to a reduction of resting CBF (5).  
The effects of first and second generation beta-blockers on maximal CBF are more 
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(0.1 mg/kg i.v.) after cold pressure test (CPT), a stimulus completely mediated to the 
endothelial function (“reactive hyperemia”) suggests that this drug leads to enhanced 
coronary vascular resistance during hyperemia, due to unopposed alpha-adrenergic 
vasomotor tone (6). The oral administration of the cardio-selective atenolol produces similar 
action in hypertensive patients without coronary artery stenosis, inducing even a reduction 
of CFR and raising the suspicion that it may worsen coronary microvascular function (7). On 
the other hand, in patients with coronary artery disease the acute intravenous 
administration of the selective beta-blocker metoprolol (5 mg) has shown an increase of 
pharmacologically induced (adenosine) CBF velocities and post-ischemic coronary flow 
velocity reserve (CFVR) measured by the means of DFW (5). Boettcher and coworker have 
reported similar results, with an increase in PET-derived CFR after 50 mg oral metoprolol, 
achieved by an increase in maximal CBF which is further enhanced by a decrease in resting 
CBF (6).  
Based on these experiences, the controversial influence of first- and second-generation beta-
blocking agents on CFR has to be acknowledged. It can be explained by taking into account 
the interaction of the pharmacological effects on CBF at rest, generally reduced under the 
action of these categories of beta-blockers, and after maximal hyperemia, when minimal 
coronary resistance can be increased (mainly by non selective beta-adrenergic antagonists 
and by selective atenolol) or reduced (by some selective beta-blockers such as metoprolol).      
3. Third generation Beta-blockers (with vasodilating action) and Coronary 
Flow Reserve 
The third generation beta-blockers have the common characteristic to combine a 
vasodilating action to the classic beta-blocking properties. The association of these two 
effects is particularly pronounced in carvedilol and nebivolol, which have earned important 
positions in the therapy of chronic heart failure, with a recognized positive influence on left 
ventricular (LV) function and prognosis (10-13). The influence of these two drugs on CFR 
has been tested in the clinical setting. The improvement of coronary microvascular function 
obtainable by both carvedilol (14-17) and nebivolol (7,18-21) could be at least one of the 
substrates underlying the improvement in LV function due to both these drugs. Except for 
the experience of Koepfli et al (14), where a significant drug-induced  increase on PET-
derived CFR was achieved only pooling 36 patients with coronary artery disease treated by 
either carvedilol or atenolol (12 week treatment), all the other clinical studies demonstrated 
a positive effect of carvedilol or nebivolol on CFR (Table 1) (22).   
The beneficial action of carvedilol on CFVR was observed in three reports, including 
exclusively patients with idiopathic dilated cardiomyopathy, with a therapy time duration 
ranging between 1 month and 6 months (16-18). In these experiences, the increase of CFVR 
was mainly due to the increase of maximal CBF velocity, attributable to diminution of 
extravascular compressive forces and of LV filling pressure (5,6), to blunted heart rate 
response beneficially affecting the diastolic myocardial perfusion during hyperemia (6), to 
alpha-adrenergic blocking action and to improved endothelial function (23,24) possibly 
producing a better hyperemic microvascular vasodilation..  
The studies performed by using nebivolol involved several clinical settings, such as patients 
with arterial hypertension (7,18,21), idiopathic dilated cardiomyopathy (19) and coronary 
artery disease (20). In particular, Togni et al (20) evaluated the acute effect of intracoronary 
administration of nebivolol, while the other studies evaluated the therapeutic effect of oral 
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* CFR change in patients with improvement of LV ejection fraction ≥ 10%.  
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HTN = Hypertension IDCM = Idiopathic dilated cardiomyopathy, PET = Positron emission 
tomography, pts = Patients, TTE = Trans-thoracic echocardiography 
Table 1. Main studies showing favourable effect of beta-blockers with vasodilator action on 
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administration (5 mg daily) after 8 weeks (7) and 4 weeks (18,19) and 3 months (21). With 
the exception of the observation of Gullu (7), where the improvement of CFVR was 
exclusively due to the decrease of CBF velocities at rest, in the other 4 studies nebivolol 
increased significantly  hyperemic CBF velocities (18-21). Coronary vasodilation due to 
either adenosine or dipyridamole is primarily endothelium independent but the increment 
in CBF may trigger further flow-induced vasodilation, which is endothelium dependent 
(25,26). Nebivolol has vasodilating properties with increasing endothelial NO release due to 
effects on the L-arginine/NO pathway that reduce peripheral vascular resistance (27). It is 
able not only to increase NO release but also to inhibit the synthesis of endothelin-1 (28), a 
mediator contributing to vascular resistance (29). Although these effects cannot be 
automatically applied to the coronary circulation of the studies which demonstrated the 
beneficial effects of nebivolol on CFVR – since they did not use any NO antagonist to target 
the mechanism of action - in our experience (18) dipyridamole-induced increase in rate-
pressure product during pharmacological stress was similar before and during nebivolol 
therapy and could not explain alone the changes induces on CBF velocities. This highlights 
indirectly the possible beneficial effect of the drug on the endothelial function. A similar 
effect of nebivolol has been demonstrated in humans on brachial artery flow mediated 
dilation (30), a completely endothelium-dependent stimulus (31). 
The increase of CFR induced by beta-blocking agents with vasodilating properties has 
potential clinical implications. This increase appears clearly beneficial in patients with 
coronary artery disease, where a better hyperemic CBF (increase of O2 supply), combined 
with a reduction of rate-pressure product (decrease of O2 demand), may be the cause 
underlying the anti-ischemic effect of these drugs. The increase of CFR might also indicate 
an improvement of coronary microvascular dysfunction, responsible of microvascular 
angina pectoris or silent ischemia in patients without epicardial artery stenosis (32). The 
improvement of coronary microvessel function could be even one of the mechanisms 
sustaining the improvement of LV function demonstrated by both carvedilol and nebivolol 
(33-40). Sugioka and coworkers (17) observed that CFVR improvement after carvedilol was 
greater in patients with LV ejection fraction increase ≥ 10% (1.3 ± 0.6) than in those with 
election fraction increase < 10% (0.4 ± 0.5) (p<0.01). Data from our laboratory have shown a 
relation between the positive influence exerted by 3-month oral administration of nebivolol 
on CFVR and the reduction of non invasively determined LV filling pressure in 
uncomplicated arterial hypertension (21). Accordingly, the absence of a significant 
restoration of CFVR after short-term third-generation beta-blockers may imply a poor 
chance of improvement in LV function, while a great CFVR increase may indicate a higher 
chance of it. Therefore, one possible clinical implication is that changes of CFVR after short-
term beta-blocking therapy is helpful to predict the response or the further improvement of 
LV function to treatment.                    
4. Conclusions  
The impact of beta-blocking medications on coronary flow reserve is related to the specific 
characteristics of the drug. First- and second-generation beta-blockers significantly reduce 
coronary flow at rest (because of reduction of myocardial oxygen demand and 
vasoconstriction effects) while their action on the hyperemic coronary flow is variable. 
Third-generation beta-blockers induce a true amelioration of the maximal hyperemia of 
coronary blood flow which appears be possibly due to alpha-adrenergic blockade and to 
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nitric oxide-mediated vasodilator action. These effects might have potential beneficial 
prognostic impact in the setting of patients where CFR reduction has a recognized 
independent, negative predictive value on outcome and mortality (41-43).            
5. References 
[1] Young MA, Vatner SE, Vatner SF. Alpa- and beta-adrenergic control of large coronary 
arteries in conscious dogs. Circ Res 1974;34:812-823. 
[2] Marshall RJ, Parratt JR. Comparative effects of propranolol and practolol in the early 
stages of experimental canine myocardial infarction. Br J Pharmacol 1976;57:295-303. 
[3] Lichtlen PR, Rafflenbeul W, Jost S, et al. Coronary vasomotion tone in large epicardial 
coronary arteries with special emphasis on beta-adrenergic vasomotion, effect of 
beta-blockade. Basic Res Cardiol 1990;85(Suppl 1):335-346.  
[4] Hoffman JIE. Maximal coronary flow and the concept of coronary flow reserve. 
Circulation 1984;70:153-159. 
[5] Billinger M, Seller C, Fleisch M, et al. Effect of beta-adrenergic blocking agents increase 
coronary flow reserve? J Am Coll Cardiol 2001;38:1866-1871.  
[6] Bottcher M, Czernin J, Sun K, et al. Effects of β1 adrenergic blockade on myocardial 
blood flow and vasodilatory capacity. J Nucl Med 1997;38:442-446.  
[7] Gullu H, Erdogan D, Caliskan M, et al. Different effects of atenolol and nebivolol on 
coronary flow reserve. Heart 2006;92:1690-1691. 
[8] Strauer BE. The hypertensive heart. Effect of atenolol on the function, coronary 
hemodynamics and oxygen uptake of the left ventricle. Dtsch Med Wochenschr 
1978;103:1785-1789.  
[9] Kern MJ, Ganz P, Horowitz DJ, Gaspar J, et al. Potentiation of coronary vasoconstriction 
by beta-adrenergic blockade in patients with coronary artery disease. Circulation 
1983;67:1178-1185.  
[10] Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with 
left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 
2001;357:1385-1390. 
[11] Packer M, Coats AJ, Fowler MB, et al. Carvedilol Prospective Randomized Cumulative 
Survival Study Group. Effect of carvedilol on survival in severe chronic heart 
failure. N Engl J Med 2001;344:1651-1658. 
[12] Poole-Wilson PA, Swedberg K, Cleland JG, et al. Carvedilol or Metoprolol European 
Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes 
in patients with chronic heart failure in the Carvedilol Or Metoprolol European 
Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13. 
[13] Flather MD, Shibata MC, Coats AJ, et al. SENIORS Investigators. Randomized trial to 
determine the effect of nebivolol on mortality and cardiovascular hospital 
admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-
225. 
[14] Koepfli P, Wyss CA, Namdar M, et al. Β-adrenergic blockade and myocardial perfusion 
in coronary artery disease: differential effects in stenotic versus remote myocardial 





administration (5 mg daily) after 8 weeks (7) and 4 weeks (18,19) and 3 months (21). With 
the exception of the observation of Gullu (7), where the improvement of CFVR was 
exclusively due to the decrease of CBF velocities at rest, in the other 4 studies nebivolol 
increased significantly  hyperemic CBF velocities (18-21). Coronary vasodilation due to 
either adenosine or dipyridamole is primarily endothelium independent but the increment 
in CBF may trigger further flow-induced vasodilation, which is endothelium dependent 
(25,26). Nebivolol has vasodilating properties with increasing endothelial NO release due to 
effects on the L-arginine/NO pathway that reduce peripheral vascular resistance (27). It is 
able not only to increase NO release but also to inhibit the synthesis of endothelin-1 (28), a 
mediator contributing to vascular resistance (29). Although these effects cannot be 
automatically applied to the coronary circulation of the studies which demonstrated the 
beneficial effects of nebivolol on CFVR – since they did not use any NO antagonist to target 
the mechanism of action - in our experience (18) dipyridamole-induced increase in rate-
pressure product during pharmacological stress was similar before and during nebivolol 
therapy and could not explain alone the changes induces on CBF velocities. This highlights 
indirectly the possible beneficial effect of the drug on the endothelial function. A similar 
effect of nebivolol has been demonstrated in humans on brachial artery flow mediated 
dilation (30), a completely endothelium-dependent stimulus (31). 
The increase of CFR induced by beta-blocking agents with vasodilating properties has 
potential clinical implications. This increase appears clearly beneficial in patients with 
coronary artery disease, where a better hyperemic CBF (increase of O2 supply), combined 
with a reduction of rate-pressure product (decrease of O2 demand), may be the cause 
underlying the anti-ischemic effect of these drugs. The increase of CFR might also indicate 
an improvement of coronary microvascular dysfunction, responsible of microvascular 
angina pectoris or silent ischemia in patients without epicardial artery stenosis (32). The 
improvement of coronary microvessel function could be even one of the mechanisms 
sustaining the improvement of LV function demonstrated by both carvedilol and nebivolol 
(33-40). Sugioka and coworkers (17) observed that CFVR improvement after carvedilol was 
greater in patients with LV ejection fraction increase ≥ 10% (1.3 ± 0.6) than in those with 
election fraction increase < 10% (0.4 ± 0.5) (p<0.01). Data from our laboratory have shown a 
relation between the positive influence exerted by 3-month oral administration of nebivolol 
on CFVR and the reduction of non invasively determined LV filling pressure in 
uncomplicated arterial hypertension (21). Accordingly, the absence of a significant 
restoration of CFVR after short-term third-generation beta-blockers may imply a poor 
chance of improvement in LV function, while a great CFVR increase may indicate a higher 
chance of it. Therefore, one possible clinical implication is that changes of CFVR after short-
term beta-blocking therapy is helpful to predict the response or the further improvement of 
LV function to treatment.                    
4. Conclusions  
The impact of beta-blocking medications on coronary flow reserve is related to the specific 
characteristics of the drug. First- and second-generation beta-blockers significantly reduce 
coronary flow at rest (because of reduction of myocardial oxygen demand and 
vasoconstriction effects) while their action on the hyperemic coronary flow is variable. 
Third-generation beta-blockers induce a true amelioration of the maximal hyperemia of 
coronary blood flow which appears be possibly due to alpha-adrenergic blockade and to 
 
Beta-Blockers and Coronary Flow Reserve 
 
133 
nitric oxide-mediated vasodilator action. These effects might have potential beneficial 
prognostic impact in the setting of patients where CFR reduction has a recognized 
independent, negative predictive value on outcome and mortality (41-43).            
5. References 
[1] Young MA, Vatner SE, Vatner SF. Alpa- and beta-adrenergic control of large coronary 
arteries in conscious dogs. Circ Res 1974;34:812-823. 
[2] Marshall RJ, Parratt JR. Comparative effects of propranolol and practolol in the early 
stages of experimental canine myocardial infarction. Br J Pharmacol 1976;57:295-303. 
[3] Lichtlen PR, Rafflenbeul W, Jost S, et al. Coronary vasomotion tone in large epicardial 
coronary arteries with special emphasis on beta-adrenergic vasomotion, effect of 
beta-blockade. Basic Res Cardiol 1990;85(Suppl 1):335-346.  
[4] Hoffman JIE. Maximal coronary flow and the concept of coronary flow reserve. 
Circulation 1984;70:153-159. 
[5] Billinger M, Seller C, Fleisch M, et al. Effect of beta-adrenergic blocking agents increase 
coronary flow reserve? J Am Coll Cardiol 2001;38:1866-1871.  
[6] Bottcher M, Czernin J, Sun K, et al. Effects of β1 adrenergic blockade on myocardial 
blood flow and vasodilatory capacity. J Nucl Med 1997;38:442-446.  
[7] Gullu H, Erdogan D, Caliskan M, et al. Different effects of atenolol and nebivolol on 
coronary flow reserve. Heart 2006;92:1690-1691. 
[8] Strauer BE. The hypertensive heart. Effect of atenolol on the function, coronary 
hemodynamics and oxygen uptake of the left ventricle. Dtsch Med Wochenschr 
1978;103:1785-1789.  
[9] Kern MJ, Ganz P, Horowitz DJ, Gaspar J, et al. Potentiation of coronary vasoconstriction 
by beta-adrenergic blockade in patients with coronary artery disease. Circulation 
1983;67:1178-1185.  
[10] Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with 
left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 
2001;357:1385-1390. 
[11] Packer M, Coats AJ, Fowler MB, et al. Carvedilol Prospective Randomized Cumulative 
Survival Study Group. Effect of carvedilol on survival in severe chronic heart 
failure. N Engl J Med 2001;344:1651-1658. 
[12] Poole-Wilson PA, Swedberg K, Cleland JG, et al. Carvedilol or Metoprolol European 
Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes 
in patients with chronic heart failure in the Carvedilol Or Metoprolol European 
Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13. 
[13] Flather MD, Shibata MC, Coats AJ, et al. SENIORS Investigators. Randomized trial to 
determine the effect of nebivolol on mortality and cardiovascular hospital 
admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-
225. 
[14] Koepfli P, Wyss CA, Namdar M, et al. Β-adrenergic blockade and myocardial perfusion 
in coronary artery disease: differential effects in stenotic versus remote myocardial 





[15] Sugioka K, Hozumi T, Takemoto Y, et al. Early recovery of impaired coronary flow 
reserve by carvedilol therapy in patients with idiopathic dilated cardiomyopathy: a 
serial transthoracic Doppler echocardiographic study. J Am Coll Cardiol 2005;45:318-
319. 
[16] Neglia D, De Maria R, Masi S, et al. Effects of long-term treatment with carvedilol on 
myocardial blood flow in idiopathic dilated cardiomyopathy. Heart 2007;93:803-
813. 
[17] Sugioka K, Hozumi T, Takemoto Y, et al. Relation of early improvement in coronary 
flow reserve to late recovery of left ventricular function after beta-blocker therapy 
in patients with idiopathic dilated cardiomyopathy. Am Heart J 2007;153:1080e1-
1080e6. 
[18] Galderisi M, Cicala S, D'Errico A, et al. Nebivolol improves coronary flow reserve in 
hypertensive patients without coronary heart disease. J Hypertens 2004;22:2201-
2208. 
[19] Erdogan D, Gullu H, Caliskan M, et al. Nebivolol improves coronary flow reserve in 
patients with idiopathic dilated cardiomyopathy. Heart 2007;93:319-324. 
[20] Togni M, Vigorito F, Windecker S, et al. Does the beta-Blocker Nebivolol Increase 
Coronary Flow Reserve? Cardiovasc Drug Ther 2007; Jan 26; [Epub ahead of 
print].   
[21] Galderisi M, D'Errico A, Sidiropulos M, Innelli P, de Divitiis O, de Simone G. 
Nebivolol induces parallel improvement of left ventricular filling pressure and 
coronary flow reserve in uncomplicated arterial hypertension. J Hypertens 
2009;27:2108-2115. 
[22] Galderisi M, D’Errico A. Beta-blocker and coronary flow reserve. The importance of a 
vasodilatory action. Drugs 2008;68:579-580.    
[23] Drexler H, Zeiber AM, Wollschlager H, et al. Flow dependent coronary artery dilation 
in humans, Circulation 1989;80:466-474.   
[24] Lorenzoni R, Rosen SD, Camici PG. Effect of alpha1-adrenoceptor blockade on resting 
and hyperemic myocardial blood flow in normal humans. Am J Physiol 
1996;271:H1302-H1306. 
[25] Yue TL, Ruffolo RR jr, Feuerstein G. Antioxidant action of carvedilol: a potential role in 
treatment of heart failure. Heart Fail Rev 1999;4:39-51. 
[26] Kuo L, Davis MJ, Chilian WH. Endothelium-dependent, flow induced dilation of 
isolated coronary arterioles. Am J Physiol 1990;259:H1063-H1070. 
[27] Ignarro LJ, Byrns RE, Trinh K, et al. Nebivolol: a selective beta(1)-adrenergic receptor 
antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-
dependent mechanisms. Nitric Oxide 2002;7:75-82. 
[28] Brehm BR, Bertsch D, von Fallois J, et al. Beta-blockers of the third generation inhibit 
endothelin-1 liberation, mRNA production and proliferation of human coronary 
smooth muscle and endothelial cells. J Cardiovasc Pharmacol 2000;36:S401-S403. 
[29] Mundhenke M, Schwartzkopff B, Köstering M, et al. Endogenous plasma endothelin 
concentrations and coronary circulation in patients with mild dilated 
cardiomyopathy. Heart 1999;81:278-284. 
 
Beta-Blockers and Coronary Flow Reserve 
 
135 
[30] Lekakis JP, Protogerou A, Papamichael C, et al. Effect of nebivolol and atenolol on 
brachial artery flow-mediated vasodilation in patients with coronary artery disease. 
Cardiovasc Drugs Ther 2005;19:277-281. 
[31] Corretti MC, Anderson TJ, Benjamin EJ, et al. International Brachial Artery Reactivity 
Task Force. Guidelines for the ultrasound assessment of endothelial-dependent 
flow-mediated vasodilation of the brachial artery: a report of the International 
Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-265. 
[32] Zeiher AM, Krause T, Schächinger V, Minners J, Moser E. Impaired endothelium-
dependent vasodilation of coronary resistance vessels is associated with exercise-
induced myocardial ischemia. Circulation 1995;91:2345-2352. 
[33] Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left ventricular function 
and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll 
Cardiol 1995;25:1225-1231. 
[34] Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, 
placebo-controlled trial of carvedilol in patients with congestive heart failure due to 
ischaemic heart disease. Lancet 1997; 349:375-380. 
[35] Di Lenarda A, Sabbadini G, Salvatore L, et al. Long-term effects of carvedilol in 
idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction 
despite chronic metoprolol. The Heart-Muscle Disease Study Group. J Am Coll 
Cardiol 1999;33:1926-1934. 
[36] Palazzuoli A, Quatrini I, Vecchiato L, et al. Left ventricular diastolic function 
improvement by carvedilol therapy in advanced heart failure. J Cardiovasc 
Pharmacol 2005;45:563-568.   
[37] Wisenbaugh T, Katz I, Davis J, et al. Long-term (3-month) effects of a new beta-blocker 
(nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol  
1993;21:1094-1100. 
[38] Nodari S, Metra M, Dei Cas L. Beta-blocker treatment of patients with diastolic heart 
failure and arterial hypertension. A prospective, randomized, comparison of the 
long-term effects of atenolol vs. nebivolol. Eur J Heart Fail 2003;5:621-627. 
[39] Edes I, Gasior Z, Wita K. Effects of nebivolol on left ventricular function in elderly 
patients with chronic heart failure: results of the ENECA study. Eur J Heart Fail 
2005;7:631-639. 
[40] Ghio S, Magrini G, Serio A, et al. Effects of nebivolol in elderly heart failure patients 
with or without systolic left ventricular dysfunction: results of the SENIORS 
echocardiographic substudy. Eur Heart J 2006;27:506-507. 
[41] Rigo F, Cortigiani L, Pasanisi E, et al. The additional prognostic value of coronary flow 
reserve on left anterior descending artery in patients with negative stress echo by 
wall motion criteria. A transthoracic vasodilator stress echocardiography study. Am 
Heart J 2006;151:124-130. 
[42] Rigo F, Gherardi S, Galderisi M, et al. The independent prognostic value of contractile 
and coronary flow reserve determined by dipyridamole stress echocardiography 






[15] Sugioka K, Hozumi T, Takemoto Y, et al. Early recovery of impaired coronary flow 
reserve by carvedilol therapy in patients with idiopathic dilated cardiomyopathy: a 
serial transthoracic Doppler echocardiographic study. J Am Coll Cardiol 2005;45:318-
319. 
[16] Neglia D, De Maria R, Masi S, et al. Effects of long-term treatment with carvedilol on 
myocardial blood flow in idiopathic dilated cardiomyopathy. Heart 2007;93:803-
813. 
[17] Sugioka K, Hozumi T, Takemoto Y, et al. Relation of early improvement in coronary 
flow reserve to late recovery of left ventricular function after beta-blocker therapy 
in patients with idiopathic dilated cardiomyopathy. Am Heart J 2007;153:1080e1-
1080e6. 
[18] Galderisi M, Cicala S, D'Errico A, et al. Nebivolol improves coronary flow reserve in 
hypertensive patients without coronary heart disease. J Hypertens 2004;22:2201-
2208. 
[19] Erdogan D, Gullu H, Caliskan M, et al. Nebivolol improves coronary flow reserve in 
patients with idiopathic dilated cardiomyopathy. Heart 2007;93:319-324. 
[20] Togni M, Vigorito F, Windecker S, et al. Does the beta-Blocker Nebivolol Increase 
Coronary Flow Reserve? Cardiovasc Drug Ther 2007; Jan 26; [Epub ahead of 
print].   
[21] Galderisi M, D'Errico A, Sidiropulos M, Innelli P, de Divitiis O, de Simone G. 
Nebivolol induces parallel improvement of left ventricular filling pressure and 
coronary flow reserve in uncomplicated arterial hypertension. J Hypertens 
2009;27:2108-2115. 
[22] Galderisi M, D’Errico A. Beta-blocker and coronary flow reserve. The importance of a 
vasodilatory action. Drugs 2008;68:579-580.    
[23] Drexler H, Zeiber AM, Wollschlager H, et al. Flow dependent coronary artery dilation 
in humans, Circulation 1989;80:466-474.   
[24] Lorenzoni R, Rosen SD, Camici PG. Effect of alpha1-adrenoceptor blockade on resting 
and hyperemic myocardial blood flow in normal humans. Am J Physiol 
1996;271:H1302-H1306. 
[25] Yue TL, Ruffolo RR jr, Feuerstein G. Antioxidant action of carvedilol: a potential role in 
treatment of heart failure. Heart Fail Rev 1999;4:39-51. 
[26] Kuo L, Davis MJ, Chilian WH. Endothelium-dependent, flow induced dilation of 
isolated coronary arterioles. Am J Physiol 1990;259:H1063-H1070. 
[27] Ignarro LJ, Byrns RE, Trinh K, et al. Nebivolol: a selective beta(1)-adrenergic receptor 
antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-
dependent mechanisms. Nitric Oxide 2002;7:75-82. 
[28] Brehm BR, Bertsch D, von Fallois J, et al. Beta-blockers of the third generation inhibit 
endothelin-1 liberation, mRNA production and proliferation of human coronary 
smooth muscle and endothelial cells. J Cardiovasc Pharmacol 2000;36:S401-S403. 
[29] Mundhenke M, Schwartzkopff B, Köstering M, et al. Endogenous plasma endothelin 
concentrations and coronary circulation in patients with mild dilated 
cardiomyopathy. Heart 1999;81:278-284. 
 
Beta-Blockers and Coronary Flow Reserve 
 
135 
[30] Lekakis JP, Protogerou A, Papamichael C, et al. Effect of nebivolol and atenolol on 
brachial artery flow-mediated vasodilation in patients with coronary artery disease. 
Cardiovasc Drugs Ther 2005;19:277-281. 
[31] Corretti MC, Anderson TJ, Benjamin EJ, et al. International Brachial Artery Reactivity 
Task Force. Guidelines for the ultrasound assessment of endothelial-dependent 
flow-mediated vasodilation of the brachial artery: a report of the International 
Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-265. 
[32] Zeiher AM, Krause T, Schächinger V, Minners J, Moser E. Impaired endothelium-
dependent vasodilation of coronary resistance vessels is associated with exercise-
induced myocardial ischemia. Circulation 1995;91:2345-2352. 
[33] Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left ventricular function 
and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll 
Cardiol 1995;25:1225-1231. 
[34] Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, 
placebo-controlled trial of carvedilol in patients with congestive heart failure due to 
ischaemic heart disease. Lancet 1997; 349:375-380. 
[35] Di Lenarda A, Sabbadini G, Salvatore L, et al. Long-term effects of carvedilol in 
idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction 
despite chronic metoprolol. The Heart-Muscle Disease Study Group. J Am Coll 
Cardiol 1999;33:1926-1934. 
[36] Palazzuoli A, Quatrini I, Vecchiato L, et al. Left ventricular diastolic function 
improvement by carvedilol therapy in advanced heart failure. J Cardiovasc 
Pharmacol 2005;45:563-568.   
[37] Wisenbaugh T, Katz I, Davis J, et al. Long-term (3-month) effects of a new beta-blocker 
(nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol  
1993;21:1094-1100. 
[38] Nodari S, Metra M, Dei Cas L. Beta-blocker treatment of patients with diastolic heart 
failure and arterial hypertension. A prospective, randomized, comparison of the 
long-term effects of atenolol vs. nebivolol. Eur J Heart Fail 2003;5:621-627. 
[39] Edes I, Gasior Z, Wita K. Effects of nebivolol on left ventricular function in elderly 
patients with chronic heart failure: results of the ENECA study. Eur J Heart Fail 
2005;7:631-639. 
[40] Ghio S, Magrini G, Serio A, et al. Effects of nebivolol in elderly heart failure patients 
with or without systolic left ventricular dysfunction: results of the SENIORS 
echocardiographic substudy. Eur Heart J 2006;27:506-507. 
[41] Rigo F, Cortigiani L, Pasanisi E, et al. The additional prognostic value of coronary flow 
reserve on left anterior descending artery in patients with negative stress echo by 
wall motion criteria. A transthoracic vasodilator stress echocardiography study. Am 
Heart J 2006;151:124-130. 
[42] Rigo F, Gherardi S, Galderisi M, et al. The independent prognostic value of contractile 
and coronary flow reserve determined by dipyridamole stress echocardiography 






[43] Cortigiani L, Rigo F, Gherardi S, et al. Additional prognostic value of coronary 
flow reserve in diabetic and non diabetic patients with negative dipyridamole 
stress echocardiography by wall motion criteria. J Am Coll Cardiol 2007;50:1354-
1361. 
6 
The Role of Enhanced External 
Counterpulsation Therapy in the 
Management of Coronary Artery Disease  
Ozlem Soran  
University of Pittsburgh, Heart and Vascular Institute 
USA 
1. Introduction 
Coronary artery disease (CAD) is a narrowing or blockage of the arteries and vessels that 
provide oxygen and nutrients to the heart. It is caused by atherosclerosis, an accumulation 
of fatty materials on the inner linings of arteries. According to the American Heart 
Association and American Stroke Association's 2010 publication on heart disease and stroke 
statistics, cardiovascular disease remains the leading cause of mortality in the United States 
in men and women of every major ethnic group. It accounts for nearly 1 million deaths per 
year as of 2006 and was responsible for one in almost three deaths in the United States in 
2006. Approximately 17 million persons have a history of coronary artery disease and 8 
million have suffered a myocardial infarction (American Heart Association 2010). 
Medication and invasive revascularization are the most common approaches for treating 
CAD. Invasive revascularization includes percutaneus coronary interventions (PCI: stent 
implantation or balloon angioplasty)and Coronary Bypass Surgery (CABG). Even though 
both treatment options are commonly used, it is important to note that neither of these 
approaches provides a cure. In other words, although the symptoms are eliminated or 
alleviated, the disease and its causes are still present after treatment. Both treatments target 
lesions that cause the obstructions however, CAD is a progressive disease. New treatment 
approaches are in need to prevent the disease from progressing and the symptoms from 
recurring. Enhanced External Counterpulsation (EECP) therapy with its different mode of 
action provides a new treatment modality in the management of CAD and complements the 
invasive revascularization (Fig. 1).  
This chapter summarizes the current evidence to support the role of EECP therapy in CAD 
management and provides information on its mechanism of action. 
2. What is EECP? 
EECP therapy consists of a treatment bed attached to an air compressor unit which is 
attached to a computerized control console. Three sets of cuffs wrapped around the lower 
legs and the buttocks of the patient. It is a noninvasive outpatient therapy consisting of 
electrocardiography (ECG)-gated sequential leg compression, which produces 
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electrocardiography (ECG)-gated sequential leg compression, which produces 
hemodynamic effects similar to those of an intra-aortic balloon pump (IABP) (Fig. 2).  
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EECP Therapy: Consisting of a patient bed attached to an air compressor unit; computerized control 
consul; 3 sets of cuffs wrapped around the lower legs and the buttocks of the patient. (With permission 
from Vasomedical Inc., NY). EECP: Enhanced External Counterpulsation 
Fig. 1. EECP Therapy 
 
 
Three pairs of pneumatic cuffs are applied to the calves, lower thighs, and upper thighs. The cuffs are 
inflated sequentially during diastole, distal to proximal. The compression of the lower extremity 
vascular bed increases diastolic pressure and flow and increases venous return. The pressure is then 
released at the onset of systole. Inflation and deflation are timed according to the R wave on the 
patient’s cardiac monitor. The pressures applied and the inflation–deflation timing can be altered by 
using the pressure waveforms and ECG on the EECP therapy monitor. (Adapted from Manchanda and 
Soran 2007) 
ECG: Electrocardiogram; EECP: Enhanced External Counterpulsation   
Fig. 2. Technique of EECP Therapy 
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However, unlike IABP therapy, EECP therapy also increases venous return (Manchanda 
and Soran 2007, Birtwell et al 1968). Cuffs resembling oversized blood pressure cuffs—on 
the calves and lower and upper thighs, including the buttocks—inflate rapidly and 
sequentially via computer interpreted ECG signals, starting from the calves and proceeding 
upward to the buttocks during the resting phase of each heartbeat (diastole). This creates a 
strong retrograde counterpulse in the arterial system, forcing freshly oxygenated blood 
toward the heart and coronary arteries while increasing the volume of venous blood return 
to the heart under increased pressure. Just before the next heartbeat, before systole, all three 
cuffs deflate simultaneously, significantly reducing the heart’s workload. This is achieved 
because the vascular beds in the lower extremities are relatively empty when the cuffs are 
deflated; significantly lowering the resistance to blood ejected by the heart and reducing the 
amount of work the heart must do to pump oxygenated blood to the rest of the body. A 
finger plethysmogram is used throughout treatment to monitor diastolic and systolic 
pressure waveforms. The current EECP device can generate external cuff pressures as high 
as 220 to 300 mmHg. A typical therapy course consists of 35 treatments administered for 1 
hour a day over 7 weeks.  
2.1 Historical perspective 
The concept of counterpulsation was introduced in the U.S. in 1953 when Kantrowitz first 
proposed that elevations of aortic diastolic pressure could improve coronary blood flow and 
could benefit patients with coronary insufficiency. Although subsequent studies suggested 
that counterpulsation would indeed benefit some patients with coronary insufficiency, the 
development of the necessary technology proved challenging. A group of devices that 
increased coronary blood flow, including flow assist devices and venoarterial bypass 
systems, proved effective in providing increased coronary blood flow but were unable to 
reduce the tension time index or work load of the heart. External cardiac massage, internal 
cardiac massage, veno-arterial bypass, implantable auxillary ventricules, intra-aortic balloon 
pumps, and cardiopulmonary bypass have all demonstrated hemodynamic benefits; 
however, their usefulness in clinical practice has been limited because of their inherent 
invasiveness. 
In the mid 1960s, several groups began to explore a non-invasive method for producing the 
salutary physiologic effects of counterpulsation. First external countrepulation device 
introduced by Harvard investigators, consisted of a hydraulically driven unit with a pair of 
water –filled bladders that could be wrapped around the lower legs and thighs of the 
patient. (Birtwell et al, 1968) However, the external pressure could only be applied to a 
limited amount of tissue mass thereby producing suboptimal diastolic augmentation of 
coronary flow. Investigators did not give up on the idea and kept working on to improve 
the technology. Over the years air-driven EECP system consisting of three sets of balloons 
wrapped around the lower legs, thighs and upper thighs of the patient has been developed. 
Air pressure was applied sequentially from the lower legs to the thigh and upper thigh 
resulting in “milking” of oxygenated blood from the lower extremities toward the heart 
with greater efficiency. (Amsterdam et al.,1980; Zeng et al., 1983). It has been demonstrated 
that the sequential inclusion of the upper thigh provided a critical advantage to EECP, 
affecting a 44% increase in diastolic augmentation compared with studies using only the 
lower extremity cuffs. Subsequent modifications of the EECP prototype with 
microprocessors allowed for precise cuff inflation and deflation and gating with the 
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Soran 2007) 
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deflated; significantly lowering the resistance to blood ejected by the heart and reducing the 
amount of work the heart must do to pump oxygenated blood to the rest of the body. A 
finger plethysmogram is used throughout treatment to monitor diastolic and systolic 
pressure waveforms. The current EECP device can generate external cuff pressures as high 
as 220 to 300 mmHg. A typical therapy course consists of 35 treatments administered for 1 
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reduce the tension time index or work load of the heart. External cardiac massage, internal 
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pumps, and cardiopulmonary bypass have all demonstrated hemodynamic benefits; 
however, their usefulness in clinical practice has been limited because of their inherent 
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In the mid 1960s, several groups began to explore a non-invasive method for producing the 
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introduced by Harvard investigators, consisted of a hydraulically driven unit with a pair of 
water –filled bladders that could be wrapped around the lower legs and thighs of the 
patient. (Birtwell et al, 1968) However, the external pressure could only be applied to a 
limited amount of tissue mass thereby producing suboptimal diastolic augmentation of 
coronary flow. Investigators did not give up on the idea and kept working on to improve 
the technology. Over the years air-driven EECP system consisting of three sets of balloons 
wrapped around the lower legs, thighs and upper thighs of the patient has been developed. 
Air pressure was applied sequentially from the lower legs to the thigh and upper thigh 
resulting in “milking” of oxygenated blood from the lower extremities toward the heart 
with greater efficiency. (Amsterdam et al.,1980; Zeng et al., 1983). It has been demonstrated 
that the sequential inclusion of the upper thigh provided a critical advantage to EECP, 
affecting a 44% increase in diastolic augmentation compared with studies using only the 
lower extremity cuffs. Subsequent modifications of the EECP prototype with 
microprocessors allowed for precise cuff inflation and deflation and gating with the 
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electrocardiogram. The lower cuffs were inflated at the start of diastole as represented by 
the beginning of the T wave, while simultaneous deflation of all three chambers was 
triggered just prior to systole at the onset of the P wave. The retrograde flow provided by 
EECP increased both the volume and pressure of diastolic flow such that diastolic to systolic 
ratios exceeded 1.0-1.2. (Soran et al., 1999). In summary, it took 40 years for investigators to 
develop the enhanced technology that is being currently used. (Fig 1) 
2.2 Acute hemodynamic effects of EECP therapy 
Acute hemodynamic effects of EECP has been assessed through both noninvasive and 
invasive techniques.(Soran  et al., 2001;  Stys et al., 2001; Michaelset al.,2001; Lakshmi et al. 
2002; Nichols et al., 2006; Taguchi  et al., 2004). 
Taguchi et al, assessed the hemodynamic effects of EECP and compared it with IABP in 39 
patients with uncomplicated acute myocardial infarction who underwent successful balloon 
coronary angioplasty within 12 hours after onset of chest pain. The radial artery and 
subclavian vein were cannulated to measure right atrial pressure, pulmonary capillary 
wedge pressure (PCWP), cardiac index, and systemic vascular resistance. Radial artery 
pressure tracing was used to measure area under artery pressure curves in systolic and 
diastolic phases. Sixty minutes treatment was administered to the patients in the EECP 
group. All parameters were measured before EECP, at 15, 30, 45, and 60 minutes after 
starting EECP, and 60 minutes after stopping EECP. After starting IABP support, 
measurements were obtained at 15, 30, 45, and 60 minutes. There were no significant 
changes in heart rate in either group before, during, and after treatments. Right atrial 
pressure increased significantly at 15 and 30 minutes after starting EECP, and then 
decreased gradually. There was no significant increase in right atrial pressure at 45 and 60 
minutes after starting EECP compared with baseline. Right atrial pressure did not change in 
the IABP group, and there was no significant difference between 2 groups, except at 15 
minutes after starting treatment. In the EECP group the PCWP significantly increased at 15 
and 30 minutes, and then decreased gradually, but no significant change was seen in IABP 
group. Between two groups, there were no significant differences at baseline and during 
treatment. However, 60 minutes after stopping treatment, PCWP was significantly lower in 
the EECP group. The cardiac index in EECP group increased significantly at 45 and 60 
minutes compared with the baseline, but no significant change was noted in IABP group. 
The increase in cardiac index at 60 minutes in the EECP group was significantly greater than 
that in the IABP group. Mean values of the area under the arterial pressure curves during 
the diastolic phase increased significantly in both groups, and there was no significant 
difference between two groups at any measuring point. Mean values of the areas under the 
artery pressure curves during the systolic phase decreased significantly during treatment 
compared with baseline in the IABP group. No significant change was observed in the EECP 
group. In both groups, systemic vascular resistance decreased significantly during treatment 
compared with baseline, but no significant difference was seen between two groups. This 
study showed that the hemodynamic effects of EECP were similar to those of IABP for 
diastolic augmentation and systemic vascular resistance. However, right atrial pressure, 
PCWP, and cardiac index increased during EECP in contrast to IABP. These effects suggest 
that EECP increases venous return, raises cardiac preload, and increases cardiac output. 
(Taguchi et al., 2004; Michaels et al., 2009) 
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In another study, Taguchi et al., assessed the hemodynamic and neurohormonal changes 
during EECP. Sixty minutes of EECP therapy has been performed in  patients with stable 
acute myocardial infarction who had undergone PCI. Right heart catheterization and 
neurohumoral parameters were assessed before, during 15, 30 and 60 minutes after EECP. 
Blood levels of atrial natriuretic peptide (ANP), brain (or B type) natriuretic peptide (BNP), 
renin, aldosterone, dopamine, and noradrenaline were assessed. Left ventricular ejection 
fraction and size were assessed invasively during the admission and between days 13 to 16. 
Cardiac index increased from 3.3±0.8 L/min before treatment to 4.1±0.8 L/min at 60 
minutes (P<0.01). Right atrial pressure increased from 6.4±3.3 mmHg at baseline to 9.8±4.0 
mmHg at 15 minutes (P<0.01), and PCWP increased from 8.9±4.0 mmHg to 12.6±5.3 mmHg 
(P<0.05). The blood levels of ANP increased from 54±42 pg/ml at baseline to 70±46 pg/ml at 
60 minutes, which returned to baseline level 60 minutes after EECP treatment. The 
pretreatment concentrations of BNP, dopamine, noradrenaline, renin and aldosterone did 
not change during or after EECP treatment. Left ventricular end-diastolic pressure 
decreased from 18.6±1.6 mmHg during the acute stage to 13.8±6.4 mmHg during subacute 
follow-up, but there was no change in left ventricular ejection fraction or end-diastolic 
volume index. Blood concentrations of ANP increased at 15 minutes after initiation of EECP, 
which suggested that EECP treatment increased the volume of venous return, resulting in 
an increased atrial load. EECP significantly improved cardiac index with a significant 
increase in blood ANP concentration but without increase in heart rate or BNP. These 
findings suggest that there be an increased atrial preload without any significant change in 
ventricular preload.( Taguchi et al.,2004; Michaels et al., 2010) 
Michaels et al., used an invasive approach to measure intracoronary, central aortic, and left 
ventricular pressure and intracoronary Doppler flow to assess the acute hemodynamic 
effects of EECP. Ten patients who were referred for cardiac catheterization (5 with suspected 
coronary artery disease, 3 with severe mitral regurgitation, and 2 with heart transplant 
patients) were included in the study. Key exclusion criteria included severe aortic 
insufficiency, decompensated heart failure, significant arrhythmia, systolic blood pressure 
more than 180 mmHg, and symptomatic peripheral arterial disease. EECP was performed at 
external cuff pressures ranging from 100 to 300 mmHg. At baseline and during EECP, 
simultaneous central aortic and intracoronary pressure, intracoronary Doppler flow 
velocity, and corrected thrombosis in Myocardial Infarction study (TIMI) frame count 
(CTFC) were measured. Peak aortic systolic pressure decreased 11% from 114 ±19 mmHg at 
baseline to 101±28 mmHg during EECP (P=0.02). These findings indicate that EECP acutely 
reduces ventricular afterload. Left ventricular end-diastolic pressure decreased during EECP 
(15±7 mmHg at baseline, 13±6 mmHg during EECP; P=0.17). Aortic diastolic pressure 
increased 92% from 71±10 mmHg to 136±22 mmHg (P<0.0001), and mean aortic pressure 
increased 16% from 88±10 mmHg to 102± 14 mmHg during EECP (P=0.0007), indicating 
significant. Intracoronary pressure was measured in an unobstructed epicardial coronary 
artery using the micromanometer-tipped 0.014-inch pressure wire. There was a 93% increase 
in intracoronary peak diastolic pressure (71±10 mmHg at baseline to 137±21 mmHg during 
EECP; P<0.0001;. (Michaels et al., 2002; Fig 3) 
Mean pressure increased by 16% from 88±9 mmHg at baseline to 102±16 mmHg during 
EECP (P=0.006). EECP decreased peak systolic pressure by 15% from 116±20 mmHg at 
baseline to 99±26 mmHg during EECP (P=0.002). Planimetry of the intracoronary pressure 
tracings showed a 28% increase in diastolic pressure (42±9 mmHg·sec at baseline;  
54±15 mmHg·sec during EECP; P=0.0003) and a 12% decrease in systolic pressure 
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electrocardiogram. The lower cuffs were inflated at the start of diastole as represented by 
the beginning of the T wave, while simultaneous deflation of all three chambers was 
triggered just prior to systole at the onset of the P wave. The retrograde flow provided by 
EECP increased both the volume and pressure of diastolic flow such that diastolic to systolic 
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develop the enhanced technology that is being currently used. (Fig 1) 
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coronary angioplasty within 12 hours after onset of chest pain. The radial artery and 
subclavian vein were cannulated to measure right atrial pressure, pulmonary capillary 
wedge pressure (PCWP), cardiac index, and systemic vascular resistance. Radial artery 
pressure tracing was used to measure area under artery pressure curves in systolic and 
diastolic phases. Sixty minutes treatment was administered to the patients in the EECP 
group. All parameters were measured before EECP, at 15, 30, 45, and 60 minutes after 
starting EECP, and 60 minutes after stopping EECP. After starting IABP support, 
measurements were obtained at 15, 30, 45, and 60 minutes. There were no significant 
changes in heart rate in either group before, during, and after treatments. Right atrial 
pressure increased significantly at 15 and 30 minutes after starting EECP, and then 
decreased gradually. There was no significant increase in right atrial pressure at 45 and 60 
minutes after starting EECP compared with baseline. Right atrial pressure did not change in 
the IABP group, and there was no significant difference between 2 groups, except at 15 
minutes after starting treatment. In the EECP group the PCWP significantly increased at 15 
and 30 minutes, and then decreased gradually, but no significant change was seen in IABP 
group. Between two groups, there were no significant differences at baseline and during 
treatment. However, 60 minutes after stopping treatment, PCWP was significantly lower in 
the EECP group. The cardiac index in EECP group increased significantly at 45 and 60 
minutes compared with the baseline, but no significant change was noted in IABP group. 
The increase in cardiac index at 60 minutes in the EECP group was significantly greater than 
that in the IABP group. Mean values of the area under the arterial pressure curves during 
the diastolic phase increased significantly in both groups, and there was no significant 
difference between two groups at any measuring point. Mean values of the areas under the 
artery pressure curves during the systolic phase decreased significantly during treatment 
compared with baseline in the IABP group. No significant change was observed in the EECP 
group. In both groups, systemic vascular resistance decreased significantly during treatment 
compared with baseline, but no significant difference was seen between two groups. This 
study showed that the hemodynamic effects of EECP were similar to those of IABP for 
diastolic augmentation and systemic vascular resistance. However, right atrial pressure, 
PCWP, and cardiac index increased during EECP in contrast to IABP. These effects suggest 
that EECP increases venous return, raises cardiac preload, and increases cardiac output. 
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Blood levels of atrial natriuretic peptide (ANP), brain (or B type) natriuretic peptide (BNP), 
renin, aldosterone, dopamine, and noradrenaline were assessed. Left ventricular ejection 
fraction and size were assessed invasively during the admission and between days 13 to 16. 
Cardiac index increased from 3.3±0.8 L/min before treatment to 4.1±0.8 L/min at 60 
minutes (P<0.01). Right atrial pressure increased from 6.4±3.3 mmHg at baseline to 9.8±4.0 
mmHg at 15 minutes (P<0.01), and PCWP increased from 8.9±4.0 mmHg to 12.6±5.3 mmHg 
(P<0.05). The blood levels of ANP increased from 54±42 pg/ml at baseline to 70±46 pg/ml at 
60 minutes, which returned to baseline level 60 minutes after EECP treatment. The 
pretreatment concentrations of BNP, dopamine, noradrenaline, renin and aldosterone did 
not change during or after EECP treatment. Left ventricular end-diastolic pressure 
decreased from 18.6±1.6 mmHg during the acute stage to 13.8±6.4 mmHg during subacute 
follow-up, but there was no change in left ventricular ejection fraction or end-diastolic 
volume index. Blood concentrations of ANP increased at 15 minutes after initiation of EECP, 
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Representative simultaneous hemodynamic tracings of central aortic pressure from the coronary 
catheter and intracoronary pressure from the PressureWire. In tracings of both phasic and mean 
pressure (bottom) obtained at the beginning of EECP (A), there is a gradual increase in peak diastolic 
(dashed arrows) and mean pressure with a decrease in peak systolic pressure (solid arrows) attributable 
to systolic unloading as the inflation pressure is increased in the EECP device. In another patient, 
diastolic augmentation is demonstrated during EECP at a cuff pressure of 300 mm Hg (B). The 
intracoronary coronary pressure was 5 mm Hg lower than central aortic pressure, attributable to diffuse 
coronary atherosclerosis. The paper speed is 25 mm/sec. ( With permission from Michaels AD,2002) 
Fig. 3. Hemodynamic tracings of central aortic pressure 
(33±6 mmHg·sec at baseline; 29±7 mmHg·sec during EECP; P=0.008). Intracoronary Doppler 
flow velocity was measured using a 0.014-inch FloWire (Fig 2). The average peak velocity 
increased 109% from 11±5 cm/s at baseline to 23 ±5 cm/s during EECP (P=0.001). The peak 
diastolic velocity increased 150% from 18±7 cm/s at baseline to 45±14 cm/s during EECP 
(P=0.0004). The diastolic-to-systolic velocity ratio increased 100% from 1.0±0.3 to 2.0±0.7 
during EECP (P=0.003). There was no significant change in peak systolic velocity. The 
CTFC, another measure of coronary flow velocity, significantly decreased 28% from 37±18 at 
baseline to 27±13 during EECP (P=0.001). This study provides solid evidence of the increase 
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in directly measured aortic and coronary diastolic pressure and flow velocity from EECP. 
There is a significant reduction in left ventricular afterload and left ventricle work secondary 
to systolic unloading.  
(Michaels et al., 2010) 
Acute hemodynamic effects of EECP can be summarized as: (Fig 4) 
1. Increased retrograde aortic blood flow; diastolic augmentation; 
2. Increased coronary blood flow ; increased perfusion pressure; 
3. Increased venous return; 
4. Increased cardiac output; 
5. Systolic unloading;  






















Right upper corner: Showing the ECG tracing and finger pletysmogram. As soon as the device turned 
on (yellow line) diastolic augmentation starts. Right lower corner: showing the diastolic augmentation 
by echocardiography. EECP: Enhanced External Counterpulsation; a: aortic notch (With permission 
from Dr Soran and Katz 1998) 
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3. EECP therapy in CAD management 
Several nonrandomized and randomized trials have demonstrated a consistently positive 
clinical response among patients with CAD treated with EECP (Lawson et al. 1992, Arora et 
al. 1999). Benefits associated with EECP therapy include reduction in angina and nitrate use, 
increased exercise tolerance, favorable psychosocial effects, and enhanced quality of life as 
well as prolongation of the time to exercise-induced ST-segment depression and an 
accompanying resolution of myocardial perfusion defects. Numerous clinical trials in the 
past two decades have shown EECP therapy to be safe and effective for patients with CAD, 
with a clinical response rate averaging 70% to 80%, which is sustained up to 5 years. 
(Lawson et al. 2000; Masuda et al. 2001; Stys et al. 2002; Pettersson et al.2006; Braverman, 
DL. 2009).  
Most studies on EECP therapy cannot be double blind and lack good control groups because 
of technical limitations, drawbacks that have frequently raised questions regarding operator 
bias. However, the Multicenter Study of EECP (MUSTEECP), a randomized double-blinded 
placebo-controlled trial, did document a clinical benefit from EECP therapy in patients with 
chronic stable angina and positive exercise stress tests. In this study, 139 patients (mean age 
63 years, range 35 years to 81 years) with angina pectoris (typical Canadian Cardiovascular 
Society (CCS) classes I, II, and III angina) and documented coronary ischemia were equally 
randomized to hemodynamically inactive counterpulsation with EECP versus active 
counterpulsation. Patients in the active EECP therapy group showed a statistically 
significant increase in time to exercise-induced ST-segment depression when compared with 
sham and baseline, and reported a statistically significant decrease in the frequency of 
angina episodes when compared with sham and baseline. Exercise duration increased 
significantly in both groups; however, the increase was greater in the active EECP group. 
Moreover, a MUST-EECP sub study demonstrated a significant improvement in quality-of 
life parameters in patients assigned to active treatment, and this improvement was 
sustained during a 12-month follow-up (Arora et al. 2002).  
Tartaglia et al assessed the effect of EECP on exercise capacity and myocardial perfusion by 
comparing results of maximal exercise radionuclide testing pre- and post-EECP treatment. 
This prospective study included 25 patients with angina who had performed maximal 
symptom-limited exercise tolerance tests with Bruce protocol and radionuclide perfusion 
single-photon emission computed tomography (SPECT) study prior to and at completion of 
EECP treatment. After 35 h of EECP, 93% improved by at least one functional angina class. 
There is a significant improvement in their total treadmill times and a significant change in 
their peak double products, from 18,891 +/- 3,939 pre-EECP to 20,464 +/- 4,305 post-EECP 
exercise tolerance tests (p < 0.03). Pre EECP, 16 patients had ST-segment depression on their 
initial exercise tolerance tests. After EECP, 80% either no longer had ST depression or had a 
significant increase in their time to ST depression. The radionuclide perfusion scores also 
showed a significant reduction in ischemic segments. In this study, patients treated with 
EECP demonstrated a reduction in angina symptoms, improvement in exercise capacity,  
increase in time to ST-segment depression, and decrease in perfusion defects despite 
performing at a higher workload.  
In another study, investigators evaluated the effects of EECP therapy on dobutamine stress-
induced wall motion score among patients with angina pectoris. In this prospective study, 
43% of patients with severe chronic angina pectoris and had a positive dobutamine stress 
echocardiogram had normal or reduced dobutamine induced wall motion abnormalities 
after EECP therapy. (Bagger et al., 2004) 
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British investigators assessed the immediate and long-term effect of EECP in treatment of 
chronic stable refractory angina. Sixty-one patients were treated with EECP and 58 
completed a course of treatment. About 52% of patients suffered from CCS III and IV angina 
prior to EECP. Immediately post-EECP, angina improved by at least one CCS class in 86% 
and by two classes in 59%. At 1-year follow-up, sustained improvement in CCS was 
observed in 78% of the patients. The median weekly angina frequency and nitroglycerin use 
were significantly reduced immediately after EECP. In 48 patients, their mean exercise time 
improved significantly after EECP. Major-adverse events were rare. This study showed that 
for patients who fail to respond to conventional measures, a high proportion gain 
symptomatic benefit from EECP.  
In 2006, Swedish investigators assess the long-term outcome of EECP treatment at a 
Scandinavian centre, in relieving angina in patients with chronic refractory angina pectoris. 
55 patients were treated with EECP. CCS class, antianginal medication and adverse clinical 
events were collected prior to EECP, at the end of the treatment, and at six and 12 months 
after EECP treatment. Clinical signs and symptoms were recorded. EECP treatment 
significantly improved the CCS class in 79% of the patients with chronic angina pectoris. 
The reduction in CCS angina class was seen in patients with CCS class III and IV and 
persisted 12 months after EECP treatment. In accordance with the reduction in CCS classes 
there was a significant decrease in the weekly nitroglycerin usage. The results showed that 
EECP was a safe and effective treatment in CAD patients and the beneficial effects were 
sustained during a 12-months follow-up period. (Pettersson et al.,2006). 
Same year, Italian investigators tested efficacy of EECP on symptoms, myocardial ischaemia 
and cardiac performance in patients with intractable angina, refractory to surgical and 
medical treatment. Twenty-five patients (mean age 65 years) with persistent ischaemia 
notwithstanding optimal medical therapy or after interventional or surgical procedure, 
received EECP sessions for 35 h. Each patient underwent dobutamine stress 
echocardiography before and after treatment. Eighty-four percent of patients showed an 
increase in at least one functional angina class. Thirty-six percent of patients had a reduction 
in the area of inducible ischaemia at dobutamine stress echocardiography after treatment. 
They concluded that EECP therapy was effective in relieving symptoms in patients with 
refractory angina and may reduce inducible ischaemia at dobutamine stress 
echocardiography, especially in patients with reduced systolic function and compromised 
segmental kinesis. (Novo et al., 2006) 
Although randomized (including placebo-controlled) and nonrandomized studies have 
shown beneficial effects of EECP therapy, investigators saw the need to assess EECP’s 
effectiveness in real-world settings, leading them to develop the International EECP Patient 
Registry (IEPR) under the management of the University of Pittsburgh (Michaels et al. 2004, 
Soran et al., 2010). More than 5000 patients were enrolled in phase I and another 2500 
patients enrolled in phase II of the study, and more than 90 centers participated. Results 
from the IEPR and the EECP Clinical Consortium have demonstrated that the symptomatic 
benefit observed in controlled studies translates to the heterogeneous patient population 
seen in clinical practice. Moreover, follow-up data indicate that the clinical benefit may be 
maintained for up to 5 years in patients with a favorable initial clinical response (Lawson et 
al. 2000; Loh et al 2008) 
Soran et al., compared the efficacy, repeat EECP and 6-months major adverse cardiovascular 
events (MACE: Death/CABG/PCI/MI) free survival rates for patients treated with EECP 
for angina management in Europe (EU) with the United States (US); 4658 were  treated and 
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followed in the US and 262 in EU. EU were younger (p<0.001) with a higher proportion of 
men. Previous revascularization rate was higher in US (p<0.001). EU had less diabetes, 
hypertension, hyperlipidemia, multivessel disease, Class IV angina, and higher rates of 
nitroglycerin usage (p<0.001). After a mean treatment course of 34 hours, both groups 
showed a significant reduction in the severity of angina (78% vs 76%). Discontinuation of 
nitroglycerin usage was similar in both groups (50%). MACE during the treatment period 
was low in both groups (<3%).Compliance with the treatment course was better in EU 
(p<0.001). 
At 6-month follow up 66% of EU and 76% of US had maintained the improvement in angina 
class; survival rate was 99% in EU and 97% in US. MACE free survival rate was 92% in EU 
vs 90% in US. Repeat EECP rates at 6months follow up were significantly lower in EU (0.5% 
vs. 4%, p<0.01).Patients presenting for EECP treatment from EU and US populations 
showed very different baseline profiles. However, both cohorts achieved substantial 
reduction in angina with high event free survival rates at 6 months. (Soran et al., 2010) 
EECP was suggested as a safe treatment option for selected symptomatic PCI candidates 
with obstructive CAD. Baseline characteristics and 1-year outcome in 2 cohorts of PCI 
candidates presenting with stable symptoms: 323 patients treated with EECP in the IEPR, 
and 448 NHLBI Dynamic Registry patients treated with elective PCI, were compared. 
Compared with patients receiving PCI, IEPR patients had a higher prevalence of many risk 
factors including prior PCI prior coronary artery bypass grafting, prior myocardial 
infarction, history of congestive heart failure, and history of diabetes. Left ventricular 
ejection fraction was lower among IEPR patients (mean 50.3% vs 59.2%, p <0.001). At 1 year, 
survival was comparable in the 2 cohorts (98.7% IEPR vs 96.8% PCI, P = NS), as were rates 
of coronary artery bypass grafting during follow-up (4.5% IEPR vs 5.7% PCI, P = NS). At 1 
year, 43.7% of IEPR patients reported no anginal symptoms compared with 73.4% of 
Dynamic Registry patients (p <0.001). Rates of severe symptoms (CCS class III, IV, or 
unstable) at 1 year were 15.5% among IEPR patients and 9.5% in the Dynamic Registry (p = 
0.02). PCI candidates suitable for and treated with EECP had 1-year major event rates 
comparable to patients receiving elective PCI. These results suggested that EECP, as a 
noninvasive treatment, could be used as a first –line treatment with invasive 
revascularization reserved for EECP failures, or high –risk patients. (Holubkov et al., 2002). 
The results of this study warrant the initiation of a randomized controlled study to 
ascertain the efficacy of EECP combined with drug therapy as a first line treatment in 
selected patients with CAD. 
3.1 EECP therapy in CAD with left ventricular dysfunction 
When providing EECP therapy to patients with heart failure, the initial researchers were 
concerned primarily that the increased venous return resulting from EECP therapy might 
precipitate pulmonary edema in angina patients with severe left ventricular dysfunction 
(SLVD). 
Using outcomes data from 363 patients enrolled in the IEPR, Soran et al. (Soran et al. 2006, 
Soran et al. 2002) evaluated the safety and efficacy of EECP therapy in those with refractory 
angina pectoris and SLVD (ejection fraction [EF] < 35%). In this study patients’ average 
duration of clinical CAD was nearly 13 years; 84% had multivessel disease and 93% were 
not candidates for further revascularization due to the extent and severity of disease, LV 
dysfunction, co-morbid conditions, previous interventions, or risk/benefit ratio. Angina was 
severe (class III/IV) in 93% of patients. There was a high prevalence of cardiac risk factors 
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(i.e., 45% had DM, 85% had prior MI, ,78% had hyperlipidemia, 77% had a history of 
smoking and 82% had a family history of premature atherosclerotic cardiovascular disease). 
More than 50% reported quality of life as poor. On average, patients underwent an EECP 
treatment course of 32 hours, with 81% completing the course. Twelve percent discontinued 
due to a clinical event, and 7% stopped due to patient preference. Major adverse 
cardiovascular events that occurred over the course of EECP therapy were low (Death/ 
myocardial infarction [MI]/CABG/PCI<2%). After completion of treatment, there was a 
significant reduction in angina severity: 72% improved from severe angina to no or mild 
angina. Fifty-two percent of the patients stopped using nitroglycerin. There was also a 
significant increase in quality of life. At 2-year follow-up, angina reduction was maintained 
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survival was 70%. Forty-three percent had no cardiac hospitalization; 81% had no 
congestive heart failure event (Fig.5). They concluded that EECP therapy for angina is safe 
and effective in patients with SLVD who are not considered good candidates for 
revascularization by CABG or PCI. 
Estahbanaty et al., evaluated the effects of EECP on  systolic and diastolic cardiac function 
using echocardiography to measure left ventricular EF, end-systolic volume, end-diastolic 
volume, systolic wave (Sm), early diastolic wave (Ea), Vp, E/Ea, E/Vp, and diastolic 
function grade in 25 patients before and after 35 hours of EECP. EECP reduced end-systolic 
volume  and end-diastolic volume  and increased EF significantly in patients with baseline 
left ventricular EF ≤ 50%, baseline E/Ea ≥ 14 , baseline grade II or III diastolic dysfunction 
(decreased compliance) , baseline Ea <7 cm/s and baseline Sm <7 cm/s. These results 
demonstrated improved systolic and diastolic function in selected patients. (Estahbanaty et 
al., 2007) 
Lawson et al. evaluated CAD patients with preserved left ventricular function (PLV; EF > 
35%) and with SLVD (EF≤ 35%) who were treated with a 35-hour course of EECP. 
Bioimpedance measurements of cardiovascular function were obtained before the first and 
after the 35th hour of EECP therapy. Twenty-five patients were enrolled, 20 with PLV and 5 
with SLVD. Angina class improved similarly in both groups. The SLVD group, in contrast to 
the PLV group, had increased cardiac power (ie, mean arterial pressure × cardiac 
output/451), stroke volume, and cardiac index and decreased systemic vascular resistance 
with treatment. This study suggests that EECP may benefit patients experiencing CAD with 
SLVD directly by improving cardiac power and indirectly by decreasing systemic vascular 
resistance (Lawson et al. 2002).  
Patients with CAD and left ventricular dysfunction exert an enormous burden on health 
care resources, primarily because of the number of recurrent emergency department visits 
and hospitalizations. Improvements in symptoms and laboratory assessments in these 
patients may not correlate with a reduction in emergency room visits and hospitalizations. 
Soran et al. assessed the impact of EECP therapy on emergency department visits and 
hospitalization rates at 6-month follow up. In this prospective cohort study, clinical 
outcomes, number of all-cause emergency department visits, and hospitalizations within the 
6 months before EECP therapy were compared with those at 6-month follow-up. The mean 
number of emergency department visits per patient decreased from 0.9 ± 2.0 before EECP to 
0.2 ± 0.7 at 6 months (P < 0.001), and hospitalizations were reduced from 1.1 ± 1.7 to 0.3 ± 0.7 
(P < 0.001) (Soran et al. 2007). 
Scientific data indicates that EECP provides a safe and effective treatment option for 
patients with CAD and left ventricular dysfunction. 
4. Mechanism of action 
Upon diastole, cuffs inflate sequentially from the calves, raising diastolic aortic pressure 
proximally and increasing coronary perfusion pressure. Compression of the vascular beds of 
the legs also increases venous return. Instantaneous decompression of all cuffs at the onset 
of systole significantly unloads the left ventricle, thereby lowering vascular impedance and 
decreasing ventricular workload. This latter effect, when coupled with augmented venous 
return, raises cardiac output. In summary, EECP therapy increases venous return, raises 
cardiac preload, increases cardiac output, and decreases systemic vascular resistance 
(Michaels et al. 2002). 
The Role of Enhanced External 
Counterpulsation Therapy in the Management of Coronary Artery Disease 149 
Mechanism of action of EECP therapy is not through one pathway, but several pathways 
affecting each other. (Fig.6) 
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Possible mechanisms responsible for the clinical benefit associated with EECP therapy. Acute 
hemodynamic and neurohormonal changes, prolonged stimulus to increase  sheer stress which 
promotes endothelial function improvement  is thought to promote myocardial collateralization via 
opening of latent conduits,  arteriogenesis, and angiogenesis. 
HGF:  hepatocyte growth factor, bFGF: basic Fibroblast Growth Factor, VEGF: Vascular endothelial 
growth factor, TNF: Tumor necrosis factor-alpha, MCP-1: Monocyte chemotactic protein-1, 
cGMP: Cyclic guanosine monophosphate 
Fig. 6. Mechanism of EECP Therapy 
4.1 Collateral development 
One of the mechanisms of action is through collateral development. Mode-of-action studies 
have shown that EECP therapy increases angiogenesis factors such as human growth, basic 
fibroblast growth, and vascular endothelial growth factors. Enhanced diastolic flow 
increases shear stress, increased shear stress activates the release of growth factors, and 
augmentation of growth factor release activates angiogenesis.(Soran et al., 1999) 
To clarify the mechanism of action of EECP therapy, Masuda et al used (13) N-ammonia 
positron emission tomography to evaluate myocardial perfusion. Eleven patients (mean age: 
61 years) with angina pectoris underwent EECP therapy for 35 1 h sessions. Treadmill 
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survival was 70%. Forty-three percent had no cardiac hospitalization; 81% had no 
congestive heart failure event (Fig.5). They concluded that EECP therapy for angina is safe 
and effective in patients with SLVD who are not considered good candidates for 
revascularization by CABG or PCI. 
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using echocardiography to measure left ventricular EF, end-systolic volume, end-diastolic 
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function grade in 25 patients before and after 35 hours of EECP. EECP reduced end-systolic 
volume  and end-diastolic volume  and increased EF significantly in patients with baseline 
left ventricular EF ≤ 50%, baseline E/Ea ≥ 14 , baseline grade II or III diastolic dysfunction 
(decreased compliance) , baseline Ea <7 cm/s and baseline Sm <7 cm/s. These results 
demonstrated improved systolic and diastolic function in selected patients. (Estahbanaty et 
al., 2007) 
Lawson et al. evaluated CAD patients with preserved left ventricular function (PLV; EF > 
35%) and with SLVD (EF≤ 35%) who were treated with a 35-hour course of EECP. 
Bioimpedance measurements of cardiovascular function were obtained before the first and 
after the 35th hour of EECP therapy. Twenty-five patients were enrolled, 20 with PLV and 5 
with SLVD. Angina class improved similarly in both groups. The SLVD group, in contrast to 
the PLV group, had increased cardiac power (ie, mean arterial pressure × cardiac 
output/451), stroke volume, and cardiac index and decreased systemic vascular resistance 
with treatment. This study suggests that EECP may benefit patients experiencing CAD with 
SLVD directly by improving cardiac power and indirectly by decreasing systemic vascular 
resistance (Lawson et al. 2002).  
Patients with CAD and left ventricular dysfunction exert an enormous burden on health 
care resources, primarily because of the number of recurrent emergency department visits 
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patients may not correlate with a reduction in emergency room visits and hospitalizations. 
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outcomes, number of all-cause emergency department visits, and hospitalizations within the 
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(P < 0.001) (Soran et al. 2007). 
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4. Mechanism of action 
Upon diastole, cuffs inflate sequentially from the calves, raising diastolic aortic pressure 
proximally and increasing coronary perfusion pressure. Compression of the vascular beds of 
the legs also increases venous return. Instantaneous decompression of all cuffs at the onset 
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decreasing ventricular workload. This latter effect, when coupled with augmented venous 
return, raises cardiac output. In summary, EECP therapy increases venous return, raises 
cardiac preload, increases cardiac output, and decreases systemic vascular resistance 
(Michaels et al. 2002). 
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Mechanism of action of EECP therapy is not through one pathway, but several pathways 
affecting each other. (Fig.6) 
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Possible mechanisms responsible for the clinical benefit associated with EECP therapy. Acute 
hemodynamic and neurohormonal changes, prolonged stimulus to increase  sheer stress which 
promotes endothelial function improvement  is thought to promote myocardial collateralization via 
opening of latent conduits,  arteriogenesis, and angiogenesis. 
HGF:  hepatocyte growth factor, bFGF: basic Fibroblast Growth Factor, VEGF: Vascular endothelial 
growth factor, TNF: Tumor necrosis factor-alpha, MCP-1: Monocyte chemotactic protein-1, 
cGMP: Cyclic guanosine monophosphate 
Fig. 6. Mechanism of EECP Therapy 
4.1 Collateral development 
One of the mechanisms of action is through collateral development. Mode-of-action studies 
have shown that EECP therapy increases angiogenesis factors such as human growth, basic 
fibroblast growth, and vascular endothelial growth factors. Enhanced diastolic flow 
increases shear stress, increased shear stress activates the release of growth factors, and 
augmentation of growth factor release activates angiogenesis.(Soran et al., 1999) 
To clarify the mechanism of action of EECP therapy, Masuda et al used (13) N-ammonia 
positron emission tomography to evaluate myocardial perfusion. Eleven patients (mean age: 
61 years) with angina pectoris underwent EECP therapy for 35 1 h sessions. Treadmill 
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exercise test and (13) N-ammonia positron emission tomography, both at rest and with 
dipyridamole, before and after EECP therapy were performed. Neurohumoral factors and 
nitric oxide were also evaluated. Myocardial perfusion increased significantly at rest after 
therapy. In ischemic regions, particularly the anterior region, myocardial perfusion at rest 
and with dipyridamole and coronary flow reserve improved significantly after therapy. 
Exercise time was prolonged and the time to 1-mm ST depression improved markedly. After 
therapy, nitric oxide levels increased significantly and neurohumoral factors decreased. 
These results suggest that one of the mechanisms of the therapy is development and 
recruitment of collateral vessels. (Masuda et al., 2001). 
To test the hypothesis that EECP augments collateral function Gloekler et al randomized 
patients with chronic stable angina to EECP therapy or sham treatment. Before and after 30 
h of randomly allocated EECP or sham EECP, the invasive collateral flow index (CFI) was 
obtained in 34 vessels. CFI was determined by the ratio of mean distal coronary occlusive 
pressure to mean aortic pressure with central venous pressure subtracted from both. 
Additionally, coronary collateral conductance (occlusive myocardial blood flow per aorto-
coronary pressure drop) was determined by myocardial contrast echocardiography and 
brachial artery flow-mediated dilatation was obtained. CFI significantly improved in the 
EECP group but not in the sham treatment. EECP appeared to be effective in promoting 
coronary collateral growth. The extent of collateral function improvement was related to the 
amount of improvement in the systemic endothelial function (Gloekler et al. 2010). 
4.2 Endothelial function improvement 
Another mechanism of action of EECP therapy is through endothelial changes. EECP therapy 
improves endothelial function and enhances vascular reactivity. Akhtar et al examined the 
effects of EECP on plasma nitric oxide and endothelin-1 (ET-1) levels. Plasma nitrate and 
nitrite (NOx) and ET-1 levels were measured serially in 13 patients with coronary artery 
disease who received 1-hour daily treatments of EECP over 6 weeks. During the course of 
EECP therapy, plasma NOx progressively increased and plasma ET-1 progressively decreased. 
After 36 hours of EECP, there was a 62 % increase in plasma NOx compared with baseline ( p 
<0.0001) and a 36% decrease in plasma ET-1 ( p <0.0001). At 3 months after completion of 
EECP, NOx remained 12% above baseline (p = 0.002), and ET-1 remained 11% below baseline 
(p = 0.0068). This data provides neurohormonal evidence to support the hypothesis that EECP 
improves endothelial function.(Akhtar  Am J Cardiol 2006) 
Braith et al investigated the effects of EECP on peripheral artery flow-mediated dilation in a 
randomized placebo-controlled study. Symptomatic patients with CAD were randomized 
(2:1 ratio) to thirty-five 1-hour sessions of either EECP or sham EECP . Flow-mediated 
dilation of the brachial and femoral arteries was performed with the use of ultrasound. 
Plasma levels of nitrate and nitrite, 6-ketoprostaglandin, F1α, endothelin-1, asymmetrical 
dimethylarginine, tumor necrosis factor-α, monocyte chemoattractant protein-1, soluble 
vascular cell adhesion molecule, high-sensitivity C-reactive protein, and 8-isoprostane were 
measured. EECP significantly increased brachial and femoral artery flow-mediated dilation, 
the nitric oxide turnover/production markers nitrate and nitrite and 6-keto-prostaglandin 
F1α, whereas it decreased endothelin-1 and the nitric oxide synthase inhibitor asymmetrical 
dimethylarginine in treatment versus sham groups, respectively. EECP significantly 
decreased the proinflammatory cytokines tumor necrosis factor-α, monocyte 
chemoattractant protein-1 , soluble vascular cell adhesion molecule-1, high-sensitivity C-
reactive protein, and the lipid peroxidation marker 8-isoprostane in treatment versus sham 
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groups, respectively. EECP also significantly reduced angina classification in treatment 
versus sham groups, respectively. Findings from this study provide novel mechanistic 
evidence that EECP has a beneficial effect on peripheral artery flow-mediated dilation and 
endothelial-derived vasoactive agents in patients with symptomatic CAD (Braith et al. 2010).  
It is known that cGMP regulates vascular smooth muscle tone that may improve arterial 
function. French investigators assessed the effect of a single session of EECP on plasma and 
platelet Cyclic GMP (cGMP) in asymptomatic subjects with cardiovascular risk factors and 
in patients with CAD. Fifty-five subjects were randomized into two groups to receive either 
sham (control) or active EECP during 1 h. Plasma and platelet cGMP were measured 
immediately before and after EECP by radioimmunoassay. One hour of EECP increased 
cGMP plasma concentration by 52% ± 66% (SD) (P< .001) and platelet content by 19%± 28% 
(P < .01). The increase in plasma cGMP was particularly marked in CAD patients receiving 
active EECP (P<.01), mainly in those with low LDL cholesterol. Platelets, inhibition of nitric 
oxide synthesis by NG-monomethyl-L-arginine (L-NMMA) reduced cGMP by 23% ± 31% (P 
_ .001), whereas presence of superoxide dismutase and inhibition of phosphodiesterase-5 
increased cGMP by 46% ± 49% and 70% ± 77%, respectively (P <.001). In all of the cases 
EECP increased additional platelet cGMP content, which suggests nitric oxide synthase 
activation. These acute results showed that very early treatment increases the cGMP 
production that may participate in the mechanism by which EECP exerts its clinical benefit. 
Analysis of the modulation of platelet cGMP content suggests that EECP activated the nitric 
oxide-dependent pathways. (Levenson et al., 2006) 
4.3 Neurohormanal changes 
As with athletic training, the vascular effects of EECP therapy may be mediated through 
changes in the neurohormonal milieu. Wu et al. showed that EECP therapy has a sustained, 
dose-related effect in stimulating endothelial cell production of the vasodilator nitric oxide 
(NO) and in decreasing production of the vasoconstrictor endothelin. (Wu et al. 1999). In 
another study, Qian et al. showed that the NO level increased linearly in proportion to the 
hours of EECP treatment.(Qian X et al. 1999). Urano et al. further showed that plasma brain 
natriuretic peptide levels decreased after EECP therapy and were positively correlated with 
left ventricular end diastolic pressure and negatively correlated with peak filling rate. They 
concluded that EECP therapy reduces exercise-induced myocardial ischemia in association 
with improved left ventricular diastolic filling in patients with CAD. (Urano et al. 2001) 
Another possible mechanism explaining EECP’s mode of action is that it may affect changes 
in ventricular function independent of changes in cardiac load. Gorcsan et al. evaluated the 
effects of EECP therapy on left ventricular function in New York Heart Association class II 
or III heart failure patients with an EF less than 40%. Their results showed that EECP 
treatment was associated with improvements in preload adjusted maximal power, a 
relatively load-independent measure of left ventricular performance and EF, along with a 
decrease in heart rate in these heart failure patients. (Gorcsan et al. 2000) 
4.4 Anti-inflammatory effect 
A recently published randomized controlled study examining the effect of EECP therapy on 
inflammatory and adhesion molecules in patients with CAD indicated that EECP therapy 
has an anti-inflammatory effect in patients with angina pectoris. Patients were randomly 
assigned to receive active EECP or sham treatment. Plasma tumor necrosis factor- α, 
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exercise test and (13) N-ammonia positron emission tomography, both at rest and with 
dipyridamole, before and after EECP therapy were performed. Neurohumoral factors and 
nitric oxide were also evaluated. Myocardial perfusion increased significantly at rest after 
therapy. In ischemic regions, particularly the anterior region, myocardial perfusion at rest 
and with dipyridamole and coronary flow reserve improved significantly after therapy. 
Exercise time was prolonged and the time to 1-mm ST depression improved markedly. After 
therapy, nitric oxide levels increased significantly and neurohumoral factors decreased. 
These results suggest that one of the mechanisms of the therapy is development and 
recruitment of collateral vessels. (Masuda et al., 2001). 
To test the hypothesis that EECP augments collateral function Gloekler et al randomized 
patients with chronic stable angina to EECP therapy or sham treatment. Before and after 30 
h of randomly allocated EECP or sham EECP, the invasive collateral flow index (CFI) was 
obtained in 34 vessels. CFI was determined by the ratio of mean distal coronary occlusive 
pressure to mean aortic pressure with central venous pressure subtracted from both. 
Additionally, coronary collateral conductance (occlusive myocardial blood flow per aorto-
coronary pressure drop) was determined by myocardial contrast echocardiography and 
brachial artery flow-mediated dilatation was obtained. CFI significantly improved in the 
EECP group but not in the sham treatment. EECP appeared to be effective in promoting 
coronary collateral growth. The extent of collateral function improvement was related to the 
amount of improvement in the systemic endothelial function (Gloekler et al. 2010). 
4.2 Endothelial function improvement 
Another mechanism of action of EECP therapy is through endothelial changes. EECP therapy 
improves endothelial function and enhances vascular reactivity. Akhtar et al examined the 
effects of EECP on plasma nitric oxide and endothelin-1 (ET-1) levels. Plasma nitrate and 
nitrite (NOx) and ET-1 levels were measured serially in 13 patients with coronary artery 
disease who received 1-hour daily treatments of EECP over 6 weeks. During the course of 
EECP therapy, plasma NOx progressively increased and plasma ET-1 progressively decreased. 
After 36 hours of EECP, there was a 62 % increase in plasma NOx compared with baseline ( p 
<0.0001) and a 36% decrease in plasma ET-1 ( p <0.0001). At 3 months after completion of 
EECP, NOx remained 12% above baseline (p = 0.002), and ET-1 remained 11% below baseline 
(p = 0.0068). This data provides neurohormonal evidence to support the hypothesis that EECP 
improves endothelial function.(Akhtar  Am J Cardiol 2006) 
Braith et al investigated the effects of EECP on peripheral artery flow-mediated dilation in a 
randomized placebo-controlled study. Symptomatic patients with CAD were randomized 
(2:1 ratio) to thirty-five 1-hour sessions of either EECP or sham EECP . Flow-mediated 
dilation of the brachial and femoral arteries was performed with the use of ultrasound. 
Plasma levels of nitrate and nitrite, 6-ketoprostaglandin, F1α, endothelin-1, asymmetrical 
dimethylarginine, tumor necrosis factor-α, monocyte chemoattractant protein-1, soluble 
vascular cell adhesion molecule, high-sensitivity C-reactive protein, and 8-isoprostane were 
measured. EECP significantly increased brachial and femoral artery flow-mediated dilation, 
the nitric oxide turnover/production markers nitrate and nitrite and 6-keto-prostaglandin 
F1α, whereas it decreased endothelin-1 and the nitric oxide synthase inhibitor asymmetrical 
dimethylarginine in treatment versus sham groups, respectively. EECP significantly 
decreased the proinflammatory cytokines tumor necrosis factor-α, monocyte 
chemoattractant protein-1 , soluble vascular cell adhesion molecule-1, high-sensitivity C-
reactive protein, and the lipid peroxidation marker 8-isoprostane in treatment versus sham 
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groups, respectively. EECP also significantly reduced angina classification in treatment 
versus sham groups, respectively. Findings from this study provide novel mechanistic 
evidence that EECP has a beneficial effect on peripheral artery flow-mediated dilation and 
endothelial-derived vasoactive agents in patients with symptomatic CAD (Braith et al. 2010).  
It is known that cGMP regulates vascular smooth muscle tone that may improve arterial 
function. French investigators assessed the effect of a single session of EECP on plasma and 
platelet Cyclic GMP (cGMP) in asymptomatic subjects with cardiovascular risk factors and 
in patients with CAD. Fifty-five subjects were randomized into two groups to receive either 
sham (control) or active EECP during 1 h. Plasma and platelet cGMP were measured 
immediately before and after EECP by radioimmunoassay. One hour of EECP increased 
cGMP plasma concentration by 52% ± 66% (SD) (P< .001) and platelet content by 19%± 28% 
(P < .01). The increase in plasma cGMP was particularly marked in CAD patients receiving 
active EECP (P<.01), mainly in those with low LDL cholesterol. Platelets, inhibition of nitric 
oxide synthesis by NG-monomethyl-L-arginine (L-NMMA) reduced cGMP by 23% ± 31% (P 
_ .001), whereas presence of superoxide dismutase and inhibition of phosphodiesterase-5 
increased cGMP by 46% ± 49% and 70% ± 77%, respectively (P <.001). In all of the cases 
EECP increased additional platelet cGMP content, which suggests nitric oxide synthase 
activation. These acute results showed that very early treatment increases the cGMP 
production that may participate in the mechanism by which EECP exerts its clinical benefit. 
Analysis of the modulation of platelet cGMP content suggests that EECP activated the nitric 
oxide-dependent pathways. (Levenson et al., 2006) 
4.3 Neurohormanal changes 
As with athletic training, the vascular effects of EECP therapy may be mediated through 
changes in the neurohormonal milieu. Wu et al. showed that EECP therapy has a sustained, 
dose-related effect in stimulating endothelial cell production of the vasodilator nitric oxide 
(NO) and in decreasing production of the vasoconstrictor endothelin. (Wu et al. 1999). In 
another study, Qian et al. showed that the NO level increased linearly in proportion to the 
hours of EECP treatment.(Qian X et al. 1999). Urano et al. further showed that plasma brain 
natriuretic peptide levels decreased after EECP therapy and were positively correlated with 
left ventricular end diastolic pressure and negatively correlated with peak filling rate. They 
concluded that EECP therapy reduces exercise-induced myocardial ischemia in association 
with improved left ventricular diastolic filling in patients with CAD. (Urano et al. 2001) 
Another possible mechanism explaining EECP’s mode of action is that it may affect changes 
in ventricular function independent of changes in cardiac load. Gorcsan et al. evaluated the 
effects of EECP therapy on left ventricular function in New York Heart Association class II 
or III heart failure patients with an EF less than 40%. Their results showed that EECP 
treatment was associated with improvements in preload adjusted maximal power, a 
relatively load-independent measure of left ventricular performance and EF, along with a 
decrease in heart rate in these heart failure patients. (Gorcsan et al. 2000) 
4.4 Anti-inflammatory effect 
A recently published randomized controlled study examining the effect of EECP therapy on 
inflammatory and adhesion molecules in patients with CAD indicated that EECP therapy 
has an anti-inflammatory effect in patients with angina pectoris. Patients were randomly 
assigned to receive active EECP or sham treatment. Plasma tumor necrosis factor- α, 
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monocyte chemoattractant protein-1, and soluble vascular cell adhesion molecule-1 were 
measured before and after a full course of 35 1-hour sessions of EECP or sham treatment. 
Patients in the EECP group demonstrated reductions in tumor necrosis factor-α and 
monocyte chemoattractant protein-1 after treatment, whereas those in the sham therapy 
group showed no changes. EECP therapy decreased circulating levels of proinflamatory 
biomarkers in patients with symptomatic CAD (Casey et al. 2008). 
5. Patient selection 
5.1 Indications 
FDA Labeled indications for the use of EECP include treatment of patients with: 
- Stable or unstable angina pectoris 
- Congestive heart failure 
- Acute MI 
- Cardiogenic shock 
5.2 Which group of patients may benefit from EECP therapy? 
Patients with angina or angina equivalent symptoms such as shortness of breath and/or 
fatigue who: 
- have coronary anatomy unsuitable for surgical or catheter-based revascularization 
- inadequately respond to optimum medical therapy 
- underwent incomplete invasive revascularization 
- are considered inoperable or at high risk of operative/interventional complications 
- have comorbid conditions that increase the risk of revascularization procedures, such as 
diabetes, heart failure, pulmonary disease, and renal dysfunction 
- are unwilling to undergo additional invasive revascularization procedures 
- have stable (NYHA class II or III) heart failure; patients with any evidence of 
decompensation should not be treated until they are stable with the use of medical 
therapy 
- have ischemic or idiopathic cardiomyopathy 
- have cardiac syndrome X or microvascular ingina 
- have LVD (EF < 35%) 
5.3 Contraindications and side effects 
It is important to point out that EECP therapy is not for everyone. This noninvasive 
outpatient procedure can be somewhat uncomfortable for patients because of the 
highpressure sequential compression of the cuffs. It is not recommended for certain types of 
valvular heart disease (especially aortic insufficiency), or for those with recent cardiac 
catheterization, an irregular heart rhythm, severe hypertension, significant blockages in the 
leg arteries, or a history of deep venous thrombosis. For anyone else, however, the 
procedure seems to be quite safe. 
5.4 Contraindications 
- Moderate to severe aortic insufficiency (regurgitation would prevent diastolic 
augmentation) 
- Arrhythmias that may interfere with EECP system triggering (uncontrolled atrial 
fibrillation or fl utter or very frequent premature ventricular contractions) 
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- Coagulopathy with an INR of prothrombin time greater than 2.5 
- Severe hypertension: greater than 180/110 mm Hg (the augmented diastolic pressure 
may exceed safe limits) 
- Cardiac catheterization or arterial puncture (risk of bleeding at femoral puncture site) 
within the past 2 weeks 
- Decompensated heart failure 
- Severe peripheral arterial disease (reduced vascular volume and muscle mass may 
prevent active counterpulsation) 
- Aortic aneurysm (≥ 5 mm) or dissection (diastolic pressure augmentation may be 
deleterious) 
- Pregnancy or being of childbearing age (effects of EECP therapy on the fetus have not 
been studied) 
- Venous disease (phlebitis, varicose veins, stasis ulcers, prior or current deep vein 
thrombosis or pulmonary embolism) 
- Severe chronic obstructive pulmonary disease (no safety data in pulmonary 
hypertension) 
5.5 Side effects  
- Skin abrasion or ecchymoses 
- Bruises (especially in patients using warfarin in whom the international normalized 
ratio [INR] is not adjusted) 
- Paresthesias 
- Leg or waist pain 
- Worsening of heart failure in patients with severe arrhythmias 
6. Future research 
Throughout the world, EECP therapy has been studied for various potential uses other than 
heart disease ((Offergeld et al 2000; Rajaram et al 2006; Hilz et al 2004; Myhre et al 2004).  
*Cardiac Syndrome X: its role in improving endothelial function might be beneficial in the 
treatment of patients with Cardiac Syndrome X, which is marked by severe chest pain 
caused by myocardial dysfunction, often without detectable atherosclerosis. Investigators 
have reported successful treatment of Cardiac Syndrome X with severely symptomatic 
coronary endothelial dysfunction in the absence of obstructive CAD with standard 35-h 
course of EECP therapy (Bonetti et al 2004).  
*Acute M/Cardiogenic Shock: Based on its acute haemodynamic effects, comparable to 
those of IABP, EECP can be proposed as a potential treatment for coronary syndromes in 
acute setting, as an inpatient therapy for patients with IABP contraindications. Recently 
developed mobile EECP Therapy system, enables its use in the catheter laboratory and 
operation room settings. 
*Erectile dysfunction: Studies looking at EECP therapy and erectile dysfunction have 
shown a 200% increase in penile artery flow and reported improvement in erectile function 
[Froschermaier et al 1998; Lawson et al 2007; El-Sakka AI et al 2007 
*Hepatorenal syndrome: Werner et al. assessed the potential role of EECP therapy in 
diuresis and increased urinary fl ow in patients with endstage liver disease awaiting a 
transplant. They found that EECP therapyincreased mean arterial pressure as well as 
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monocyte chemoattractant protein-1, and soluble vascular cell adhesion molecule-1 were 
measured before and after a full course of 35 1-hour sessions of EECP or sham treatment. 
Patients in the EECP group demonstrated reductions in tumor necrosis factor-α and 
monocyte chemoattractant protein-1 after treatment, whereas those in the sham therapy 
group showed no changes. EECP therapy decreased circulating levels of proinflamatory 
biomarkers in patients with symptomatic CAD (Casey et al. 2008). 
5. Patient selection 
5.1 Indications 
FDA Labeled indications for the use of EECP include treatment of patients with: 
- Stable or unstable angina pectoris 
- Congestive heart failure 
- Acute MI 
- Cardiogenic shock 
5.2 Which group of patients may benefit from EECP therapy? 
Patients with angina or angina equivalent symptoms such as shortness of breath and/or 
fatigue who: 
- have coronary anatomy unsuitable for surgical or catheter-based revascularization 
- inadequately respond to optimum medical therapy 
- underwent incomplete invasive revascularization 
- are considered inoperable or at high risk of operative/interventional complications 
- have comorbid conditions that increase the risk of revascularization procedures, such as 
diabetes, heart failure, pulmonary disease, and renal dysfunction 
- are unwilling to undergo additional invasive revascularization procedures 
- have stable (NYHA class II or III) heart failure; patients with any evidence of 
decompensation should not be treated until they are stable with the use of medical 
therapy 
- have ischemic or idiopathic cardiomyopathy 
- have cardiac syndrome X or microvascular ingina 
- have LVD (EF < 35%) 
5.3 Contraindications and side effects 
It is important to point out that EECP therapy is not for everyone. This noninvasive 
outpatient procedure can be somewhat uncomfortable for patients because of the 
highpressure sequential compression of the cuffs. It is not recommended for certain types of 
valvular heart disease (especially aortic insufficiency), or for those with recent cardiac 
catheterization, an irregular heart rhythm, severe hypertension, significant blockages in the 
leg arteries, or a history of deep venous thrombosis. For anyone else, however, the 
procedure seems to be quite safe. 
5.4 Contraindications 
- Moderate to severe aortic insufficiency (regurgitation would prevent diastolic 
augmentation) 
- Arrhythmias that may interfere with EECP system triggering (uncontrolled atrial 
fibrillation or fl utter or very frequent premature ventricular contractions) 
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- Coagulopathy with an INR of prothrombin time greater than 2.5 
- Severe hypertension: greater than 180/110 mm Hg (the augmented diastolic pressure 
may exceed safe limits) 
- Cardiac catheterization or arterial puncture (risk of bleeding at femoral puncture site) 
within the past 2 weeks 
- Decompensated heart failure 
- Severe peripheral arterial disease (reduced vascular volume and muscle mass may 
prevent active counterpulsation) 
- Aortic aneurysm (≥ 5 mm) or dissection (diastolic pressure augmentation may be 
deleterious) 
- Pregnancy or being of childbearing age (effects of EECP therapy on the fetus have not 
been studied) 
- Venous disease (phlebitis, varicose veins, stasis ulcers, prior or current deep vein 
thrombosis or pulmonary embolism) 
- Severe chronic obstructive pulmonary disease (no safety data in pulmonary 
hypertension) 
5.5 Side effects  
- Skin abrasion or ecchymoses 
- Bruises (especially in patients using warfarin in whom the international normalized 
ratio [INR] is not adjusted) 
- Paresthesias 
- Leg or waist pain 
- Worsening of heart failure in patients with severe arrhythmias 
6. Future research 
Throughout the world, EECP therapy has been studied for various potential uses other than 
heart disease ((Offergeld et al 2000; Rajaram et al 2006; Hilz et al 2004; Myhre et al 2004).  
*Cardiac Syndrome X: its role in improving endothelial function might be beneficial in the 
treatment of patients with Cardiac Syndrome X, which is marked by severe chest pain 
caused by myocardial dysfunction, often without detectable atherosclerosis. Investigators 
have reported successful treatment of Cardiac Syndrome X with severely symptomatic 
coronary endothelial dysfunction in the absence of obstructive CAD with standard 35-h 
course of EECP therapy (Bonetti et al 2004).  
*Acute M/Cardiogenic Shock: Based on its acute haemodynamic effects, comparable to 
those of IABP, EECP can be proposed as a potential treatment for coronary syndromes in 
acute setting, as an inpatient therapy for patients with IABP contraindications. Recently 
developed mobile EECP Therapy system, enables its use in the catheter laboratory and 
operation room settings. 
*Erectile dysfunction: Studies looking at EECP therapy and erectile dysfunction have 
shown a 200% increase in penile artery flow and reported improvement in erectile function 
[Froschermaier et al 1998; Lawson et al 2007; El-Sakka AI et al 2007 
*Hepatorenal syndrome: Werner et al. assessed the potential role of EECP therapy in 
diuresis and increased urinary fl ow in patients with endstage liver disease awaiting a 
transplant. They found that EECP therapyincreased mean arterial pressure as well as 
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urinary production (urinary flow rate) in patients with end-stage cirrhosis and hepatorenal 
syndrome. (Werner et al 2005. )Studies involving larger sample sizes are necessary to 
confirm the effectiveness of EECP therapy in erectile dysfunction and hepatorenal 
syndrome. 
* Ischemic stroke: Investigators sought to determine effect of EECP on middle cerebral 
artery blood flow augmentation in normal controls as a first step to support future clinical 
trials in acute stroke. (Alexandrow et al.,2008) 
* Primary /Secondary Prevention: New studies are under way to explore the role of EECP 
therapy in primary and secondary prevention of coronary artery disease and its potential 
use in failing fontan operation. 
7. Conclusion 
Scientific data indicates that EECP provides a safe and effective treatment option for 
patients with CAD. Its different mode of action complements the invasive revascularization 
treatment. Currently, The American College of Cardiology/ The American Heart 
Association recommends EECP Therapy as a Class IIb (Level of Evidence: B) intervention 
for treatment of CAD. Due to the volume and quality of scientific data now available and 
per the descriptions of the rating and evidence levels as defined by American College of 
Cardiology and American Heart Association guidelines it is believed that EECP therapy has 
earned a Class IIa treatment recommendation with level of evidence A. 
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urinary production (urinary flow rate) in patients with end-stage cirrhosis and hepatorenal 
syndrome. (Werner et al 2005. )Studies involving larger sample sizes are necessary to 
confirm the effectiveness of EECP therapy in erectile dysfunction and hepatorenal 
syndrome. 
* Ischemic stroke: Investigators sought to determine effect of EECP on middle cerebral 
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7. Conclusion 
Scientific data indicates that EECP provides a safe and effective treatment option for 
patients with CAD. Its different mode of action complements the invasive revascularization 
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Association recommends EECP Therapy as a Class IIb (Level of Evidence: B) intervention 
for treatment of CAD. Due to the volume and quality of scientific data now available and 
per the descriptions of the rating and evidence levels as defined by American College of 
Cardiology and American Heart Association guidelines it is believed that EECP therapy has 
earned a Class IIa treatment recommendation with level of evidence A. 
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Iran 
1. Introduction 
The treatment of angina pectoris as an important symptom of coronary artery disease is 
usually focused on restoring the balance between myocardial oxygen demand and supply 
by administration of drugs interfering in heart rate, preload, afterload, and coronary 
vascular tone. For non responders to drug therapy or for those with jeopardized 
myocardium, revascularization procedures such as coronary artery bypass graft surgery 
(CABG) and percutaneous transluminal coronary angioplasty (PTCA) are at hand. 
However, these therapies cannot stop the disease process and, at longer terms, angina may 
recur. It is not always possible to revascularize all the patients who do not sufficiently react 
to medical treatment. In these group patients alternative therapies are more effective. A 
major difference between alternative therapies versus traditional therapies is that alternative 
therapy tends to look at the entire patient rather than simply treating a disorder as 
traditional treatments do. Some kinds of these therapies are applicable in all patients with 
coronary artery disease irrespective of their symptoms and the other ones would be 
considered in patients with refractory angina who are not suitable for revascularization. 
2. General alternative therapy 
These therapies are applicable in all patients with coronary artery disease whether they are 
symptomatic or not. 
2.1 Heart healthy lifestyle 
2.1.1 Goals                 
Preventing heart disease, living heart healthy, and overcoming stress-related heart illness 
requires more than just a physical approach to heart problems. Whether or not patients had 
an interventional angioplasty or bypass surgery, it's obvious that some changes in lifestyle 
will need to be made. To continue living a normal active life, one needs to begin making 
heart healthy lifestyle changes that include eating a heart healthy diet. Maintaining a 
healthy diet and lifestyle offers the greatest potential of all known approaches for reducing 
the risk for CVD in the general public. Specific goals are to consume an overall healthy diet; 
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aim for a healthy body weight; recommended levels of low-density lipoprotein cholesterol, 
high-density lipoprotein cholesterol, and triglycerides; normal blood pressure; normal blood 
glucose level; be physically active and avoid use of and exposure to tobacco products. 
Consume a Healthy Diet: 
An emphasis on whole diet should be done to ensure nutrient adequacy and energy balance. 
Hence, rather than focusing on a single nutrient or food, individuals should aim to improve 
their whole or overall diet. (1) The American Heart Association has provided dietary 
recommendations and recommendations for an overall healthy lifestyle to the American 
public with the goal of reducing risk for cardiovascular diseases. (1) 
Achievement or maintaining an ideal body weight: 
A healthy body weight is currently defined as a body mass index (BMI) of 18.5 to 24.9 
kg/m2. Overweight is a BMI between 25 and 29.9 kg/m2, and obesity is a BMI 30 kg/m2. 
Achieving and maintaining a healthy weight throughout life is particularly difficult and are 
critical factors in reducing CVD risk in the general public. Great emphasis should be put on 
prevention of weight gain (2), because achievement and maintenance of weight loss, 
although certainly possible, require more difficult behavioral changes ie, greater calorie 
reduction and more physical activity, than prevention of weight gain in the first place. 
Prevention of excess weight gain:  
Prevention of excess weight gain relies on the maintenance of energy balance, whereby 
energy intake equals energy consumption over the long term.(1, 2) This means maintaining 
a relatively stable weight across life stages. A positive imbalance will increase energy 
storage, deposited as body fat and observed as weight gain. Although the concept is 
seemingly simple, the physiological systems that regulate body weight through energy 
intake and consumption mechanisms are complex, interactive, homeostatic, and still poorly 
understood. Furthermore, the components of energy balance are not weighed easily or with 
adequate precision to be practical as a guide to help individuals maintain energy balance. In 
theory, a small persistent energy imbalance of 50 kcal per day could result in a 5-lb weight 
gain in 1 year, provided that all other things being equal. (2)                 
Treatment of obesity: 
Although prevention and treatment of obesity both depends on the same principles of 
energy balance, the application of the principles is completely different. For treatment of 
obesity, a large reduction in calorie intake of about 500 to 1000 kcal per day, along with 
increased physical activity, can result in a loss of approximately 8- 10% of body weight over 
the relatively short period of about 6 months. Although the types of low-calorie diets that 
best promote weight loss are the subject of current investigations, behaviors for weight loss 
focused on caloric reduction such as decreasing overall food intake, reducing portion sizes, 
substituting lower-calorie for higher calorie foods, and increasing physical activity. Weight 
loss is best achieved by participation in a behavioral program using self-monitoring, goal-
setting, and problem-solving techniques. Motivation levels may be high for appearance 
reasons or if adverse health consequences and quality of life impairments associated with 
obesity are readily perceived.(2) However, because weight regain after weight loss is 
common, motivations and strategies to maintain weight may differ largely from those 
initiating weight loss.(2) 
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A diet rich in vegetables and fruits: 
Most vegetables and fruits are rich in nutrients, low in calories, and high in fiber. Diets high 
in fiber, especially from cereal sources, substantially reduce the risk of coronary heart 
disease. Short-term randomized trials have shown that diets rich in vegetables and fruits not 
only provide micronutrient, macronutrient, and fiber requirements, but also lower BP and 
improve other CVD risk factors. Vegetables and fruits that are deeply colored, for example, 
spinach, carrots, peaches and berries, ought to be emphasized because they tend to be 
higher in micronutrient contents compared to other vegetables and fruits such as potatoes 
and corn. Equally important is the method of preparation which includes techniques 
preserving nutrient and fiber content without adding unnecessary calories, saturated or 
trans fat, sugar, and salt.(1) 
2.2 Supplements 
It is ideal to get the body nutritional needs in foods .When that is not enough, a registered 
dietitian may also start a series of supplements to make up for nutrients not getting through 
the diet. Some of the more popular supplements for both healthy and those at risk for 
coronary artery disease include antioxidants such as vitamins C and E, B-complex, omega-3 
fish oil and coenzyme Q10. The American Heart Association recommends 2-4 grams of 
Omega-3 per day for anyone with high triglycerides and at least 1 gram per day for anyone 
with documented coronary heart disease. (1) According to the results of  many clinical trials 
performed to clear the role of dietary supplements in the prevention and /or slowing the 
progression of cardiovascular diseases , the long-term effects of most dietary supplements 
other than for vitamins and minerals are not known, so these agents should be prescribed 
under professional supervision of physician or a registered dietitian. 
Essential Fatty Acids 
Omega-3 and Flaxseed oil 
Flaxseed oil comes from the seeds of the flax plant (Linum usitatissimum, L.) which 
contains both omega-3 and omega-6 fatty acids, which are vital for health. They are 
composed of essential fatty acid alpha-linolenic acid (ALA), which the body turns into 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), the omega-3 fatty acids 
found in fish oil. Some researchers argue that flaxseed oil might have some of the same 
usefulness as fish oil, but the body is not very efficient at converting ALA into EPA and 
DHA, however, the benefits of ALA, EPA, and DHA are not necessarily the same. The 
human body is not able to make its own omega-3 fatty acids, so it is important that they are 
part of everyone’s dietary intake. (3) The consumption of 2 servings (8 ounces) per week of 
fish high in EPA and DHA can result in a reduction of risk of mortality and morbidity from 
coronary artery disease. In addition to providing EPA and DHA, regular fish consumption 
may facilitate the displacement of other foods higher in saturated and trans fatty acids from 
the diet, such as fatty meats and full-fat dairy products.(1) Omega-3 fatty acids seem to have 
a small, dose-dependent, hypotensive effect, the extent of which seems to be dependent on 
the degree of hypertension.(4) In a meta-analysis, Morris et al found a significant reduction 
in blood pressure of ≤ 3.4/ 2.0 mmHg in studies with hypertensive subjects who consumed 
5.6 g/d of omega-3 fatty acids.(4) Likewise, Appel et al found that blood pressure was 
decreased ≤ 5.5/ 3.5 mmHg in trials of untreated hypertensives given 3 g/d of omega-3 fatty 
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good balance of omega 3 and 6 fatty acids in the diet is important which are examples of 
polyunsaturated fatty acids (PUFAs).  Omega 3 fatty acids help reduce inflammation, while 
most omega 6 fatty acids tend to contribute to inflammation. A healthy diet should consist 
of roughly 2 to 4 times fewer omega 6 fatty acids than omega 3 fatty acids.  Some species of 
fish may contain significant levels of methylmercury, polychlorinated biphenyls (PCBs), 
dioxins, and other environmental contaminants which is a potential concern for using 
them.(1,4) Subgroups of the population, primarily children and pregnant women are 
advised by the FDA to avoid eating those fish with the potential for the highest level of 
mercury contamination. Eating up to 12 ounces (2 average meals) per week of a variety of 
fish and shellfish that are lower in mercury is also recommended. (1) The American Heart 
Association recommends inclusion of omega 3 fatty acids in patients with stable CAD 
because of evidence from randomized controlled trials. The recommended daily dose in 
patients with stable coronary artery disease is 1 gram of eicosapentaenoic 
acid/docosahexaenoic acid (EPA/DHA) by capsule supplement, the equivalent amount in 
alpha-linolenic acid (LNA) from vegetable source, or by eating daily fatty fish(1). Since 
maintaining daily fish meals can be difficult, capsule supplements may be preferred 
although there is no uniformity of EPA/DHA content or purity. 
Niacin 
Niacin (nicotinic acid) is a B vitamin that has been used in high doses (1.0–4.5 grams per 
day) as a treatment for hyperlipidemia which is associated with increased risk of CAD. 
Niacin reduces cholesterol and TG levels, and increases the concentration of high-density 
lipoprotein (HDL). (5) It is also effective at modulating blood lipids, but side effects 
sometimes dampen enthusiasm for therapy. Although side effects are dose-related, few 
studies have determined an optimal dose of nicotinic acid that alters lipid levels with the 
fewest side effects. Martin-Jadraque et al. (6) found improvement in blood lipid levels in 
75% of subjects who tolerated low-dose nicotinic acid therapy. Nicotinic acid may also be 
useful in combination drug therapy for prevention of CAD if higher doses cannot be 
tolerated. Use of a lower dose should still be beneficial for producing a moderate rise in 
HDL levels. Women seem to have a greater LDL response to niacin, but experience more 
side effects at higher dosages. (7) 
Long-term treatment with nicotinic acid (4 g/day for 6 weeks) not only corrects serum 
lipoprotein abnormalities, but also reduces the fibrinogen concentration in plasma and 
stimulates fibrinolysis. (8) Although most medications used to treat dyslipidemias will raise 
HDL levels modestly; however, niacin appears to have the greatest potential to do so, 
increasing HDL up to 30%. (9)  
Vitamin C 
A widely publicized study showed that men who took 800 mg daily of vitamin C lived 
about 6 years longer than those consuming of 60 mg per day. (10) A study of elderly 
subjects; being supplemented by vitamin C and vitamin E to subjects using no vitamin 
supplements showed that use of vitamin E alone reduced death from myocardial infarction 
(MI) by 63% and overall mortality by 34%. When the vitamin C and E were used together, 
overall mortality was reduced by 42%. (11) 
A proper supply of nutrients will allow the cellular damage to vascular walls to be repaired 
properly and prevent further cracks and lesions. The results of a clinical studies, published 
in the Journal of Applied Nutrition (12), determine the effect of a nutritional supplement 
program, consisting of vitamin C therapy, on the natural progression of coronary artery 
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disease. The study used Ultrafast Computed Tomography to document the level of coronary 
artery disease and the sample of patients composed of people with early and advanced 
stages of the disease. During the course of the 12-month study, the rate of coronary artery 
calcification decreased in all patients by an average of 15%. In the subset of early stage 
patients, the progression of calcification was stopped completely. In some cases, calcification 
was actually reversed, including a case of the disappearance of all calcification deposits.  
Vitamin E 
Evidence demonstrates that vitamin E protects against development of atherosclerosis by 
reducing oxidation of LDL, inhibiting proliferation of 4smooth muscle cells, decreasing 
platelet adhesion and aggregation, and changing the expression and function of adhesion 
molecules. The biological functions of vitamin E (attenuating the synthesis of leukotrienes 
and potentiating release of prostacyclin) which reduces platelet aggregation and acts as a 
vasodilator may protect against the development of atherosclerosis. (13) 
A large study that examined the relationship between the intake of dietary carotene, vitamin 
C, and vitamin E and subsequent coronary mortality found an inverse association between 
dietary vitamin E and coronary mortality, supporting the hypothesis that antioxidant 
vitamins provide protection against CAD. (14) Large epidemiological studies revealed that 
higher vitamin E levels in plasma result in a reduced incidence of CAD. Dose-response 
studies in humans have demonstrated that 400 IU per day of vitamin E increased vitamin E 
plasma levels twofold and delayed oxidation of LDL, while the length of time was more 
important than the amount of the nutrient used. (15) The type and blend of vitamin E 
selected for supplementation can affect the end results. Studies show that -tocopherol may 
offer better protection against CAD when it is combined with gamma tocopherol, which has 
a greater activity. Unfortunately, gamma tocopherol is poorly retained in body because it is 
excreted in urine following liver metabolism, whilst -tocopherol is more abundant in body 
tissues which does not provide for maximum protection against free radical attack. So 
complexing -tocopherol (80%) with gamma tocopherol (20%) is an ideal blend for 
individuals seeking protective cardiovascular effects from vitamin E tocopherol. 
Coenzyme Q10 
Coenzyme Q10 (CoQ10; ubiquinone) is a fat-soluble cofactor substance. It is a naturally 
occurring substance that prevents cell damage due to myocardial ischemia (hypoxia) or 
subsequent to reestablishment of blood flow to the heart after temporary ischemia. 
CoQ10 is involved in several key enzymes in energy production within a cell, and has 
membrane-stabilizing activity. Numerous studies provide details of the efficacy of CoQ10 in 
the prevention and treatment of heart disease, as detailed below. Oral CoQ10 (150 mg daily 
in 3 doses) was given for 4 weeks to exercising angina patients. Average levels of CoQ10 in 
plasma increased after CoQ10 treatment and were significantly related to an increase in 
exercise duration. The study suggested that: "CoQ10 is a safe and promising treatment for 
angina pectoris". (16) Pretreatment with intravenous CoQ10 minimized myocardial injury 
caused by cardiac bypass graft (CABG) surgery and improved heart function. In patients 
undergoing CABG pretreatment with intravenous CoQ10 (5 mg/kg, intravenously 2 hours 
before cardiopulmonary bypass) prevents left ventricular depression in early reperfusion 
and minimizes myocardial cellular injury during CABG following reperfusion. (17) 
In comparison with younger individuals, the outcome of surgery in the elderly, is 
compromised by age-related reduction of cellular energy production in the myocardium 
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simulated ischemia compared to younger patients. This age-associated effect was prevented 
by pretreatment with CoQ10 (18), in addition CoQ10 pretreatment prior to stress improved 
recovery of the myocardium after stress (19). Because of the popular use of "statin" drugs 
(Zocor, Lipitor, Pravachol, Lescol, and Mevacor) it is important to emphasize that statins act by 
inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. Drugs 
inhibiting HMG-CoA reductase activity decrease CoQ10 levels (20) because HMG-CoA 
reductase is required for CoQ10 synthesis. Individuals using statins ought to increase their 
intake of CoQ10 to negate the decrease in CoQ10 biosynthesis caused by the statin drugs. So it 
is recommended to administer it with statin therapy. CoQ10 is free of toxicity and typically 
produces no side effects and may change the insulin requirements of people with diabetes. 
2.3 Mind-body relaxation techniques  
While living a type A lifestyle isn't typically categorized as a main risk factor for heart disease, 
learning how to deal with life and lower stress levels can help down road to recovery.  
Mind-body approach aimed at diminishing excess activation in the nervous system and 
thereby improving one's own ability to modulate emotional and behavioral responses. 
Relaxation therapy is a broad term used to describe a number of techniques that promote 
stress reduction, the elimination of tension throughout the body, and a calm and peaceful 
state of mind. 
Relaxation techniques include behavioral therapeutic approaches that differ widely in 
philosophy, methodology, and practice. There are two basic methods, deep methods include 
autogenic training, progressive muscle relaxation, and meditation (although meditation is 
sometimes distinguished from relaxation based on the state of "thoughtless awareness" that 
occurs during meditation). Brief methods include self-control relaxation, paced respiration, 
and deep breathing. Brief methods generally are less time consuming and often represent a 
summarized form of a deep method. In order to be able to evoke the relaxation, several 
months of practice (at least three times per week) is required. 
Some of the more popular relaxation techniques include massage therapy, yoga, listening to 
music, pray and meditation.  
Massage therapy 
Massage therapy is the scientific manipulation of the soft tissues of the body, consisting 
primarily of manual (hands-on) techniques such as applying fixed or movable pressure, 
holding, and moving muscles and body tissues. 
Various forms of therapeutic superficial tissue manipulation have been practiced for 
thousands of years across cultures. Chinese use of massage dates to 1600 BC, and 
Hippocrates made reference to the importance of physicians being experienced with 
"rubbing" as early as 400 BC. There are references to massage in ancient records of the 
Chinese, Japanese, Arabic, Egyptian, Indian, Greek, and Roman nations. Many different 
therapeutic techniques can be classified as massage therapy. Most involve the application of 
fixed or moving pressure or manipulation of the muscles/connective tissues of clients. 
Practitioners may use their hands or other areas such as forearms, elbows, or feet. Used 
techniques during massage therapy include (1) superficial stroking away from the heart or 
deep stroking towards the heart; (2) kneading in a circular pattern using fingers and 
thumbs; (3) deep muscle stimulation; (4) rhythmic movements such as slapping or tapping; 
and (5) vibration. Scientific research of massage is limited, and existing studies use a variety 
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of techniques and trial designs. Firm evidence-based conclusions about the effectiveness of 
massage cannot be drawn at this time for any health condition. 
Shiatsu 
Shiatsu literally means ‘finger pressure’. Shiatsu is based on the same principles as 
acupuncture concentrating on meridians or energy lines but without the needles. Everything 
is related to the five elements that correspond to different parts of the body:  
Heart: Fire, Kidney: Water, Spleen: Earth, Lungs: Metal, Liver: Wood.  
The idea, as in acupuncture, is to balance the life energy in the body which is disturbed 
when we become ill. Through a series of finger pressures all over the body along the specific 
pathways, Shiatsu can rebalance the body’s energies, regulate the organs’ function and 
improve circulation. Shiatsu  last up to 1 hour during which practitioners often use their 
elbows, knees and feet as well as their fingers for palpation of the abdomen and other areas 
which may be lacking energy , but they seldom use the hands’ palms unlike other 
traditional Western contact therapies.  
Yoga 
The term “Yoga” comes from a Sanskrit word meaning "union." Yoga combines physical 
exercises, mental meditation, and breathing techniques to strengthen the muscles and 
relieve stress.The first known work is "The Yoga Sutras," written more than 2,000 years ago, 
although yoga may have been practiced up to 5,000 years ago. Yoga has been described as 
"the union of mind, body, and spirit," which addresses physical, mental, intellectual, 
emotional, and spiritual dimensions towards an overall harmonious state of being. It works 
towards self-realization and control of mental, physiological, and psychological parameters. 
Yoga is often practiced by healthy individuals with the aim to achieve relaxation, fitness, 
and a healthy lifestyle. Yoga has also been recommended and used for a variety of medical 
conditions and consists 30 to 90 minutes sessions.  
Meditation  
Meditation is usually suggested as a stress management technique used to cause a tranquil 
and relaxed state of mind. However, researchers have lately found that meditation offers 
other significant health benefits by changing deeper and more dynamic processes in the 
body, even so far as being able to strengthen the heart. Researchers at the Margaret and H.A. 
Rey Laboratory, Boston, USA discovered that meditation impacts prominent heart rate 
variability traditionally associated with practicing slow breathing during specific traditional 
forms of Chinese Yoga meditation techniques. (21) The magnitude of this variability during 
meditation was much far greater than when compared to those not practicing any 
meditation in healthy young adults and even elite athletes during sleep. These results 
uncovered that meditation can have a profound effect on the heart and its activity. The 
researchers observed that the variability of beat-to-beat heart rate was directly affected by 
meditation. The report concluded that meditation should not be seen as just a method of 
relaxation and stress management, but also as an aid to strengthen the heart and create a 
more active state in the body.(21) 
2.4 Cardiac rehabilitation and exercise training   
I. Cardiac rehabilitation definition  
Cardiac rehabilitation (CR) is welcomed not only as integral in the management of patients 
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of techniques and trial designs. Firm evidence-based conclusions about the effectiveness of 
massage cannot be drawn at this time for any health condition. 
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more active state in the body.(21) 
2.4 Cardiac rehabilitation and exercise training   
I. Cardiac rehabilitation definition  
Cardiac rehabilitation (CR) is welcomed not only as integral in the management of patients 





prevention which consists of a number of activities or measures that may be adapted by 
patients so as to reduce the symptoms or the risk of a further event. 
More recently CR has been redefined as follows: “Cardiac rehabilitation is the process by 
which patients with cardiac disease, in partnership with a multidisciplinary team of health 
professionals, are encouraged and supported to achieve and maintain optimal physical and 
psychosocial health”. (22,23)  
According to guidelines, CR including exercise training, patient education, psychological 
support, risk factor management, and clinical assessment, is indicated for patients with 
ischemic heart disease (IHD), chronic heart failure,  patients with a high risk for developing 
IHD (24-27), patients with valvular heart diseases, cardiac transplantation, Implanted 
cardioverter defibrillators, and congenital heart diseases (23). 
II. Cardiac rehabilitation phases 
Cardiac rehabilitation is divided into four phases, ranging from the acute hospital admission 
stage to long-term maintenance of lifestyle changes, as follows (23,25,26): 
Phase I (in patient period): is started after a ‘step change’ in cardiac condition including 
myocardial infarction, onset of angina, any emergency hospital admission for coronary heart 
disease, cardiac surgery or angioplasty and/or stenting, and first diagnosis of heart failure. 
This should begin as soon as possible after admission.  Phase I consists of  assessment, 
education, exercise/mobilization. 
Phase II (Early post-discharge): exercise consultation and behavior change strategies are 
benefecial at this stage to improve adherence to both lifestyle change and maintenance of 
exercise in phase II and uptake of phase III in the future. This is the stage for risk factors 
modification and goal setting in phase I (lasting over a period of between 8 and 12 weeks).  
Phase III (supervised out-patient): at this stage, risk factor changes and education are 
continued. Phase III is usually consists of at least two supervised exercise sessions per week, 
lasting over a period of between 6 and 12 weeks. Patients may be provided with one session 
of education per week. Physical training is often the essential part of phase III, while 
psycho-social counseling and education considering risk factors and lifestyle are of primary 
importance. In addition to the aerobic conditioning phase, resistance training is part of CR 
exercise. Home-based exercise is also prescribed with self monitoring skills being used by 
the patients. 
Phase IV (long-term maintenance of exercise and other lifestyle changes): For the benefits of 
physical activity and lifestyle change to be sustained, the available evidence suggests that 
both are necessary to be retained.  As clinically indicated, referral to specialist clinicians, 
such as smoking cessation or psychological support, may still be needed. Continuation and 
progression of appropriate physical activities are persuaded outside the hospital setting. By 
this time it is looked forward that individuals will be aware of their exercise capabilities and 
be able to monitor themselves properly. 
III. Cardiac rehabilitation and exercise training in Ischemia  
There are several mechanisms by which regular exercise training exercise training may 
improve myocardial oxygen supply and thereby result in an anti ischemic effect. Exercise 
training reduces cardiac workload at a given (sub maximal) exercise level by improved 
adaptation of the peripheral circulation. A alternative external work can be gained with a 
lower heart rate and blood pressure, thereby reducing myocardial oxygen demands and 
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coronary blood flow requirements in areas with a potentially critical perfusion deficit.  Since 
myocardial perfusion is related to the length of the diastole, the time for perfusion of the 
myocardium decreases with increasing heart rate. Thus, exercise training improves the 
economy of the heart work and facilitates myocardial perfusion in patients with coronary 
artery stenoses. A lower heart rate and a lower systolic blood pressure during exercise is a 
usual though somewhat transient phenomenon after exercise training in normal persons as 
well as in patients with CAD. To maintain this training effect exercise needs to be 
incorporated into the daily routine – such as medication. (22, 25)  Many studies have 
revealed that the symptomatic improvement as a result of exercise training is mainly owing 
to a decrease in the rate–pressure product at sub maximal workloads with no change in the 
rate–pressure product at the onset of angina (22, 28) Later reports also showed a rise in the 
rate–pressure product at the onset of angina along with a reduction in the ischemic response 
measured as angina or ST-segment depression, at a given rate–pressure product, suggesting 
that exercise training improves myocardial oxygen delivery. There are controversial aspects 
about improvement in angiographic collateralization or regression of coronary 
atherosclerosis- that might be a reason for less ischemia- despite the endurance exercise 
training program. However, some surveys showed a significant tendency toward decreasing 
progression after prolonged rather intense, particularly in those patients who took part 
more sessions of the structured training program (22,29,30). 
The question whether ischemia should be avoided during endurance training in stable 
patients is open to question. The studies of Ehsani et al. suggest that in selected patients 
significant ST-segment depression can be borne without adverse effects (31). However, for 
safety reasons it is usually recommended to avoid ischemia during endurance training in 
order to minimize risks and maximize benefits. In patients with symptoms suggesting 
instability, exercise is not recommended until the phase of instability has resolved. (32) 
Randomized clinical trials (RCTs) and meta-analyses have demonstrated significant (14% to 
24%) relative reductions in all-cause mortality over 1 to 2 years in patients with coronary 
artery disease randomized to cardiac rehabilitation programs. Women, elderly patients, low-
income groups, and ethnic minorities tend to be under-represented in RCTs. (33 - 35) CR 
also resulted in a comparable effects in terms of cardiac overall survival, event-free survival 
and other secondary outcome measures like cardiac morbidity. (36,37)  Stukel et al argued 
whether the true size of the effect is 10% or 30%, but both are large when translated into 
absolute population numbers .(38)  
The effects of Cardiac rehabilitation on Endothelial function 
One of the positive effects of exercise is the improvement of endothelial dysfunction. 
Endothelial dysfunction is a precursor of clinically significant atherosclerotic disease and is 
a signal for an increased cardiovascular event rate.(39-41)  
Different efforts have been made to correct the impaired endothelium-dependent 
vasodilatation. In recent years it has become apparent that exercise affects the functional 
activity of the vascular endothelium.Whereas normal coronary arteries dilate, atherosclerotic 
coronary arteries often exhibit a paradoxical vasoconstriction in response to exercise, thereby 
causing critical ischemia even in moderate epicardial stenosis. Endothelium-derived NO is the 
main mediator of improved endothelial function and enforces a multitude of anti 
atherosclerotic functions. Acting on the endothelial cell itself, NO inhibits endothelial cell 
apoptosis, suppresses inflammatory activation, and increases the activity of oxygen radical-
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coronary blood flow requirements in areas with a potentially critical perfusion deficit.  Since 
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atherosclerosis- that might be a reason for less ischemia- despite the endurance exercise 
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progression after prolonged rather intense, particularly in those patients who took part 
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also resulted in a comparable effects in terms of cardiac overall survival, event-free survival 
and other secondary outcome measures like cardiac morbidity. (36,37)  Stukel et al argued 
whether the true size of the effect is 10% or 30%, but both are large when translated into 
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Endothelial dysfunction is a precursor of clinically significant atherosclerotic disease and is 
a signal for an increased cardiovascular event rate.(39-41)  
Different efforts have been made to correct the impaired endothelium-dependent 
vasodilatation. In recent years it has become apparent that exercise affects the functional 
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causing critical ischemia even in moderate epicardial stenosis. Endothelium-derived NO is the 
main mediator of improved endothelial function and enforces a multitude of anti 
atherosclerotic functions. Acting on the endothelial cell itself, NO inhibits endothelial cell 
apoptosis, suppresses inflammatory activation, and increases the activity of oxygen radical-





the endothelium and also inhibits vascular smooth muscle cell proliferation and promotion 
of positive arterial remodeling. Studies using cultured endothelial cells and animal 
experiments suggest that increases in endothelial NO synthesis expression and protein 
phosphorylation are possible mechanisms. Exercise training in stable CAD leads to an 
improved agonist-mediated endothelium-dependent vasodilatory capacity. (42-45)  Exercise 
training induces adaptations in cellular mechanisms of nitric oxide regulation in collateral-
dependent coronary arteries of chronically occluded vessels that contribute to enhanced 
nitric oxide production (46). Also arterial production of reactive oxygen species could 
significantly reduced by exercise training.  
Improvement in Exercise Capacity 
Physical activity is seen as a behavior that generally has advantages on exercise capacity and 
many of the physiologic processes involved in the development of primary prevention of 
coronary artery disease. (26) Lavie et al reported a 34% improvement in exercise capacity 
after cardiac rehabilitation participation. (47) Some newer studies showed every one MET 
increase in exercise capacity can induce more than 17% improvement in survival rate, it is 
especially important in heart failure patients .(25,26) 
Improvement in Left Ventricular Function (systolic and diastolic) 
Ehsani et al studied 25 patients, 52 (±2) years old with coronary artery disease and mildly 
impaired LV function (ejection fraction 53%)[31], They compared these to 14 patients with 
comparable maximal exercise capacities and ejection fractions who did not undergo an 
exercise training program. The exercise group completed a 12- month program of very 
intense endurance exercise training of progressively increasing intensity, frequency, and 
duration. Ejection fraction did not change during maximal supine exercise before training 
(52 ± 3%),but after training it increased during exercise to 58 ±3% (P<0.01), despite a higher 
rate–pressure product during maximal exercise, providing some evidence for an 
improvement in contractile state after training – or also for improved perfusion with less 
ischemic impairment of myocardial function during exercise. (22,31)                            
In one of the first small prospective studies of endurance training in HF patients, Sullivan et 
al confirmed that 4 to 6 months of training did not deteriorate LV ejection fraction and 
tended to improve maximal cardiac output. (48) Another larger randomized clinical trial 
provided evidence for a training- induced reverse remodeling with modest improvements 
of LVEF and reductions of LV end-diastolic diameter in a mixed population of ischemic and 
dilated cardiomyopathy.(49)     
Heart failure with preserved left ventricular ejection fraction (HFPEF) is the most popular 
form of HF in the older population. Exercise intolerance is the primary chronic symptom in 
patients with HFPEF and is a strong determinant of their reduced quality of life (QOL). 
Exercise training improves exercise intolerance and diastolic function and QOL in patients 
with HF with preserved and reduced ejection fraction. (50)   
Improvement of quality of life      
Cardiac rehabilitation is increasingly known as an integral part of comprehensive cardiac 
care. The evidence supporting its effectiveness in reducing morbidity and mortality and 
improving quality of life (51) Frank suggested that those who have greater physical 
functionality, the confidence to perform physical activities, and are not restricted clinically, 
may more readily adjust to cardiac rehabilitation and progress more rapidly. Those patients 
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with the poorest exercise capacities at entrance to the program tended to make the greatest 
gains in health related quality of life. (52)  
Improvement in risk factors profile 
Regular physical activity is associated with favorable modification of cardiovascular risk 
factors such as hypercholesterolemia, hypertension, diabetes, and obesity. (22,53-57)  
Cost- benefit 
Cardiac rehabilitation is one of the most effective treatments of secondary prevention for 
patients with heart disease. These standard training programs are safe and cost-effective. (37) 
IV. Cardiac rehabilitation components 
IV.a Exercise program 
Not only a universal understanding of patient’s medical history, current status, and 
medication regimen need to be taken into account, while prescribing an exercise, but also a 
solid understanding of exercise physiology as relates to recreational and vocational 
activities. Experience and individualization of exercise prescription are essential for optimal 
success in activity programming. A staged exercise test (preferably Ramp protocols) is 
recommended for exercise prescription. Every activity program should be consist of a 
warm-up, conditioning, and cool-down periods. (25,58)      
Warm up:  is a 5 to 15 minutes period, during which the musculature and joint structures 
are stimulated gently with a series of static stretches and dynamic range of motion (ROM) 
activities. A large group of muscle is involved in the warm-up stretches. The stretch should 
be maintained 15-30 seconds and should not result in discomfort or pain. Patients should be 
encouraged to continue to breathe to avoid Valsalva maneuver that can cause exaggerated 
BP responses. 
Conditioning period: The conditioning period may be designed to focus on the following 
activities: 
1. To increase caloric expenditure to aid with weight management 
2. To improve overall functional capacity 
3. To delay the onset of symptom 
4. To improve muscle tone and strength 
5. To optimize job or vocational abilities 
6. To optimize recreational activity performance 
7. To optimize ability to perform activities of daily living (ADL) 
It must address 5 keys factors: Frequency, Intensity, Mode, Duration, Rate of progression  
Frequency: Typically, the exercise stimulus must be done at least three times per week. It is 
recommended that the sessions be allocated equally throughout the week. From an FC 
improvement standpoint, there is trivial achievement by extending the program beyond 5 
days per week. It is recommended that the average rehabilitation program being with an 
exercise frequency of 3 times per week for at least the first 3-6 months, if after this time the 
patient has remained free of musculoskeletal complications and expresses an interest in 
increasing the frequency, the program can reach to four to five times per week. 
Intensity: According to ACSM guideline the intensity threshold for healthy adults is 
between 60-90% of HR max in a staged exercise test or 50-85% of Vo2max or heart rate 
reserve (HRR).The typical range of exercise intensity for patients involved in cardiac 
rehabilitation is between 40% and 85%. Exercise intensity is not static. The cost of the 
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with the poorest exercise capacities at entrance to the program tended to make the greatest 
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factors, and time since medications were last taken. Medications, especially β-blockers, can 
alter the patient’s FC significantly. If significant stable ischemic changes or symptoms occur 
with activity, the exercise intensity must be established at a level adequately below the 
threshold for these findings (usually 10-15 beat/min below the onset of ischemic changes). 
If possible, to minimize any flaw in prescribing exercise intensity, it is advised to carry out 
the exercise test for exercise prescription on all usual medications and the same approximate 
time of day as patients exercise.  
Mode: Any activity that ingages a mass of muscle group in a rhythmic and repetitive fashion 
(dynamic exercises) at the approximate intensity and duration leads to improved FC. The most 
common sorts of the activity used in CR are walking and appropriate jogging. Cycling, 
swimming, rowing, stair climbing, and aerobic dancing are other popular activities used in CR 
programs. Recent studies, however, have demonstrated the safety and benefit  
of isotonic and weight training programs. Strengthening is recommended 2-3 times per week. 
Duration: The duration of conditioning period is typically 15 and 60 minutes. A minimum 
of 15 minutes is necessary to achieve an improvement in FC. The optimal duration is 20-40 
minutes. It can be extended if the intensity is reduced and a goal of the program is increased 
caloric consumptions. Patients with significant claudication, low FC, or marked weakness 
may require an interval program (limited by symptoms), until the total time of all intervals 
equals the prescribed duration.  
Rate of progression: The first scale developed by Borg ranges from 6 to 20 and is linear, 
with word anchors that describe the exercise intensity equally spaced along the length of the 
scale. On average, a perceived exertion of 12 to 14(somewhat hard), on the 6 to 20 scale, 
corresponds with a HR response of between 60% and 85%, respectively. The second scale 
has an exponential design to the spacing of the word anchors and runs from 0 to 10. For 
ratings on the 10 point scale; values between 3 and 6 correspond to a similar HR response. 
Cool- down: this period should promptly follow the conditioning period in an activity 
session. It lasts 3-10 minutes. The patients should perform low- level, rhythmic, aerobic 
activities during period. After the active aerobic cool- down, static stretching and fine ROM 
activity included again. Stretching exercises are essential segment in each training session. 
IV.b Education 
Patient education can play an integral role in acomplishment of any CR program, provided 
that it is done properly. The inclusion of the patient education program changes, depending 
on the background of the patient and on the phase of CR. Some topics which should be 
taken into consideration are the following: management of risk factors through lifestyle 
modifications of smoking, diet, stress management and exercise behavior; return to work; 
medications; sexual activity; exercise prescription and psychological issue.  
IV.c Psychological consideration and stress management 
Depression: The relationship between depression and CAD is well atated. Depression is 
highly prevalent in cardiac patients, and is a considerable risk factor for cardiac outcomes. 
Patients should be screened for depression at entry to CR programs, using either a few 
verbal screening questions or a standardized depression questionnaire. Depressed patients 
enrolled in CR programs will need more attention to insure continued adherence and close 
monitoring to rapidly intervene provided that depressive symptoms worsen. (22,23,25,59) 
Several treatments have shown some success in treating depression in cardiac patients, 
including antidepressant medication (sertraline), psychological interventions (such as 
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cognitive behavioral therapy), and exercise training. Other psychological disorders such as 
type A personality behavior, anger and hostility should be managed in CR setting. (23, 25, 
26) Treatment with cardiac rehabilitation can improve mental health related quality of life in 
a significant way. (60)  
Stress management: The previous researches has indicated that mental and emotional stress 
can result in myocardial ischemia and is associated with a several fold increase in 
occurrence of subsequent fatal, and nonfatal, cardiac events. Although the efficacy research 
on stress management in cardiac rehabilitation is fraught with methodological issues, it 
appears that psychological interventions that are successful in reducing distress are also 
successful in reducing morbidity and mortality. Key components for providing sufficient 
stress management interventions include envolving patients through joining the process of 
heart disease to their own experiences, assissting them to understand the ability they have 
in slowing or reversing the process through the choices they make in dealing with 
responses, providing adequate training and opportunities for guided practice in producing 
the relaxation response, and teaching patients to shift perceptions and beliefs that tend to 
increase stress and effect healthy coping.  
Relaxation Training: Relaxation training has also been found to reduce heart rate, 
respiratory rate and muscle   tension. The patients can take advantage of relaxation training 
that instructs them to use abdominal breathing and visual imagery to focus attention on 
healing stimuli, memories, or fantasies.  
V. Home- based cardiac rehabilitation 
Home-based secondary prevention programs for CAD are an effective and fairly low-cost 
alternative measure to hospital-based CR and should be noticed for stable patients unlikely 
to access or adhere to hospital-based services.(61,62)  
VI. Safety of exercise training 
In the meanwhile, the benefits of comprehensive cardiac rehabilitation have been obviously 
demonstrated, but the exercise training-induced complications and benefit-risk ratio of 
cardiac rehabilitation remains poorly understood. Screening procedures can be used to 
identify subjects at increased risk for an exercise-related cardiac event. These are patients 
who are generally at increased risk of sudden cardiac death; particularly patients with 
severe LV dysfunction or ischemia at low levels of exercise. The results of studies reporting 
the risks of sudden cardiac arrest during exercise training depict that this risk is low even 
during vigorous exercise. These studies strongly suggest that the incidence of sudden 
cardiac arrest across a variety of activities, with the exception of jogging, is similar to that 
expected by chance alone. In summary, the risk of cardiac events during exercise testing and 
training appears to be very low, but such events seem difficult to for see. Finally, although 
risk stratification remains necessary at the beginning of a CR program, the occurrence of a 
severe cardiac event seems to be difficult to predict in most cases. This difficulty emphasizes 
the role of the cardiologist in the prescription and supervision of CR sessions. (63-66) 
VII. Problems exist in cardiac rehabilitation 
Underutilization of cardiac rehabilitation  
Unfortunately despite the obvious benefits and effectiveness of CR on quality of life and 
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people who would benefit from this program fails to participate in it and right now the main 
present problem with exercise-based cardiac rehabilitation is its underutilization. (37,70,71)  
Barrier to cardiac rehabilitation 
There are multiple interrelated factors that influence a patient’s decision to use cardiac 
rehabilitation services. These factors divided into environmental and individual categories. 
(72) The healthcare delivery systems and policies within hospitals and cardiac rehabilitation 
programs represent factors within the internal environment. These factors are amenable to 
improvement. The external environment which includes factors that affect the patient’s 
ability to use healthcare services are not as amenable to change, such as where they reside or 
their access to these services. Individual factors (at the patient and provider level) are 
composed of 4 categories. 1) Predisposing factors are socio-demographic characteristics and 
prior experiences with cardiac rehabilitation. 2) Enabling factors are any skill or resource 
required to enroll and participate regularly (income, social support, work/personal schedules, 
transportation, knowledge, attitude, and beliefs). 3) Reinforcing factors strengthen or lessen 
the motivation for program attendance and adherence (strength of physician endorsement, 
encouragement and support of healthcare providers, family, and friends). 4) Need factors in 
term of physician’s and patient’s perceptions are influenced by the clinical condition, 
psychological factors, and anticipated benefits of the service. Many of the barriers that arise 
from these categories provide opportunities for healthcare professionals to attempt to improve 
rates of CR referral, registration, and completion. (72-79) 
3. Specific alternative therapy 
Treatment of patients with refractory angina pectoris has still remained challenging in 
patients with end-stage coronary artery disease not suitable for revascularization (even 
bypass surgery or angioplasty with stent).    
3.1 ESMR (Extracorporeal Shockwave Myocardial Revascularization) 
Extracor Extracorporeal Shock Wave Therapy (ESWT) was introduced in the early 1990s as a 
spin-off of urological lithotripsy.(80) Since then, ESWT has been applied to treat various 
musculoskeletal conditions. Right now Shockwave Myocardial Revascularization (ESMR) is 
a breakthrough in management of refractory angina pectoris with end-stage coronary artery 
disease not suitable for revascularization (81). The treatment is performed using a special 
generator that produces low intensity shockwaves, a kind of sound waves similar to, but of 
lower strength than Extracorporeal Shock Wave Lithotripsy (ESWL) that is used in the 
treatment of kidney stones . These acoustic shock waves are not dissolving plaque in the 
same way that lithotripsy breaks up a stone, instead, these waves result in release 
substances which stimulate the formation of new blood vessels in the heart.( 82) The shock 
wave schedule consists of three 20-minute sessions per week over nine weeks.  
The patient must first undergo cardiac SPECT (single photon emission computed 
tomography) testing to identify the location of the ischemic areas. Afterwards a handheld 
device called a transducer is placed over the skin and shockwaves will then be delivered 
directly to the ischemic region under echocardiographic guidance. (83)The therapy sessions 
that have already been conducted have yielded positive results among treated patients who 
claim they have had their pain alleviated since the beginning of the treatment. ESMR is an 
alternative therapy for patients who have angina, even though they take medicine, and are 
not suitable candidates for coronary angioplasty or bypass surgery. 
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3.2 EECP (Extracorporeal Electrical Counter pulsation) 
EECP is sometimes known as a "natural bypass" since it optimizes the body's ability to 
develop new vessels around stenotic arteries. EECP seems to be a noninvasive, well-
tolerated therapeutic option for patients with coronary artery disease (CAD) and refractory 
angina who are not amenable to standard revascularization procedures. (84-86)The EECP 
device consists of three paired pneumatic cuffs applied to the lower extremities. Patients are 
typically treated for 1 hour daily program for a total of 35 sessions over 7 weeks. The cuffs 
are inflated in sequence, placing pressure on the legs which pushes blood flow from the 
lower limbs up towards the heart. The inflation of the cuffs occurs during diastole so it 
increases blood flow delivery to the heart at the precise moment it is relaxing. Then, just 
before the heart pumps, the cuffs deflate, reducing resistance and decreasing the heart's 
workload.  
Prospective clinical trials and large treatment registries have shown major reductions in 
anginal symptoms and improvements in objective measures of myocardial ischemia in 
response to EECP in patients with symptomatic CAD. Its potential role in heart failure 
management, which improves quality of life and reduces symptoms, has been also 
shown.(84)  
EECP treatment is associated with an immediate increase in blood flow in multiple vascular 
beds including the coronary artery circulation and causes acute changes in hemodynamics 
including an increase in preload and a decrease in afterload.(87-90) Several published 
studies were designed to assess objective evidence of improvement in myocardial perfusion 
and beneficial hemodynamic effects. They have also shown improvements in various organ 
system perfusions and LV diastolic filling after EECP treatment and it is even recommended 
as initial revascularization treatment for refractory angina. The abrupt drop in intra-aortic 
pressure unloads the left ventricle during systole, thus reducing the cardiac workload in 
ejection period and reducing myocardial oxygen demands.  
EECP greatly accelerates the formation of collateral vessels, helping restore adequate 
circulation to organs and tissues that have been deprived of blood and oxygen. EECP was 
developed at Harvard University almost 50 years ago as a therapy for angina. Several 
studies have shown that patients who undergo a course of EECP experience fewer episodes 
of angina, experience less intense episodes of angina, need less anti-angina medication, can 
walk farther without experiencing angina, and resume work and enjoy more social 
activities.(86, 91) 
In a recent study by Esmaeilzadeh et.al, the effects of EECP on regional myocardial function 
were evaluated. Given their findings, EECP can improve global and regional LV systolic and 
diastolic functions by means of strain and strain rate imaging.(91)  
Unlike drugs that are prescribed for angina, EECP is completely safe and without side 
effects. And unlike angioplasty and bypass surgery, EECP can be done on an outpatient 
basis and requires no post-treatment recovery period. Patients suffering a heart attack or 
enduring one or even several surgeries for coronary artery disease are best candidates for 
this kind of treatment. In some cases, EECP is their only option. Yet this noninvasive 
therapy is so safe and effective that it should be considered as a first-line treatment for 
angina, not just a last resort after surgery has been ruled out.  
For a growing number of patients, who are imposed a potentially dangerous surgical 
procedure, recommending EECP is a wise decision; because in less time than it takes to 
recover from bypass surgery, these patients can complete a full course of EECP and begin 
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For the first time healing power of electric current was described by Scribonius Largus, the 
physician of the Roman emperor Claudius, in the treatment of headache and gout.(92)  
Because of the very promising results of neurostimulation in different ischemic syndromes, 
it seemed obvious to try electrical neurostimulation therapy as an adjuvant therapy in 
patients suffering from medically refractory angina pectoris. The beneficial effects of 
transcutaneous electrical nerve stimulation (TENS) were described by Mannheimer and 
colleagues. (93,94)  
For patients not responding to adequate medication and not being suitable anymore for 
revascularization and suffering from refractory angina pectoris, neurostimulation has been 
described repeatedly as an effective and safe therapy.(95,96) The mechanism of action of 
neurostimulation is not completely known, however, recent studies suggest that anti-
ischemic effect expressed by decrease in the serum catecholamine level, exerted by reducing 
sympathetic tone. (97-99) 
The effect of TENS on coronary flow was not accomplished in patients with a heart 
transplant which suggests that neurostimulation employs its effect through neural 
mechanisms employed at the microcirculatory level. (100)   Considering the lack of resting 
heart rate and blood pressure variability under neurostimulation, it’s unlikely that beta-
adrenergic mechanisms are involved. (101) Moreover, beta-mediated coronary dilatation is 
of less importance in the ischemic myocardium. (102)  On the other hand, alpha- adrenergic 
receptors may play a role in the anti-ischemic mechanism of action of neurostimulation. 
Inhibition of the alpha receptors may cause relative vasodilation at the subendocardial 
coronary level,(103) which in turn may cause a redistribution effect. 
At present it is unknown which neural pathways are involved in neurostimulation for 
angina pectoris. It is discovered that angina begins with stimulation of cardiac nerve 
endings.(104,105) by visceral afferent nerve fibers, converging in common pathways into the 
dorsal spinal cord at C7-T5 level, where they have synaptic connections with other 
neurons.(106) Afferent fibers from the heart and cutaneous input are assumed to cover 
specific interneurons in the same segment of the spinal cord, explaining the ensuing referred 
projection of pain to the related dermatome.(107, 108) Consequently, angina is felt in areas 
of the chest that refer to the dermatome from which afferent nerves project to the same 
segment of the spinal cord (C7-T5) as the heart. For an optimal clinical result of 
neurostimulation it is of great importance to achieve paresthesia in the same dermal regions.  
Although there is increasing evidence that neurostimulation is effective in angina pectoris, 
its safety needs to be established. In a 5-year follow-up study of 23 patients on spinal cord 
stimulation (SCS), Sanderson reported that it is a safe therapy based on the fact that; 
(109) only three patients died during this follow-up. In another follow up study, out of 46 
patients with severe coronary artery disease who were treated at the Groningen University 
Hospital Department of Cardiology with SCS; only six patients died during a7- year  
period. (110) 
However, despite declining mortality rates in patients with coronary artery disease, little is 
known about mortality rates in patients with refractory angina due to severe coronary artery 
disease. It is estimated that 3% (about 7 million) of Americans have active coronary artery 
disease implying an annual death rate of 7 %. (111)  
Another important issue which needs further attention before the general acceptance of 
neurostimulation as an alternative therapy in angina pectoris is its complication rate. 
Because of the high skin impedance, TENS is frequently complicated by persistent skin 
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irritation, which makes adequate continuation of therapy difficult. Meanwhile, SCS has a 
rather high incidence of dislocation of the epidural lead,(112) and this often impairs its 
effect. 
Once the safety of neurostimulation in angina pectoris is convincingly established and the 
aforementioned side effects can be further reduced, both TENS and SCS may be 
commonly used as alternatives in the therapeutic spectrum of intractable angina pectoris. 
3.4 Acupuncture 
Acupuncture involves the insertion of extremely thin needles in skin at strategic points of 
body. Acupuncture originated in China six thousands of years ago, but during the past three 
decades it was grown significantly as a popular therapy within the world. 
It works by stimulating the body to naturally correct the imbalances of energy. This is done 
by inserting ultra-fine, disposable needles, underneath the skin at specific points of the 
body. (113) These acupuncture points are related to energy pathways that run throughout 
the entire length of the body. Acupuncture points are also related to specific internal organs. 
The earliest known text on acupuncture was published more than 4,500 years ago. 
Acupuncture has been traditionally used to treat a wide variety of cardiovascular diseases, 
and recent controlled studies have demonstrated that it is particularly beneficial for angina 
pectoris by offering a proven option to drug therapy. 
Traditional Chinese theory explains acupuncture as a technique for balancing the flow of 
energy through specific pathways (meridians) in the body. In contrast, many Western 
practitioners believe the acupuncture points as places to stimulate nerves, muscles and 
connective tissue. This stimulation seems to boost the activity of natural painkillers and 
increase blood flow. (114)  
Basically, acupuncture is a method of encouraging the body to enhance its own natural 
healing. The idea is to balance overall energy in order to establish or re-establish well-being. 
Research has shown that the body response to acupuncture is releasing endorphins 
(neurotransmitters that stop pain), increasing blood cell counts, and heightening the 
immune system. Acupuncture is used worldwide both as a primary and complementary 
form of medical treatment. The frequency of treatment depends greatly on the condition. 
Most people will begin to see results from acupuncture in approximately 4-10 treatments. 
Treatments are generally administered once per week until improvement is made and then 
follow-up appointments may range from a few times per year to monthly to bi-weekly.  
In one study (115) at the Human College of Traditional Chinese Medicine, forty patients 
with stable type of angina pectoris were assessed during and after acupuncture treatments 
and compared to a control group. After only one acupuncture treatment, 15 (37.5%) of the 
patients were already noticing a marked improvement in degree and area of pain, but after 7 
treatments 25 (63%) of the patients recorded significant reductions both in extent and area of 
pain, and they also experienced a reduction in the number and the duration of attacks. 
Furthermore the patients in the acupuncture group who did get angina attacks recovered 
much faster than the patients in the control group. 
Similar findings were reported in another study, this time in Sweden (116), where 21 
patients with stable effort angina pectoris were treated with acupuncture. All of the patients 
had a history of at least five anginal attacks per week despite intensive conventional medical 
treatment. They were given three acupuncture treatments per week which led to a 40% 
reduction in the number of anginal attacks and the researchers also observed that the 
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The effect of TENS on coronary flow was not accomplished in patients with a heart 
transplant which suggests that neurostimulation employs its effect through neural 
mechanisms employed at the microcirculatory level. (100)   Considering the lack of resting 
heart rate and blood pressure variability under neurostimulation, it’s unlikely that beta-
adrenergic mechanisms are involved. (101) Moreover, beta-mediated coronary dilatation is 
of less importance in the ischemic myocardium. (102)  On the other hand, alpha- adrenergic 
receptors may play a role in the anti-ischemic mechanism of action of neurostimulation. 
Inhibition of the alpha receptors may cause relative vasodilation at the subendocardial 
coronary level,(103) which in turn may cause a redistribution effect. 
At present it is unknown which neural pathways are involved in neurostimulation for 
angina pectoris. It is discovered that angina begins with stimulation of cardiac nerve 
endings.(104,105) by visceral afferent nerve fibers, converging in common pathways into the 
dorsal spinal cord at C7-T5 level, where they have synaptic connections with other 
neurons.(106) Afferent fibers from the heart and cutaneous input are assumed to cover 
specific interneurons in the same segment of the spinal cord, explaining the ensuing referred 
projection of pain to the related dermatome.(107, 108) Consequently, angina is felt in areas 
of the chest that refer to the dermatome from which afferent nerves project to the same 
segment of the spinal cord (C7-T5) as the heart. For an optimal clinical result of 
neurostimulation it is of great importance to achieve paresthesia in the same dermal regions.  
Although there is increasing evidence that neurostimulation is effective in angina pectoris, 
its safety needs to be established. In a 5-year follow-up study of 23 patients on spinal cord 
stimulation (SCS), Sanderson reported that it is a safe therapy based on the fact that; 
(109) only three patients died during this follow-up. In another follow up study, out of 46 
patients with severe coronary artery disease who were treated at the Groningen University 
Hospital Department of Cardiology with SCS; only six patients died during a7- year  
period. (110) 
However, despite declining mortality rates in patients with coronary artery disease, little is 
known about mortality rates in patients with refractory angina due to severe coronary artery 
disease. It is estimated that 3% (about 7 million) of Americans have active coronary artery 
disease implying an annual death rate of 7 %. (111)  
Another important issue which needs further attention before the general acceptance of 
neurostimulation as an alternative therapy in angina pectoris is its complication rate. 
Because of the high skin impedance, TENS is frequently complicated by persistent skin 
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irritation, which makes adequate continuation of therapy difficult. Meanwhile, SCS has a 
rather high incidence of dislocation of the epidural lead,(112) and this often impairs its 
effect. 
Once the safety of neurostimulation in angina pectoris is convincingly established and the 
aforementioned side effects can be further reduced, both TENS and SCS may be 
commonly used as alternatives in the therapeutic spectrum of intractable angina pectoris. 
3.4 Acupuncture 
Acupuncture involves the insertion of extremely thin needles in skin at strategic points of 
body. Acupuncture originated in China six thousands of years ago, but during the past three 
decades it was grown significantly as a popular therapy within the world. 
It works by stimulating the body to naturally correct the imbalances of energy. This is done 
by inserting ultra-fine, disposable needles, underneath the skin at specific points of the 
body. (113) These acupuncture points are related to energy pathways that run throughout 
the entire length of the body. Acupuncture points are also related to specific internal organs. 
The earliest known text on acupuncture was published more than 4,500 years ago. 
Acupuncture has been traditionally used to treat a wide variety of cardiovascular diseases, 
and recent controlled studies have demonstrated that it is particularly beneficial for angina 
pectoris by offering a proven option to drug therapy. 
Traditional Chinese theory explains acupuncture as a technique for balancing the flow of 
energy through specific pathways (meridians) in the body. In contrast, many Western 
practitioners believe the acupuncture points as places to stimulate nerves, muscles and 
connective tissue. This stimulation seems to boost the activity of natural painkillers and 
increase blood flow. (114)  
Basically, acupuncture is a method of encouraging the body to enhance its own natural 
healing. The idea is to balance overall energy in order to establish or re-establish well-being. 
Research has shown that the body response to acupuncture is releasing endorphins 
(neurotransmitters that stop pain), increasing blood cell counts, and heightening the 
immune system. Acupuncture is used worldwide both as a primary and complementary 
form of medical treatment. The frequency of treatment depends greatly on the condition. 
Most people will begin to see results from acupuncture in approximately 4-10 treatments. 
Treatments are generally administered once per week until improvement is made and then 
follow-up appointments may range from a few times per year to monthly to bi-weekly.  
In one study (115) at the Human College of Traditional Chinese Medicine, forty patients 
with stable type of angina pectoris were assessed during and after acupuncture treatments 
and compared to a control group. After only one acupuncture treatment, 15 (37.5%) of the 
patients were already noticing a marked improvement in degree and area of pain, but after 7 
treatments 25 (63%) of the patients recorded significant reductions both in extent and area of 
pain, and they also experienced a reduction in the number and the duration of attacks. 
Furthermore the patients in the acupuncture group who did get angina attacks recovered 
much faster than the patients in the control group. 
Similar findings were reported in another study, this time in Sweden (116), where 21 
patients with stable effort angina pectoris were treated with acupuncture. All of the patients 
had a history of at least five anginal attacks per week despite intensive conventional medical 
treatment. They were given three acupuncture treatments per week which led to a 40% 
reduction in the number of anginal attacks and the researchers also observed that the 





a life quality questionnaire which confirmed that they all felt better as a result of the 
acupuncture treatment. The report concluded that acupuncture should be considered a 
beneficial treatment even for patients with severe, intensively treated angina pectoris. 
Other studies have come to the same conclusion (117,118) in the treatment of angina. In one 
research project at the Nanjing Medical College involving 267 patients, all suffering from 
angina pectoris, acupuncture treatment was shown to have a 93.3% success rate with no 
harmful side effects (119). 
There are some possible side effects and risks that could be involved in patients and depend 
completely upon the experience and expertise of the acupuncturist, but these are relatively 
less when compared to other forms of treatment. Some of the common acupuncture side 
effects or inconveniences experienced during or after acupuncture are: a regular sensation of 
warmth, tenderness, and tingling when the acupuncture needles reach the acupoint or 
trigger point, mild bruising and bleeding, temporary drop in blood pressure which may 
result in fatigue and rarely fainting, allergic reactions to stainless steel acupuncture needles, 
infections, and perforation of some of the vital organs by needles.  
Acupuncture is safe and complications are extremely rare and side effects, if any, are 
limited. There are a number of guidelines, however, which govern the use of particular 
acupuncture points. A precaution may be related to use in certain conditions, with 
particular techniques, or because of a points location, however, in some cases, practitioner 
may still use a point or technique even if it is listed as a precaution. 
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